
<html lang="en"     class="pb-page"  data-request-id="9ec4ab35-c55b-4dde-bbd8-7c7d1c1a3209"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2009.52.issue-4;article:article:10.1021/jm801406h;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Pyrido[2,3-d]pyrimidin-5-ones: A Novel Class of Antiinflammatory Macrophage Colony-Stimulating Factor-1 Receptor Inhibitors†" /></meta><meta name="dc.Creator" content="Hui  Huang" /></meta><meta name="dc.Creator" content="Daniel A.  Hutta" /></meta><meta name="dc.Creator" content="James M.  Rinker" /></meta><meta name="dc.Creator" content="Huaping  Hu" /></meta><meta name="dc.Creator" content="William H.  Parsons" /></meta><meta name="dc.Creator" content="Carsten  Schubert" /></meta><meta name="dc.Creator" content="Renee L.  DesJarlais" /></meta><meta name="dc.Creator" content="Carl S.  Crysler" /></meta><meta name="dc.Creator" content="Margery A.  Chaikin" /></meta><meta name="dc.Creator" content="Robert R.  Donatelli" /></meta><meta name="dc.Creator" content="Yanmin  Chen" /></meta><meta name="dc.Creator" content="Deping  Cheng" /></meta><meta name="dc.Creator" content="Zhao  Zhou" /></meta><meta name="dc.Creator" content="Edward  Yurkow" /></meta><meta name="dc.Creator" content="Carl L.  Manthey" /></meta><meta name="dc.Creator" content="Mark R.  Player" /></meta><meta name="dc.Description" content="A series of pyrido[2,3-d]pyrimidin-5-ones has been synthesized and evaluated as inhibitors of the kinase domain of macrophage colony-stimulating factor-1 receptor (FMS). FMS inhibitors may be usefu..." /></meta><meta name="Description" content="A series of pyrido[2,3-d]pyrimidin-5-ones has been synthesized and evaluated as inhibitors of the kinase domain of macrophage colony-stimulating factor-1 receptor (FMS). FMS inhibitors may be usefu..." /></meta><meta name="dc.Publisher" content=" American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 4, 2009" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm801406h" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2009 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm801406h" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm801406h" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm801406h" /></link>
        
    
    

<title>Pyrido[2,3-d]pyrimidin-5-ones: A Novel Class of Antiinflammatory Macrophage Colony-Stimulating Factor-1 Receptor Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm801406h" /></meta><meta property="og:title" content="Pyrido[2,3-d]pyrimidin-5-ones: A Novel Class of Antiinflammatory Macrophage Colony-Stimulating Factor-1 Receptor Inhibitors†" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0006.jpeg" /></meta><meta property="og:description" content=" A series of pyrido[2,3-d]pyrimidin-5-ones has been synthesized and evaluated as inhibitors of the kinase domain of macrophage colony-stimulating factor-1 receptor (FMS). FMS inhibitors may be useful in treating rheumatoid arthritis and other chronic inflammatory diseases. Structure-based optimization of the lead amide analogue 10 led to hydroxamate analogue 37, which possessed excellent potency and an improved pharmacokinetic profile. During the chronic phase of streptococcal cell wall-induced arthritis in rats, compound 37 (10, 3, and 1 mg/kg) was highly effective at reversing established joint swelling. In an adjuvant-induced arthritis model in rats, 37 prevented joint swelling partially at 10 mg/kg. In this model, osteoclastogenesis and bone erosion were prevented by low doses (1 or 0.33 mg/kg) that had minimal impact on inflammation. These data underscore the potential of FMS inhibitors to prevent erosions and reduce symptoms in rheumatoid arthritis." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm801406h"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm801406h">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm801406h&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm801406h&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm801406h&amp;href=/doi/10.1021/jm801406h" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2009</span><span class="cit-fg-volume">, 52</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1081-1099</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/52/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm8014102" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm8013585" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Pyrido[2,3-<i>d</i>]pyrimidin-5-ones: A Novel Class of Antiinflammatory Macrophage Colony-Stimulating Factor-1 Receptor Inhibitors<a class="ref internalNav" href="#fn2" aria-label="†">†</a></span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hui++Huang">Hui Huang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+A.++Hutta">Daniel A. Hutta</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+M.++Rinker">James M. Rinker</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Huaping++Hu">Huaping Hu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William+H.++Parsons">William H. Parsons</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carsten++Schubert">Carsten Schubert</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Renee+L.++DesJarlais">Renee L. DesJarlais</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carl+S.++Crysler">Carl S. Crysler</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Margery+A.++Chaikin">Margery A. Chaikin</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+R.++Donatelli">Robert R. Donatelli</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yanmin++Chen">Yanmin Chen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deping++Cheng">Deping Cheng</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhao++Zhou">Zhao Zhou</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Edward++Yurkow">Edward Yurkow</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carl+L.++Manthey">Carl L. Manthey</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+R.++Player">Mark R. Player</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info"><span class="aff-text">Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776</span></div><div class="corresp-info"><strong>*</strong> To whom correspondence should be addressed. Phone: 610-458-6980. Fax: 610-458-6980. E-mail: <a href="/cdn-cgi/l/email-protection#82eff2eee3fbe7f0c2ebf6f1ace8ece8ace1edef"><span class="__cf_email__" data-cfemail="ff928f939e869a8dbf968b8cd1959195d19c9092">[email protected]</span></a></div><div class="corresp-fn" id="fn2">†PDB ID: 3DPK.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm801406h&amp;href=/doi/10.1021%2Fjm801406h" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2009</span></span><span class="cit-volume">, 52</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1081–1099</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 4, 2009</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 November 2008</li><li><span class="item_label"><b>Published</b> online</span>4 February 2009</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 February 2009</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm801406h" title="DOI URL">https://doi.org/10.1021/jm801406h</a></div><div class="article_header-article-copyright"><strong>Copyright © 2009 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1081%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHui%2BHuang%252C%2BDaniel%2BA.%2BHutta%252C%2BJames%2BM.%2BRinker%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D52%26issueNum%3D4%26contentID%3Djm801406h%26title%3DPyrido%255B2%252C3-d%255Dpyrimidin-5-ones%253A%2BA%2BNovel%2BClass%2Bof%2BAntiinflammatory%2BMacrophage%2BColony-Stimulating%2BFactor-1%2BReceptor%2BInhibitors%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1099%26publicationDate%3DFebruary%2B2009">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm801406h"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3461</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">36</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm801406h" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Pyrido[2,3-d]pyrimidin-5-ones: A Novel Class of Antiinflammatory Macrophage Colony-Stimulating Factor-1 Receptor Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Hui&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;A. Hutta&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;M. Rinker&quot;},{&quot;first_name&quot;:&quot;Huaping&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;H. Parsons&quot;},{&quot;first_name&quot;:&quot;Carsten&quot;,&quot;last_name&quot;:&quot;Schubert&quot;},{&quot;first_name&quot;:&quot;Renee&quot;,&quot;last_name&quot;:&quot;L. DesJarlais&quot;},{&quot;first_name&quot;:&quot;Carl&quot;,&quot;last_name&quot;:&quot;S. Crysler&quot;},{&quot;first_name&quot;:&quot;Margery&quot;,&quot;last_name&quot;:&quot;A. Chaikin&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;R. Donatelli&quot;},{&quot;first_name&quot;:&quot;Yanmin&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Deping&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Zhao&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Edward&quot;,&quot;last_name&quot;:&quot;Yurkow&quot;},{&quot;first_name&quot;:&quot;Carl&quot;,&quot;last_name&quot;:&quot;L. Manthey&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;R. Player&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2009&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;04&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;52&quot;,&quot;pages&quot;:&quot;1081-1099&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm801406h&quot;},&quot;abstract&quot;:&quot;A series of pyrido[2,3-d]pyrimidin-5-ones has been synthesized and evaluated as inhibitors of the kinase domain of macrophage colony-stimulating factor-1 receptor (FMS). FMS inhibitors may be useful in treating rheumatoid arthritis and other chronic inflammatory diseases. Structure-based optimization of the lead amide analogue 10 led to hydroxamate analogue 37, which possessed excellent potency and an improved pharmacokinetic profile. During the chronic phase of streptococcal cell wall-induced arthritis in rats, compound 37 (10, 3, and 1 mg/kg) was highly effective at reversing established joint swelling. In an adjuvant-induced arthritis model in rats, 37 prevented joint swelling partially at 10 mg/kg. In this model, osteoclastogenesis and bone erosion were prevented by low doses (1 or 0.33 mg/kg) that had minimal impact on inflammation. These data underscore the potential of FMS inhibitors to prevent erosions and reduce symptoms in rheumatoid arthritis.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm801406h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm801406h" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm801406h&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm801406h" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm801406h&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm801406h" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm801406h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm801406h&amp;href=/doi/10.1021/jm801406h" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm801406h" /></input><a href="/doi/pdf/10.1021/jm801406h" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm801406h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm801406h%26sid%3Dliteratum%253Aachs%26pmid%3D19193011%26genre%3Darticle%26aulast%3DHuang%26date%3D2009%26atitle%3DPyrido%255B2%252C3-d%255Dpyrimidin-5-ones%253A%2BA%2BNovel%2BClass%2Bof%2BAntiinflammatory%2BMacrophage%2BColony-Stimulating%2BFactor-1%2BReceptor%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D52%26issue%3D4%26spage%3D1081%26epage%3D1099%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/52/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A series of pyrido[2,3-<i>d</i>]pyrimidin-5-ones has been synthesized and evaluated as inhibitors of the kinase domain of macrophage colony-stimulating factor-1 receptor (FMS). FMS inhibitors may be useful in treating rheumatoid arthritis and other chronic inflammatory diseases. Structure-based optimization of the lead amide analogue <b>10</b> led to hydroxamate analogue <b>37</b>, which possessed excellent potency and an improved pharmacokinetic profile. During the chronic phase of streptococcal cell wall-induced arthritis in rats, compound <b>37</b> (10, 3, and 1 mg/kg) was highly effective at reversing established joint swelling. In an adjuvant-induced arthritis model in rats, <b>37</b> prevented joint swelling partially at 10 mg/kg. In this model, osteoclastogenesis and bone erosion were prevented by low doses (1 or 0.33 mg/kg) that had minimal impact on inflammation. These data underscore the potential of FMS inhibitors to prevent erosions and reduce symptoms in rheumatoid arthritis.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40210" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40210" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Macrophage colony-stimulating factor-1 receptor (FMS<a class="ref internalNav" href="#fn1" aria-label="a">a</a><div class="NLM_fn" id="fn1">a<p class="last">Abbreviations: SCF, stem cell factor; FMS, macrophage colony-stimulating factor-1 receptor; ITD, internal tandem duplication; FLT-3, FMS-like tyrosine kinase-3; FCS, fetal calf serum; MEM, minimal essential media; RNase, ribonuclease; DNase, deoxyribonuclease; SEM, standard error of the mean.</p></div> ) (cellular homologue of the V-FMS oncogene product of the Susan McDonough strain of feline sarcoma virus) is a class III receptor tyrosine kinase and is the exclusive receptor for colony stimulating factor-1 (CSF-1).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> CSF-1 is an important growth factor for bone progenitor cells, monocytes, macrophages,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and cells of macrophage lineage such as osteoclasts<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and dendritic cells.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Binding of CSF-1 to the FMS extracellular domain induces FMS dimerization and trans-autophosphorylation of the intracellular FMS kinase domain on several tyrosine residues. Once phosphorylated, FMS serves as a docking site for several cytoplasmic signaling molecules the activation of which leads to de novo gene expression and proliferation.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Robust expression of FMS is restricted to monocytes, tissue macrophages, and osteoclasts. For this reason it is anticipated that FMS inhibitors will be useful in treating diseases where osteoclasts, dendritic cells, and macrophages are pathogenic, e.g., rheumatoid arthritis (RA) and other autoimmune/inflammatory diseases.</div><div class="NLM_p">Rheumatoid arthritis afflicts approximately 1% of the U.S. population and exacts a large personal and economic burden. It is an autoimmune disease, and several cartilage autoantigens have been proposed but none proven to drive pathogenesis. Acquired cellular and humoral immunity activates synovial tissue macrophages to express cytokines that further orchestrate leukocytic infiltration, edema, and pain. The synovial inflammation is chronic and eventually organizes to form granulation tissue known as a pannus. Pannus is a highly invasive tissue that progressively erodes cartilage, bone, tendons, and ligaments with irreversible loss of joint function, particularly of the hands and feet. Because of a generalized increase in inflammatory mediators, RA also has systemic manifestations. RA patients have a greater incidence of vascular disease<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and osteoporosis.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Although patients seek relief from pain and stiffness, new agents are needed that prevent progressive loss of joint function and reduce the manifestations of systemic disease.</div><div class="NLM_p">Low-dose methotrexate is the first-line therapy for moderate to severe RA. Although methotrexate is economical and has reduced a great deal of suffering, some 35−55% of patients fail to achieve (American College of Rheumatology-20) ACR20 response rates with methotrexate alone and methotrexate does not adequately control focal bone erosions and generalized osteoporosis in RA.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Patients using methotrexate must be monitored closely for elevated liver enzymes to prevent liver fibrosis, and use of methotrexate is associated with transient nausea and fatigue in a majority of patients.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Patients that do not respond adequately to methotrexate may be prescribed one of several biological agents that neutralize TNF (infliximab, etanercept, adalimumab, and abatacept) or CD20 (rituxamab). These agents effectively reduce local and systemic symptoms and prevent joint space narrowing and bone erosions in the majority of patients. However, they are expensive and require parenteral administration. Thus, there remains an untapped market for an efficacious oral drug that is better tolerated than methotrexate, particularly one that protects the patient from joint destruction.</div><div class="NLM_p">There is evidence that CSF-1 may drive the macrophage population in RA. CSF-1 levels are elevated in rheumatoid plasma, synovium, and synovial fluid.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Monocytes from RA patients express elevated levels of FcγR I, IIa, and IIIa, increased CD14 and oxygen radicals, and reduced HLA-DR.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> This monocyte phenotype can be produced in vitro and in vivo with recombinant CSF-1.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Thusly, CSF-1 may drive the recruitment, differentiation and survival of RA synovial macrophages, and the local proliferation of myeloid progenitors. Further, CSF-1 primes macrophages for greater expression of TNF and other cytokines.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> It has been proposed that CSF-1 is a component of a positive feedback loop in chronic inflammation.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In this loop, macrophages secrete TNF and IL-1 that induce stromal cell expression of CSF-1, causing further expansion of macrophage numbers and increased TNF and IL-1 expression. Therapeutic targeting of TNF and IL-1 with biologic agents has been successful.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Interruption of CSF-1 signaling with oral FMS inhibitors may provide a novel alternative approach to break the positive feedback loop in inflammatory disease. Further, because FMS was shown to mediate TNF-induced osteolysis,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> we anticipate that oral FMS inhibitors will be useful for preventing focal bone loss, deformity, and loss of joint function in rheumatoid arthritis.</div><div class="NLM_p">There are a number of small molecule FMS inhibitors reported in the literature, such as <b>1</b> (Ki20227),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a><b>2</b> (GW2580),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a><b>3</b> (P-0728),<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a><b>4</b> (XLS-002),<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a><b>5</b> (sunitinib),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a><b>6</b> (AG13736),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and <b>7</b> (ABT869).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> While many of them have demonstrated in vivo antiinflammatory efficacy and are in various stages of development, <b>5</b>−<b>7</b> are multitargeted kinase inhibitors in clinical trials for cancer therapies (Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>).</div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0007.jpeg" id="gc1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. FMS Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We have identified several classes of novel FMS inhibitors: arylamides (<b>8</b>),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> 3,4,6-substituted 2-quinolones (<b>9</b>),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and pyrido[2,3-<i>d</i>]pyrimidin-5-ones (<b>10</b>),<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> which have good in vitro and in vivo activities (Chart <a class="ref internalNav" href="#cht2" aria-label="2">2</a>). Herein is reported the structure-based optimization of the pyrido[2,3-<i>d</i>]pyrimidin-5-one core, which has led to FMS inhibitors with significantly improved pharmacokinetic properties and potent anti-inflammatory efficacy in in vivo arthritis models.</div><figure id="cht2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0017.jpeg" id="_i4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Three Novel Classes of FMS Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08527" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08527" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of pyrido[2,3-<i>d</i>]pyrimidin-5-one amide <b>10</b> is shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. 5-Aminoindan was reacted with ethyl 3-chloropropionate at elevated temperature in the presence of an inorganic base and a catalytic amount of tetrabutylammonium bromide, affording the aminopropionate ester <b>11</b>. Compound <b>11</b> was then treated with ethyl 4-chloro-2-methylthio-5-pyrimidinecarboxylate to produce 4-aminopyrimidine <b>12</b>. Cyclization of this diester under Dieckmann conditions afforded bicyclic compound <b>13</b>. Subsequent halogenation with bromine followed by dehydrohalogenation gave <b>14</b>.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The thiomethyl moiety was then oxidized to sulfone <b>15</b>, which was subsequently displaced with an alkyl amine or aniline by nucleophilic substitution. The resulting carboxylate ester <b>16</b> was converted to amides <b>10</b>, <b>17a</b>−<b>e</b>, and <b>18a</b>−<b>c</b> by reaction with corresponding amines in methanol at elevated temperatures.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0008.jpeg" id="gs1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ethyl 3-chloropropionate, K<sub>2</sub>CO<sub>3</sub>, Bu<sub>4</sub>NBr (cat.), 100 °C; (b) Et<sub>3</sub>N, <i>n</i>-BuOH, rt; (c) <i>t</i>-BuONa, toluene, 90 °C; (d) Br<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt; (e) Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt; (f) <i>m</i>-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (g) arylamine, <i>i</i>-PrOH, 90 °C; (h) R<sup>1</sup>NH<sub>2</sub>, MeOH, rt or 80−100 °C.</p></p></figure><div class="NLM_p">After the methyl hydroxamate group was shown to be optimal at the C-6 position (<b>18a</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>), an alternate route was developed in order to incorporate the methyl hydroxamate group earlier in the synthetic sequence (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). Ethyl 4-chloro-2-methylthio-5-pyrimidinecarboxylate was saponified to the corresponding acid <b>19</b>. The 4-chloride was displaced by a methoxyl group under the conditions noted. However, the methoxyl group was found to serve the same role as the chloride in subsequent steps. Ketoester <b>20</b>, prepared from an acid chloride intermediate, was converted to an enaminoester intermediate by reaction with ethyl orthoformate and acetic anhydride, followed by reaction with a primary amine R<sup>3</sup>NH<sub>2</sub>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> A base-assisted cyclization reaction of the unisolated enaminoester led to bicyclic ester <b>21</b>. Acid <b>22</b>, obtained through acidic hydrolysis of <b>21</b>, was coupled with methoxyamine to form <b>23</b>. The 2-methylthio group of <b>23</b> was oxidized to give methylsulfone <b>24</b>, which was subsequently displaced with anilines R<sup>2</sup>NH<sub>2</sub> to give final products. This route allowed rapid exploration of the C-2 anilino substituents and facilitated evaluation of N-8 substitutions using common intermediate <b>20</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Effect of C-6 Amide Substitution on Biological Activity and Rat Liver Microsomal Stability</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0011.gif" alt="" id="_i7" /></img><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead valign="middle"><tr valign="top"><th align="center" valign="bottom">compd</th><th align="center" valign="bottom">R<sup>1</sup></th><th align="center" valign="bottom">X</th><th align="center" valign="bottom" char=".">FMS enzyme IC<sub>50</sub><a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a> (nM)</th><th align="center" valign="bottom" char=".">BMDM IC<sub>50</sub><a class="ref internalNav" href="#tbl1-fn2" aria-label="b">b</a> (nM)</th><th align="center" valign="bottom">RLM stability<a class="ref internalNav" href="#tbl1-fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top"><td align="left"><b>10</b></td><td align="left"> </td><td align="left"> </td><td align="char" char=".">13</td><td align="char" char=".">16</td><td align="left">87</td></tr><tr valign="top"><td align="left"><b>17a</b></td><td align="left">H</td><td align="left">NCH<sub>3</sub></td><td align="char" char=".">0.8</td><td align="char" char=".">9</td><td align="left">96</td></tr><tr valign="top"><td align="left"><b>17b</b></td><td align="left">Me</td><td align="left">NCH<sub>3</sub></td><td align="char" char=".">1.2</td><td align="char" char=".">26</td><td align="left">73</td></tr><tr valign="top"><td align="left"><b>17c</b></td><td align="left">Me</td><td align="left">O</td><td align="char" char=".">1.4</td><td align="char" char=".">55</td><td align="left">100</td></tr><tr valign="top"><td align="left"><b>17d</b></td><td align="left">Et</td><td align="left">NCH<sub>3</sub></td><td align="char" char=".">3.2</td><td align="char" char=".">45</td><td align="center">ND<a class="ref internalNav" href="#tbl1-fn4" aria-label="d">d</a></td></tr><tr valign="top"><td align="left"><b>17e</b></td><td align="left">CH<sub>2</sub>CH<sub>2</sub>OH</td><td align="left">NCH<sub>3</sub></td><td align="char" char=".">0.7</td><td align="char" char=".">56</td><td align="left">84</td></tr><tr valign="top"><td align="left"><b>18a</b></td><td align="left">OMe</td><td align="left">NCH<sub>3</sub></td><td align="char" char=".">0.7</td><td align="char" char=".">1.3</td><td align="left">78</td></tr><tr valign="top"><td align="left"><b>18b</b></td><td align="left">OEt</td><td align="left">NCH<sub>3</sub></td><td align="char" char=".">0.5</td><td align="char" char=".">3.3</td><td align="left">84</td></tr><tr valign="top"><td align="left"><b>18c</b></td><td align="left">OCH(CH<sub>3</sub>)<sub>2</sub></td><td align="left">NCH<sub>3</sub></td><td align="char" char=".">0.5</td><td align="char" char=".">5.4</td><td align="left">100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>a</sup><p class="last">Reported IC<sub>50</sub> values are means of three experiments. Interassay variance was <10%.</p></div><div class="footnote" id="tbl1-fn2"><sup>b</sup><p class="last">Dose−response data are the average of at least two replicates per dose.</p></div><div class="footnote" id="tbl1-fn3"><sup>c</sup><p class="last">Percentage of compound remaining after 10 min incubation in rat liver microsomes.</p></div><div class="footnote" id="tbl1-fn4"><sup>d</sup><p class="last">Not determined.</p></div></div></div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0009.jpeg" id="gs2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaOH, methanol, rt; (b) oxalyl chloride, DMF (cat.), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (c) ethyl hydrogen malonate, MeMgBr, 0 °C to rt; (d) triethylorthoformate, Ac<sub>2</sub>O, 130 °C; (e) aminoindan, THF, rt; (f) K<sub>2</sub>CO<sub>3</sub>, THF, rt; (g) 1 N HCl, 1,4-dioxane, 105 °C; (h) oxalyl chloride, DMF (cat.), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (i) methoxyamine hydrochloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (j) <i>m</i>-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (k) R<sup>2</sup>NH<sub>2</sub>, AcOH, 110 °C.</p></p></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65404" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65404" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As previously reported, pyrido[2,3-<i>d</i>]pyrimidin-5-one <b>10</b> was a potent FMS inhibitor with an IC<sub>50</sub> of 13 nM.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Further optimization of the C-2 anilino substituents led to <b>17a</b> with improved potency in the enzyme assay<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and in the cellular assay that measures proliferation of bone marrow-derived macrophages (BMDM)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> in response to CSF-1 stimulation (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Small alkyl substitution on the C-6 amide was well tolerated, though activity diminished with increasing size (<b>17b</b>,<b>d</b>). Despite good in vitro activity, the amide series (<b>10</b>, <b>17a</b>, and <b>17c</b>) exhibited poor oral exposure when administered at 10 mg/kg to male Sprague−Dawley rats (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Moreover, these compounds showed high volumes of distribution and high clearance rates. Because the amide series was stable in rat liver microsomal (RLM) incubations, the lack of oral exposure was suspected to be a result of poor absorption.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Pharmacokinetic Profile of Selected Analogues in Sprague−Dawley Rats</div></div></div><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead valign="middle"><tr valign="top"><th align="center" valign="bottom">compd<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></th><th align="center" valign="middle" char="."><i>C</i><sub>max</sub>po<a class="ref internalNav" href="#tbl2-fn2" aria-label="b">b</a> (μM)</th><th align="center" valign="middle" char="."><i>t</i><sub>1/2</sub>po (h)</th><th align="center" valign="middle" char="."><i>t</i><sub>1/2</sub>iv (h)</th><th align="center" valign="middle" char="."><i>Cl</i>(mL/min/kg)</th><th align="center" valign="middle" char="."><i>Vd</i><sub><i>ss</i></sub><a class="ref internalNav" href="#tbl2-fn4" aria-label="d">d</a>(L/kg)</th><th align="center" valign="middle" char="."><i>F</i>(%)</th></tr></thead><tbody><tr valign="top"><td align="left"><b>10</b></td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char=".">133</td><td align="char" char=".">18.7</td><td align="char" char=".">0</td></tr><tr valign="top"><td align="left"><b>17a</b></td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char=".">7</td><td align="char" char=".">25</td><td align="char" char=".">15.5</td><td align="char" char=".">0</td></tr><tr valign="top"><td align="left"><b>17c</b></td><td align="char" char=".">0.13</td><td align="char" char=".">1.8</td><td align="char" char=".">0.7</td><td align="char" char=".">47</td><td align="char" char=".">2.6</td><td align="char" char=".">4</td></tr><tr valign="top"><td align="left"><b>18a</b></td><td align="char" char=".">2.7</td><td align="char" char=".">6.5</td><td align="char" char=".">4.5</td><td align="char" char=".">4</td><td align="char" char=".">1.5</td><td align="char" char=".">57</td></tr><tr valign="top"><td align="left"><b>31</b></td><td align="char" char=".">0.08</td><td align="char" char=".">9.7</td><td align="char" char=".">6</td><td align="char" char=".">10</td><td align="char" char=".">0.8</td><td align="char" char=".">3</td></tr><tr valign="top"><td align="left"><b>35</b></td><td align="char" char=".">0.13</td><td align="char" char="."> </td><td align="char" char=".">3</td><td align="char" char=".">34</td><td align="char" char=".">8.8</td><td align="char" char=".">8</td></tr><tr valign="top"><td align="left"><b>36</b></td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char=".">1.7</td><td align="char" char=".">38</td><td align="char" char=".">5.1</td><td align="char" char=".">0</td></tr><tr valign="top"><td align="left"><b>37</b></td><td align="char" char=".">1.6</td><td align="char" char=".">6.9</td><td align="char" char=".">4.6</td><td align="char" char=".">11</td><td align="char" char=".">4.3</td><td align="char" char=".">100</td></tr><tr valign="top"><td align="left"><b>39</b></td><td align="char" char=".">0.4</td><td align="char" char="."> </td><td align="char" char=".">5.2</td><td align="char" char=".">20.4</td><td align="char" char=".">5.6</td><td align="char" char=".">28</td></tr><tr valign="top"><td align="left"><b>45</b></td><td align="char" char=".">3.4</td><td align="char" char=".">8.1</td><td align="char" char=".">8</td><td align="char" char=".">8</td><td align="char" char=".">5.9</td><td align="char" char=".">103</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup>a</sup><p class="last">Formulated in 20% hydroxypropyl-β-cyclodextrin (HPβCD).</p></div><div class="footnote" id="tbl2-fn2"><sup>b</sup><p class="last">Administrated at 10 mg/kg po.</p></div><div class="footnote" id="tbl2-fn3"><sup>c</sup><p class="last">Administrated at 2 mg/kg iv.</p></div><div class="footnote" id="tbl2-fn4"><sup>d</sup><p class="last">Volume of distribution at steady state. Both <i>Cl</i> and <i>Vd</i> determined from iv dosing.</p></div></div></div><div class="NLM_p">The cocrystal structure of an amide compound bound in the active site of FMS revealed that the amide NH is part of a water-mediated hydrogen bonding network.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> It was hypothesized that displacing the water molecule and preserving the hydrogen bonding network might improve potency. Molecular modeling suggested that 2-hydroxyethyl amide (<b>17e</b>) had the potential to achieve this. Compound <b>17e</b> was potent in the enzyme assay but substantially less active than the corresponding amide <b>17a</b> in the BMDM assay. Alkyl hydroxamates (<b>18a</b>−<b>c</b>) were also designed to explore this hypothesis. The hydroxamate group presents a distinct electrostatic surface for interaction and was expected to displace one of the bound water molecules. Methyl hydroxamate <b>18a</b> exhibited significantly increased potency in the BMDM assay while retaining the enzyme activity of the amide <b>17a</b>. Furthermore, <b>18a</b> had an improved pharmacokinetic profile in rat with an oral bioavailability of 57%, a <i>C</i><sub>max</sub> of 2.7 μM at a 10 mg/kg oral dose, and a low systemic clearance rate (4 mL/min/kg) (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Small alkyl hydroxamates were all potent FMS inhibitors, although BMDM activity decreased with increasing size of the alkyl group (<b>18b</b>,<b>c</b>). Some of these analogues have kinase assay IC<sub>50</sub>s around the enzyme concentration of 0.9 nM. As enzyme activity approached this limit, the BMDM cell-based assay was more sensitive to differences in potency.</div><div class="NLM_p">Subsequently, one of the methyl hydroxamates (<b>25</b>) was cocrystallized with FMS (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Like previously analyzed FMS inhibitors,<a onclick="showRef(event, 'ref25 ref30'); return false;" href="javascript:void(0);" class="ref ref25 ref30">(25, 30)</a> the hydroxamate series interacts with the hinge region of the kinase via hydrogen bonding interactions mediated through the C-2 anilino NH and the pyrimidine N-3 (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>A). A water-mediated hydrogen bonding network is formed between the C-5 carbonyl oxygen, the hydroxyl group of Thr663 and a water molecule present in the active site (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>B). The hydroxamate group preserves the conformational constraint of the intramolecular hydrogen bond between the NH and C-5 carbonyl oxygen. This in turn enables the acetamide carbonyl to interact with Lys616. In addition, the hydroxamate oxygen forms hydrogen bonds with Lys616. It is believed that this complex hydrogen bonding network contributes to the improved potency.</div><figure id="fig1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0016.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Cocrystal structure of <b>25</b> in FMS (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DPK">3DPK</a>). (A) Ball-and-stick representation of <b>25</b> (yellow) bound in the active site of cFMS (gray). Additionally shown is the 2<i>f</i><sub>o</sub> − <i>f</i><sub>c</sub> electron density map (blue) contoured at 1.4σ and truncated to a radius of 2 Å beyond each atom for clarity. Hydrogen bonds to the backbone of the protein are depicted as green dashed lines. (B) Close-up view of the water-mediated hydrogen-bonding network in the active site. The internal hydrogen bond between the amide nitrogen and the pyridopyrimidinone carbonyl oxygen is drawn in magenta.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The importance of the aromatic nature of the C-2 substituents is evident, given that compounds with alkyl amino substitutions at C-2 position (<b>26</b>, <b>27</b>) had poor activity (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). The cocrystal structure of <b>25</b> bound in FMS shows that the pocket for C-2 substitution is quite narrow and cannot accommodate alkyl groups that would have a significant out-of-plane geometry. Crystal structures also predict that the substitution at the 4-position of the C-2 anilino phenyl ring would be solvent exposed. This region of the molecule has been used to modulate various properties of the compound while maintaining potent FMS inhibition.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Effect of C-2 Substitution on Biological Activity and Rat/Human Liver Microsomal Stability</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0012.gif" alt="" id="gr8" /></img><div class="scrollable-table-wrap"><table class="table single-image frame_bottom"><colgroup><col align="left" /></col></colgroup><tbody><tr valign="top"><td align="left"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0013.gif" alt="" id="gr9" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup>a</sup><p class="last">Reported IC<sub>50</sub> values are means of three experiments. Interassay variance was <10%.</p></div><div class="footnote" id="tbl3-fn2"><sup>b</sup><p class="last">Dose−response data are the average of at least two replicates per dose.</p></div><div class="footnote" id="tbl3-fn3"><sup>c</sup><p class="last">Percentage of compound remaining after 10 min incubation in human liver microsomes.</p></div><div class="footnote" id="tbl3-fn4"><sup>d</sup><p class="last">Percentage of compound remaining after 10 min incubation in rat liver microsomes.</p></div></div></div><div class="NLM_p">To assess the specificity profile of FMS inhibitors as the program progressed, compounds were routinely assessed in a 50-assay counterscreening profile (GPCRs, ion channels, and transporters) at Cerep.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> In this screen, compound <b>18a</b> inhibited 16 targets by 50% or more at a concentration of 10 μM. In contrast, compounds with less basic substituents on the C-2 anilino phenyl inhibited fewer targets (data not shown). Therefore, efforts refocused on replacement of the basic piperazine tail of <b>18a.</b> At first, piperazine was replaced by less basic rings such as morpholine (<b>29</b>), 4,4-difluoropiperazine (<b>30</b>), and piperazin-2-one (<b>31</b>) (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Morpholino analogue <b>29</b> was more potent than its amide counterpart <b>17c</b> but was unstable in human and rat liver microsomes. While stable in HLM and RLM and clean in the counterscreening profile, the difluorinated piperidine analogue (<b>30</b>) was less active in the BMDM assay. Piperazin-2-one analogue (<b>31</b>) also exhibited a clean counterscreening profile, confirming the refocused strategy. However, its oral bioavalability in rat was only 3% (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Methylated analogue <b>32</b> was prepared in an attempt to improve on the permeability of <b>31</b>, but it decomposed rapidly in HLM incubations. Neutral and acidic compounds were also prepared and had clean counterscreening profiles. However, it was difficult to formulate the neutral compounds for in vivo assessment due to poor solubility. Incorporation of acidic “tails” resulted in loss of activity in the BMDM assay, as seen in acetyl sulfonamide <b>33</b>.</div><div class="NLM_p">The ethyl linker was removed to give piperidine analogues <b>34</b>−<b>37</b>. Compound <b>34</b> was as potent as <b>18a</b> and had a similar counterscreening profile. Introduction of a hydroxyl ethyl group (<b>35</b>) had minimal impact on the potency, while acetic acid analogue (<b>36</b>) reduced BMDM activity more than 20-fold compared to <b>34</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Both <b>35</b> and <b>36</b> had very low oral exposure in rat (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). The <i>N</i>-methylated piperidine analogue (<b>37</b>) stood out not only for its excellent potency, but also for its good rat pharmacokinetic profile with an oral <i>C</i><sub>max</sub> of 1.6 μM, a clearance rate of 11 mL/min/kg, and bioavailability of 100% (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Although <b>37</b> was not optimal in the counterscreening profile as measured by inhibition of paradigm compound binding in the Cerep panel, follow-up functional assays showed that hM1 was the only target where modest functional activity was observed.</div><div class="NLM_p">In an effort to attenuate basicity of the piperidine ring, difluoro-substituted piperidine analogue <b>38</b> and 3-hydroxyl piperidine analogue <b>39</b> were prepared. The aniline precursor of <b>38</b>, 4-(3,3-difluoro-1-methyl-piperidin-4-yl)-phenylamine (<b>44</b>) was synthesized as shown in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Suzuki coupling of the boronic acid with 3-methoxy-4-bromopyridine provided biaryl <b>40</b>. It was then converted to the corresponding <i>N</i>-methyl pyridinium salt, followed by borohydride reduction to give tetrahydropyridine <b>41</b>.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Acidic treatment of <b>41</b> gave 1-methylpiperid-3-one <b>42</b>, which was subsequently treated with bis-(2-methoxyethyl)aminosulfur trifluoride to give 3,3-difluoro-substituted piperidine <b>43</b>. Hydrogenolytic deprotection of the Cbz group provided the aniline <b>44</b>. The electron withdrawing effect of the difluoro group of <b>38</b> did not affect FMS activity but resulted in poor solubility and low liver microsomal stability (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Compounds containing 1,3-substitution patterns on the C-2 aniline were also explored (<b>39</b>) and were potent FMS inhibitors. However, <b>39</b> demonstrated a <i>C</i><sub>max</sub> of only 0.4 μM after oral administration in rat and had a moderate clearance rate (20 mL/min/kg) (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0010.jpeg" id="gs3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, toluene, ethanol, 110 °C; (b) MeI, acetone, 50 °C; (c) NaBH<sub>4</sub>, 0 °C to rt; (d) 6 N HCl, THF, 60 °C; (e) Deoxo-Fluor, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (f) H<sub>2</sub>, Pd/C, methanol, rt.</p></p></figure><div class="NLM_p">Having identified the <i>N</i>-methylpiperidine tail as an optimal C-2 substitution, N-8 substitution was next investigated (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). When bound to FMS, N-8 substituents occupy a hydrophobic pocket, which can accommodate a variety of aromatic (<b>37</b>, <b>45</b>−<b>47</b>) or aliphatic rings (<b>25</b>, <b>48</b>−<b>49</b>). The 4-ethylphenyl analogue <b>45</b> was equipotent to indan analogue <b>37</b> and had a slightly improved rat pharmacokinetic profile compared to <b>37</b> in terms of oral exposure and clearance rate (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). The 3-ethylphenyl analogue <b>46</b> was comparable to <b>37</b> and <b>45</b> in activity. The loss in activity by incorporation of nitrogen into the indan phenyl ring (<b>47)</b> confirmed the importance of hydrophobic substitution at the N-8 position. Aliphatic rings were well tolerated, and the bulkier dimethyl cyclohexyl analogue <b>48</b> was more potent than the cyclohexyl analogue <b>49</b>. A rat tolerability study was carried out to differentiate compounds <b>37</b> and <b>45</b>. While <b>37</b> was well tolerated at doses of 10 and 40 mg/kg, rats treated with <b>45</b> showed nonspecific signs of toxicity such as mucoid feces, cold body, and weight loss (data not shown).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Effect of N-8 Substitution on Biological Activity and Rat/Human Liver Microsomal Stability</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0014.gif" alt="" id="gr11" /></img><div class="scrollable-table-wrap"><table class="table single-image frame_topbot"><colgroup><col align="left" /></col></colgroup><tbody><tr valign="top"><td align="left"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0015.gif" alt="" id="gr12" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup>a</sup><p class="last">Reported IC<sub>50</sub> values are means of three experiments. Interassay variance was <10%.</p></div><div class="footnote" id="tbl4-fn2"><sup>b</sup><p class="last">Dose−response data are the average of at least two replicates per dose.</p></div><div class="footnote" id="tbl4-fn3"><sup>c</sup><p class="last">Percentage of compound remaining after 10 min incubation in human liver microsomes.</p></div><div class="footnote" id="tbl4-fn4"><sup>d</sup><p class="last">Percentage of compound remaining after 10 min incubation in rat liver microsomes.</p></div></div></div><div class="NLM_p">Selectivity profiles of some of these FMS inhibitors against other type III receptor tyrosine kinases were obtained (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). In the enzyme assays all were potent inhibitors of FLT3 and KIT but highly selective vs PDGFR-β, Axl, IRK, TrkA, and Src. In the cell-based assays of these kinases, <b>37</b> inhibited ITD-FLT3-dependent MV-4−11 cell growth<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and SCF/KIT-dependent M-o7e cell growth<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> with mean IC<sub>50</sub> values of 80 nM and 20 nM, respectively (<i>n</i> = 4). Relative to CSF-1/FMS-dependent BMDM cell growth (IC<sub>50</sub> = 0.6 nM), this represented modest selectivity versus KIT (33-fold) and good selectivity over FLT3 (133-fold). Inhibition of KIT and FLT3 may have anti-inflammatory potential due to suppression of mast cell or dendritic cell functions, but chronic inhibition of KIT may result in anemia and myelosuppression.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Kinase Selectivity of Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead valign="middle"><tr valign="top"><th align="center" valign="middle">kinase<a class="ref internalNav" href="#tbl5-fn1" aria-label="a">a</a></th><th align="center" valign="middle"><b>17a</b> (μM)<a class="ref internalNav" href="#tbl5-fn2" aria-label="b">b</a></th><th align="center" valign="middle"><b>18a</b> (μM)</th><th align="center" valign="middle"><b>36</b> (μM)</th><th align="center" valign="middle"><b>37</b> (μM)</th></tr></thead><tbody><tr valign="top"><td align="left">FMS</td><td align="left">0.0008</td><td align="left">0.0007</td><td align="left">0.0022</td><td align="left">0.0004</td></tr><tr valign="top"><td align="left">FLT3</td><td align="left">0.001</td><td align="left">0.036</td><td align="left">0.041</td><td align="left">0.006</td></tr><tr valign="top"><td align="left">KIT</td><td align="left">0.020</td><td align="left">0.006</td><td align="left">0.013</td><td align="left">0.006</td></tr><tr valign="top"><td align="left">PDGFR-β</td><td align="left">>42</td><td align="left">5.3</td><td align="left">>2</td><td align="left">0.15</td></tr><tr valign="top"><td align="left">Axl</td><td align="left">>0.5</td><td align="left">>0.5</td><td align="left">>0.5</td><td align="left">>1</td></tr><tr valign="top"><td align="left">TrkA</td><td align="left">0.17</td><td align="left">>0.5</td><td align="left">>0.5</td><td align="left">0.5</td></tr><tr valign="top"><td align="left">IRK-β</td><td align="left">>42</td><td align="left">19.8</td><td align="left">9.3</td><td align="left">3.7</td></tr><tr valign="top"><td align="left">Src</td><td align="left">5.9</td><td align="left">1.5</td><td align="left">0.93</td><td align="left">1.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl5-fn1"><div class="footnote" id="tbl5-fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values were determined at the respective ATP K<sub>m</sub> of each kinase.</p></div><div class="footnote" id="tbl5-fn2"><sup>b</sup><p class="last">IC<sub>50</sub> values are means of three experiments. Interassay variance was <10%.</p></div></div></div><div class="NLM_p">The pharmacokinetic profiles of <b>37</b> in mouse, dog, and monkey were assessed (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). In the mouse, <b>37</b> had good bioavailability (51%), an oral <i>C</i><sub>max</sub> of 0.9 μM at a 10 mg/kg dose and a moderate clearance rate. In the dog and monkey, <b>37</b> had lower <i>C</i><sub>max</sub> levels of 0.12 and 0.06 μM, respectively. The clearance rates in both species were also high, in line with its low liver microsomal stability (51% and 14% remaining after 10 min incubation in dog and monkey liver microsomes, respectively).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic Profiles of <b>37</b> in Multiple Species</div></div></div><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead valign="middle"><tr valign="top"><th align="center" valign="bottom">species<a class="ref internalNav" href="#tbl6-fn1" aria-label="a">a</a></th><th align="center" valign="middle" char="."><i>C</i><sub>max</sub>po (μM)</th><th align="center" valign="middle" char="."><i>t</i><sub>1/2</sub>po (h)</th><th align="center" valign="middle" char="."><i>t</i><sub>1/2</sub>iv (h)</th><th align="center" valign="middle" char="."><i>Cl</i>(mL/min/kg)</th><th align="center" valign="middle" char="."><i>Vd</i><sub>ss</sub>(L/kg)</th><th align="center" valign="middle" char="."><i>F</i>(%)</th></tr></thead><tbody><tr valign="top"><td align="left">rat</td><td align="char" char=".">1.6</td><td align="char" char=".">6.9</td><td align="char" char=".">4.6</td><td align="char" char=".">11</td><td align="char" char=".">4.3</td><td align="char" char=".">100</td></tr><tr valign="top"><td align="left">mouse</td><td align="char" char=".">0.9</td><td align="char" char=".">4</td><td align="char" char=".">1.8</td><td align="char" char=".">34</td><td align="char" char=".">3.6</td><td align="char" char=".">51</td></tr><tr valign="top"><td align="left">dog</td><td align="char" char=".">0.12</td><td align="char" char="."> </td><td align="char" char=".">9.3</td><td align="char" char=".">30</td><td align="char" char=".">20.3</td><td align="char" char=".">33</td></tr><tr valign="top"><td align="left">monkey</td><td align="char" char=".">0.06</td><td align="char" char="."> </td><td align="char" char=".">6.6</td><td align="char" char=".">48.7</td><td align="char" char=".">22.6</td><td align="char" char=".">16.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl6-fn1"><div class="footnote" id="tbl6-fn1"><sup>a</sup><p class="last">Administrated at 10 mg/kg po, 2 mg/kg iv for all species in 20% hydroxypropyl-β-cyclodextrin (HPβCD).</p></div></div></div><div class="NLM_p">Compound <b>37</b> was further evaluated in in vivo studies. A pharmacodynamic model was developed based on the ability of CSF-1 to elevate macrophage c-fos mRNA.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Because significant numbers of macrophages are present in the spleen, spleens of mice were assessed for c-fos mRNA following intravenous administration of 1 μg/mouse recombinant CSF-1. Splenic c-fos mRNA was increased by approximately 10-fold within 15 min after CSF-1 induction (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) and returned to baseline by 30 min (data not shown). An oral dose of 3 mg/kg of <b>37</b>, administered 6 h prior to the CSF-1 challenge, reduced c-fos mRNA induction by 90% (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). The corresponding plasma concentration of <b>37</b> at the 6 h time point was 0.29 μM.</div><figure id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0001.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. In vivo inhibition of FMS 6 h after dosing mice with <b>37</b>. B6C3R1 mice were dosed orally with <b>37</b> 6 h prior to a tail-vein injection of 1 μg recombinant CSF-1. Fifteen minutes following the CSF-1 challenge, mice were sacrificed and the functional status of FMS signaling was assessed by assay of c-fos mRNA in spleens as described in the <a class="ref internalNav" href="#sec3_1" aria-label="Experimental Section">Experimental Section</a>.></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>37</b> was further evaluated in rats using streptococcal cell wall (SCW)-induced and adjuvant-induced models of arthritis. Both models are responsive to prednisone and anti-TNF therapy, and adjuvant arthritis is responsive to methotrexate.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> SCW-induced polyarthritis in female Lewis rats is characterized by an acute, transient phase (days 3−7) that is complement- and neutrophil-dependent, which evolves into a chronic erosive phase (after day 10) that is dependent on the development of specific T cell immunity to SCW.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> An important characteristic of the SCW model is the predominance of macrophages in the inflamed synovial pannus<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> that accurately models macrophage involvement in rheumatoid arthritis.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> For this reason, the chronic phase of the SCW-induced arthritis model was selected to investigate the ability of <b>37</b> to reduce chronic joint inflammation and bone erosion. Twice-daily oral dosing was initiated on day 19 when chronic inflammation was well established, and <b>37</b> was highly effective at reversing established ankle swelling at doses of 10, 3, or 1 mg/kg (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). The progressive increase in ankle thickness in the vehicle-treated group was delayed in rats dosed with 0.3 mg/kg of <b>37</b>.</div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0002.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>37</b> reversed ankle swelling during the chronic phase of SCW-induced arthritis. Arthritis was induced in rats by a single ip injection of SCW on day 0. Twice daily oral dosing with vehicle or <b>37</b> was commenced on day 19 when chronic inflammation was well established. Ankle thickness was measured using calipers as described in the <a class="ref internalNav" href="#sec3_1" aria-label="Experimental Section">Experimental Section</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>37</b> was less effective in preventing the progressive inflammatory response in adjuvant-induced arthritis. When dosed twice daily from the onset of arthritis (day 8), <b>37</b> reduced paw swelling partially at 10 mg/kg, with lower doses showing no improvement (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). Despite the limited effect on inflammation, microscopic examination revealed preservation of the bones of the tibiotarsal joint. Preservation was nearly complete at 1 mg/kg, and good partial protection was observed even at 0.33 mg/kg (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). By day 21, osteoclasts were abundant in the pannus and trabecular bone of adjuvant rats treated with vehicle. In contrast, there was minimal evidence of reactive osteoclastogenesis in the tibiotarsal joints of rats dosed with 1 mg/kg of <b>37</b>. Microradiographs of representative paws further confirmed the impressive protection of bone structures by <b>37</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). In vehicle-treated rats, foci of increased radiotranslucency were apparent in the distal tibia, while calcanus, talus, and tarsus bones were frequently difficult to delineate. In contrast, bones from animals treated with <b>37 (</b>1 mg/kg) were similar to those of disease-free rats. Mean plasma levels taken 7 h after the last dose of 0.33, 1, and 3 mg/kg were 0.014, 0.055, and 0.189 μM, respectively.</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0003.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>37</b> reduced paw swelling in adjuvant-induced arthritis. Adjuvant arthritis was induced in rats as described in the <a class="ref internalNav" href="#sec3_1" aria-label="Experimental Section">Experimental Section</a>. Twice daily oral dosing with vehicle or <b>37</b> was commenced on day 8. Calipers were used to measure ankle thickness daily (mean ± SEM). **<i>p</i> < 0.001, * <i>p</i> < 0.01 vs arthritis + vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Effect of <b>37</b> on Swelling, Bone Erosion, and Osteoclast Counts in Adjuvant Arthritis</div></div></div><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead valign="middle"><tr valign="top"><th align="center" valign="bottom">treatment</th><th align="center" valign="bottom">percent inhibition of ankle swelling, AUC</th><th align="center" valign="bottom">bone erosion score<a class="ref internalNav" href="#tbl7-fn1" aria-label="a">a</a></th><th align="center" valign="bottom">osteoclast counts<a class="ref internalNav" href="#tbl7-fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top"><td colspan="4" align="center">Experiment no. 1<a class="ref internalNav" href="#tbl7-fn3" aria-label="c">c</a></td></tr><tr valign="top"><td align="left">vehicle (20% HPβCD)</td><td align="left"> </td><td align="left">4.88 (0.41)</td><td align="left">29.3 (5.2)</td></tr><tr valign="top"><td align="left"><b>37</b>, 1 mg/kg</td><td align="left">−0.9</td><td align="left">0.6 (0.6)**</td><td align="left">0.2 (0.1)**</td></tr><tr valign="top"><td align="left"><b>37</b>, 3 mg/kg</td><td align="left">−0.9</td><td align="left">0 (0)**</td><td align="left">0.1 (0.1)**</td></tr><tr valign="top"><td align="left"><b>37</b>, 10 mg/kg</td><td align="left">17*</td><td align="left">0 (0)**</td><td align="left">0 (0)**</td></tr><tr valign="top"><td colspan="4" align="center">Experiment no. 2<a class="ref internalNav" href="#tbl7-fn3" aria-label="c">c</a></td></tr><tr valign="top"><td align="left">vehicle (20% HPβCD)</td><td align="left"> </td><td align="left">4.25 (0.41</td><td align="left">29.9 (3.2)</td></tr><tr valign="top"><td align="left"><b>37</b>, 0.33 mg/kg</td><td align="left">7</td><td align="left">1.88 (0.23)**</td><td align="left">9.9 (2.4)*</td></tr><tr valign="top"><td align="left"><b>37</b>, 1 mg/kg</td><td align="left">2</td><td align="left">0 (0)**</td><td align="left">0 (0)**</td></tr><tr valign="top"><td align="left"><b>37</b>, 3 mg/kg</td><td align="left">8</td><td align="left">0 (0)**</td><td align="left">0 (0)**</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl7-fn1"><div class="footnote" id="tbl7-fn1"><sup>a</sup><p class="last">Based on microscopic examination of H and E stained sections and a 5-point scale described in <a class="ref internalNav" href="#sec3_1" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="footnote" id="tbl7-fn2"><sup>b</sup><p class="last">Osteoclast counts (Five, 400× fields) were performed on ankles in the areas of greatest bone resorption.</p></div><div class="footnote" id="tbl7-fn3"><sup>c</sup><p class="last">Groups (<i>n</i> = 8) were dosed with vehicle or <b>37</b> orally twice daily beginning on day 8 until sacrifice on day 21. Values represent group means and (SEM). *<i>p</i> < 0.05 vs vehicle; **<i>p</i> < 0.001 vs vehicle (Student’s <i>t</i> test).</p></div></div></div><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0004.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>37</b> prevented the development of bone lesions in the tibial tarsal joint. Following necropsy on day 21, microradiographic images were prepared of tibial tarsal joints. Representative images are shown obtained from a disease-free rat (A), a rat with adjuvant-arthritis treated with vehicle (B), and a rat with adjuvant-arthritis treated with 1 mg/kg <b>37</b> (C). Note the presence of radiotranslucent pits (arrows) in the tibia, calcanus, talus, and tarsus of the rat with adjuvant-arthritis treated with vehicle, while the tibial tarsal joint of the rat with adjuvant-arthritis treated with <b>37</b> was difficult to discern from the disease-free rat.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The disease modifying activity of <b>37</b> in adjuvant arthritis was further examined in combination with methotrexate, the standard first line therapy for RA. A low dose of <b>37</b> (0.33 mg/kg) was administered alone or in combination with an efficacious dose of methotrexate and compared to methotrexate alone. As before, 0.33 mg/kg of <b>37</b> alone did not reduce ankle swelling (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). However, <b>37</b> significantly reduced to nearly undetectable levels the mild swelling and inflammation otherwise present in rats administered methotrexate alone. By day 20, swelling was evident in only 2 of 16 ankles in the combination group compared to 12 of 16 joints in the methotrexate alone group.</div><figure id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0005.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>37</b> reduced ankle swelling in adjuvant-induced arthritis in combination with methotrexate. Adjuvant arthritis was induced in rats as described in the <a class="ref internalNav" href="#sec3_1" aria-label="Experimental Section">Experimental Section</a>. Oral dosing was commenced on day 8. Blue squares, dosed twice daily with 20% HPβCD and once daily with 1% carboxymethylcelluose (CMC); black squares, dosed twice daily with 0.33 mg/kg <b>37</b> in 20% HPβCD and once daily with 1% CMC; white squares, dosed twice daily with 20% HPβCD and once daily with 0.1 mg/kg methotrexate in 1% CMC; red squares, dosed twice daily with 0.33 mg/kg <b>37</b> in 20% HPβCD and once daily with 0.1 mg/kg methotrexate in 1% CMC. Calipers were used to measure ankle thickness daily (mean ± SEM). *<i>p</i> < 0.05 vs methotrexate alone.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The anti-inflammatory effects of <b>37</b> in the SCW-induced and adjuvant-induced arthritis models are consistent with the requirement for FMS for optimal macrophage survival and proliferation. Indeed, mice that are genetically deficient in FMS or CSF-1 lack synovial macrophages<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and CSF-1-deficient mice are highly resistant to collagen-induced arthritis.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41, 42)</a> Similarly, the bone preserving effect of <b>37</b> is consistent with the requirement for FMS/CSF-1 for osteoclast differentiation revealed by severe osteopetrosis of the FMS-deficient mice<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and the ability of FMS neutralizing antibody to block TNF-induced osteolysis.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> We therefore attribute the therapeutic effects of <b>37</b> primarily to FMS inhibition, although we cannot exclude the possibility that inhibition of secondary targets may contribute to the pharmacology of <b>37</b>. Indeed, inhibition of KIT or FLT3 may augment the beneficial pharmacology of <b>37</b>, although at the cellular level the selectivity of <b>37</b> for FMS was 33- and 133-fold vs KIT and FLT3, respectively. Other FMS inhibitors (i.e., <b>1</b>, <b>2</b>, and <b>8</b>) have demonstrated efficacy in rodent models of arthritis despite nonoverlapping selectivity profiles, further supporting FMS as a promising target for the treatment of rheumatoid arthritis.<a onclick="showRef(event, 'ref16 ref17 cit23b'); return false;" href="javascript:void(0);" class="ref ref16 ref17 cit23b">(16, 17, 23b)</a> At present, the primary advantage of <b>37</b> may be its exemplary potency.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00148" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00148" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A novel class of FMS kinase inhibitors based on the pyrido[2,3-<i>d</i>]pyrimidin-5-one scaffold was developed. Introduction of a C-6 hydroxamate group resulted in significant potency increases in the cell-based BMDM assay and an improved pharmacokinetic profile. The cocrystal structure of <b>25</b> in FMS revealed a complex hydrogen-bonding network between the hydroxamate group and the kinase active site, which is believed to contribute to the improved potency. Further optimization afforded <b>37</b>. Among known FMS inhibitors, <b>37</b> demonstated exemplary in vitro potency together with outstanding rodent PK. Compound <b>37</b> reversed established ankle swelling in the chronic phase of SCW arthritis and enhanced the anti-inflammatory activity of methotrexate in adjuvant arthritis as well as providing profound suppression of bone erosion as a single agent. Collectively, the data provide strong preclinical validation for testing the therapeutic utility of FMS inhibitors in RA, both for the treatment of signs and symptoms and to prevent the loss of function resulting from joint erosions.</div></div><div id="sec3_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17012" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17012" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Chemistry</h3><div class="NLM_p last">Reagents and solvents were obtained from commercial suppliers and used without further purification. Flash chromatography was performed using Fisher Chemical Silica Gel Sorbent (230−400 mesh, grade 60). Preparative thin-layer chromatography was performed on Analtech Silica Gel GF plates (1000 or 2000 μm, 20 cm × 20 cm). Preparative HPLC was performed on a Gilson 215 HPLC system using a C-18 YMC ODS-A 5m 30 × 100 mm, 120 A column with a flow rate of 32 mL/min. The solvents, both acetonitrile (MeCN) and water, contain 0.1% of trifluoroacetic acid (TFA, v/v). Hydrogenation was performed in a H-Cube<sup></sup> (ThalesNano, Inc., Budapest, Hungary). <sup>1</sup>H NMR spectra were recorded on a Bruker B-ACS-120 (400 MHz) spectrophotometer at rt. Chemical shifts are given in ppm (δ), coupling constants (<i>J</i>) are in hertz (Hz), and signals are designed as follows: (s) singlet, (d) doublet, (t) triplet, (q) quartet, (m) multiplet, (br s) broad singlet, (dd) doublet of doublet, (dt) doublet of triplet. Elemental analysis was performed by Quantitative Technologies, Inc., Whitehouse, NJ. LC-MS was performed on a system consisting of an atmospheric pressure ionization (API) source on a Finnigan LCQ ion trap mass spectrometer, an Agilent 1100 DAD UV detector (214 nm wavelength), an Agilent 1100-LC binary gradient pumping system, a Gilson 215 configured as an autosampler, and a Zorbax SB-C18 HPLC column (5 μm, 50 mm × 2.1 mm). The purities of the key target compounds were determined on the Finnigan LCQ instrument, which gave both the MS and LC trace of the compound in an 11 min run. The HPLC method used was as follows: column, Zorbax SB-C18 HPLC column (5 μm, 50 mm × 2.1 mm); column temperature, ambient; flow rate, 0.5 mL/min; gradient, 5% acetonitrile in water to 100% acetonitrile in water in 10 min, both MeCN and water contain 0.1% of TFA, v/v.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> 3-(Indan-5-ylamino)-propionic Acid Ethyl Ester (<b>11</b>)</h3><div class="NLM_p last">Tetrabutylammonium bromide (200 mg) was added to a mixture of 5-aminoindan (5 g, 37.6 mmol), ethyl 3-chloropropionate (4.7 mL, 37.6 mmol), and potassium carbonate (5.2 g, 37.6 mmol). The mixture was stirred at 100 °C for 16 h. After cooling to rt, the mixture was extracted into ethyl acetate, washed with water and brine, and dried with sodium sulfate (Na<sub>2</sub>SO<sub>4</sub>). After evaporation of the solvent and chromatography on silica (eluted with ethyl acetate/hexanes, 1:20 to 1:10, v/v), the title compound was obtained as brown oil (6.2 g, 71%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.04 (d, <i>J</i> = 7.91 Hz, 1H), 6.56 (s, 1H), 6.45 (dd, <i>J</i> = 1.98, 7.91 Hz, 1H), 4.15 (q, <i>J</i> = 7.09 Hz, 2H), 3.44 (t, <i>J</i> = 6.43 Hz, 2H), 2.82 (q, <i>J</i> = 7.69 Hz, 4H), 2.61 (t, <i>J</i> = 6.43 Hz, 2H), 1.94 − 2.13 (m, 2H), 1.27 (t, <i>J</i> = 7.09 Hz, 3H).</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 4-[(2-Ethoxycarbonylethyl)-indan-5-yl-amino]-2-methylsulfanylpyrimidine-5-carboxylic Acid Ethyl Ester (<b>12</b>)</h3><div class="NLM_p last">To a solution of <b>11</b> (5 g, 21.4 mmol) and ethyl 4-chloro-2-methylthio-5-pyrimidinecarboxylate (5 g, 21.4 mmol) in 40 mL of <i>n</i>-butanol was added triethylamine (3 mL, 21.4 mmol). The solution was stirred at rt for 2 days. The solvent was removed under vacuum. The residue was extracted into EtOAc, washed with water and brine, and dried with Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed and the residue was purified by flash chromatography (eluted with ethyl acetate/hexanes, 1:10 to 1:6, v/v) to yield the title compound as a white solid (8.2 g, 90%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.24 (s, 1H), 7.17 (d, <i>J</i> = 7.91 Hz, 1H), 6.96 (s, 1H), 6.85−6.92 (m, 1H), 4.28−4.39 (m, 2H), 4.05 (q, <i>J</i> = 7.03 Hz, 2H), 3.57 (q, <i>J</i> = 6.92 Hz, 2H), 2.86 (t, <i>J</i> = 7.42 Hz, 4H), 2.63−2.72 (m, 2H), 2.55 (s, 3H), 2.00−2.13 (m, 2H), 1.19 (t, <i>J</i> = 7.25 Hz, 3H), 1.01 (t, <i>J</i> = 7.25 Hz, 3H).</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 8-Indan-5-yl-2-methylsulfanyl-5-<i>oxo</i>-5,6,7,8-tetrahydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Ethyl Ester (<b>13</b>)</h3><div class="NLM_p last">To sodium (25 wt % dispersion in paraffin wax, 1.6 g, 16.9 mmol) was added <i>t</i>-butanol (30 mL) under N<sub>2</sub> with stirring. After 10 min, a solution of <b>12</b> (6.6 g, 15.4 mmol) in 40 mL of toluene was added to the sodium <i>t</i>-butoxide solution. The mixture was then heated at 90 °C for 30 min. The solution was cooled and poured into crushed ice. The solution was adjusted to pH 7 using concentrated aq HCl. The precipitates were extracted into ethyl acetate (2 × 30 mL). The solvent was evaporated under vacuum and the product (bright-yellow solid, 4 g, 62%) was recrystallized from isopropanol. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) indicated that the presence of both enol and keto forms in a 4:1 ratio.</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 8-Indan-5-yl-2-methylsulfanyl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Ethyl Ester (<b>14</b>)</h3><div class="NLM_p last">To a solution of <b>13</b> (0.32 g, 0.84 mmol) in 5 mL of methylene chloride (CH<sub>2</sub>Cl<sub>2</sub>) was added bromine (43 μL, 0.84 mmol) slowly under N<sub>2</sub>. The solution was stirred at rt for 2 h. The solvent was removed under vacuum without heating. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (2 mL), to which was added triethylamine (234 μL, 1.68 mmol) in 1 mL of CH<sub>2</sub>Cl<sub>2</sub>. The solution was stirred at rt for 4 h. The solvent was evaporated and the residue was purified by flash chromatography (eluted with ethyl acetate/hexanes, 1:5 to 2:5, v/v). The title compound was obtained as a white solid (0.30 g, 94%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.42 (s, 1H), 8.59 (s, 1H), 7.37 (d, <i>J</i> = 7.91 Hz, 1H), 7.23−7.25 (m, 1H), 7.16 (d, <i>J</i> = 7.91 Hz, 1H), 4.39 (q, <i>J</i> = 7.14 Hz, 2H), 2.96−3.05 (m, 4H), 2.33 (s, 3H), 2.16−2.25 (m, 2H), 1.40 (t, <i>J</i> = 7.09 Hz, 3H).</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 8-Indan-5-yl-2-methanesulfonyl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Ethyl Ester (<b>15</b>)</h3><div class="NLM_p last">To a solution of <b>14</b> (0.3 g, 0.79 mmol) in 5 mL of CH<sub>2</sub>Cl<sub>2</sub>, was added 3-chloroperoxybenzoic acid (<i>m-</i>CPBA, 69.5%, 431 mg, 1.73 mmol) portionwise. The solution was stirred at rt for 3 h. An aqueous solution of 10% sodium thiosulfate (2 mL) was added to quench the reaction. After 30 min, saturated sodium bicarbonate solution (10 mL) was added, and the aqueous solution was extracted by CH<sub>2</sub>Cl<sub>2</sub> (2 × 10 mL). The combined organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated and the residue was purified by flash chromatography (eluted with ethyl acetate/hexanes, 1:3 to 2:3, v/v). The title compound was obtained as an off-white solid (0.22 g, 67%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.74 (s, 1H), 8.70 (s, 1H), 7.39 (d, <i>J</i> = 7.91 Hz, 1H), 7.25 (s, 1H), 7.12−7.21 (m, 1H), 4.38 (q, <i>J</i> = 7.25 Hz, 2H), 3.19 (s, 3H), 2.93−3.06 (m, 4H), 2.11−2.27 (m, 2H), 1.38 (t, <i>J</i> = 7.25 Hz, 3H).</div></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 8-Indan-5-yl-2-{4-[2-(4-methylpiperazin-1-yl)-ethyl]phenylamino}-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Ethyl Ester (<b>16a</b>)</h3><div class="NLM_p last">The mixture of 4-[2-(4-methylpiperazin-1-yl)-ethyl]-phenylamine (53 mg, 0.24 mmol) and <b>15</b> (100 mg, 0.24 mmol) in 1 mL of isopropanol was heated to 90 °C for 1 h. The solvent was evaporated and the residue was redissolved in a mixture of methanol and CH<sub>2</sub>Cl<sub>2</sub> (1:1, v/v) and applied to a preparative TLC plate (2000 micro). The plate was developed in NH<sub>4</sub>OH/MeOH/CH<sub>2</sub>Cl<sub>2</sub> (1:9:90, v/v/v). The title compound was obtained as a yellow solid (70 mg, 53%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.32 (br s., 1H), 8.52 (br s, 1H), 8.18 (br s, 1H), 7.40 (d, <i>J</i> = 7.43 Hz, 1H), 7.23 (br s, 3H), 7.16 (d, <i>J</i> = 7.43 Hz, 1H), 6.90 (br s, 2H), 4.35 (q, <i>J</i> = 7.04 Hz, 2H), 3.05 (t, <i>J</i> = 6.85 Hz, 2H), 2.98 (t, <i>J</i> = 7.24 Hz, 2H), 2.66−2.77 (m, 2H), 2.41−2.64 (m, 8H), 2.37 (br s, 2H), 2.29 (s, 3H), 2.14−2.26 (m, 2H), 1.36 (t, <i>J</i> = 7.04 Hz, 3H).</div></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 8-Indan-5-yl-2-[4-(2-morpholin-4-yl-ethyl)phenylamino]-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Ethyl Ester (<b>16b</b>)</h3><div class="NLM_p last">Using a similar procedure described in the preparation of <b>16a</b>, the title compound was prepared from 4-(2-morpholin-4-yl-ethyl)-phenylamine (49 mg, 0.24 mmol) and <b>15</b> (100 mg, 0.24 mmol). The title compound was obtained as a yellow solid (60 mg, 46%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.27 (s, 1H), 8.47 (s, 1H), 8.21 (br s, 1H), 7.35 (d, <i>J</i> = 7.43 Hz, 1H), 7.20 (d, <i>J</i> = 5.09 Hz, 3H), 7.11 (d, <i>J</i> = 7.43 Hz, 1H), 6.85 (br s, 2H), 4.30 (q, <i>J</i> = 7.04 Hz, 2H), 3.68 (br s, 4H), 3.00 (t, <i>J</i> = 6.85 Hz, 2H), 2.93 (t, <i>J</i> = 7.04 Hz, 2H), 2.58−2.72 (m, 2H), 2.36−2.54 (m, 6H), 2.07−2.23 (m, 2H), 1.31 (t, <i>J</i> = 7.04 Hz, 3H).</div></div><div id="sec3_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 8-Indan-5-yl-2-{4-[2-(4-methylpiperazin-1-yl)-ethyl]phenylamino}-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Amide (<b>17a</b>)</h3><div class="NLM_p last">To the solution of <b>16a</b> (20 mg, 0.036 mmol) in methanol (2 mL) was bubbled ammonia at −78 °C for 5 min in a pressure bottle. The bottle was then capped and warmed up to rt with stirring for 16 h. The solvent was evaporated to leave a yellow solid, which was purified by preparative HPLC (MeCN/H<sub>2</sub>O, 1:19 to 4:1, v/v, linear gradient over 12 min). The fractions were pooled and made basic with sat. NaHCO<sub>3</sub> solution and were then extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and filtered. The solvent was evaporated to leave a yellow solid, which was treated with 1 N aq HCl solution to give a dihydrochloride salt (5.8 mg, 30%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.48 (br s, 1H), 9.31 (s, 1H), 9.10 (s, 1H), 8.62 (s, 1H), 7.75 (m, 1H), 7.54 (m, 2H), 7.41 (m, 2H), 6.97 (br, 2H), 3.55 (m, 4H), 3.09 (t, <i>J</i> = 7.31 Hz, 2H), 3.01 (t, <i>J</i> = 7.42 Hz, 2H), 2.71 (m, 2H), 2.57 (m, 13H), 2.22 (m, 2H). Anal. (C<sub>30</sub>H<sub>35</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub>·0.35H<sub>2</sub>O) C, H, N, Cl, H<sub>2</sub>O.</div></div><div id="sec3_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 8-Indan-5-yl-2-{4-[2-(4-methylpiperazin-1-yl)-ethyl]phenylamino}-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methyl Amide (<b>17b</b>)</h3><div class="NLM_p last">To the solution of <b>16a</b> (20 mg, 0.036 mmol) in 1 mL methanol was added a solution of methylamine in THF (2 N, 2 mL). The mixture was stirred at 80 °C for 4 h. The solvent was removed by vacuum to leave a yellow solid. After a preparative HPLC purification (MeCN/H<sub>2</sub>O 1:20 to 100:0, v/v, linear gradient over 10 min), a yellow solid was obtained (5.1 mg, 26%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>/CD<sub>3</sub>OD 20:1, v/v) δ 9.61 (m, 1H), 9.29 (s, 1H), 8.75 (s, 1H), 7.35 (d, <i>J</i> = 7.83 Hz, 1H), 7.19 (m, 3H), 7.09 (d, <i>J</i> = 7.83 Hz, 1H), 6.84 (br s, 2H), 3.00−2.90 (m, 7H), 2.64 (m, 2H), 2.47 (m, 10H), 2.24 (s, 3H), 2.15 (m, 2H). Mass spectrum (LCMS, ESI pos.) calcd for C<sub>31</sub>H<sub>35</sub>N<sub>7</sub>O<sub>2</sub>, 538.29 (M + H); found, 538.2. HPLC: <i>t</i><sub>R</sub> = 4.24 min (100% pure).</div></div><div id="sec3_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 8-Indan-5-yl-2-[4-(2-morpholin-4-yl-ethyl)phenylamino]-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methyl Amide (<b>17c</b>)</h3><div class="NLM_p last">The ester <b>16b</b> (20 mg, 0.037 mmol) was converted to the methyl amide <b>17c</b> (yellow solid, 17 mg, 87%) using a similar procedure as described in the preparation of <b>17b</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.60 (br s, 1H), 9.29 (s, 1H), 8.78 (s, 1H), 7.75 (s, 1H), 7.60 (br s, 1H), 7.34 (d, <i>J</i> = 7.83 Hz, 1H), 7.20 (m, 2H), 7.12 (d, <i>J</i> = 7.43 Hz, 1H), 6.87 (br s, 2H), 3.69 (t, <i>J</i> = 4.30 Hz, 4H), 3.01 (t, <i>J</i> = 6.85 Hz, 2H), 2.88−3.06 (m, 5H), 2.61−2.73 (m, 2H), 2.38−2.55 (m, 6H), 2.16 (quin, <i>J</i> = 7.24 Hz, 2H). Mass spectrum (LCMS, ESI pos.) calcd for C<sub>30</sub>H<sub>32</sub>N<sub>6</sub>O<sub>3</sub>, 525.25 (M + H); found 525.2. HPLC: <i>t</i><sub>R</sub> = 4.66 min (100% pure).</div></div><div id="sec3_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 8-Indan-5-yl-2-{4-[2-(4-methylpiperazin-1-yl)ethyl]phenylamino}-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Ethyl Amide (<b>17d</b>)</h3><div class="NLM_p last">To the solution of <b>16a</b> (20 mg, 0.036 mmol) in 1 mL methanol was added a solution of ethylamine in THF (2 N, 2 mL). The mixture was stirred at 80 °C for 16 h. The solvent was removed by vacuum to leave a yellow solid. After a preparative HPLC purification (MeCN/H<sub>2</sub>O 1:20 to 100:0, v/v, linear gradient over 10 min), a yellow solid was obtained (7.1 mg, 36%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>/CD<sub>3</sub>OD 20:1 v/v) δ 9.69 (br s, 1H), 9.37 (s, 1H), 8.84 (br s, 1H), 7.41 (d, <i>J</i> = 7.83 Hz, 1H), 7.26 (s, 3H), 7.17 (d, <i>J</i> = 7.83 Hz, 1H), 6.85 (br s, 2H), 3.50 (q, <i>J</i> = 7.24 Hz, 2H), 3.05 (t, <i>J</i> = 7.04 Hz, 2H), 2.98 (t, <i>J</i> = 7.04 Hz, 2H), 2.66−2.82 (m, 4H), 2.38−2.64 (m, 8H), 2.31 (s, 3H), 2.12−2.28 (m, 2H), 1.27 (t, <i>J</i> = 7.24 Hz, 3H). Mass spectrum (LCMS, ESI pos.) calcd for C<sub>32</sub>H<sub>37</sub>N<sub>7</sub>O<sub>2</sub>, 553.30 (M + H); found 553.3. HPLC: <i>t</i><sub>R</sub> = 4.56 min (100% pure).</div></div><div id="sec3_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 8-Indan-5-yl-2-{4-[2-(4-methylpiperazin-1-yl)ethyl]phenylamino}-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid (2-Hydroxyethyl)amide (<b>17e</b>)</h3><div class="NLM_p last">To a solution of <b>16a</b> (25 mg, 0.045 mmol) in methanol (1 mL) was added 2-aminoethanol (0.5 mL). The sealed vial was heated at 110 °C overnight. The solvent was evaporated under vacuum, and the residue was purified by preparative HPLC (MeCN/ H<sub>2</sub>O 1:19 to 4:1, v/v, linear gradient over 12 min). The title compound was obtained as an off-white solid (22.8 mg, TFA salt, 64%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>/CD<sub>3</sub>OD 10:1, v/v) δ 9.30(s, 1H), 8.75 (s, 1H), 7.38 (d, <i>J</i> = 7.83 Hz, 1H), 7.22 (m, 3H), 7.15 (d, <i>J</i> = 7.83 Hz, 1H), 6.90 (br. s, 2H), 3.72 (t, <i>J</i> = 5.28 Hz, 2H), 3.55 (t, <i>J</i> = 5.28 Hz, 2H), 2.90 (m, 4H), 2.30−2.80 (m, 15H), 2.18 (m, 2H). Mass spectrum (LCMS, ESI pos.) calcd for C<sub>32</sub>H<sub>37</sub>N<sub>7</sub>O<sub>3</sub>, 568.30 (M + H); found, 568.3. HPLC: <i>t</i><sub>R</sub> = 4.03 min (100% pure).</div></div><div id="sec3_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 8-Indan-5-yl-2-{4-[2-(4-methylpiperazin-1-yl)ethyl]phenylamino}-5-<b>oxo</b>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>18a</b>)</h3><div class="NLM_p last">To a mixture of <b>16a</b> (10 mg, 0.018 mmol) and methoxyamine hydrochloride (141 mg) in methanol (0.5 mL) was added triethylamine (1 mL). The sealed vial was stirred at 100 °C for 12 h. After cooling, water (20 mL) was added and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (30 mL). The organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under vacuum and the residue was purified by preparative HPLC (MeCN/ H<sub>2</sub>O 1:19 to 4:1, v/v linear gradient over 12 min). The fractions were pooled, made basic with sat. NaHCO<sub>3</sub> solution, and were then extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and filtered. The solvent was evaporated to leave a yellow solid, which was treated with 1 N HCl solution to give a dihydrochloride salt (yellow solid, 8.6 mg, 86%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.98 (s, 1H), 9.32 (d, <i>J</i> = 4.30 Hz, 1H), 8.83 (br s, 1H), 8.01 (br s, 1H), 7.40 (d, <i>J</i> = 7.43 Hz, 1H), 7.24 (br. s, 3H), 7.14 (d, <i>J</i> = 6.65 Hz, 1H), 6.90 (br s, 2H), 3.88 (s, 3H), 3.05 (t, <i>J</i> = 6.85 Hz, 2H), 2.97 (t, <i>J</i> = 7.43 Hz, 3H), 2.66−2.78 (m, 2H), 2.41−2.65 (m, 10H), 2.31 (s, 3H), 2.21 (quin, <i>J</i> = 7.34 Hz, 2H). Mass spectrum (LCMS, ESI pos.) calcd for C<sub>31</sub>H<sub>35</sub>N<sub>7</sub>O<sub>3</sub>, 554.28 (M + H); found, 554.2. Anal. (C<sub>31</sub>H<sub>37</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>3</sub>·3H<sub>2</sub>O) C, H, N, Cl.</div></div><div id="sec3_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 8-Indan-5-yl-2-{4-[2-(4-methylpiperazin-1-yl)ethyl]phenylamino}-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Ethoxyamide (<b>18b</b>)</h3><div class="NLM_p last">Using a similar procedure described in the preparation of <b>18a</b>, the title compound was prepared from ethoxyamine hydrochloride (150 mg) and <b>16a</b> (10 mg, 0.018 mmol). The title compound was obtained as a yellow solid (6 mg, 60%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.83 (s, 1H), 9.30 (s, 1H), 8.78 (s, 1H), 7.58 (br s, 1H), 7.36 (d, <i>J</i> = 7.43 Hz, 1H), 7.20 (br s, 3H), 7.10 (d, <i>J</i> = 7.43 Hz, 1H), 6.85 (br s, 2H), 4.03 (q, <i>J</i> = 7.04 Hz, 2H), 3.05 (t, <i>J</i> = 6.85 Hz, 2H), 2.95 (t, <i>J</i> = 7.42 Hz, 2H), 2.50−2.80 (m, 12H), 2.38 (s, 3H), 2.20 (m, 2H), 1.30 (t, <i>J</i> = 7.04 Hz, 3H). Mass spectrum (LCMS, ESI pos.) calcd for C<sub>32</sub>H<sub>37</sub>N<sub>7</sub>O<sub>3</sub>, 568.30 (M + H); found 568.3. HPLC: <i>t</i><sub>R</sub> = 4.41 min (100% pure).</div></div><div id="sec3_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 8-Indan-5-yl-2-{4-[2-(4-methylpiperazin-1-yl)ethyl]phenylamino}-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Isopropoxyamide (<b>18c</b>)</h3><div class="NLM_p last">Using a similar procedure described in the preparation of <b>18a</b>, the title compound was prepared from <i>O</i>-isopropylhydroxylamine hydrochloride (170 mg) and <b>16a</b> (10 mg, 0.018 mmol). The title compound was obtained as a yellow solid (4.8 mg, 46%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.83 (s, 1H), 9.35 (br. s, 1H), 8.82 (br s, 1H), 7.70 (br s, 1H), 7.41 (d, <i>J</i> = 8.22 Hz, 1H), 7.26 (br s, 3H), 7.16 (d, <i>J</i> = 7.83 Hz, 1H), 6.91 (br s, 2H), 4.28 (dt, <i>J</i> = 6.21, 12.23 Hz, 1H), 3.06 (t, <i>J</i> = 7.24 Hz, 2H), 2.99 (t, <i>J</i> = 7.24 Hz, 2H), 2.69−2.80 (m, 2H), 2.40−2.68 (m, 10H), 2.33 (s, 3H), 2.22 (quin, <i>J</i> = 7.43 Hz, 2H), 1.35 (s, 3H), 1.33 (s, 3H). Mass spectrum (LCMS, ESI pos.) calcd for C<sub>33</sub>H<sub>39</sub>N<sub>7</sub>O<sub>3</sub>, 582.31 (M + H); found, 582.2. HPLC: <i>t</i><sub>R</sub> = 4.66 min (100% pure).</div></div><div id="sec3_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 4-Methoxy-2-methylsulfanylpyrimidine-5-carboxylic Acid (<b>19</b>)</h3><div class="NLM_p last">To a suspension of ethyl 4-chloro-2-methylthio-5-pyrimidinecarboxylate (20 g, 86 mmol) in 100 mL of MeOH was added 200 mL of 1 N NaOH solution. After stirring at rt for 3 h, the mixture became a homogeneous orange solution. Ethyl acetate (100 mL) was used to extract the solution and the aqueous solution was acidified with conc aq HCl. The precipitates were twice extracted by ethyl acetate (200 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and the solvent was evaporated under vacuum to leave a white solid (16 g, 93%), which was dried under vacuum overnight. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>/CD<sub>3</sub>OD 10:1, v/v) δ 8.95 (s, 1H), 4.30 (s, 3H), 2.77 (s, 3H).</div></div><div id="sec3_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 3-(4-Methoxy-2-methylsulfanylpyrimidin-5-yl)-3-<i>oxo</i>-propionic Acid Ethyl Ester (<b>20</b>)</h3><div class="NLM_p">Acid <b>19</b> (16 g, 80 mmol) was suspended in CH<sub>2</sub>Cl<sub>2</sub> (300 mL) and cooled in an ice bath. To the stirring solution was added a drop of DMF and then oxalyl chloride (23 mL, 258 mmol) dropwise. Upon the completion of the addition, the mixture was allowed to stir at rt for 4 h. The solvent was evaporated without heating to leave a brown solid, which was used for next step without further purification.</div><div class="NLM_p last">To a solution of ethyl hydrogen malonate (23 mL, 214 mmol) in THF (150 mL) was added dropwise MeMgBr in Et<sub>2</sub>O (3 M, 143 mL, 429 mmol) under nitrogen in an ice bath. After the mixture was stirred for 20 min, a suspension of the above acid chloride in THF (300 mL) was added slowly. After being stirred at rt for 2 h, the reaction mixture was poured into ice water, acidified to pH 5−6 with conc aq HCl, and twice extracted with ethyl acetate (200 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum to afford a crude product, which was purified by flash chromatography (eluted with ethyl acetate/hexanes 1:19 to 1:9, v/v) to give a white solid (7.0 g, 28%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) indicated that the presence of both enol and keto forms in a 1:2 ratio: δ 12.64 (s, 1H), 8.85 (s, 2H), 8.84 (s, 1H), 6.03 (s, 1H), 4.25 (q, <i>J</i> = 7.17 Hz, 2H), 4.19 (q, <i>J</i> = 7.17 Hz, 4H), 4.09 (s, 3H), 4.07(s, 6H), 3.91 (s, 4H), 2.60 (s, 6H), 2.59 (s, 3H), 1.33 (t, <i>J</i> = 7.04 Hz, 3H), 1.25 (t, <i>J</i> = 7.04 Hz, 6H).</div></div><div id="sec3_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 8-Indan-2-methylsulfanyl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Ethyl Ester (<b>21</b>)</h3><div class="NLM_p last">A mixture of <b>20</b> (10 g, 37 mmol), acetic anhydride (10 mL, 100 mmol), and triethylorthoformate (10 mL, 60 mmol) was heated to reflux at 130 °C for 4 h, during which period the resulting ethyl acetate was distilled off under atmospheric pressure. After concentration under vacuum, the dark-brown oil that was obtained was diluted with THF (100 mL) and 5-aminoindan (5.5 g 39 mmol) was added. The mixture was stirred at rt for 16 h. Then K<sub>2</sub>CO<sub>3</sub> (5.6 g, 40 mmol) was added. The mixture was stirred at rt for 16 h. After an aqueous work up using CH<sub>2</sub>Cl<sub>2</sub> as extracting solvent, the organic solvent was evaporated to leave a yellow solid, which was used in the next step without further purification.</div></div><div id="sec3_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 8-Indan-2-methylsulfanyl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid (<b>22</b>)</h3><div class="NLM_p last">To a solution of <b>21</b> in 1,4-dioxane (100 mL) was added aq HCl (1 N, 120 mL). The mixture was heated to reflux for 4 h. The solution was cooled in an ice water bath, filtered, and the resulting solid was washed with water. The title compound (11.1 g, 85%) was obtained as a white solid after drying under vacuum. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 14.02 (br s, 1H), 9.50 (br s, 1H), 8.89 (s, 1H), 7.38 (d, <i>J</i> = 7.69 Hz, 1H), 7.24 (s, 1H), 7.16 (d, <i>J</i> = 7.69 Hz, 1H), 3.01 (q, <i>J</i> = 8.12 Hz, 4H), 2.34 (s, 3H), 2.15−2.25 (m, 2H).</div></div><div id="sec3_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 8-Indan-5-yl-2-methylsulfanyl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>23</b>)</h3><div class="NLM_p last">To a suspension of <b>22</b> (1.30 g, 3.68 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) at 0 °C was added a drop of DMF followed by oxalyl chloride (0.5 mL, 5.52 mmol). The solution was stirred at rt for 1 h. The solvent was evaporated under vacuum without heating, and the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (30 mL). To this solution was added methoxyamine hydrochloride (0.52 g, 6 mmol), followed by slow addition of triethylamine (1.4 mL, 10 mmol) at 0 °C. The solution was stirred at 0 °C for 10 min and rt for 1 h. Water was added and the aqueous solution was twice extracted with CH<sub>2</sub>Cl<sub>2</sub> (200 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum to afford a crude product, which was purified by recrystallization from ethyl acetate/hexanes (2:1, v/v). The title compound was obtained as an off-white solid (1.35 g, 96%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.84 (s, 1H), 9.45 (br s, 1H), 8.88 (s, 1H), 7.36 (d, <i>J</i> = 7.83 Hz, 1H), 7.23 (s, 1H), 7.12−7.17 (m, 1H), 3.90 (s, 3H), 3.00 (q, <i>J</i> = 7.69 Hz, 4H), 2.33 (s, 3H), 2.19 (quin, <i>J</i> = 7.43 Hz, 2H).</div></div><div id="sec3_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 8-Indan-5-yl-2-methanesulfonyl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>24</b>)</h3><div class="NLM_p last">To a stirring solution of <b>23</b> (2.4 g, 6.3 mmol)) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) was slowly added <i>m</i>CPBA (3.8 g, 15.8 mmol) at 0 °C. The mixture was then stirred at rt for 5 h. A Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (10%, 20 mL) was added to quench the reaction. The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> and the organic layer was twice washed with sat. NaHCO<sub>3</sub> solution and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated to leave a pale-yellow solid (2.3 g, 88%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.61 (s, 1H), 9.85 (s, 1H), 9.05 (s, 1H), 7.39 (d, <i>J</i> = 7.83 Hz, 1H), 7.23 (s, 1H), 7.15 (d, <i>J</i> = 8.22 Hz, 1H), 3.91 (s, 3H), 3.22 (s, 3H), 3.01 (q, <i>J</i> = 7.43 Hz, 4H), 2.20 (t, <i>J</i> = 7.63 Hz, 2H).</div></div><div id="sec3_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 8-Cyclohexyl-5-<i>oxo</i>-2-[4-(2-pyrrolidin-1-yl-ethyl)phenylamino]-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>25</b>)</h3><div class="NLM_p last">8-Cyclohexyl-2-methanesulfonyl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic acid ethyl ester (100 mg, 0.26 mmol, prepared similarly to <b>15</b>) and 4-(2-pyrrolidin-1-yl-ethyl)phenylamine (100 mg, 0.53 mmol) in AcOH (1 mL) was heated at 110 °C for 10 min. The reaction mixture was concentrated, and the remaining residue was partitioned between sat. NaHCO<sub>3</sub> and CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated. The residue was purified by preparative HPLC (MeCN/ H<sub>2</sub>O 1:10 to 10:1, v/v, linear gradient over 12 min). The ester obtained was converted to the title compound using a similar procedure described in the preparation of <b>18a</b>. A yellow solid was obtained (50 mg, 39%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.95 (s, 1H), 9.30 (s, 1H), 8.75 (s, 1H), 7.75 (br s, 1H), 7.55 (d, <i>J</i> = 8.61 Hz, 2H), 7.20 (d, <i>J</i> = 8.61 Hz, 2H), 5.08 (t, <i>J</i> = 11.93 Hz, 1H), 3.81 (s, 3H), 2.79−2.92 (m, 2H), 2.68−2.78 (m, 2H), 2.60 (br, 4H), 1.86−2.10 (m, 6H), 1.56−1.86 (m, 4H), 1.38−1.56 (m, 2H), 1.15−1.38 (m, 2H). Mass spectrum (LCMS, ESI pos.) calcd for C<sub>27</sub>H<sub>34</sub>N<sub>6</sub>O<sub>3</sub>, 491.27 (M + H); found, 491.2. HPLC: <i>t</i><sub>R</sub> = 4.39 min (100% pure).</div></div><div id="sec3_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 2-Benzylamino-8-indan-5-yl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>26</b>)</h3><div class="NLM_p last">A solution of <b>24</b> (30 mg, 0.075 mmol) and benzylamine (16 mg, 0.15 mmol) in acetic acid (1 mL) was stirred at 110 °C for 10 min. A precipitate formed upon cooling, which was filtered and washed with acetonitrile. The white solid (8 mg, 24%) was dried and no further purification was required. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 12.00 (s, 1H), 9.25 (s, 1H), 8.74 (s, 1H), 7.29−7.35 (m, 2H), 7.22−7.25 (m, 2H), 7.18 (s, 1H), 7.01−7.10 (m, 2H), 6.25 (br s, 1H), 4.34 (d, <i>J</i> = 6.26 Hz, 2H), 3.89 (s, 3H), 2.93−3.03 (m, 4H), 2.13−2.22 (m, 2H). Mass spectrum (LCMS, ESI pos.) calcd for C<sub>25</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub>, 442.18 (M + H); found, 442.1. HPLC: <i>t</i><sub>R</sub> = 6.74 min (100% pure).</div></div><div id="sec3_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 2-Butylamino-8-indan-5-yl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>27</b>)</h3><div class="NLM_p last">A solution of <b>24</b> (50 mg, 0.12 mmol) and <i>n</i>-butylamine (18 mg, 0.24 mmol) in acetic acid (1 mL) was stirred at 110 °C for 10 min. A precipitate formed upon cooling, which was filtered and washed with acetonitrile. The white solid (15 mg, 30%) was dried and no further purification was required. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.87 (s, 1H), 9.18 (s, 1H), 8.76 (s, 1H), 7.34 (d, <i>J</i> = 7.83 Hz, 1H), 7.21 (s, 1H), 7.12 (d, <i>J</i> = 7.83 Hz, 1H), 3.89 (s, 3H), 3.12−3.22 (m, 2H), 2.99 (q, <i>J</i> = 7.83 Hz, 4H), 2.18 (t, <i>J</i> = 7.43 Hz, 2H), 1.44 (t, <i>J</i> = 7.24 Hz, 2H), 1.22 (dt, <i>J</i> = 7.48, 15.16 Hz, 2H), 0.80 (t, <i>J</i> = 7.43 Hz, 3H). Mass spectrum (LCMS, ESI pos.) calcd for C<sub>22</sub>H<sub>25</sub>N<sub>5</sub>O<sub>3</sub>, 408.20 (M + H); found, 408.1. HPLC: <i>t</i><sub>R</sub> = 6.91 min (100% pure).</div></div><div id="sec3_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 8-Indan-5-yl-2-(6-methoxypyridin-3-ylamino)-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>28</b>)</h3><div class="NLM_p last">A solution of <b>24</b> (50 mg, 0.12 mmol) and 6-methoxy-pyridin-3-ylamine (50 mg, 0.4 mmol) in acetic acid (1 mL) was stirred at 110 °C for 10 min. The solvent was evaporated, and the residue was purified by preparative HPLC (MeCN/ H<sub>2</sub>O 1:4 to 100:0, v/v, linear gradient over 12 min). The title compound was obtained as a yellow solid (37.2 mg, 68%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>/CD<sub>3</sub>OD 19:1, v/v) δ 9.34 (s, 1H), 8.81 (br s, 1H), 8.03 (br s, 1H), 7.70 (d, <i>J</i> = 7.83 Hz, 1H), 7.41 (d, <i>J</i> = 7.83 Hz, 1H), 7.25 (s, 1H), 7.13 (d, <i>J</i> = 7.43 Hz, 1H), 6.38 (d, <i>J</i> = 8.61 Hz, 1H), 3.90 (s, 3H), 2.95−3.12 (m, 4H), 2.57 (br s, 3H), 2.23 (quin, <i>J</i> = 7.43 Hz, 2H). Mass spectrum (LCMS, APCI pos.) calcd for C<sub>24</sub>H<sub>22</sub>N<sub>6</sub>O<sub>4</sub>, 459.17 (M + H); found, 459.1. HPLC: <i>t</i><sub>R</sub> = 6.17 min (100% pure).</div></div><div id="sec3_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 8-Indan-5-yl-2-[4-(2-morpholin-4-yl-ethyl)phenylamino]-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>29</b>)</h3><div class="NLM_p last">A solution of <b>24</b> (20 mg, 0.048 mmol) and 4-(2-morpholin-4-yl-ethyl)-phenylamine (18 mg, 0.087 mmol) in acetic acid (1 mL) was stirred at 110 °C for 10 min. The solvent was evaporated, and the residue was purified by preparative HPLC (MeCN/ H<sub>2</sub>O 1:19 to 4:1, v/v, linear gradient over 12 min). The title compound was obtained as a yellow solid (8 mg, HCl salt, 31%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>/CD<sub>3</sub>OD 10:1 v/v) δ 9.30 (br s, 1H), 8.75 (br s, 1H), 7.40 (d, <i>J</i> = 7.43 Hz, 1H), 7.25−7.36 (m, 2H), 7.21 (s, 1H), 7.13 (d, <i>J</i> = 7.83 Hz, 1H), 6.93 (br s, 2H), 4.08−4.25 (m, 2H), 3.96 (d, <i>J</i> = 10.96 Hz, 2H), 3.84 (s, 3H), 3.47 (d, <i>J</i> = 12.13 Hz, 2H), 2.80−3.09 (m, 10H), 2.13−2.32 (m, 2H). Mass spectrum (LCMS, APCI pos.) calcd for C<sub>30</sub>H<sub>32</sub>N<sub>6</sub>O<sub>4</sub>, 541.24 (M + H); found, 541.2. HPLC: <i>t</i><sub>R</sub> = 4.61 min (100% pure).</div></div><div id="sec3_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 2-{4-[2-(4,4-Difluoropiperidin-1-yl)ethyl]phenylamino}-8-indan-5-yl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>30</b>)</h3><div id="sec3_29_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45">A 4,4-Difluoro-1-[2-(4-nitro-phenyl)-ethyl]-piperidine</h4><div class="NLM_p last">To the solution of the 1-(2-bromo-ethyl)-4-nitro-benzene (450 mg) and 4,4-difluoro-piperidine or 3,3-difluoro-piperidine (250 mg) in DMSO (5 mL) was added K<sub>2</sub>CO<sub>3</sub> (400 mg). The mixture was heated at 90 °C for 2 h. Water was added, and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and the filtrate concentrated and purified by flash chromatography (EtOAc/hexanes 1:5 v/v) to afford a yellow solid (200 mg). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.14 (m, 2H), 7.37 (t, 2H, <i>J</i> = 7.0), 2.91 (m, 2H), 2.68 (m, 2H), 2.62 (m, 4H), 2.00 (m, 4H).</div></div><div id="sec3_29_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46">B 4-[2-(4,4-Difluoro-piperidin-1-yl)-ethyl]-phenylamine</h4><div class="NLM_p last">4,4-Difluoro-1-[2-(4-nitro-phenyl)-ethyl]-piperidine (200 mg) was dissolved in EtOH/AcOH (6 mL, 1:1 v/v). Iron powder (200 mg) was then added. The mixture was refluxed at 100 °C for 2 h. After cooling down, the mixture was filtered through celite and washed with methanol. The solvent was evaporated, and the residue was suspended in sat. NaHCO<sub>3</sub> solution (100 mL). The suspension was extracted with CH<sub>2</sub>Cl<sub>2</sub> (100 mL) twice. The organic layers were combined and washed with brine and dried (Na<sub>2</sub>SO<sub>4</sub>). The solvent was evaporated to leave brown oil, which was used for next step without further purification.</div></div><div id="sec3_29_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47">C 2-{4-[2-(4,4-Difluoropiperidin-1-yl)ethyl]phenylamino}-8-indan-5-yl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>30</b>)</h4><div class="NLM_p last">A solution of <b>24</b> (100 mg, 0.24 mmol) and 4-[2-(4,4-difluoropiperidin-1-yl)ethyl]phenylamine (prepared similarly as <b>31</b>, 125 mg, 0.52 mmol) in acetic acid (1 mL) was stirred at 110 °C for 10 min. The solvent was evaporated, and the residue was purified by preparative HPLC (MeCN/ H<sub>2</sub>O 1:4 to 100:0, v/v, linear gradient over 12 min). The title compound was obtained as a yellow solid (75.4 mg, 55%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.96 (s, 1H), 9.37 (s, 1H), 8.83 (s, 1H), 7.42 (d, <i>J</i> = 7.83 Hz, 1H), 7.26 (s, 7H), 7.18 (d, <i>J</i> = 7.83 Hz, 1H), 6.93 (br s, 2H), 3.90 (s, 3H), 3.07 (t, <i>J</i> = 7.33 Hz, 2H), 3.01 (t, <i>J</i> = 7.33 Hz, 2H), 2.69−2.79 (m, 2H), 2.55−2.67 (m, 6H), 2.19−2.29 (m, 2H), 1.95−2.10 (m, 4H). Mass spectrum (LCMS, ESI pos.) calcd for C<sub>31</sub>H<sub>32</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub>, 575.25 (M + H); found, 575.2. HPLC: <i>t</i><sub>R</sub> = 5.02 min (100% pure).</div></div></div><div id="sec3_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 8-Indan-5-yl-5-<i>oxo</i>-2-{4-[2-(3-<i>oxo</i>-piperazin-1-yl)ethyl]phenylamino}-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>31</b>)</h3><div class="NLM_p">To a solution of 1-(2-bromo-ethyl)-4-nitro-benzene (0.6 g, 2.6 mmol) and 2-piperidinone (0.26 g, 2.6 mmol) in DMSO (10 mL) was added K<sub>2</sub>CO<sub>3</sub> (0.4 g, 3.0 mmol). The mixture was stirred at 80 °C for 4 h. Water was then added, and the mixture was twice extracted with CH<sub>2</sub>Cl<sub>2</sub> (100 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the filtrate concentrated and purified by flash chromatograghy (ethyl acetate/hexanes 1:5, v/v) to afford an off-white solid. The nitro compound was then reduced to the aniline using H-cube (1 mL/min, 10% Pd/C). 4-[2-(4-Aminophenyl)ethyl]piperazin-2-one was obtained as a yellow solid (0.42 g, 74%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.97 (d, <i>J</i> = 8.22 Hz, 2H), 6.62 (d, <i>J</i> = 8.22 Hz, 2H), 3.51 (br. s., 2H), 3.30−3.38 (m, 2H), 3.18 (s, 2H), 2.64−2.72 (m, 4H), 2.55−2.64 (m, 2H).</div><div class="NLM_p last">Using a similar procedure as described in the preparation of <b>29</b>, the title compound was prepared from <b>24</b> (25 mg, 0.06 mmol) and 4-[2-(4-aminophenyl)ethyl]piperazin-2-one (20 mg, 0.09 mmol). A yellow solid (10.9 mg, HCl salt, 31%) was obtained. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>/CD<sub>3</sub>OD 19:1, v/v) δ 9.35 (br s, 1H), 8.81 (br s, 1H), 7.44 (d, <i>J</i> = 7.83 Hz, 1H), 7.28 (br s, 3H), 7.18 (d, <i>J</i> = 7.83 Hz, 1H), 6.91 (br s, 2H), 3.90 (s, 3H), 3.34−3.42 (m, 2H), 3.21 (s, 2H), 3.08 (t, <i>J</i> = 7.24 Hz, 2H), 3.01 (t, <i>J</i> = 7.43 Hz, 2H), 2.59−2.78 (m, 6H), 2.24 (quin, <i>J</i> = 7.43 Hz, 2H). Mass spectrum (LCMS, APCI pos.) calcd for C<sub>30</sub>H<sub>31</sub>N<sub>7</sub>O<sub>4</sub>, 554.24 (M + H); found, 554.2. HPLC: <i>t</i><sub>R</sub> = 4.35 min (98.8% pure).</div></div><div id="sec3_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 8-Indan-5-yl-2-{4-[2-(4-methyl-3-oxo-piperazin-1-yl)ethyl]phenylamino}-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>32</b>)</h3><div class="NLM_p last">Using a similar procedure as described in the preparation of <b>31</b>, the title compound was prepared from <b>24</b> (80 mg, 0.19 mmol) and 4-[2-(4-aminophenyl)ethyl]-1-methylpiperazin-2-one (60 mg, 0.26 mmol). The title compound was obtained as a yellow solid (41.1 mg, 38%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.97 (s, 1H), 9.36 (br s, 1H), 8.83 (s, 1H), 7.77 (br s, 1H), 7.42 (d, <i>J</i> = 7.83 Hz, 1H), 7.27 (s, 3H), 7.10−7.20 (m, 1H), 6.92 (br s, 2H), 3.90 (s, 3H), 3.34 (t, <i>J</i> = 5.48 Hz, 2H), 3.21 (s, 2H), 3.07 (t, <i>J</i> = 7.24 Hz, 2H), 2.88−3.04 (m, 5H), 2.74 (t, <i>J</i> = 5.48 Hz, 4H), 2.54−2.65 (m, 2H), 2.23 (quin, <i>J</i> = 7.43 Hz, 2H). Mass spectrum (LCMS, APCI pos.) calcd for C<sub>31</sub>H<sub>33</sub>N<sub>7</sub>O<sub>4</sub>, 568.24 (M + H); found, 568.2. HPLC: <i>t</i><sub>R</sub> = 4.47 min (99.2% pure).</div></div><div id="sec3_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 2-[4-(2-Acetylsulfamoyl-ethyl)phenylamino]-8-indan-5-yl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>33</b>)</h3><div id="sec3_32_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51">A 2-(4-Nitro-phenyl)ethanesulfonyl Chloride</h4><div class="NLM_p last">1-(2-Bromo-ethyl)-4-nitrobenzene (3 g, 13 mmol) and potassium thioacetate (3 g, 26 mmol) in DMSO (10 mL) were stirred at rt for 3 h. EtOAc was used to dilute the reaction mixture. The organic layer was washed with water twice (2× 100 mL) and then with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated in vacuo to give a brown solid (∼3 g), which was taken up in 50 mL of acetic acid. To the stirring solution was added 20 mL of hydrogen peroxide (30% in water). The resulting yellow solution was stirred at rt overnight. Water (50 mL) was added, and the solvent was evaporated in vacuo with minimal heating. The yellow residue was dried in vacuo for two days, suspended in thionyl chloride (18 mL), and heated at reflux (80 °C) for 6 h. The volatiles were evaporated to give the title compound as a yellow solid, which was used in the next step without further purification</div></div><div id="sec3_32_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52">B 2-(4-Aminophenyl)ethanesulfonic Acid Acetylamide</h4><div class="NLM_p last">A mixture of 2-(4-nitro-phenyl)ethanesulfonyl chloride (200 mg, 0.8 mmol) and ammonium hydroxide (5 mL) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was stirred at rt for 2 h. To the reaction mixture was added CH<sub>2</sub>Cl<sub>2</sub> (100 mL) and water (100 mL). The organic fraction was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the filtrate was concentrated in vacuo. To a solution of the residue in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added pyridine (0.3 mL) and acetic anhydride (75 μL), and the reaction mixture was stirred at rt for 3 days. After an aqueous workup, the reaction mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic fractions were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the filtrate was concentrated. The residue was purified by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH 19:1, v/v). The resulting nitro compound was hydrogenated over Pd/C (10%) in methanol under atmosphere pressure. The reaction mixture was filtered, and the filtrate was concentrated to give the title compound as a pink solid (66 mg)</div></div><div id="sec3_32_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53">C 2-[4-(2-Acetylsulfamoyl-ethyl)phenylamino]-8-indan-5-yl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>33</b>)</h4><div class="NLM_p last">The title compound was prepared by reacting 2-(4-aminophenyl)ethanesulfonic acid acetylamide (15 mg, 0.062 mmol) with <b>24</b> (20 mg, 0.048 mmol) using a similar procedure as described in the preparation of <b>31</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>/CD<sub>3</sub>OD 10:1 v/v) δ 9.32 (s, 1H), 8.77 (s, 1H), 7.40 (d, <i>J</i> = 7.81 Hz 1H), 7.30 (br, 2H), 7.25 (s, 1H), 7.15 (d, <i>J</i> = 8.22 Hz, 1H), 6.90 (br, 2H), 3.85 (s, 3H), 3.58 (m, 2H), 3.00 (m, 6H), 2.20 (m, 2H), 1.95 (s, 3H). Mass spectrum (LCMS, APCI pos.) calcd for C<sub>28</sub>H<sub>28</sub>N<sub>6</sub>O<sub>6</sub>S, 577.18 (M + H); found 577.1. HPLC: <i>t</i><sub>R</sub> = 5.63 min (100% pure).</div></div></div><div id="sec3_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 8-Indan-5-yl-5-<i>oxo</i>-2-(4-piperidin-4-yl-phenylamino)-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>34</b>)</h3><div class="NLM_p last">The title compound was prepared from <b>24</b> (100 mg, 0.24 mmol) and 4-(4-amino-phenyl)-piperidine-1-carboxylic acid <i>tert</i>-butyl ester (60 mg, 0.22 mmol) using a similar procedure to that described in the preparation of <b>29</b>. The Boc group was removed by TFA. The title compound was obtained as a yellow solid (66 mg, 59%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ11.90 (br s, 1H), 9.30 (br s, 1H), 8.76 (br s, 1H), 7.54 (br s, 1H), 7.36 (d, <i>J</i> = 7.83 Hz, 1H), 7.15−7.27 (m, 3H), 7.11 (d, <i>J</i> = 8.22 Hz, 1H), 6.88 (br s, 2H), 3.83(s, 3H), 3.19 (d, <i>J</i> = 12.13 Hz, 2H), 3.02 (t, <i>J</i> = 6.65 Hz, 2H), 2.94 (t, <i>J</i> = 7.43 Hz, 2H), 2.63−2.76 (m, 2H), 2.49 (br s, 1H), 2.17 (quin, <i>J</i> = 7.24 Hz, 2H), 1.67−1.79 (m, 2H), 1.62 (br s, 2H). Mass sSpectrum (LCMS, APCI pos.) calcd for C<sub>29</sub>H<sub>30</sub>N<sub>6</sub>O<sub>3</sub>, 511.24 (M + H); found, 511.2. HPLC: <i>t</i><sub>R</sub> = 4.57 min (100% pure).</div></div><div id="sec3_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 2-{4-[1-(2-Hydroxy-ethyl)piperidin-4-yl]phenylamino}-8-indan-5-yl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>35</b>)</h3><div class="NLM_p last">To a solution of <b>34</b> (36 mg, 0.07 mmol) in DMSO (0.5 mL) was added 2-bromoethanol (7 μL, 0.1 mmol) and triethylamine (14 μL, 0.1 mmol). The solution was stirred at 80 °C for 2 h. Water was added, and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (100 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was evaporated. The product was purified by preparative HPLC (MeCN/ H<sub>2</sub>O 1:19 to 4:1, v/v, linear gradient over 12 min). A yellow solid was obtained (11 mg, 28%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.98 (s, 1H), 9.36 (br s, 1H), 8.83 (br s, 1H), 7.64 (br s, 1H), 7.43 (d, <i>J</i> = 7.83 Hz, 1H), 7.26 (s, 4H), 7.17 (d, <i>J</i> = 7.83 Hz, 1H), 6.94 (br s, 1H), 3.90 (s, 3H), 3.67 (t, <i>J</i> = 5.28 Hz, 2H), 3.08 (m, 2H), 3.00 (t, <i>J</i> = 7.43 Hz, 2H), 2.57−2.66 (m, 2H), 2.47 (t, <i>J</i> = 11.54 Hz, 1H), 2.16−2.30 (m, 4H), 1.67−1.90 (m, 6H). Mass spectrum (LCMS, ESI pos.) calcd for C<sub>31</sub>H<sub>34</sub>N<sub>6</sub>O<sub>4</sub>, 555.24 (M + H); found, 555.3. HPLC: <i>t</i><sub>R</sub> = 4.48 min (99.6% pure).</div></div><div id="sec3_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> {4-[4-(8-Indan-5-yl-6-methoxycarbamoyl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidin-2-ylamino)phenyl]piperidin-1-yl}-acetic Acid (<b>36</b>)</h3><div class="NLM_p last">To a solution of <b>34</b> (30 mg, 0.06 mmol) in DMSO (2 mL) was added <i>t</i>-butyl bromoacetate (10 μL, 0.065 mmol) and K<sub>2</sub>CO<sub>3</sub> (11 mg, 0.08 mmol). The solution was stirred at 60 °C for 1 h. Water was added, and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (100 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was evaporated. The solvent was removed under vacuum. The residue was purified by preparative TLC (developed in MeOH/CH<sub>2</sub>Cl<sub>2</sub> 1:10, v/v) to afford a yellow solid. The solid was then treated with TFA/CH<sub>2</sub>Cl<sub>2</sub> (5 mL, 1:1 v/v) at rt for 1 h. The solvent was evaporated, and the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (50 mL). The organic layer was washed with sat. NaHCO<sub>3</sub> and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated to leave a yellow solid (10.5 mg, 31%). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 9.25 (s, 1H), 8.68 (s, 1H), 7.46 (d, <i>J</i> = 7.83 Hz, 1H), 7.36 (br s, 3H), 7.24 (d, <i>J</i> = 7.83 Hz, 1H), 6.95 (br s., 2H), 4.14 (s, 2H), 3.83 (s, 3H), 3.77 (d, <i>J</i> = 12.13 Hz, 2H), 3.19−3.26 (m, 2H), 3.11 (br s, 2H), 3.01 (t, <i>J</i> = 7.24 Hz, 2H), 2.83 (br s, 1H), 2.17−2.31 (m, 2H), 1.93−2.12 (m, 4H). Mass spectrum (LCMS, APCI pos.) calcd for C<sub>31</sub>H<sub>32</sub>N<sub>6</sub>O<sub>5</sub>, 569.24 (M + H); found, 569.1. HPLC: <i>t</i><sub>R</sub> = 4.53 min (98.9% pure).</div></div><div id="sec3_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 8-Indan-5-yl-2-[4-(1-methylpiperidin-4-yl)phenylamino]-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>37</b>)</h3><div class="NLM_p last">To a well-ground mixture of <b>24</b> (4 g, 9.66 mmol) and 4-(1-methylpiperidin-4-yl)phenylamine (2.5 g, 13.5 mmol) was added 20 mL of AcOH. The mixture was stirred at 110 °C for 20 min. The AcOH was evaporated under high vacuum. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (400 mL), and the solution was washed with sat. NaHCO<sub>3</sub> and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was evaporated. The product was purified by flash chromatography, followed by recrystallization from methanol twice. The off-white solid was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and methanol and treated with aq HCl (1 N, 1 equiv). The solvent was evaporated in high vacuum to leave a yellow solid (3.8 g, 70%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.98 (s, 1H), 9.35 (br s, 1H), 8.82 (br s, 1H), 7.70 (br s, 1H), 7.41 (d, <i>J</i> = 8.22 Hz, 1H), 7.26 (br s, 3H), 7.17 (d, <i>J</i> = 7.83 Hz, 1H), 6.95 (br s, 2H), 3.90 (s, 3H), 3.07 (t, <i>J</i> = 7.04 Hz, 2H), 2.90−3.04 (m, 4H), 2.36−2.48 (m, 1H), 2.32 (s, 3H), 2.23 (quin, <i>J</i> = 7.34 Hz, 2H), 1.95−2.12 (m, 2H), 1.63−1.86 (m, 4H). Mass spectrum (LCMS, ESI pos.) calcd for C<sub>30</sub>H<sub>32</sub>N<sub>6</sub>O<sub>3</sub>, 525.25 (M + H); found, 525.2. Anal. (C<sub>30</sub>H<sub>33</sub>ClN<sub>6</sub>O<sub>3</sub>·0.3H<sub>2</sub>O) C, H, N.</div></div><div id="sec3_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 2-[4-(3,3-Difluoro-1-methylpiperidin-4-yl)phenylamino]-8-indan-5-yl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>38</b>)</h3><div id="sec3_37_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59">A [4-(3-Methoxy-pyridin-4-yl)phenyl]carbamic Acid Benzyl Ester (<b>40</b>)</h4><div class="NLM_p last">4-Bromo-3-methoxy-pyridine (400 mg, 2.13 mmol) and 4-Cbz-amino-phenyl boronic acid (576 mg, 2.13 mmol) was dissolved in a mixture of ethanol (4 mL) and toluene (2 mL). To the solution was added 2 M Na<sub>2</sub>CO<sub>3</sub> solution (5 mL). The system was purged with N<sub>2</sub>. Pd(PPh<sub>3</sub>)<sub>4</sub> (20 mg) was added under N<sub>2</sub>. The mixture was refluxed at 110 °C for 2 h. After cooling, water was added, and the reaction mixture was twice extracted with ethyl acetate (30 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by flash chromatography (eluted with ethyl acetate/hexanes 2:3, v/v). A white solid was obtained (563 mg, 79%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.35 (s, 1H), 8.30 (d, <i>J</i> = 4.80 Hz, 1H), 7.53−7.59 (m, <i>J</i> = 8.59 Hz, 2H), 7.45−7.51 (m, <i>J</i> = 8.59 Hz, 2H), 7.33−7.44 (m, 5H), 7.24 (d, <i>J</i> = 4.80 Hz, 1H), 6.79 (br s., 1H), 5.23 (s, 2H), 3.91 (s, 3H).</div></div><div id="sec3_37_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60">B [4-(5-Methoxy-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]carbamic Acid Benzyl Ester (<b>41</b>)</h4><div class="NLM_p last">To a solution of <b>40</b> (563 mg, 1.68 mmol) in acetone (10 mL) was added iodomethane (158 μL, 2.5 mmol). The mixture was stirred at 50 °C for 1 h then at rt overnight. The solvent was evaporated, and the residue was dissolved in ethanol (10 mL). To the solution cooled in an ice water bath was added sodium borohydride (95 mg, 2.5 mmol) portionwise. The solution was stirred at rt for 1 h. Water was added, and the reaction mixture was twice extracted with ethyl acetate (50 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to give the title compound as a brown solid (460 mg, 81%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.29−7.43 (m, 9H), 6.75 (br s, 1H), 5.20 (s, 2H), 3.43 (s, 3H), 3.10 (m, 2H), 2.55−2.63 (m, 2H), 2.46−2.53 (m, 2H), 2.43 (s, 3H).</div></div><div id="sec3_37_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61">C [4-(1-Methyl-3-<i>oxo</i>-piperidin-4-yl)phenyl]carbamic Acid Benzyl Ester (<b>42</b>)</h4><div class="NLM_p last">To a solution of <b>41</b> (460 mg, 1.31 mmol) in THF (10 mL) was added aq HCl (6 N, 5 mL). The mixture was stirred at 50 °C for 16 h. The solvent was evaporated, and the residue was purified by flash chromatography (CH<sub>3</sub>OH/CH<sub>2</sub>Cl<sub>2</sub> 1:9, v/v). A white solid was obtained (300 mg, 68%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.28−7.43 (m, 7H), 7.05 (d, <i>J</i> = 8.59 Hz, 2H), 6.91 (br s, 1H), 5.18 (s, 2H), 3.65 (t, <i>J</i> = 6.32 Hz, 0.5H), 3.56 (t, <i>J</i> = 6.57 Hz, 0.5H), 3.44 (t, <i>J</i> = 9.35 Hz, 1H), 3.27−3.35 (m, 1H), 2.95−3.04 (m, 1H), 2.85 (d, <i>J</i> = 13.89 Hz, 1H), 2.53 (dt, <i>J</i> = 7.07, 11.62 Hz, 1H), 2.38 (s, 3H), 2.16−2.25 (m, 2H), 1.81−1.91 (m, 0.5H), 1.68−1.73 (m, 0.5H).</div></div><div id="sec3_37_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62">D [4-(3,3-Difluoro-1-methylpiperidin-4-yl)phenyl]carbamic Acid Benzyl Ester (<b>43</b>)</h4><div class="NLM_p last">To a solution of <b>42</b> (300 mg, 0.89 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) cooled in an ice−water bath was added Deoxo-Fluor (50% in toluene, 1 mL, 2.7 mmol) slowly under argon. The mixture was stirred at rt overnight. Water was added, and the reaction mixture was twice extracted with CH<sub>2</sub>Cl<sub>2</sub> (20 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to a brown oil, which was purified by flash chromatography (eluted with CH<sub>3</sub>OH/CH<sub>2</sub>Cl<sub>2</sub> 1:9, v/v). A yellow solid was obtained (90 mg, 28%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36 (m, 7H), 7.25 (d, <i>J</i> = 8.42, 2H), 6.82 (s, 1H), 5.18 (s, 2H), 3.16 (m, 1H), 2.99 (d, <i>J</i> = 10.7, 1H), 2.82 (m, 1H), 2.38 (s, 3H), 2.33 (m, 2H), 1.84 (m, 1H).</div></div><div id="sec3_37_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63">E 4-(3,3-Difluoro-1-methylpiperidin-4-yl)phenylamine (<b>44</b>)</h4><div class="NLM_p last">Compound <b>43</b> (90 mg, 0.25 mmol) was dissolved in methanol (100 mL) and the solution was passed through an H-Cube (1 mL/min, 10% Pd/C). The solvent was evaporated to leave the title compound as pale-yellow oil (45 mg, 80%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.05 (d, <i>J</i> = 8.22 Hz, 2H), 6.69 (d, <i>J</i> = 8.61 Hz, 2H), 3.18−3.26 (m, 1H), 3.08 (d, <i>J</i> = 10.17 Hz, 1H), 2.83−3.02 (m, 1H), 2.49−2.65 (m, 1H), 2.47 (s, 3H), 2.39 (t, <i>J</i> = 12.13 Hz, 1H), 2.10−2.26 (m, 1H), 1.86 (ddd, <i>J</i> = 2.35, 4.70, 11.35 Hz, 1H).</div></div><div id="sec3_37_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64">F 2-[4-(3,3-Difluoro-1-methylpiperidin-4-yl)phenylamino]-8-indan-5-yl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>38</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>24</b> (60 mg, 0.14 mmol) and <b>44</b> (45 mg, 0.2 mmol) using the similar procedure as described in the preparation of <b>29</b>. The title compound was obtained as a yellow solid (45.3 mg, 58%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>/CD<sub>3</sub>OD, 19:1, v/v) δ 9.35 (br. s, 1H), 8.83 (br s, 1H), 7.42 (d, <i>J</i> = 7.83 Hz, 1H), 7.29 (br s, 2H), 7.26 (s, 1H), 7.17 (d, <i>J</i> = 7.83 Hz, 1H), 7.04 (br s, 2H), 3.89 (s, 3H), 3.12−3.25 (m, 1H), 2.92−3.11 (m, 5H), 2.71−2.92 (m, 1H), 2.41 (s, 3H), 2.26−2.39 (m, 1H), 2.10−2.26 (m, 4H), 1.79−1.91 (m, 1H). Mass spectrum (LCMS, ESI pos.) calcd for C<sub>30</sub>H<sub>30</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub>, 561.23 (M + H); found, 561.2. HPLC: <i>t</i><sub>R</sub> = 4.65 min (100% pure).</div></div></div><div id="sec3_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 2-[3-(1-Ethyl-3-hydroxy-piperidin-3-yl)phenylamino]-8-indan-5-yl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>39</b>). A</h3><div id="sec3_38_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 3-(3-Aminophenyl)-1-ethylpiperidin-3-ol</h4><div class="NLM_p last">To a solution of 1-ethylpiperidin-3-one (4 g, 31.4mmol) in THF (40 mL) at −10 °C is added dropwise 3-[bis(trimethylsilyl)amino]phenylmagnesium chloride (32 mL, 1 M in THF). The reaction was stirred for 1 h with gradual warming to rt. The mixture was then diluted with ethyl acetate, and a 0.5 M solution of aq HCl was added. The aqueous layer was washed once more with ethyl acetate and then was neutralized with sodium bicarbonate and concentrated in vacuo. The resulting solid was triturated with ethyl acetate and filtered. The filtrate was then concentrated in vacuo, and the crude was purified by flash chromatography (CH<sub>3</sub>OH/CH<sub>2</sub>Cl<sub>2</sub> 1:9, v/v). The title compound was obtained as yellow oil (3.7 g, 53%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.97 (t, <i>J</i> = 7.83 Hz, 1H), 6.78 (s., 1H), 6.65 (d, <i>J</i> = 8.02 Hz, 1H), 6.45 (dd, <i>J</i> = 1.56, 8.02 Hz, 1H), 2.93 (d, 1H), 2.53 (m, 6H), 2.05 (m, 2H), 1.75 (m, 2H), 1.05 (t, <i>J</i> = 7.48, 3H).</div></div><div id="sec3_38_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67">B 2-[3-(1-Ethyl-3-hydroxy-piperidin-3-yl)phenylamino]-8-indan-5-yl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>39</b>)</h4><div class="NLM_p last">To a solution of <b>24</b> (50 mg, 0.12 mmol) in DMF/1,4 dioxane (2 mL, 1:1 v/v) was added 3-(3-aminophenyl)-1-ethylpiperidin-3-ol (42 mg, 0.144 mmol) and silver triflate (40 mg, 0.157 mmol). The mixture was stirred at 107 °C for 2 h. The reaction mixture was diluted with ethyl acetate and ammonia (7 M in MeOH, 2 mL) was added. The organics were washed twice with water. The organic solvent was evaporated, and the crude was purified on prep. TLC plate (7 N ammonia in MeOH/CH<sub>2</sub>Cl<sub>2</sub> 19:1, v/v) affording the title compound as a yellow solid (22 mg, 33%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.30 (s, 1H), 8.73 (s, 1H), 7.34 (d, <i>J</i> = 7.83 Hz, 1H), 7.19 (s, 1H), 7.06 (m, 2H), 6.86 (t, <i>J</i> = 2.02 Hz, 1H), 6.75 (d, <i>J</i> = 7.83 Hz, 1H), 6.535(dd, <i>J</i> = 2.02, 7.83 Hz, 1H), 3.82 (s, 3H), 2.99 (t, <i>J</i> = 7.33 Hz, 2H), 2.92 (t, <i>J</i> = 7.33 Hz, 2H), 2.83 (d, <i>J</i> = 11.11 Hz, 1H), 2.77 (m, 2H), 2.53 (m, 4H), 2.28 (q, <i>J</i> = 6.58 Hz, 2H), 2.15 (m, 2H), 1.66 (m, 2H), 1.05 (t, <i>J</i> = 7.48, 3H) Mass spectrum (LCMS, ESI pos.) calcd for C<sub>31</sub>H<sub>34</sub>N<sub>6</sub>O<sub>4</sub>, 555.26 (M + H); found, 555.1. HPLC: <i>t</i><sub>R</sub> = 4.91 min (100% pure).</div></div></div><div id="sec3_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 8-(4-Ethylphenyl)-2-[4-(1-methylpiperidin-4-yl)phenylamino]-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>45</b>)</h3><div class="NLM_p last">8-(4-Ethylphenyl)-2-methanesulfonyl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic acid methoxyamide (1.5 g, 3.73 mmol, prepared similarly as <b>24</b> from the common intermediate <b>20</b>) and 4-(1-methyl-piperidin-4-yl)-phenylamine (1.42 g, 7.46 mmol) in AcOH (10 mL) was heated at 110 °C for 15 min. The reaction mixture was concentrated, and the remaining residue was partitioned between sat. NaHCO<sub>3</sub> and CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated. MeOH (20 mL) was added, and a fine precipitate formed that was collected by filtration to provide the title compound as an off-white solid (800 mg, 42%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.97 (s, 1H), 9.36 (s, 1H), 8.81 (s, 1H), 7.63 (br s, 1H), 7.38−7.46 (m, 2H), 7.30−7.36 (m, 2H), 7.23 (br s, 2H), 6.95 (br s, 2H), 3.90 (s, 3H), 2.97 (d, <i>J</i> = 11.35 Hz, 2H), 2.82 (q, <i>J</i> = 7.56 Hz, 2H), 2.35−2.45 (m, 1H), 2.32 (s, 3H), 1.98−2.09 (m, 2H), 1.72−1.82 (m, 4H), 1.37 (t, <i>J</i> = 7.63 Hz, 3H). Mass spectrum (LCMS, APCI pos.) calcd for C<sub>29</sub>H<sub>32</sub>N<sub>6</sub>O<sub>3</sub>, 513.25 (M + H); found, 513.2. HPLC: <i>t</i><sub>R</sub> = 4.57 min (100% pure).</div></div><div id="sec3_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 8-(3-Ethylphenyl)-2-[4-(1-methylpiperidin-4-yl)phenylamino]-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>46</b>)</h3><div class="NLM_p last">Using a similar procedure described in the preparation of <b>45</b>, the title compound was obtained as a yellow solid (34.8 mg, 67%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.98 (s, 1H), 9.36 (s, 1H), 8.82 (s, 1H), 7.66 (br s, 1H), 7.42−7.55 (m, 2H), 7.17−7.26 (m, 4H), 6.94 (br s, 2H), 3.90 (s, 3H), 3.08 (d, <i>J</i> = 10.17 Hz, 2H), 2.75 (q, <i>J</i> = 7.43 Hz, 2H), 2.41 (m, 4H), 2.15 (br s, 2H), 1.80 (br s, 4H), 1.27 (t, <i>J</i> = 7.63 Hz, 3H). Mass spectrum (LCMS, APCI pos.) calcd for C<sub>29</sub>H<sub>32</sub>N<sub>6</sub>O<sub>3</sub>, 513.25 (M + H); found, 513.2. HPLC: <i>t</i><sub>R</sub> = 4.53 min (100% pure).</div></div><div id="sec3_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 8-(6,7-Dihydro-5<i>H</i>-[1]pyrindin-3-yl)-2-[4-(1-methylpiperidin-4-yl)phenylamino]-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>47</b>)</h3><div class="NLM_p last">8-(6,7-Dihydro-5<i>H</i>-[1]pyrindin-3-yl)-2-methanesulfonyl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic acid methoxyamide (30 mg, 0.07 mmol), prepared similarly to <b>24</b> from the common intermediate <b>20</b> and 6,7-dihydro-5<i>H</i>-[1]pyrindin-3-ylamine<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a>) and 4-(1-methyl-piperidin-4-yl)-phenylamine (20 mg, 0.1 mmol) in AcOH (1 mL) was heated at 110 °C for 10 min. The reaction mixture was concentrated, and the remaining residue was partitioned between sat. NaHCO<sub>3</sub> and CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated. The residue was purified by preparative HPLC (MeCN/H<sub>2</sub>O 1:10 to 10:1, v/v, linear gradient over 12 min). A yellow solid was obtained (7.3 mg, 20%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.89 (s, 1H), 9.38 (s, 1H), 8.76 (s, 1H), 8.38−8.52 (m, 1H), 7.57 (s, 1H), 7.23 (br s, 2H), 7.00 (br s, 2H), 3.90 (s, 3H), 3.19 (t, <i>J</i> = 7.63 Hz, 2H), 3.05 (t, <i>J</i> = 7.43 Hz, 2H), 2.98 (d, <i>J</i> = 11.35 Hz, 2H), 2.42 (m, 1H), 2.24−2.36 (m, 5H), 2.04 (td, <i>J</i> = 2.93, 11.44 Hz, 2H), 1.64−1.86 (m, 4H). Mass spectrum (LCMS, APCI pos.) calcd for C<sub>29</sub>H<sub>31</sub>N<sub>7</sub>O<sub>3</sub>, 526.25 (M + H); found, 526.3. HPLC: <i>t</i><sub>R</sub> = 3.94 min (100% pure).</div></div><div id="sec3_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 8-(4,4-Dimethylcyclohexyl)-2-[4-(1-methylpiperidin-4-yl)phenylamino]-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>48</b>)</h3><div class="NLM_p last">Using a similar procedure described in the preparation of <b>47</b>, the title compound was obtained as a yellow solid (25.9 mg, 43%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 12.02 (s, 1H), 9.36 (s, 1H), 8.82 (s, 1H), 7.68 (br s., 1H), 7.55 (d, <i>J</i> = 8.61 Hz, 2H), 7.25 (d, <i>J</i> = 7.04 Hz, 2H), 4.98−5.14 (m, 1H), 3.88 (s, 3H), 3.05 (d, <i>J</i> = 10.96 Hz, 2H), 2.53 (quin, <i>J</i> = 7.83 Hz, 1H), 2.37 (s, 3H), 2.06−2.22 (m, 2H), 1.83−2.03 (m, 8H), 1.66 (d, <i>J</i> = 13.30 Hz, 2H), 1.39−1.56 (m, 2H), 1.06 (s, 3H), 1.04 (s, 3H). Mass spectrum (LCMS, APCI pos.) calcd for C<sub>29</sub>H<sub>38</sub>N<sub>6</sub>O<sub>3</sub>, 519.30 (M + H); found, 519.2. HPLC: <i>t</i><sub>R</sub> = 4.83 min (100% pure).</div></div><div id="sec3_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 8-Cyclohexyl-2-[4-(1-methylpiperidin-4-yl)phenylamino]-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid Methoxyamide (<b>49</b>)</h3><div class="NLM_p last">Using a similar procedure described in the preparation of <b>47</b>, the title compound was obtained as a yellow solid (34 mg, 38%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 12.00 (s, 1H), 9.37 (s, 1H), 8.81 (s, 1H), 7.53−7.65 (m, <i>J</i> = 8.22 Hz, 2H), 7.20−7.25 (m, <i>J</i> = 8.61 Hz, 2H), 5.16 (t, <i>J</i> = 11.93 Hz, 1H), 3.89 (s, 3H), 3.10−3.28 (m, 1H), 2.72−2.84 (m, 1H), 2.58−2.70 (m, 1H), 2.33 (s, 3H), 1.99−2.12 (m, 5H), 1.72−1.97 (m, 5H), 1.47−1.71 (m, 4H), 1.21−1.39 (m, 2H). Mass spectrum (LCMS, APCI pos.) calcd for C<sub>27</sub>H<sub>34</sub>N<sub>6</sub>O<sub>3</sub>, 491.27 (M + H); found, 491.2. HPLC: <i>t</i><sub>R</sub> = 4.37 min (100% pure).</div></div><div id="sec3_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Biology</h3><div id="sec3_44_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Kinase Assays</h4><div class="NLM_p last">Assays for FMS and the other kinases listed in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a> were carried out using a fluorescence polarization competition immunoassay format and have been described elsewhere in detail.<a onclick="showRef(event, 'cit23b'); return false;" href="javascript:void(0);" class="ref cit23b">(23b)</a> The full cytoplasmic regions of FMS (538−972) encompassing the tyrosine kinase domain was expressed and purified from a baculovirus system.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The FMS kinase assay measured FMS-mediated phosphorylation of tyrosine residues present on a synthetic FMS<sub>555−568</sub> peptide (SYEGNSYTFIDPTQ). To each well of a black 96-well microplate (cat. no. 42-000-0117, Molecular Devices, Sunnyvale, CA), Then 5 μL of compound (in 4% DMSO) were mixed with 2 μL of 3.5 nM FMS, 25 mM MgCl<sub>2</sub> in assay buffer (100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20), and 2 μL of 1540 μM peptide in assay buffer. The kinase reaction was initiated by adding 1 μL of 10 mM ATP in assay buffer. Final concentrations in the 10 μL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 μM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl<sub>2</sub>, and 0.7 nM FMS. The plates were incubated at room temperature for 80 min. Reactions were stopped by addition of 1.2 μL of 50 mM EDTA. Each well then received 10 μL of a 1:1:3 mixture of 10× antiphosphotyrosine antibody, 10× PTK green tracer, and fluorescence polarization dilution buffer (cat. no. P2837, Invitrogen, Carlsbad, CA). The plates were incubated for 30 min at room temperature, and the fluorescence polarization was read (485 nm excitation, 530 nm emission) on an Analyst plate reader (Molecular Devices). Fluorescence polarization values for positive (EDTA) and negative (DMSO) controls were approximately 290 and 160, respectively, and were used to define 100% and 0% inhibition of the FMS reaction.</div></div><div id="sec3_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Bone Marrow-Derived Macrophage (BMDM) Proliferation Assay</h4><div class="NLM_p last">Functional impact on cellular FMS activity was determined by measuring compound inhibition of CSF-1-driven proliferation of mouse bone marrow-derived macrophages as previously described.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Macrophages were derived by culturing mouse bone marrow in α-MEM supplemented with 10% FCS and 50 ng/mL recombinant mouse CSF-1 in bacteriologic dishes. On the sixth day, macrophages were resuspended to 50000 cells/mL in α-MEM containing 10% FCS, and 100 μL of cell suspension were distributed per well into 96-well culture plates for overnight culture. Next, wells were further supplemented with the addition of 50 μL media containing 15 ng/mL CSF-1, 3 μM indomethacin, and a dilution series of test compound. The cells were cultured for 30 h at 37 °C and 5% CO<sub>2</sub>. During the final 6 h, cultures were supplemented with an additional 30 μL of media containing a 1:500 dilution of bromodeoxyuridine (BrDU) reagent, and incorporation of BrDU into cellular DNA was quantified using a specific ELISA (cat. no. X1327K) from Exalpha Corporation (Watertown, MA).</div></div><div id="sec3_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> MV-4-11 and M-o7e Leukemia Cell Line Proliferation Assays</h4><div class="NLM_p last">Functional impact on cellular FLT3 activity was determined by measuring compound inhibition of MV-4-11 (ATCC no.: CRL-9591) cell proliferation, and M-07e (DSMZ no.: ACC 104) cells were used to assess compound effects on cellular KIT activity. MV-4-11 cells grew independent of growth factor due to expression of a constitutive active FLT3 mutation, and M-07e cells were driven to proliferate in a KIT-dependent fashion by 25 ng/mL stem cell factor. Following a culture period of 72 h, relative cell numbers were determined using CellTiterGlo reagent (Promega).</div></div><div id="sec3_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> Biochemical Pharmacodynamic Mouse Model</h4><div class="NLM_p last">Groups of six B6C3F1 mice (Taconic Farms), 8 weeks of age, were given oral doses of vehicle (aq 20% hydroxypropyl-β-cyclodextrin (HPβCD)) or <b>37</b> at 1 or 3 mg/kg. Six hours later, mice were administered saline alone or saline containing 1 μg of recombinant mouse CSF-1 (Cell Biosciences Inc., Norwood, MA) via the tail vein. Fifteen minutes after CSF-1 injection, mice were sacrificed and spleens were isolated and snap frozen on dry ice. The frozen tissue was homogenized in 1 mL of Trizol (Invitrogen) per 50 mg of tissue, and RNA was purified according to the Trizol instructions and treated with 6.8 Kunitz units of RNase-free DNase (Qiagen, Valencia, CA) to degrade contaminating genomic DNA. The RNA was purified further using RNeasy columns (Qiagen). RT-PCR was performed in 25 μL reaction volumes using Reverse Transcriptase qPCR Master Mix (Eurogentec) and approximately 50 ng of RNA. Applied Biosystems, Inc., (Foster City, CA) was the source for the primers and probes for mouse c-fos mRNA (cat. no. Mm00487425) and 18S rRNA (cat. no. 4333760F). Amplification and detection were performed using an ABI Prism 7900. Standard curves were created for c-fos mRNA and for 18s rRNA using RNA isolated from a vehicle-treated, CSF-1-induced mouse and used to calculate relative expression levels in all other samples. c-fos mRNA values were normalized to 18S rRNA content. Averaged, normalized c-fos content in the saline (no CSF-1) group was assigned a value of one and all other groups were expressed as “fold-induced”.</div></div><div id="sec3_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> SCW-Induced Arthritis Model</h4><div class="NLM_p last">Female Lewis rats (80−100 g each) were purchased from Charles River. Streptococcal cell wall peptidoglycan−polysaccharide polymers (PG-PS 10S) were purchased from BD (cat. no. 210866). On day 0, rats were anesthetized using isoflurane and injected ip with PG-PS 10S equivalent to 15 μg of rhamnose/gram (body weight) in the lower left quadrant of the abdomen. Control rats were treated in a similar manner with sterile saline. On day 5, rats were injected with PG-PS 10S, and those that showed a distinct acute phase arthritic response based on joint swelling were randomized into the treatment groups. A chronic, T cell dependent, erosive arthritis begins in this model on about day 10. Animals were dosed orally twice a day beginning on day 19. Compound <b>37</b> was formulated in 20% HPβCD. The dose volume was 6 mL/kg. Left and right hind ankles of each rat were measured with calipers every day for the first six days (postinjection) and then at least every two or three days for the remainder of the study.</div></div><div id="sec3_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Adjuvant-Induced Arthritis Model</h4><div class="NLM_p last">The adjuvant-induced arthritis study was performed by Bolder BioPath, Inc., (Boulder, CO). Male Lewis rats (Harlan Cat. no. 1439444), 165−185 g, were anesthetized with isoflurane and injected with 100 μL of Freund’s complete adjuvant (FCA, Sigma)/lipoidal amine (LA, Sigma) at the base of the tail on day 0. Oral dosing was initiated on day 8 (the first day of clinical disease). Compound <b>37</b> or vehicle (20% HPβCD) were dosed orally twice daily. Caliper measurements of ankles were taken on days 7−21. To calculate the area under the curve (AUC), the daily caliper measurements for each rat were integrated vs time (treatment day). Mean AUC values for each group were determined, and the percent inhibition from arthritis vehicle-treated controls was calculated after subtracting the AUC of age-matched normal control animals. Following necropsy on day 21, digital radiographs of left paws were prepared using a VetTek Universal AP500 (Del Medical Imaging Corporation, Franklin Park, IL). Both hind paws were then fixed in formalin and processed for H and E microscopy. H and E sections were scored for bone resorption as follows: 0 = normal; 0.5 = normal on low magnification but have the earliest hint of small areas of resorption in the metaphysis with no resorption in the tarsal bones; 1 = (minimal) small definite areas of resorption in distal tibial trabecular or cortical bone, or in the tarsal bones, not readily apparent on low magnification, rare osteoclasts; 2 = (mild) more numerous areas (≤25% loss of bone in growth plate area) of resorption in distal tibial trabecular or cortical bone and tarsals apparent on low magnification, osteoclasts more numerous; 3 = (moderate) obvious resorption of medullary trabecular and cortical bone without full thickness defects in both distal tibial cortices, loss of some medullary trabeculae with 26−50% loss across growth plate and cortices, some loss in tarsal bones, lesion apparent on low magnification, osteoclasts more numerous; 4 = (marked) full or near full thickness defects in both distal tibial cortices, often with distortion of profile of remaining cortical surface, marked loss of medullary bone of distal tibia (50−100% loss across growth plate area and cortices and up to 50% loss in small tarsals if minor in tibia), numerous osteoclasts, minor to mild resorption in smaller tarsal bones; 5 = (severe) full thickness defects in both distal tibial cortices with >75% loss across growth plate and both cortices and >50% loss in tarsals, often with distortion of profile of remaining cortical surface, marked loss of medullary bone of distal tibia, numerous osteoclasts. Osteoclast counts (5, 400× fields) were performed on ankles in the areas of greatest bone resorption.</div></div></div><div id="sec3_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Statistical Analysis</h3><div class="NLM_p last">Ankle thickness, bone erosion scores, osteoclast counts, and c-fos expression values (mean ± SE) were analyzed for group differences using the Student’s <i>t</i> test. Significance was set at <i>p</i> ≤ 0.05.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="si1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81"><a href="/doi/suppl/10.1021/jm801406h">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78077" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78077" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">LC-MS data for target compounds. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm801406h/suppl_file/jm801406h_si_001.pdf">jm801406h_si_001.pdf (653.56 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm801406h" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68507" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68507" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark R. Player</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#35584559544c5047755c41461b5f5b5f1b565a58"><span class="__cf_email__" data-cfemail="dfb2afb3bea6baad9fb6abacf1b5b1b5f1bcb0b2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui Huang</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel A. Hutta</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James M. Rinker</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huaping Hu</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William H. Parsons</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carsten Schubert</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Renee L. DesJarlais</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carl S. Crysler</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Margery A. Chaikin</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert R. Donatelli</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanmin Chen</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deping Cheng</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhao Zhou</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edward Yurkow</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carl L. Manthey</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i82">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31016" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31016" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 42 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sacca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherr, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettenmier, C. W.</span><span> </span><span class="NLM_article-title">Specific binding of the mononuclear phagocyte colony-stimulating factor CSF-1 to the product of the v-fms oncogene</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">3331</span><span class="NLM_x">–</span> <span class="NLM_lpage">3335</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1986&pages=3331-3335&author=R.+Saccaauthor=E.+R.+Stanleyauthor=C.+J.+Sherrauthor=C.+W.+Rettenmier&title=Specific+binding+of+the+mononuclear+phagocyte+colony-stimulating+factor+CSF-1+to+the+product+of+the+v-fms+oncogene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSacca%26aufirst%3DR.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26aulast%3DSherr%26aufirst%3DC.%2BJ.%26aulast%3DRettenmier%26aufirst%3DC.%2BW.%26atitle%3DSpecific%2520binding%2520of%2520the%2520mononuclear%2520phagocyte%2520colony-stimulating%2520factor%2520CSF-1%2520to%2520the%2520product%2520of%2520the%2520v-fms%2520oncogene%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1986%26volume%3D83%26spage%3D3331%26epage%3D3335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pixley, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, E. R.</span><span> </span><span class="NLM_article-title">CSF-1 Regulation of the wandering macrophage: complexity in action</span> <span class="citation_source-journal">Trends Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">628</span><span class="NLM_x">–</span> <span class="NLM_lpage">638</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1016%2Fj.tcb.2004.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=15519852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpt1Wgsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=628-638&author=F.+J.+Pixleyauthor=E.+R.+Stanley&title=CSF-1+Regulation+of+the+wandering+macrophage%3A+complexity+in+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">CSF-1 regulation of the wandering macrophage: complexity in action</span></div><div class="casAuthors">Pixley, Fiona J.; Stanley, E. Richard</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">628-638</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Most tissue macrophages and osteoclasts are regulated by colony-stimulating factor-1 (CSF-1, also known as macrophage CSF).  The effects of CSF-1 are mediated by the CSF-1 receptor tyrosine kinase (CSF-1R), through autophosphorylation of CSF-1R and the subsequent phosphorylation of downstream mols.  Triggering this phosphorylation cascade increases gene transcription and protein translation, and induces cytoskeletal remodeling by several signaling pathways, leading to the survival, proliferation and differentiation of target cells.  CSF-1-regulated tissue macrophages are important for innate immunity and for tissue development and function.  Because CSF-1 regulates the survival, proliferation and chemotaxis of macrophages and supports their activation, this factor is involved in the pathogenesis of several diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouh_AnBDWTs7Vg90H21EOLACvtfcHk0lhCq9VO-L_taQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpt1Wgsrw%253D&md5=0b2639ed4de1366b5fba48fc6c3758ba</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2004.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2004.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DPixley%26aufirst%3DF.%2BJ.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DCSF-1%2520Regulation%2520of%2520the%2520wandering%2520macrophage%253A%2520complexity%2520in%2520action%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2004%26volume%3D14%26spage%3D628%26epage%3D638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Wiktor-Jedrzejczak, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczylik, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelly, R. R.</span><span> </span><span class="NLM_article-title">Hematological characterization of congenital osteopetrosis in op/op mouse</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">1516</span><span class="NLM_x">–</span> <span class="NLM_lpage">1527</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=1982&pages=1516-1527&author=W.+Wiktor-Jedrzejczakauthor=A.+Ahmedauthor=C.+Szczylikauthor=R.+R.+Skelly&title=Hematological+characterization+of+congenital+osteopetrosis+in+op%2Fop+mouse"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWiktor-Jedrzejczak%26aufirst%3DW.%26aulast%3DAhmed%26aufirst%3DA.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DSkelly%26aufirst%3DR.%2BR.%26atitle%3DHematological%2520characterization%2520of%2520congenital%2520osteopetrosis%2520in%2520op%252Fop%2520mouse%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1982%26volume%3D156%26spage%3D1516%26epage%3D1527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Pollard, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, E. R.</span><span> </span><span class="NLM_article-title">Pleotropic roles for CSF-1 in development defined by the mouse mutation osteopetrotic (op)</span> <span class="citation_source-journal">Adv. Dev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1016%2FS1064-2722%2808%2960060-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1995&pages=153-193&author=J.+W.+Pollardauthor=E.+R.+Stanley&title=Pleotropic+roles+for+CSF-1+in+development+defined+by+the+mouse+mutation+osteopetrotic+%28op%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1064-2722%2808%2960060-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1064-2722%252808%252960060-2%26sid%3Dliteratum%253Aachs%26aulast%3DPollard%26aufirst%3DJ.%2BW.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DPleotropic%2520roles%2520for%2520CSF-1%2520in%2520development%2520defined%2520by%2520the%2520mouse%2520mutation%2520osteopetrotic%2520%2528op%2529%26jtitle%3DAdv.%2520Dev.%2520Biochem.%26date%3D1995%26volume%3D4%26spage%3D153%26epage%3D193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">MacDonald, K. P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowe, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bofinger, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasmono, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hume, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. R.</span><span> </span><span class="NLM_article-title">The colony-stimulating factor 1 receptor is expressed on dendritic cells during differentiation and regulates their expansion</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">1399</span><span class="NLM_x">–</span> <span class="NLM_lpage">1405</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2005&pages=1399-1405&author=K.+P.+A.+MacDonaldauthor=V.+Roweauthor=H.+M.+Bofingerauthor=R.+Thomasauthor=T.+Sasmonoauthor=D.+A.+Humeauthor=G.+R.+Hill&title=The+colony-stimulating+factor+1+receptor+is+expressed+on+dendritic+cells+during+differentiation+and+regulates+their+expansion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMacDonald%26aufirst%3DK.%2BP.%2BA.%26aulast%3DRowe%26aufirst%3DV.%26aulast%3DBofinger%26aufirst%3DH.%2BM.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DSasmono%26aufirst%3DT.%26aulast%3DHume%26aufirst%3DD.%2BA.%26aulast%3DHill%26aufirst%3DG.%2BR.%26atitle%3DThe%2520colony-stimulating%2520factor%25201%2520receptor%2520is%2520expressed%2520on%2520dendritic%2520cells%2520during%2520differentiation%2520and%2520regulates%2520their%2520expansion%26jtitle%3DJ.%2520Immunol.%26date%3D2005%26volume%3D175%26spage%3D1399%26epage%3D1405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Pixley, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, E. R.</span><span> </span><span class="NLM_article-title">CSF-1 regulation of the wandering macrophage: complexity in action</span> <span class="citation_source-journal">Trends Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">628</span><span class="NLM_x">–</span> <span class="NLM_lpage">638</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1016%2Fj.tcb.2004.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=15519852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpt1Wgsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=628-638&author=F.+J.+Pixleyauthor=E.+R.+Stanley&title=CSF-1+regulation+of+the+wandering+macrophage%3A+complexity+in+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">CSF-1 regulation of the wandering macrophage: complexity in action</span></div><div class="casAuthors">Pixley, Fiona J.; Stanley, E. Richard</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">628-638</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Most tissue macrophages and osteoclasts are regulated by colony-stimulating factor-1 (CSF-1, also known as macrophage CSF).  The effects of CSF-1 are mediated by the CSF-1 receptor tyrosine kinase (CSF-1R), through autophosphorylation of CSF-1R and the subsequent phosphorylation of downstream mols.  Triggering this phosphorylation cascade increases gene transcription and protein translation, and induces cytoskeletal remodeling by several signaling pathways, leading to the survival, proliferation and differentiation of target cells.  CSF-1-regulated tissue macrophages are important for innate immunity and for tissue development and function.  Because CSF-1 regulates the survival, proliferation and chemotaxis of macrophages and supports their activation, this factor is involved in the pathogenesis of several diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouh_AnBDWTs7Vg90H21EOLACvtfcHk0ljcedA0w3OQcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpt1Wgsrw%253D&md5=0b2639ed4de1366b5fba48fc6c3758ba</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2004.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2004.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DPixley%26aufirst%3DF.%2BJ.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DCSF-1%2520regulation%2520of%2520the%2520wandering%2520macrophage%253A%2520complexity%2520in%2520action%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2004%26volume%3D14%26spage%3D628%26epage%3D638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Park, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">In, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span> </span><span class="NLM_article-title">Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1714</span><span class="NLM_x">–</span> <span class="NLM_lpage">1719</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1002%2Fart.10359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=12124853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A280%3ADC%252BD38znslyktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=1714-1719&author=Y.+Parkauthor=C.+Ahnauthor=H.+K.+Choiauthor=S.+Leeauthor=B.+Inauthor=H.+Leeauthor=C.+Namauthor=S.+Lee&title=Atherosclerosis+in+rheumatoid+arthritis%3A+morphologic+evidence+obtained+by+carotid+ultrasound"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound</span></div><div class="casAuthors">Park Yong-Beom; Ahn Chul-Woo; Choi Hyon K; Lee Seung-Hoon; In Byung-Hyun; Lee Hyun-Chul; Nam Chung-Mo; Lee Soo-Kon</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis and rheumatism</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1714-9</span>
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    </div><div class="casAbstract">OBJECTIVE:  Recent studies have suggested increased cardiovascular disease among patients with rheumatoid arthritis (RA).  We undertook this study to obtain morphologic evidence of subclinical atherosclerosis in RA patients.  METHODS:  We used high-resolution B-mode ultrasound to compare carotid artery intima-media wall thickness (IMT) between 53 postmenopausal women with RA and 53 controls matched by age, sex, and menopause status.  No subject in either group had a history of atherosclerosis or its complications.  We investigated the association between IMT and relevant clinical and therapeutic variables, including the impact of low-dose corticosteroid therapy (< or = 10 mg/day prednisolone).  RESULTS:  The mean +/- SD IMT of the left and right common carotid arteries in RA patients was significantly greater than that in controls (0.77 +/- 0.09 mm versus 0.68 +/- 0.14 mm; P < 0.001).  Early RA (duration < or = 1 year) was associated with lesser IMT than was RA of longer duration (0.72 +/- 0.03 mm versus 0.78 +/- 0.01 mm; P < 0.04).  Prednisolone use was not associated with increased IMT (0.78 +/- 0.02 mm in nonusers versus 0.76 +/- 0.01 mm in users; P = 0.38).  CONCLUSION:  Our data indicate that RA patients have an ultrasonic marker of early atherosclerosis consistent with an increased risk for atherosclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXPznsnxkDyBFwe7cAcrfPfW6udTcc2eaXPy5sdk8iGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38znslyktQ%253D%253D&md5=64eed6937bbd9210928466ae3f6e21a2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fart.10359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.10359%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DY.%26aulast%3DAhn%26aufirst%3DC.%26aulast%3DChoi%26aufirst%3DH.%2BK.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DIn%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DNam%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DS.%26atitle%3DAtherosclerosis%2520in%2520rheumatoid%2520arthritis%253A%2520morphologic%2520evidence%2520obtained%2520by%2520carotid%2520ultrasound%26jtitle%3DArthritis%2520Rheum.%26date%3D2002%26volume%3D46%26spage%3D1714%26epage%3D1719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Joffe, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, S.</span><span> </span><span class="NLM_article-title">Osteoporosis associated with rheumatoid arthritis: pathogenesis and management</span> <span class="citation_source-journal">Semin. Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">256</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1016%2F0049-0172%2891%2990021-Q" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=2042057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A280%3ADyaK3M3lt1ynug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1991&pages=256-272&author=I.+Joffeauthor=S.+Epstein&title=Osteoporosis+associated+with+rheumatoid+arthritis%3A+pathogenesis+and+management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Osteoporosis associated with rheumatoid arthritis: pathogenesis and management</span></div><div class="casAuthors">Joffe I; Epstein S</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in arthritis and rheumatism</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">256-72</span>
        ISSN:<span class="NLM_cas:issn">0049-0172</span>.
    </div><div class="casAbstract">Rheumatoid arthritis is associated with both localized and generalized osteoporosis.  Localized osteoporosis can be considered to be caused by local disease mechanisms, including the generation of factors from activation of the cytokine pathway.  The etiology of generalized osteoporosis has been difficult to elucidate, particularly because of the lack of sensitive techniques to measure bone mineral density.  The introduction of single- and dual-photon absorptiometry and quantitative computed tomography has allowed more accurate assessment of bone mineral density.  In general, bone mineral density loss at appendicular sites does not correlate well with axial bone density loss.  Corticosteroid treatment exaggerates the development of osteoporosis in up to 40% of patients with rheumatoid arthritis.  Sex hormone status, physical activity, disease duration, and functional class are all significant predictors for the development of osteoporosis.  Current therapy for prevention and treatment is based largely on theoretical considerations.  Physical activity should be encouraged once acute joint inflammation has settled.  Postmenopausal women and amenorrheic premenopausal women will benefit from cyclical estrogen replacement.  Patients with low serum 1,25-dihydroxy vitamin D3 levels, and males with low serum testosterone levels, are candidates for replacement therapy with the appropriate hormones.  In patients who are receiving corticosteroids the dose should be limited, and oral calcium supplements are of benefit.  The use of the newer corticosteroid deflazacort, and disease-modifying immunosuppressive drugs, are discussed.  Other therapeutic options which should be considered, although published trials are scarce, are calcitonin and the diphosphonates.  Further studies are awaited concerning the optimum prevention and treatment of osteoporosis associated with rheumatoid arthritis.(ABSTRACT TRUNCATED AT 250 WORDS)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdrBiM3Zv340odMGTatQ7LfW6udTcc2ebNJ-DQQRAWB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M3lt1ynug%253D%253D&md5=cde992363b22540720e1aa9c61f6fbcf</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2F0049-0172%2891%2990021-Q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0049-0172%252891%252990021-Q%26sid%3Dliteratum%253Aachs%26aulast%3DJoffe%26aufirst%3DI.%26aulast%3DEpstein%26aufirst%3DS.%26atitle%3DOsteoporosis%2520associated%2520with%2520rheumatoid%2520arthritis%253A%2520pathogenesis%2520and%2520management%26jtitle%3DSemin.%2520Arthritis%2520Rheum.%26date%3D1991%26volume%3D20%26spage%3D256%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Lipsky, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Der Heijde, D. M. F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Clair, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furst, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breedveld, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalden, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolen, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maini, R. N.</span><span> </span><span class="NLM_article-title">Infliximab and methotrexate in the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">1594</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1056%2FNEJM200011303432202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=11096166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovVeltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2000&pages=1594-602&author=P.+E.+Lipskyauthor=D.+M.+F.+M.+Van+Der+Heijdeauthor=E.+W.+St.+Clairauthor=D.+E.+Furstauthor=F.+C.+Breedveldauthor=J.+R.+Kaldenauthor=J.+S.+Smolenauthor=M.+Weismanauthor=P.+Emeryauthor=M.+Feldmannauthor=G.+R.+Harrimanauthor=R.+N.+Maini&title=Infliximab+and+methotrexate+in+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Infliximab and methotrexate in the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Lipsky, Peter E.; Van Der Heijde, Desiree M. F. M.; St. Clair, E. William; Furst, Daniel E.; Breedveld, Ferdinand C.; Kalden, Joachim R.; Smolen, Josef S.; Weisman, Michael; Emery, Paul; Feldmann, Marc; Harriman, Gregory R.; Maini, Ravinder N.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1594-1602</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Neutralization of tumor necrosis factor α (TNF-α) for three to six months reduces the symptoms and signs of rheumatoid arthritis.  However, the capacity of this approach to effect a more sustained benefit and its effect on joint damage are not known.  We treated 428 patients who had active rheumatoid arthritis despite methotrexate therapy with placebo or infliximab, a chimeric monoclonal antibody against TNF-α, in i.v. doses of 3 or 10 mg per kg of body wt. every 4 or 8 wk in combination with oral methotrexate for 54 wk.  We assessed clin. responses with use of the criteria of the American College of Rheumatol., the quality of life with a health-status questionnaire, and the effect on joint damage radiog.  The combination of infliximab and methotrexate was well tolerated and resulted in a sustained redn. in the symptoms and signs of rheumatoid arthritis that was significantly greater than the redn. assocd. with methotrexate therapy alone (clin. response, 51.8 % vs. 17.0 %; P<0.001).  The quality of life was also significantly better with infliximab plus methotrexate than with methotrexate alone.  Radiog. evidence of joint damage increased in the group given methotrexate, but not in the groups given infliximab and methotrexate (mean change in radiog. score, 7.0 vs. 0.6; P<0.001).  Radiog. evidence of progression of joint damage was absent in infliximab-treated patients whether or not they had a clin. response.  In patients with persistently active rheumatoid arthritis despite methotrexate therapy, repeated doses of infliximab in combination with methotrexate provided clin. benefit and halted the progression of joint damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqasmJKB3fqgrVg90H21EOLACvtfcHk0lgyL3521FG4iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovVeltLk%253D&md5=b67ff09ce24a2c808a265204aac20e53</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJM200011303432202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200011303432202%26sid%3Dliteratum%253Aachs%26aulast%3DLipsky%26aufirst%3DP.%2BE.%26aulast%3DVan%2BDer%2BHeijde%26aufirst%3DD.%2BM.%2BF.%2BM.%26aulast%3DSt.%2BClair%26aufirst%3DE.%2BW.%26aulast%3DFurst%26aufirst%3DD.%2BE.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DKalden%26aufirst%3DJ.%2BR.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DWeisman%26aufirst%3DM.%26aulast%3DEmery%26aufirst%3DP.%26aulast%3DFeldmann%26aufirst%3DM.%26aulast%3DHarriman%26aufirst%3DG.%2BR.%26aulast%3DMaini%26aufirst%3DR.%2BN.%26atitle%3DInfliximab%2520and%2520methotrexate%2520in%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2000%26volume%3D343%26spage%3D1594%26epage%3D602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Borchers, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keen, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheema, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gershwin, M. E.</span><span> </span><span class="NLM_article-title">The use of methotrexate in rheumatoid arthritis</span> <span class="citation_source-journal">Semin. Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">483</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1016%2Fj.semarthrit.2003.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=15305245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslalsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2004&pages=465-483&author=A.+T.+Borchersauthor=C.+L.+Keenauthor=G.+S.+Cheemaauthor=M.+E.+Gershwin&title=The+use+of+methotrexate+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The use of methotrexate in rheumatoid arthritis</span></div><div class="casAuthors">Borchers, Andrea T.; Keen, Carl L.; Cheema, Gurtej S.; Gershwin, M. Eric</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Arthritis and Rheumatism</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">465-483</span>CODEN:
                <span class="NLM_cas:coden">SAHRBF</span>;
        ISSN:<span class="NLM_cas:issn">0049-0172</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objective: To address the long-term efficacy and toxicity issues related to methotrexate (MTX) and compare it with other disease-modifying antirheumatic drugs (DMARDs).  Methods: Review of the international literature on the clin. use of MTX in rheumatoid arthritis (RA) disease.  Results: MTX has emerged as a relatively safe and effective treatment for RA that compares favorably with other therapies, particularly because of its considerably longer median drug survival.  The toxicity profile of MTX is well established and includes serious and sometimes fatal liver disease, pneumonitis, and cytopenias.  Hence, regular and careful monitoring of patients taking MTX is essential, particularly when MTX is combined with other DMARDs.  Folate supplementation can reduce some of the most common side effects of MTX, but it has not yet been established whether this translates into a reduced risk of serious disease.  Another potential approach to reducing the toxicity of MTX is therapeutic drug monitoring and dose individualization.  However, correlations between pharmacokinetics and clin. response have been addressed in only a few studies and with conflicting results.  Conclusions: MTX is an effective DMARD with a relatively safe profile compared with other therapies.  Folate supplementation can significantly reduce the risk of MTX toxicity.  Finally, it is essential that patients be monitored carefully to reduce the potential serious toxicities of MTX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD7IuayGisFLVg90H21EOLACvtfcHk0ljEC4qqrrMiyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslalsbo%253D&md5=1b4d0358af3f1fdd5f2cf94c04dc0ce8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.semarthrit.2003.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semarthrit.2003.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DBorchers%26aufirst%3DA.%2BT.%26aulast%3DKeen%26aufirst%3DC.%2BL.%26aulast%3DCheema%26aufirst%3DG.%2BS.%26aulast%3DGershwin%26aufirst%3DM.%2BE.%26atitle%3DThe%2520use%2520of%2520methotrexate%2520in%2520rheumatoid%2520arthritis%26jtitle%3DSemin.%2520Arthritis%2520Rheum.%26date%3D2004%26volume%3D34%26spage%3D465%26epage%3D483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kawaji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokomuro, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somoto, Y</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirai, Y.</span><span> </span><span class="NLM_article-title">Macrophage colony-stimulating factor in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Nippon Ika Daigaku Zasshi</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1272%2Fjnms1923.62.260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=7615698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADyaK2MXms1WhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1995&pages=260-270&author=H.+Kawajiauthor=K.+Yokomuroauthor=K.+Kikuchiauthor=Y+Somotoauthor=Y.+Shirai&title=Macrophage+colony-stimulating+factor+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage colony-stimulating factor in patients with rheumatoid arthritis</span></div><div class="casAuthors">Kawaji, Hidemi; Yokomuro, Kozo; Kikuchi, Kyoko; Somoto, Youki; Shirai, Yasumasa</div><div class="citationInfo"><span class="NLM_cas:title">Nippon Ika Daigaku Zasshi</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">260-70</span>CODEN:
                <span class="NLM_cas:coden">NIDZAJ</span>;
        ISSN:<span class="NLM_cas:issn">0048-0444</span>.
    </div><div class="casAbstract">We developed a new ELISA technique to measure macrophage colony-stimulating factor (M-CSF) levels in synovial fluid with high sensitivity and reproducibility.  The mean M-CSF level in the synovial fluid of patients with rheumatoid arthritis (RA) was 1.38 ± 0.56 ng/mL, and that of patients with osteoarthritis (OA) was 0.67 ± 0.13 ng/mL.  In contrast, serum levels of M-CSF in patients with RA and in normal controls were 1.32 ± 0.50 ng/mL and 0.90 ± 0.09 ng/mL, resp.  These differences were both statistically significant.  Since serum M-CSF levels correlate with inflammatory signs obtained from examn. of blood, they indicate the general condition of patients with RA.  Synovial fluid M-CSF levels increase even in the early phase of RA and remain high despite drug therapy, which suggests that they reflect the condition of affected joints including joint spaces and inflamed synovia more directly than do the levels of serum M-CSF.  Measurement of the M-CSF level in the synovial fluid may be useful in the diagnosis, clin. evaluation, and assessment of the effects of treatment in patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomBgcRjuSmvLVg90H21EOLACvtfcHk0ljEC4qqrrMiyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXms1WhtrY%253D&md5=2d5c872c01ea9a95560af0412a2967e2</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1272%2Fjnms1923.62.260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1272%252Fjnms1923.62.260%26sid%3Dliteratum%253Aachs%26aulast%3DKawaji%26aufirst%3DH.%26aulast%3DYokomuro%26aufirst%3DK.%26aulast%3DKikuchi%26aufirst%3DK.%26aulast%3DSomoto%26aufirst%3DY%26aulast%3DShirai%26aufirst%3DY.%26atitle%3DMacrophage%2520colony-stimulating%2520factor%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DNippon%2520Ika%2520Daigaku%2520Zasshi%26date%3D1995%26volume%3D62%26spage%3D260%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ritchlin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucala, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winchester, R.</span><span> </span><span class="NLM_article-title">Sustained and distinctive patterns of gene activation in synovial fibroblasts and whole synovial tissue obtained from inflammatory synovitis</span> <span class="citation_source-journal">Scand. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1111%2Fj.1365-3083.1994.tb03465.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=8091128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADyaK2cXmt1yls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1994&pages=292-298&author=C.+Ritchlinauthor=E.+Dwyerauthor=R.+Bucalaauthor=R.+Winchester&title=Sustained+and+distinctive+patterns+of+gene+activation+in+synovial+fibroblasts+and+whole+synovial+tissue+obtained+from+inflammatory+synovitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained and distinctive patterns of gene activation in synovial fibroblasts and whole synovial tissue obtained from inflammatory synovitis</span></div><div class="casAuthors">Ritchlin, C.; Dwyer, E.; Bucala, R.; Winchester, R.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">292-8</span>CODEN:
                <span class="NLM_cas:coden">SJIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0300-9475</span>.
    </div><div class="casAbstract">Fibroblastoid synovial lining cells isolated from rheumatoid and other chronic inflammatory synovial tissue exhibit distinctive and sustained alterations in serial culture not commonly found in similarly cultured cells from osteoarthritic synovium.  These are demonstrable using a multi-gene dot blot assay by labeling reverse transcribed fibroblast cDNA which is hybridized to plasmids contg. relevant target gene inserts.  Cultured synovial fibroblastoid cells from patients with chronic inflammatory synovitis expressed significantly higher levels of stromelysin, vimentin and TIMP-1 mRNA and lower levels of c-myc compared to cells isolated from osteoarthritis synovium although with considerable variation.  Early fetal synovial lining cells were similar to cells from osteoarthritis synovium but vimentin expression was higher.  Marked differences in patterns of gene expression between cell lines persisted through 10 serial passages over 6-8 mo.  In whole synovia, the av. level of mRNA for stromelysin, vimentin, IL-4, IL-6, TIMP-1, cathepsin D, gelatinase, TGFα, c-fms and DRβ were preferentially expressed in inflammatory tissue while c-myc expression was higher in osteoarthritis synovium.  Inflammatory synovium also expressed TNFα, IL-1α, IL-1β, IL-2, c-sis, tissue plasminogen activator, CSF-1, and GM-CSF.  This pattern resembles, in part, that found in cultured inflammatory fibroblasts but, in addn., gene products apparently reflecting the presence of activated monocytes and lymphocytes were detected.  These results provide evidence that profiles of certain gene activation in cells from patients with inflammatory synovitis differ from those with non-inflammatory disease and suggest that the fibroblastoid cells are responsible for a considerable proportion of the altered phenotypic expression pattern in whole tissue.  Furthermore, this modulated pattern of gene activation appears to be an intrinsic pro-inflammatory characteristic of the fibroblastoid cells initiated in response to chronic inflammation and persists for a prolonged period in the absence of other inflammatory cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUd6F-8PCMFbVg90H21EOLACvtfcHk0ljEC4qqrrMiyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmt1yls7g%253D&md5=0e00011784fe504612c79350cea6a90a</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-3083.1994.tb03465.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-3083.1994.tb03465.x%26sid%3Dliteratum%253Aachs%26aulast%3DRitchlin%26aufirst%3DC.%26aulast%3DDwyer%26aufirst%3DE.%26aulast%3DBucala%26aufirst%3DR.%26aulast%3DWinchester%26aufirst%3DR.%26atitle%3DSustained%2520and%2520distinctive%2520patterns%2520of%2520gene%2520activation%2520in%2520synovial%2520fibroblasts%2520and%2520whole%2520synovial%2520tissue%2520obtained%2520from%2520inflammatory%2520synovitis%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D1994%26volume%3D40%26spage%3D292%26epage%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Takei, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ida, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santavirta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konttinen, Y. T.</span><span> </span><span class="NLM_article-title">High macrophage-colony stimulating factor levels in synovial fluid of loose artificial hip joints</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">894</span><span class="NLM_x">–</span> <span class="NLM_lpage">899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=10782812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXivFOrsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2000&pages=894-899&author=I.+Takeiauthor=M.+Takagiauthor=H.+Idaauthor=T.+Oginoauthor=S.+Santavirtaauthor=Y.+T.+Konttinen&title=High+macrophage-colony+stimulating+factor+levels+in+synovial+fluid+of+loose+artificial+hip+joints"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">High macrophage-colony stimulating factor levels in synovial fluid of loose artificial hip joints</span></div><div class="casAuthors">Takei, Isao; Takagi, Michiaki; Ida, Hideo; Ogino, Toshihiko; Santavirta, Seppo; Konttinen, Yrjo T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">894-899</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective. To clarify a macrophage-colony stimulating factor (M-CSF) related mechanism of aseptic loosening of artificial hip joints.  Methods. Synovium-like interface tissues between bone and prosthesis, regenerated pseudocapsular tissues, and synovial fluid (SF) were collected from 9 patients with loose artificial hip joint at revision surgery.  Tissue distribution, prodn. site, and SF level of M-CSF in loose hip joints were investigated by immunohistochem., reverse transcription-polymerase chain reaction (RT-PCR), and ELISA, resp.  For a comparative assessment of the M-CSF level in loose hip joints, SF of active rheumatoid arthritis (RA) and mild osteoarthritis (OA) also were analyzed by ELISA.  Results. Immunohistochem. anal. showed the presence of M-CSF immunoreactive cells mainly in the interface tissues between bone and prosthesis and inner pseudocapsular tissues, both of which were in contact with joint fluid.  RT-PCR anal. confirmed the local prodn. of M-CSF in these periprosthetic tissues.  Significantly higher M-CSF level in loose hip joint fluid than in active RA and mild OA fluid was revealed by ELISA.  Conclusion. High M-CSF level in loose hip joint fluid suggests transportation of M-CSF from prodn. sites to joint fluid.  This indicates that not only polyethylene wear particles (reported to induce foreign body reaction at the bone-prosthesis interface), but also M-CSF, abundant in joint fluid, are transported to and affect the interface.  Thus, M-CSF is locally produced in periprosthetic tissues of loose hip joints and possibly contributes to periprosthetic weakening and osteolysis via joint fluid, leading to prosthetic loosening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlI9pPe59SQbVg90H21EOLACvtfcHk0ljXckpipXtqoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXivFOrsb8%253D&md5=08e093f0c23066d5df935638e9fac9d0</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakei%26aufirst%3DI.%26aulast%3DTakagi%26aufirst%3DM.%26aulast%3DIda%26aufirst%3DH.%26aulast%3DOgino%26aufirst%3DT.%26aulast%3DSantavirta%26aufirst%3DS.%26aulast%3DKonttinen%26aufirst%3DY.%2BT.%26atitle%3DHigh%2520macrophage-colony%2520stimulating%2520factor%2520levels%2520in%2520synovial%2520fluid%2520of%2520loose%2520artificial%2520hip%2520joints%26jtitle%3DJ.%2520Rheumatol.%26date%3D2000%26volume%3D27%26spage%3D894%26epage%3D899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Shinohara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirohata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, K.</span><span> </span><span class="NLM_article-title">Phenotypic analysis of peripheral blood monocytes isolated from patients with rheumatoid arthritis</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=1378495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A280%3ADyaK38zjtlCmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1992&pages=211-215&author=S.+Shinoharaauthor=S.+Hirohataauthor=T.+Inoueauthor=K.+Ito&title=Phenotypic+analysis+of+peripheral+blood+monocytes+isolated+from+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic analysis of peripheral blood monocytes isolated from patients with rheumatoid arthritis</span></div><div class="casAuthors">Shinohara S; Hirohata S; Inoue T; Ito K</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of rheumatology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-5</span>
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    </div><div class="casAbstract">The expression of CD14, Fc gamma receptor I (Fc gamma RI), Fc gamma RII, and HLA-DR on peripheral blood monocytes from patients with rheumatoid arthritis (RA) was studied to investigate their nature and their role in the pathogenesis of rheumatoid synovitis.  Peripheral blood mononuclear cells obtained from 9 patients with active RA, 8 patients with RA in complete remission, and 14 healthy individuals, were stained with various monoclonal antibodies and analyzed on a fluorescence activated cell sorter.  The expression of CD14 as well as Fc gamma RI and Fc gamma RII was upregulated on peripheral blood monocytes from patients with active RA, although the expression of HLA-DR was not increased.  In addition, the expression of Fc gamma RI and Fc gamma RII on monocytes was still upregulated in patients with RA in complete remission, whereas the expression of CD14 on monocytes was normalized in these patients.  These results indicate that peripheral blood monocytes in patients with active RA are already activated to express higher densities of CD14.  In addition, our observation that CD14 density was increased on a subset of circulating blood monocytes in active RA, that HLA-DR was not significantly altered and that Fc gamma RI and Fc gamma RII were increased in both active and inactive RA is not compatible with the expected actions of interferon gamma.  Finally, it is suggested that peripheral blood monocytes in patients with RA may have intrinsic abnormalities as evidenced by the enhanced expression of Fc gamma R, which is repeatedly observed regardless of the disease activity of RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqPwmnMlyxYwMthz5_Rx5rfW6udTcc2ebWAhjM6mDYA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38zjtlCmtQ%253D%253D&md5=4e6bbbeeee044cd4ac39f73566c9e1e3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShinohara%26aufirst%3DS.%26aulast%3DHirohata%26aufirst%3DS.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DK.%26atitle%3DPhenotypic%2520analysis%2520of%2520peripheral%2520blood%2520monocytes%2520isolated%2520from%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Rheumatol.%26date%3D1992%26volume%3D19%26spage%3D211%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Weiner, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catalano, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dovnarsky, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padavic, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alpaugh, R. K.</span><span> </span><span class="NLM_article-title">Phase 1 trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4084</span><span class="NLM_x">–</span> <span class="NLM_lpage">4090</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1994&pages=4084-4090&author=L.+M.+Weinerauthor=W.+Liauthor=M.+Holmesauthor=R.+B.+Catalanoauthor=M.+Dovnarskyauthor=K.+Padavicauthor=R.+K.+Alpaugh&title=Phase+1+trial+of+recombinant+macrophage+colony-stimulating+factor+and+recombinant+gamma-interferon%3A+toxicity%2C+monocytosis%2C+and+clinical+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DHolmes%26aufirst%3DM.%26aulast%3DCatalano%26aufirst%3DR.%2BB.%26aulast%3DDovnarsky%26aufirst%3DM.%26aulast%3DPadavic%26aufirst%3DK.%26aulast%3DAlpaugh%26aufirst%3DR.%2BK.%26atitle%3DPhase%25201%2520trial%2520of%2520recombinant%2520macrophage%2520colony-stimulating%2520factor%2520and%2520recombinant%2520gamma-interferon%253A%2520toxicity%252C%2520monocytosis%252C%2520and%2520clinical%2520effects%26jtitle%3DCancer%2520Res.%26date%3D1994%26volume%3D54%26spage%3D4084%26epage%3D4090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Hanamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asakura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanabe, T.</span><span> </span><span class="NLM_article-title">Macrophage colony-stimulating factor (CSF-1) augments cytokine induction by lipopolysaccharide (LPS)-stimulation and by bacterial infections in mice</span> <span class="citation_source-journal">Immunopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1016%2FS0162-3109%2896%2900166-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=9285240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADyaK2sXktlGjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1997&pages=15-23&author=T.+Hanamuraauthor=E.+Asakuraauthor=T.+Tanabe&title=Macrophage+colony-stimulating+factor+%28CSF-1%29+augments+cytokine+induction+by+lipopolysaccharide+%28LPS%29-stimulation+and+by+bacterial+infections+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage colony-stimulating factor (M-CSF) augments cytokine induction by lipopolysaccharide (LPS)-stimulation and by bacterial infections in mice</span></div><div class="casAuthors">Hanamura, Takuji; Asakura, Eiji; Tanabe, Toshizumi</div><div class="citationInfo"><span class="NLM_cas:title">Immunopharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-23</span>CODEN:
                <span class="NLM_cas:coden">IMMUDP</span>;
        ISSN:<span class="NLM_cas:issn">0162-3109</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The authors studied the effects of M-CSF on cytokine induction in vivo by LPS or by bacterial infection by comparing between the serum cytokine levels of mice administered with and without M-CSF.  M-CSF at 250 μg/kg/day for 3 days significantly augmented serum IL-6 level induced by a subsequent injection of 25 μg/kg of LPS.  The augmented IL-6-induction was dose-dependent from 50 to 1250 μg/kg/day of M-CSF, and required 2- to 3-doses of M-CSF at 250 μg/kg/day.  Mice primed with M-CSF induced IL-6 in response to a 5-fold lower dose of LPS, and also produced higher levels of IL-1α, IL-10, GM-CSF, TNF-α, and IFN-γ than control mice.  The priming effect of M-CSF was transient and reversible, and elicited independently of T-cells.  An injection with intact bacteria, such as Gram-neg. Escherichia coli and Gram-pos. Staphylococcus aureus also induced IL-6 in normal mice, and M-CSF administration augmented the induction of these cytokines.  These results showed that M-CSF pos. regulates LPS-dependent and -independent cytokine induction, suggesting a defensive effect against infectious agents through enhanced cytokine prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAhwp8qASs0rVg90H21EOLACvtfcHk0ljXckpipXtqoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlGjt74%253D&md5=108c02bd05528f09a498c36296ff5265</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0162-3109%2896%2900166-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0162-3109%252896%252900166-X%26sid%3Dliteratum%253Aachs%26aulast%3DHanamura%26aufirst%3DT.%26aulast%3DAsakura%26aufirst%3DE.%26aulast%3DTanabe%26aufirst%3DT.%26atitle%3DMacrophage%2520colony-stimulating%2520factor%2520%2528CSF-1%2529%2520augments%2520cytokine%2520induction%2520by%2520lipopolysaccharide%2520%2528LPS%2529-stimulation%2520and%2520by%2520bacterial%2520infections%2520in%2520mice%26jtitle%3DImmunopharmacology%26date%3D1997%26volume%3D37%26spage%3D15%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Hamilton, J. A.</span><span> </span><span class="NLM_article-title">Rheumatoid arthritis: opposing actions of haemopoietic growth factors and slow-acting anti-rheumatic drugs</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">342</span><span class="NLM_x">, </span> <span class="NLM_fpage">536</span><span class="NLM_x">–</span> <span class="NLM_lpage">539</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=1993&pages=536-539&author=J.+A.+Hamilton&title=Rheumatoid+arthritis%3A+opposing+actions+of+haemopoietic+growth+factors+and+slow-acting+anti-rheumatic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamilton%26aufirst%3DJ.%2BA.%26atitle%3DRheumatoid%2520arthritis%253A%2520opposing%2520actions%2520of%2520haemopoietic%2520growth%2520factors%2520and%2520slow-acting%2520anti-rheumatic%2520drugs%26jtitle%3DLancet%26date%3D1993%26volume%3D342%26spage%3D536%26epage%3D539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Castro-Rueda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavanaugh, A.</span><span> </span><span class="NLM_article-title">Biologic therapy for early rheumatoid arthritis: the latest evidence</span> <span class="citation_source-journal">Curr. Opin. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1097%2FBOR.0b013e3282f5fcf6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=18388524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A280%3ADC%252BD1c3ivFaisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2008&pages=314-9&author=H.+Castro-Ruedaauthor=A.+Kavanaugh&title=Biologic+therapy+for+early+rheumatoid+arthritis%3A+the+latest+evidence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Biologic therapy for early rheumatoid arthritis: the latest evidence</span></div><div class="casAuthors">Castro-Rueda Hernan; Kavanaugh Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in rheumatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">314-9</span>
        ISSN:<span class="NLM_cas:issn">1040-8711</span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  To describe current therapeutic trials with biologic agents for early rheumatoid arthritis, analyzing clinical and radiographic outcomes.  RECENT FINDINGS:  The use of tumor necrosis factor-alpha inhibitors in combination with disease-modifying antirheumatic drugs early after the diagnosis of aggressive rheumatoid arthritis seems to provide increased clinical benefit over methotrexate or tumor necrosis factor-alpha inhibitors as monotherapy, with better outcomes in terms of faster and more extensive clinical improvement.  There also seems to be an increased likelihood of low-disease activity in some cases even after tapering therapy.  Control of radiographic progression appears to be most effective among early rheumatoid arthritis patients treated with combination tumor necrosis factor-alpha inhibitors and methotrexate, although radiographic outcomes are better with tumor necrosis factor-alpha inhibitor monotherapy than with methotrexate alone.  SUMMARY:  The addition of antitumor necrosis factor-alpha agents to traditional disease-modifying antirheumatic drugs in early rheumatoid arthritis is a novel strategy which follows the principle of early and aggressive therapeutic intervention.  Results from recent trials show greater levels of disease control.  The impact on long-term safety and cost-efficacy are factors which will need to be better characterized over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWKzyGlFkUClf1XRtfYM0dfW6udTcc2eZAYl5SS1I9ZLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3ivFaisw%253D%253D&md5=10d5b46198ef31506e94697c056aa84b</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1097%2FBOR.0b013e3282f5fcf6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FBOR.0b013e3282f5fcf6%26sid%3Dliteratum%253Aachs%26aulast%3DCastro-Rueda%26aufirst%3DH.%26aulast%3DKavanaugh%26aufirst%3DA.%26atitle%3DBiologic%2520therapy%2520for%2520early%2520rheumatoid%2520arthritis%253A%2520the%2520latest%2520evidence%26jtitle%3DCurr.%2520Opin.%2520Rheumatol.%26date%3D2008%26volume%3D20%26spage%3D314%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ilowite, N. T.</span><span> </span><span class="NLM_article-title">Update on biologics in juvenile idiopathic arthritis</span> <span class="citation_source-journal">Curr. Opin. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">613</span><span class="NLM_x">–</span> <span class="NLM_lpage">618</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1097%2FBOR.0b013e3283060778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=18698187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A280%3ADC%252BD1crhsV2htg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2008&pages=613-618&author=N.+T.+Ilowite&title=Update+on+biologics+in+juvenile+idiopathic+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Update on biologics in juvenile idiopathic arthritis</span></div><div class="casAuthors">Ilowite Norman T</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in rheumatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">613-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  The purpose of this review is to summarize the recent data on biologic therapies in juvenile rheumatoid arthritis.  The armamentarium for treatment of juvenile idiopathic arthritis is expanding at a rapid rate, and improved physical and functional outcomes are anticipated.  New data from large prospective randomized trials have demonstrated efficacy of anti-tumor necrosis factor agents and a costimulator signal inhibitor.  RECENT FINDINGS:  The results of a pivotal trial of infliximab in polyarticular juvenile idiopathic arthritis suggested efficacy, but the primary outcome was not significantly different from placebo.  Important information regarding dosing in children was obtained, however.  A pivotal trial of adalimumab did prove efficacy, and resulted in U.S.  Food and Drug Administration (FDA) approval.  The monoclonal antibodies to tumor necrosis factor appear to be more effective in treating chronic uveitis associated with juvenile idiopathic arthritis than etanercept.  Anti-IL-1 and anti-IL-6 therapy, particularly for systemic disease patients, looks very promising, as well.  The costimulation modifier abatacept was shown to be effective and relatively well tolerated in the short term, also resulting in FDA approval this year.  Continued experience with these agents and appropriate systems-based methods such as formal registries, to complement existing FDA procedures for monitoring safety, will improve our ability to identify short-term and long-term toxicities of these new agents.  SUMMARY:  As experience is gained, and longer-term safety is demonstrated, it is likely that biologics will be introduced as therapy earlier in the course of patients who inadequately respond to conventional disease-modifying antirheumatic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuDvMZ7pFzijToTC3aBaesfW6udTcc2eZAYl5SS1I9ZLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1crhsV2htg%253D%253D&md5=8c331db6f34c9a8ad7663905aed917df</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1097%2FBOR.0b013e3283060778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FBOR.0b013e3283060778%26sid%3Dliteratum%253Aachs%26aulast%3DIlowite%26aufirst%3DN.%2BT.%26atitle%3DUpdate%2520on%2520biologics%2520in%2520juvenile%2520idiopathic%2520arthritis%26jtitle%3DCurr.%2520Opin.%2520Rheumatol.%26date%3D2008%26volume%3D20%26spage%3D613%26epage%3D618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kitaura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novack, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teitelbaum, S. L.</span><span> </span><span class="NLM_article-title">M-CSF mediates TNF-induced inflammatory osteolysis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">3418</span><span class="NLM_x">–</span> <span class="NLM_lpage">3427</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=3418-3427&author=H.+Kitauraauthor=P.+Zhouauthor=H.+Kimauthor=D.+V.+Novackauthor=F.+P.+Rossauthor=S.+L.+Teitelbaum&title=M-CSF+mediates+TNF-induced+inflammatory+osteolysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKitaura%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DNovack%26aufirst%3DD.%2BV.%26aulast%3DRoss%26aufirst%3DF.%2BP.%26aulast%3DTeitelbaum%26aufirst%3DS.%2BL.%26atitle%3DM-CSF%2520mediates%2520TNF-induced%2520inflammatory%2520osteolysis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D3418%26epage%3D3427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Uemura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohzeki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murooka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serizawa, I.</span><span> </span><span class="NLM_article-title">The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis</span> <span class="citation_source-journal">J. Neuroimmunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">195</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">80</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1016%2Fj.jneuroim.2008.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=18378004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvVOrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2008&pages=73-80&author=Y.+Uemuraauthor=H.+Ohnoauthor=Y.+Ohzekiauthor=H.+Takanashiauthor=H.+Murookaauthor=K.+Kuboauthor=I.+Serizawa&title=The+selective+M-CSF+receptor+tyrosine+kinase+inhibitor+Ki20227+suppresses+experimental+autoimmune+encephalomyelitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis</span></div><div class="casAuthors">Uemura, Yasunori; Ohno, Hiroaki; Ohzeki, Yumiko; Takanashi, Hiromi; Murooka, Hideko; Kubo, Kazuo; Serizawa, Isao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroimmunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">73-80</span>CODEN:
                <span class="NLM_cas:coden">JNRIDW</span>;
        ISSN:<span class="NLM_cas:issn">0165-5728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Exptl. autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), can be induced by the immunization of mice with myelin antigens in the form of myelin oligodendrocyte glycoprotein (MOG).  Macrophage colony-stimulating factor (M-CSF) is required for the development of individual mononuclear phagocyte populations and is involved in the immune response.  We previously reported that Ki20227 (N-{4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-methoxyphenyl}-N'-[1-(1,3-thiazole-2-yl)ethyl]urea) is a highly selective M-CSF receptor (c-fms) tyrosine kinase inhibitor.  In our current study, we investigated whether Ki20227 has suppressive effects upon EAE and indeed found that this drug significantly reduced the severity of this disease both preventively and therapeutically.  Notably also, Ki20227 treatments inhibited the turn-over/expansion of myeloid cells provoked by the immunization and subsequent MOG-specific T cell responses in our EAE animal model.  These findings suggest that M-CSF plays a pivotal role in the development of EAE and that Ki20227 and its derivs. may be candidate drugs for the treatment of human MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobS3ECXzImwbVg90H21EOLACvtfcHk0liqXHUmVfaWQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvVOrsbc%253D&md5=92b102002c788d12d3ad7d7194b9607f</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1016%2Fj.jneuroim.2008.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jneuroim.2008.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DUemura%26aufirst%3DY.%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DOhzeki%26aufirst%3DY.%26aulast%3DTakanashi%26aufirst%3DH.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DSerizawa%26aufirst%3DI.%26atitle%3DThe%2520selective%2520M-CSF%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520Ki20227%2520suppresses%2520experimental%2520autoimmune%2520encephalomyelitis%26jtitle%3DJ.%2520Neuroimmunol.%26date%3D2008%26volume%3D195%26spage%3D73%26epage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ohno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uemura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murooka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokieda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohzeki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serizawa, I.</span><span> </span><span class="NLM_article-title">The orally-active and selective c-FMS tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model</span> <span class="citation_source-journal">Eur. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">291</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=283-291&author=H.+Ohnoauthor=Y.+Uemuraauthor=H.+Murookaauthor=H.+Takanashiauthor=T.+Tokiedaauthor=Y.+Ohzekiauthor=K.+Kuboauthor=I.+Serizawa&title=The+orally-active+and+selective+c-FMS+tyrosine+kinase+inhibitor+Ki20227+inhibits+disease+progression+in+a+collagen-induced+arthritis+mouse+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DUemura%26aufirst%3DY.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DTakanashi%26aufirst%3DH.%26aulast%3DTokieda%26aufirst%3DT.%26aulast%3DOhzeki%26aufirst%3DY.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DSerizawa%26aufirst%3DI.%26atitle%3DThe%2520orally-active%2520and%2520selective%2520c-FMS%2520tyrosine%2520kinase%2520inhibitor%2520Ki20227%2520inhibits%2520disease%2520progression%2520in%2520a%2520collagen-induced%2520arthritis%2520mouse%2520model%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2008%26volume%3D38%26spage%3D283%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Conway, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parham, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frick, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadepalli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Votta, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kull, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chamberlain, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchins, J. T.</span><span> </span><span class="NLM_article-title">Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580</span> <span class="citation_source-journal">Proc. Nat. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">16078</span><span class="NLM_x">–</span> <span class="NLM_lpage">16083</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1073%2Fpnas.0502000102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=16249345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WqsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=16078-16083&author=J.+G.+Conwayauthor=B.+McDonaldauthor=J.+Parhamauthor=B.+Keithauthor=D.+W.+Rusnakauthor=E.+Shawauthor=M.+Jansenauthor=P.+Linauthor=A.+Payneauthor=R.+M.+Crosbyauthor=J.+H.+Johnsonauthor=L.+Frickauthor=M.+J.+Linauthor=S.+Depeeauthor=S.+Tadepalliauthor=B.+Vottaauthor=I.+Jamesauthor=K.+Fullerauthor=T.+J.+Chambersauthor=F.+C.+Kullauthor=S.+D.+Chamberlainauthor=J.+T.+Hutchins&title=Inhibition+of+colony-stimulating-factor-1+signaling+in+vivo+with+the+orally+bioavailable+cFMS+kinase+inhibitor+GW2580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580</span></div><div class="casAuthors">Conway, James G.; McDonald, Brad; Parham, Janet; Keith, Barry; Rusnak, David W.; Shaw, Eva; Jansen, Marilyn; Lin, Peiyuan; Payne, Alan; Crosby, Renae M.; Johnson, Jennifer H.; Frick, Lloyd; Lin, Min-Hwa Jasmine; Depee, Scott; Tadepalli, Sarva; Votta, Bart; James, Ian; Fuller, Karen; Chambers, Timothy J.; Kull, Frederick C.; Chamberlain, Stanley D.; Hutchins, Jeff T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">16078-16083</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Colony-stimulating-factor-1 (CSF-1) signaling through cFMS receptor kinase is increased in several diseases.  To help investigate the role of cFMS kinase in disease, the authors identified GW2580, an orally bioavailable inhibitor of cFMS kinase.  GW2580 completely inhibited human cFMS kinase in vitro at 0.06 μM and was inactive against 26 other kinases.  GW2580 at 1 μM completely inhibited CSF-1-induced growth of mouse M-NFS-60 myeloid cells and human monocytes and completely inhibited bone degrdn. in cultures of human osteoclasts, rat calvaria, and rat fetal long bone.  In contrast, GW2580 did not affect the growth of mouse NS0 lymphoblastoid cells, human endothelial cells, human fibroblasts, or five human tumor cell lines.  GW2580 also did not affect lipopolysaccharide (LPS)-induced TNF, IL-6, and prostaglandin E2 prodn. in freshly isolated human monocytes and mouse macrophages.  After oral administration, GW2580 blocked the ability of exogenous CSF-1 to increase LPS-induced IL-6 prodn. in mice, inhibited the growth of CSF-1-dependent M-NFS-60 tumor cells in the peritoneal cavity, and diminished the accumulation of macrophages in the peritoneal cavity after thioglycolate injection.  Unexpectedly, GW2580 inhibited LPS-induced TNF prodn. in mice, in contrast to effects on monocytes and macrophages in vitro.  In conclusion, GW2580's selective inhibition of monocyte growth and bone degrdn. is consistent with cFMS kinase inhibition.  The ability of GW2580 to chronically inhibit CSF-1 signaling through cFMS kinase in normal and tumor cells in vivo makes GW2580 a useful tool in assessing the role of cFMS kinase in normal and disease processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR5EGN2P59OrVg90H21EOLACvtfcHk0ljDMX97LmhNiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WqsrzM&md5=6a5afc80faa9acec528fdbf766ad05bd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0502000102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0502000102%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DJ.%2BG.%26aulast%3DMcDonald%26aufirst%3DB.%26aulast%3DParham%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DB.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DShaw%26aufirst%3DE.%26aulast%3DJansen%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DPayne%26aufirst%3DA.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DFrick%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DM.%2BJ.%26aulast%3DDepee%26aufirst%3DS.%26aulast%3DTadepalli%26aufirst%3DS.%26aulast%3DVotta%26aufirst%3DB.%26aulast%3DJames%26aufirst%3DI.%26aulast%3DFuller%26aufirst%3DK.%26aulast%3DChambers%26aufirst%3DT.%2BJ.%26aulast%3DKull%26aufirst%3DF.%2BC.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DHutchins%26aufirst%3DJ.%2BT.%26atitle%3DInhibition%2520of%2520colony-stimulating-factor-1%2520signaling%2520in%2520vivo%2520with%2520the%2520orally%2520bioavailable%2520cFMS%2520kinase%2520inhibitor%2520GW2580%26jtitle%3DProc.%2520Nat.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D16078%26epage%3D16083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Conway, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pink, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergquist, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadepalli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumrine, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selph, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stimpson, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchins, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chamberlain, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodie, T. A.</span><span> </span><span class="NLM_article-title">Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in mormal and arthritic rats</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">326</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1124%2Fjpet.107.129429" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=18434589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlylsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=2008&pages=41-50&author=J.+G.+Conwayauthor=H.+Pinkauthor=M.+L.+Bergquistauthor=B.+Hanauthor=S.+Depeeauthor=S.+Tadepalliauthor=P.+Linauthor=R.+C.+Crumrineauthor=J.+Binzauthor=R.+L.+Clarkauthor=J.+L.+Selphauthor=S.+A.+Stimpsonauthor=T.+J.+Hutchinsauthor=S.+D.+Chamberlainauthor=T.+A.+Brodie&title=Effects+of+the+cFMS+kinase+inhibitor+5-%283-methoxy-4-%28%284-methoxybenzyl%29oxy%29benzyl%29pyrimidine-2%2C4-diamine+%28GW2580%29+in+mormal+and+arthritic+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats</span></div><div class="casAuthors">Conway, James G.; Pink, Heather; Bergquist, Mandy L.; Han, Bajin; Depee, Scott; Tadepalli, Sarva; Lin, Peiyuan; Crumrine, R. Christian; Binz, Jane; Clark, Richard L.; Selph, Jeffrey L.; Stimpson, Stephen A.; Hutchins, Jeff T.; Chamberlain, Stanley D.; Brodie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">326</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The cFMS (cellular homolog of the V-FMS oncogene product of the Susan McDonough strain of feline sarcoma virus) kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) inhibits colony-stimulating factor (CSF)-1-induced monocyte growth and bone degrdn. in vitro and inhibits CSF-1 signaling through cFMS kinase in 4-day models in mice.  In the present study, the kinase selectivity of GW2580 was further characterized, and the effects of chronic treatment were evaluated in normal and arthritic rats.  GW2580 selectively inhibited cFMS kinase compared with 186 other kinases in vitro and completely inhibited CSF-1-induced growth of rat monocytes, with an IC50 value of 0.2 μM.  GW2580 dosed orally at 25 and 75 mg/kg 1 and 5 h before the injection of lipopolysaccharide inhibited tumor necrosis factor-α prodn. by 60 to 85%, indicating a duration of action of at least 5 h.  In a 21-day adjuvant arthritis model, GW2580 dosed twice a day (b.i.d.) from days 0 to 21, 7 to 21, or 14 to 21 inhibited joint connective tissue and bone destruction as assessed by radiol., histol. and bone mineral content measurements.  In contrast, GW2580 did not affect ankle swelling in the adjuvant model nor did it affect ankle swelling in a model where local arthritis is reactivated by peptidoglycan polysaccharide polymers.  GW2580 administered to normal rats for 21 days showed no effects on tissue histol. and only modest changes in serum clin. chem. and blood hematol.  In conclusion, GW2580 was effective in preserving joint integrity in the adjuvant arthritis model while showing minimal effects in normal rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtnXf8t6eWrLVg90H21EOLACvtfcHk0ljDMX97LmhNiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlylsL0%253D&md5=51bf18b72ebba4c5ea862b088d0c1ad1</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.129429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.129429%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DJ.%2BG.%26aulast%3DPink%26aufirst%3DH.%26aulast%3DBergquist%26aufirst%3DM.%2BL.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DDepee%26aufirst%3DS.%26aulast%3DTadepalli%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DCrumrine%26aufirst%3DR.%2BC.%26aulast%3DBinz%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DR.%2BL.%26aulast%3DSelph%26aufirst%3DJ.%2BL.%26aulast%3DStimpson%26aufirst%3DS.%2BA.%26aulast%3DHutchins%26aufirst%3DT.%2BJ.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DBrodie%26aufirst%3DT.%2BA.%26atitle%3DEffects%2520of%2520the%2520cFMS%2520kinase%2520inhibitor%25205-%25283-methoxy-4-%2528%25284-methoxybenzyl%2529oxy%2529benzyl%2529pyrimidine-2%252C4-diamine%2520%2528GW2580%2529%2520in%2520mormal%2520and%2520arthritic%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D326%26spage%3D41%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Ibrahim, P. N.; Artis, D. R.; Bremer, R.; Habets, G.; Mamo, S.; Nespi, M.; Zhang, C.; Zhang, J.; Zhu, Y.; Zuckerman, R.; West, B.; Suzuki, Y.; Tsai, J.; Hirth, K.-P.; Bollag, G.; Spevak, W.; Cho, H.; Gillette, S. J.; Wu, G.; Zhu, H.; Shi, S.</span><span> </span><span class="NLM_article-title">Pyrrolo[2,3-<i>b</i>]pyridine derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases</span>. PCT Int. Appl. WO 2007002433,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=P.+N.+Ibrahim&author=D.+R.+Artis&author=R.+Bremer&author=G.+Habets&author=S.+Mamo&author=M.+Nespi&author=C.+Zhang&author=J.+Zhang&author=Y.+Zhu&author=R.+Zuckerman&author=B.+West&author=Y.+Suzuki&author=J.+Tsai&author=K.-P.+Hirth&author=G.+Bollag&author=W.+Spevak&author=H.+Cho&author=S.+J.+Gillette&author=G.+Wu&author=H.+Zhu&author=S.+Shi&title=Pyrrolo%5B2%2C3-b%5Dpyridine+derivatives+as+protein+kinase+inhibitors+and+their+preparation%2C+pharmaceutical+compositions+and+use+in+the+treatment+of+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26atitle%3DPyrrolo%255B2%252C3-b%255Dpyridine%2520derivatives%2520as%2520protein%2520kinase%2520inhibitors%2520and%2520their%2520preparation%252C%2520pharmaceutical%2520compositions%2520and%2520use%2520in%2520the%2520treatment%2520of%2520diseases%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Ajami, A. M.; Boss, M. A.; Paterson, J.</span><span> </span><span class="NLM_article-title">Treatment of autoimmune and demyelinating diseases with Symadex and related imidazoacridine derivatives</span>. PCT Int. Appl. WO 2006081431,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=A.+M.+Ajami&author=M.+A.+Boss&author=J.+Paterson&title=Treatment+of+autoimmune+and+demyelinating+diseases+with+Symadex+and+related+imidazoacridine+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAjami%26aufirst%3DA.%2BM.%26atitle%3DTreatment%2520of%2520autoimmune%2520and%2520demyelinating%2520diseases%2520with%2520Symadex%2520and%2520related%2520imidazoacridine%2520derivatives%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Patyna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Farrell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vojkovsky, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasile, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grazzini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haznedar, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sukbuntherng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu-Lowe, D.</span><span> </span><span class="NLM_article-title">SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1774</span><span class="NLM_x">–</span> <span class="NLM_lpage">1782</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1158%2F1535-7163.MCT-05-0333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=16891463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslWksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1774-1782&author=S.+Patynaauthor=A.+D.+Lairdauthor=D.+B.+Mendelauthor=A.+O%E2%80%99Farrellauthor=C.+Liangauthor=H.+Guanauthor=T.+Vojkovskyauthor=S.+Vasileauthor=X.+Wangauthor=J.+Chenauthor=M.+Grazziniauthor=C.+Y.+Yangauthor=J.+O.+Haznedarauthor=J.+Sukbuntherngauthor=W.+Zhongauthor=J.+M.+Cherringtonauthor=D.+Hu-Lowe&title=SU14813%3A+a+novel+multiple+receptor+tyrosine+kinase+inhibitor+with+potent+antiangiogenic+and+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity</span></div><div class="casAuthors">Patyna, Shem; Laird, A. Douglas; Mendel, Dirk B.; O'Farrell, Anne-Marie; Liang, Chris; Guan, Huiping; Vojkovsky, Tomas; Vasile, Stefan; Wang, Xueyan; Chen, Jeffrey; Grazzini, Maren; Yang, Cheng Y.; Haznedar, Joshua Oe.; Sukbuntherng, Juthamas; Zhong, Wei-Zhu; Cherrington, Julie M.; Hu-Lowe, Dana</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1774-1782</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases (RTK), such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (KIT), and fms-like tyrosine kinase 3 (FLT3), are expressed in malignant tissues and act in concert, playing diverse and major roles in angiogenesis, tumor growth, and metastasis.  With the exception of a few malignancies, seemingly driven by a single genetic mutation in a signaling protein, most tumors are the product of multiple mutations in multiple aberrant signaling pathways.  Consequently, simultaneous targeted inhibition of multiple signaling pathways could be more effective than inhibiting a single pathway in cancer therapies.  Such a multitargeted strategy has recently been validated in a no. of preclin. and clin. studies using RTK inhibitors with broad target selectivity.  SU14813, a small mol. identified from the same chem. library used to isolate sunitinib, has broad-spectrum RTK inhibitory activity through binding to and inhibition of VEGFR, PDGFR, KIT, and FLT3.  In cellular assays, SU14813 inhibited ligand-dependent and ligand-independent proliferation, migration, and survival of endothelial cells and/or tumor cells expressing these targets.  SU14813 inhibited VEGFR-2, PDGFR-{szligbeta}, and FLT3 phosphorylation in xenograft tumors in a dose- and time-dependent fashion.  The plasma concn. required for in vivo target inhibition was estd. to be 100 to 200 ng/mL.  Used as monotherapy, SU14813 exhibited broad and potent antitumor activity resulting in regression, growth arrest, or substantially reduced growth of various established xenografts derived from human or rat tumor cell lines.  Treatment in combination with docetaxel significantly enhanced both the inhibition of primary tumor growth and the survival of the tumor-bearing mice compared with administration of either agent alone.  In summary, SU14813 inhibited target RTK activity in vivo in assocn. with redn. in angiogenesis, target RTK-mediated proliferation, and survival of tumor cells, leading to broad and potent antitumor efficacy.  These data support the ongoing phase I clin. evaluation of SU14813 in advanced malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpEfsqMfo2jbVg90H21EOLACvtfcHk0lgnHJTsFg_WAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslWksb4%253D&md5=e35e1d0f5695b03d7341689e12b2aef2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0333%26sid%3Dliteratum%253Aachs%26aulast%3DPatyna%26aufirst%3DS.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DMendel%26aufirst%3DD.%2BB.%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DGuan%26aufirst%3DH.%26aulast%3DVojkovsky%26aufirst%3DT.%26aulast%3DVasile%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DGrazzini%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DHaznedar%26aufirst%3DJ.%2BO.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DW.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DHu-Lowe%26aufirst%3DD.%26atitle%3DSU14813%253A%2520a%2520novel%2520multiple%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520with%2520potent%2520antiangiogenic%2520and%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1774%26epage%3D1782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Tamaskar, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mekhail, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreicer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rini, B. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukowski, R. M.</span><span> </span><span class="NLM_article-title">Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy</span> <span class="citation_source-journal">J. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">179</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1016%2Fj.juro.2007.08.127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=17997441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2008&pages=81-86&author=I.+Tamaskarauthor=J.+A.+Garciaauthor=P.+Elsonauthor=L.+Woodauthor=T.+Mekhailauthor=R.+Dreicerauthor=B.+I.+Riniauthor=R.+M.+Bukowski&title=Antitumor+effects+of+sunitinib+or+sorafenib+in+patients+with+metastatic+renal+cell+carcinoma+who+received+prior+antiangiogenic+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy</span></div><div class="casAuthors">Tamaskar, Ila; Garcia, Jorge A.; Elson, Paul; Wood, Laura; Mekhail, Tarek; Dreicer, Robert; Rini, Brian I.; Bukowski, Ronald M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-86</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Purpose: Antiangiogenic therapy with sunitinib and sorafenib has become the std. of care for patients with advanced renal cell carcinoma.  However, the clin. benefit of these agents after prior antiangiogenic therapy has not been defined.  Currently, several agents with a putative antiangiogenic mechanism exist and they are often being used in sequence with little to no data regarding activity in a second line or later setting.  Materials and Methods: Patients with advanced renal cell carcinoma currently being treated with either sunitinib or sorafenib after receiving 1 or more prior antiangiogenic agent(s) were investigated in a retrospective anal.  Time to progression and the overall response rate by Response Evaluation Criteria in Solid Tumors were evaluated.  Results: Thirty patients receiving current sunitinib (16 patients) or sorafenib (14 patients) were identified.  Patients received 1 or more prior antiangiogenic therapies: thalidomide, lenalidomide, bevacizumab, volociximab, AG13736, sorafenib or sunitinib.  Of 16 patients treated with sunitinib 13 had some degree of tumor shrinkage, including 9 with a partial response by Response Evaluation Criteria in Solid Tumors.  Of 14 patients treated with sorafenib 10 had some degree of tumor shrinkage, including 1 with a partial response.  The median time to progression for the entire cohort was 10.4 mo.  Conclusions: Significant antitumor activity is obsd. when sorafenib or sunitinib are used in patients who have failed prior therapy with an antiangiogenic agent.  Prior response to an antiangiogenic agent does not appear to predict subsequent clin. benefit to either sunitinib or sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX2_pRDPqsY7Vg90H21EOLACvtfcHk0lj47rGxhHBUAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1Wnsw%253D%253D&md5=25b13dc69fc85da49d4575fc60bf1978</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2007.08.127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2007.08.127%26sid%3Dliteratum%253Aachs%26aulast%3DTamaskar%26aufirst%3DI.%26aulast%3DGarcia%26aufirst%3DJ.%2BA.%26aulast%3DElson%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DL.%26aulast%3DMekhail%26aufirst%3DT.%26aulast%3DDreicer%26aufirst%3DR.%26aulast%3DRini%26aufirst%3DB.%2BI.%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26atitle%3DAntitumor%2520effects%2520of%2520sunitinib%2520or%2520sorafenib%2520in%2520patients%2520with%2520metastatic%2520renal%2520cell%2520carcinoma%2520who%2520received%2520prior%2520antiangiogenic%2520therapy%26jtitle%3DJ.%2520Urol.%26date%3D2008%26volume%3D179%26spage%3D81%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCall, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span> </span><span class="NLM_article-title">Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-FMS) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1007</span><span class="NLM_x">–</span> <span class="NLM_lpage">1013</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1158%2F1535-7163.MCT-05-0359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=16648572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFCksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1007-1013&author=J.+Guoauthor=P.+A.+Marcotteauthor=J.+O.+McCallauthor=Y.+Daiauthor=L.+J.+Peaseauthor=M.+R.+Michaelidesauthor=S.+K.+Davidsenauthor=K.+B.+Glaser&title=Inhibition+of+phosphorylation+of+the+colony-stimulating+factor-1+receptor+%28c-FMS%29+tyrosine+kinase+in+transfected+cells+by+ABT-869+and+other+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors</span></div><div class="casAuthors">Guo, Jun; Marcotte, Patrick A.; McCall, J. Owen; Dai, Yujia; Pease, Lori J.; Michaelides, Michael R.; Davidsen, Steven K.; Glaser, Keith B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1007-1013</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The properties of several multitargeted receptor tyrosine kinase inhibitors were studied for their inhibition of colony-stimulating factor-1 receptor (CSF-1R) signaling.  A structurally novel, multitargeted tyrosine kinase inhibitor (ABT-869), imatinib (STI571), and 4 compds. currently in clin. development (AG013736, BAY 43-9006, CHIR258, and SU11248) were tested for inhibition of CSF-1R signaling in both the enzymic and cellular assays.  ABT-869 showed potent CSF-1R inhibition in both the enzyme and cell-based assays (IC50s < 20 nmol/L).  In contrast to a previous report, we have found that imatinib has activity against human CSF-1R in both assays at submicromolar concns.  In enzyme assays, we have found that the inhibition of CSF-1R by both ABT-869 and imatinib are competitive with ATP, with Ki values of 3 and 120 nmol/L, resp.  SU11248 is a potent inhibitor of CSF-1R in the enzyme assay (IC50 = 7 nmol/L) and inhibits receptor phosphorylation in the cellular assay (IC50 = 61 nmol/L).  AG013736 was also a potent inhibitor of CSF-1R in both assays (enzyme, IC50 = 16 nmol/L; cellular, IC50 = 21 nmol/L), whereas BAY 43-9006 is less potent in the enzyme assay (IC50 = 107 nmol/L) than in the cellular system (IC50 = 20 nmol/L).  In contrast, we found that CHIR258 had less activity in the cellular assay (IC50 = 535 nmol/L) relative to its enzymic potency (IC50 = 26 nmol/L).  These results show the use of a cell-based assay to confirm the inhibitory activity of lead compds. and drug candidates, such as ABT-869, against the CSF-1R protein in situ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ5C32GMFCGbVg90H21EOLACvtfcHk0lj47rGxhHBUAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFCksL4%253D&md5=b8ce108aba7cd655ef627a8248b8cb7f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0359%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DMcCall%26aufirst%3DJ.%2BO.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26atitle%3DInhibition%2520of%2520phosphorylation%2520of%2520the%2520colony-stimulating%2520factor-1%2520receptor%2520%2528c-FMS%2529%2520tyrosine%2520kinase%2520in%2520transfected%2520cells%2520by%2520ABT-869%2520and%2520other%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1007%26epage%3D1013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Patch, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asgari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baindur, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chadha, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georgiadis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span> </span><span class="NLM_article-title">Potent 2′-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6070</span><span class="NLM_x">–</span> <span class="NLM_lpage">6074</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6070-6074&author=R.+J.+Patchauthor=B.+M.+Brandtauthor=D.+Asgariauthor=N.+Baindurauthor=N.+K.+Chadhaauthor=T.+Georgiadisauthor=W.+S.+Cheungauthor=I.+P.+Petrouniaauthor=R.+R.+Donatelliauthor=M.+A.+Chaikinauthor=M.+R.+Player&title=Potent+2%E2%80%B2-aminoanilide+inhibitors+of+cFMS+as+potential+anti-inflammatory+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPatch%26aufirst%3DR.%2BJ.%26aulast%3DBrandt%26aufirst%3DB.%2BM.%26aulast%3DAsgari%26aufirst%3DD.%26aulast%3DBaindur%26aufirst%3DN.%26aulast%3DChadha%26aufirst%3DN.%2BK.%26aulast%3DGeorgiadis%26aufirst%3DT.%26aulast%3DCheung%26aufirst%3DW.%2BS.%26aulast%3DPetrounia%26aufirst%3DI.%2BP.%26aulast%3DDonatelli%26aufirst%3DR.%2BR.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26atitle%3DPotent%25202%25E2%2580%25B2-aminoanilide%2520inhibitors%2520of%2520cFMS%2520as%2520potential%2520anti-inflammatory%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6070%26epage%3D6074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Illig, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballentine, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczuk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegalla, S. K.</span><span> </span><span class="NLM_article-title">Discovery of novel FMS kinase inhibitors as anti-inflammatory agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1642</span><span class="NLM_x">–</span> <span class="NLM_lpage">1648</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1642-1648&author=C.+R.+Illigauthor=J.+Chenauthor=M.+J.+Wallauthor=K.+J.+Wilsonauthor=S.+K.+Ballentineauthor=M.+J.+Rudolphauthor=R.+L.+DesJarlaisauthor=Y.+Chenauthor=C.+Schubertauthor=I.+Petrouniaauthor=C.+S.+Cryslerauthor=C.+J.+Molloyauthor=M.+A.+Chaikinauthor=C.+L.+Mantheyauthor=M.+R.+Playerauthor=B.+E.+Tomczukauthor=S.+K.+Meegalla&title=Discovery+of+novel+FMS+kinase+inhibitors+as+anti-inflammatory+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIllig%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DRudolph%26aufirst%3DM.%2BJ.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DPetrounia%26aufirst%3DI.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DMolloy%26aufirst%3DC.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26aulast%3DMeegalla%26aufirst%3DS.%2BK.%26atitle%3DDiscovery%2520of%2520novel%2520FMS%2520kinase%2520inhibitors%2520as%2520anti-inflammatory%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1642%26epage%3D1648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Meegalla, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballentine, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczuk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illig, C. R.</span><span> </span><span class="NLM_article-title">Structure-based optimization of a potent class of arylamide FMS inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3632</span><span class="NLM_x">–</span> <span class="NLM_lpage">3637</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3632-3637&author=S.+K.+Meegallaauthor=M.+J.+Wallauthor=J.+Chenauthor=K.+J.+Wilsonauthor=S.+K.+Ballentineauthor=R.+L.+DesJarlaisauthor=C.+Schubertauthor=C.+S.+Cryslerauthor=Y.+Chenauthor=C.+J.+Molloyauthor=M.+A.+Chaikinauthor=C.+L.+Mantheyauthor=M.+R.+Playerauthor=B.+E.+Tomczukauthor=C.+R.+Illig&title=Structure-based+optimization+of+a+potent+class+of+arylamide+FMS+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeegalla%26aufirst%3DS.%2BK.%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMolloy%26aufirst%3DC.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26aulast%3DIllig%26aufirst%3DC.%2BR.%26atitle%3DStructure-based%2520optimization%2520of%2520a%2520potent%2520class%2520of%2520arylamide%2520FMS%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3632%26epage%3D3637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegalla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballentine, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurkow, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boczon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzulla, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patch, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczuk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illig, C. R.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2097</span><span class="NLM_x">–</span> <span class="NLM_lpage">2102</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2097-2102&author=M.+J.+Wallauthor=J.+Chenauthor=S.+Meegallaauthor=S.+K.+Ballentineauthor=K.+J.+Wilsonauthor=R.+L.+DesJarlaisauthor=C.+Schubertauthor=M.+A.+Chaikinauthor=C.+Cryslerauthor=I.+P.+Petrouniaauthor=R.+R.+Donatelliauthor=E.+J.+Yurkowauthor=L.+Boczonauthor=M.+Mazzullaauthor=M.+R.+Playerauthor=R.+J.+Patchauthor=C.+L.+Mantheyauthor=C.+Molloyauthor=B.+E.+Tomczukauthor=C.+R.+Illig&title=Synthesis+and+evaluation+of+novel+3%2C4%2C6-substituted+2-quinolones+as+FMS+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMeegalla%26aufirst%3DS.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DCrysler%26aufirst%3DC.%26aulast%3DPetrounia%26aufirst%3DI.%2BP.%26aulast%3DDonatelli%26aufirst%3DR.%2BR.%26aulast%3DYurkow%26aufirst%3DE.%2BJ.%26aulast%3DBoczon%26aufirst%3DL.%26aulast%3DMazzulla%26aufirst%3DM.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DPatch%26aufirst%3DR.%2BJ.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DMolloy%26aufirst%3DC.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26aulast%3DIllig%26aufirst%3DC.%2BR.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%25203%252C4%252C6-substituted%25202-quinolones%2520as%2520FMS%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2097%26epage%3D2102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutta, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span> </span><span class="NLM_article-title">Design and Synthesis of a Pyrido[2,3-<i>d</i>]pyrimidin-5-one Class of Anti-inflammatory FMS Inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2355</span><span class="NLM_x">–</span> <span class="NLM_lpage">2361</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2355-2361&author=H.+Huangauthor=D.+A.+Huttaauthor=H.+Huauthor=R.+L.+DesJarlaisauthor=C.+Schubertauthor=I.+P.+Petrouniaauthor=M.+A.+Chaikinauthor=C.+L.+Mantheyauthor=M.+R.+Player&title=Design+and+Synthesis+of+a+Pyrido%5B2%2C3-d%5Dpyrimidin-5-one+Class+of+Anti-inflammatory+FMS+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHutta%26aufirst%3DD.%2BA.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DPetrounia%26aufirst%3DI.%2BP.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520a%2520Pyrido%255B2%252C3-d%255Dpyrimidin-5-one%2520Class%2520of%2520Anti-inflammatory%2520FMS%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2355%26epage%3D2361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Pesson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoine, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabassier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geiger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Lajudie, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leriche, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patte, S.</span><span> </span><span class="NLM_article-title">Antibacterial derivatives of 8-alkyl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic acids. I. New procedure of preparation</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1974</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">585</span><span class="NLM_x">–</span> <span class="NLM_lpage">590</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1974&pages=585-590&author=M.+Pessonauthor=M.+Antoineauthor=S.+Chabassierauthor=S.+Geigerauthor=P.+Girardauthor=D.+Richerauthor=P.+De+Lajudieauthor=E.+Horvathauthor=B.+Lericheauthor=S.+Patte&title=Antibacterial+derivatives+of+8-alkyl-5-oxo-5%2C8-dihydropyrido%5B2%2C3-d%5Dpyrimidine-6-carboxylic+acids.+I.+New+procedure+of+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPesson%26aufirst%3DM.%26aulast%3DAntoine%26aufirst%3DM.%26aulast%3DChabassier%26aufirst%3DS.%26aulast%3DGeiger%26aufirst%3DS.%26aulast%3DGirard%26aufirst%3DP.%26aulast%3DRicher%26aufirst%3DD.%26aulast%3DDe%2BLajudie%26aufirst%3DP.%26aulast%3DHorvath%26aufirst%3DE.%26aulast%3DLeriche%26aufirst%3DB.%26aulast%3DPatte%26aufirst%3DS.%26atitle%3DAntibacterial%2520derivatives%2520of%25208-alkyl-5-oxo-5%252C8-dihydropyrido%255B2%252C3-d%255Dpyrimidine-6-carboxylic%2520acids.%2520I.%2520New%2520procedure%2520of%2520preparation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D1974%26volume%3D9%26spage%3D585%26epage%3D590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Tomita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuzuki, Y.i</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibamori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tashima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kajikawa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashimoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hino, K.</span><span> </span><span class="NLM_article-title">Synthesis and structure−activity relationships of novel 7-substituted 1,4-dihydro-4-<i>oxo</i>-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor Agents. Part 1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">5564</span><span class="NLM_x">–</span> <span class="NLM_lpage">5575</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm010057b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=5564-5575&author=K.+Tomitaauthor=Y.i+Tsuzukiauthor=K.+Shibamoriauthor=M.+Tashimaauthor=F.+Kajikawaauthor=Y.+Satoauthor=S.+Kashimotoauthor=K.+Chibaauthor=K.+Hino&title=Synthesis+and+structure%E2%88%92activity+relationships+of+novel+7-substituted+1%2C4-dihydro-4-oxo-1-%282-thiazolyl%29-1%2C8-naphthyridine-3-carboxylic+acids+as+antitumor+Agents.+Part+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm010057b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010057b%26sid%3Dliteratum%253Aachs%26aulast%3DTomita%26aufirst%3DK.%26aulast%3DTsuzuki%26aufirst%3DY.i%26aulast%3DShibamori%26aufirst%3DK.%26aulast%3DTashima%26aufirst%3DM.%26aulast%3DKajikawa%26aufirst%3DF.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DKashimoto%26aufirst%3DS.%26aulast%3DChiba%26aufirst%3DK.%26aulast%3DHino%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520structure%25E2%2588%2592activity%2520relationships%2520of%2520novel%25207-substituted%25201%252C4-dihydro-4-oxo-1-%25282-thiazolyl%2529-1%252C8-naphthyridine-3-carboxylic%2520acids%2520as%2520antitumor%2520Agents.%2520Part%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D5564%26epage%3D5575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Ruesdale, L. K.; Sherbine, J. P.; Vanasse, B. J.</span><span> </span><span class="NLM_article-title">Preparation of 2,4-dihydroxypyridine and 2,4-dihydroxy-3-nitropyridine and nucleoside derivatives useful for treating cardiovascular diseases</span>. PCT Int. Appl. WO9724327A1,<span class="NLM_x"> </span><span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=L.+K.+Ruesdale&author=J.+P.+Sherbine&author=B.+J.+Vanasse&title=Preparation+of+2%2C4-dihydroxypyridine+and+2%2C4-dihydroxy-3-nitropyridine+and+nucleoside+derivatives+useful+for+treating+cardiovascular+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRuesdale%26aufirst%3DL.%2BK.%26atitle%3DPreparation%2520of%25202%252C4-dihydroxypyridine%2520and%25202%252C4-dihydroxy-3-nitropyridine%2520and%2520nucleoside%2520derivatives%2520useful%2520for%2520treating%2520cardiovascular%2520diseases%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Schalk-Hihi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struble, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayoumy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mezzasalma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasberger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deckman, I. C.</span><span> </span><span class="NLM_article-title">Protein engineering of the colony-stimulating factor-1 receptor kinase domain for structural studies</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">4085</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=4085&author=C.+Schalk-Hihiauthor=H.+C.+Maauthor=G.+T.+Strubleauthor=S.+Bayoumyauthor=R.+Williamsauthor=E.+Devineauthor=I.+P.+Petrouniaauthor=T.+Mezzasalmaauthor=L.+Zengauthor=C.+Schubertauthor=B.+Grasbergerauthor=B.+A.+Springerauthor=I.+C.+Deckman&title=Protein+engineering+of+the+colony-stimulating+factor-1+receptor+kinase+domain+for+structural+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchalk-Hihi%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DH.%2BC.%26aulast%3DStruble%26aufirst%3DG.%2BT.%26aulast%3DBayoumy%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DDevine%26aufirst%3DE.%26aulast%3DPetrounia%26aufirst%3DI.%2BP.%26aulast%3DMezzasalma%26aufirst%3DT.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DGrasberger%26aufirst%3DB.%26aulast%3DSpringer%26aufirst%3DB.%2BA.%26aulast%3DDeckman%26aufirst%3DI.%2BC.%26atitle%3DProtein%2520engineering%2520of%2520the%2520colony-stimulating%2520factor-1%2520receptor%2520kinase%2520domain%2520for%2520structural%2520studies%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D4085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Schubert, C.; Schalk-Hihi, C.; Struble, G. T.; Ma, H. C.; Petrounia, I. P.; Brandt, B.; Deckman, I. C.; Patch, R. J.; Player, M. R.; Spurlino, J. C.; Springer, B. A.</span><span> </span><span class="NLM_article-title">Crystal Structure of the Tyrosine Kinase Domain of Colony-stimulating Factor-1 Receptor (cFMS) in Complex with Two Inhibitors</span>.  <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">4094</span><div class="note"><p class="first last">(PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2I0Y">2I0Y</a>)</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=4094&author=C.+Schubert&author=C.+Schalk-Hihi&author=G.+T.+Struble&author=H.+C.+Ma&author=I.+P.+Petrounia&author=B.+Brandt&author=I.+C.+Deckman&author=R.+J.+Patch&author=M.+R.+Player&author=J.+C.+Spurlino&author=B.+A.+Springer&title=Crystal+Structure+of+the+Tyrosine+Kinase+Domain+of+Colony-stimulating+Factor-1+Receptor+%28cFMS%29+in+Complex+with+Two+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchubert%26aufirst%3DC.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Tyrosine%2520Kinase%2520Domain%2520of%2520Colony-stimulating%2520Factor-1%2520Receptor%2520%2528cFMS%2529%2520in%2520Complex%2520with%2520Two%2520Inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D4094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><div class="note"><p class="first last">The Cerep high-throughput profile consists of a broad collection of 50 transmembrane and soluble receptors, ion channels, and monoamine transporters. It has been specifically designed to provide information not only on potential limitations or liabilities of drug candidates, but also for off-target activity identification. For the test compounds, the results are expressed as a percent inhibition of control specific binding (mean values, <i>n</i> = 2).</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+Cerep+high-throughput+profile+consists+of+a+broad+collection+of+50+transmembrane+and+soluble+receptors%2C+ion+channels%2C+and+monoamine+transporters.+It+has+been+specifically+designed+to+provide+information+not+only+on+potential+limitations+or+liabilities+of+drug+candidates%2C+but+also+for+off-target+activity+identification.+For+the+test+compounds%2C+the+results+are+expressed+as+a+percent+inhibition+of+control+specific+binding+%28mean+values%2C+n+%3D+2%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Swindell, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, R. H.</span><span> </span><span class="NLM_article-title">A Useful Construction of 4-Substituted 1-Alkylpiperid-3-ones</span> <span class="citation_source-journal">Heterocycles</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">3373</span><span class="NLM_x">–</span> <span class="NLM_lpage">3377</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1986&pages=3373-3377&author=C.+S.+Swindellauthor=R.+H.+Duffy&title=A+Useful+Construction+of+4-Substituted+1-Alkylpiperid-3-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSwindell%26aufirst%3DC.%2BS.%26aulast%3DDuffy%26aufirst%3DR.%2BH.%26atitle%3DA%2520Useful%2520Construction%2520of%25204-Substituted%25201-Alkylpiperid-3-ones%26jtitle%3DHeterocycles%26date%3D1986%26volume%3D24%26spage%3D3373%26epage%3D3377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ratajczak, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luger, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerwirtz, A. M.</span><span> </span><span class="NLM_article-title">The c-kit proto-oncogene in normal and malignant human hematopoiesis</span> <span class="citation_source-journal">Int. J. Cell Cloning</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">214</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=1379619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADyaK38XlvV2itrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1992&pages=205-214&author=M.+Z.+Ratajczakauthor=S.+M.+Lugerauthor=A.+M.+Gerwirtz&title=The+c-kit+proto-oncogene+in+normal+and+malignant+human+hematopoiesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">The c-kit proto-oncogene in normal and malignant human hematopoiesis</span></div><div class="casAuthors">Ratajczak, Mariusz Z.; Luger, Selina M.; Gewirtz, Alan M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cell Cloning</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">205-14</span>CODEN:
                <span class="NLM_cas:coden">IJCCE3</span>;
        ISSN:<span class="NLM_cas:issn">0737-1454</span>.
    </div><div class="casAbstract">A review with 94 refs.  The c-kit proto-oncogene encodes a tyrosine kinase receptor (KIT) which is expressed on many types of human cells, including ∼4% of bone marrow mononuclear cells.  Numerous studies attest to the importance of the c-kit receptor and its ligand, known variously as stem cell factor (SCF), mast cell growth factor (MGF), Steel factor (SF), or kit ligand (KL) (the nomenclature the authors prefer), in the development of human hematopoietic cells.  KL, which is produced in membrane-bound and sol. froms by bone marrow stromal cells, acts on pre-colony forming units (pre-CFU) and CFU cells.  In synergistic combination with other cytokines, KL enhances the growth of myeloid progenitor cells.  However, using an antisense oligodeoxynucleotide strategy to disrupt c-kit function, the author demonstrated that the KL-KIT complex is of greatest importance for generation and/or proliferation of normal human erythropoietic progenitor cells.  In malignant hematopoietic cells, the complex also appears to be important for growth of granulocyte/macrophage (GM) CFU as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9TGmflMqWsrVg90H21EOLACvtfcHk0ljWO1s3qv0rMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvV2itrk%253D&md5=1ebd90ce8ec954eff24eed7a225b3832</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRatajczak%26aufirst%3DM.%2BZ.%26aulast%3DLuger%26aufirst%3DS.%2BM.%26aulast%3DGerwirtz%26aufirst%3DA.%2BM.%26atitle%3DThe%2520c-kit%2520proto-oncogene%2520in%2520normal%2520and%2520malignant%2520human%2520hematopoiesis%26jtitle%3DInt.%2520J.%2520Cell%2520Cloning%26date%3D1992%26volume%3D10%26spage%3D205%26epage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Smolich, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span> </span><span class="NLM_article-title">The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">1413</span><span class="NLM_x">–</span> <span class="NLM_lpage">1421</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2001&pages=1413-1421&author=B.+D.+Smolichauthor=H.+A.+Yuenauthor=K.+A.+Westauthor=F.+J.+Gilesauthor=M.+Albitarauthor=J.+M.+Cherrington&title=The+antiangiogenic+protein+kinase+inhibitors+SU5416+and+SU6668+inhibit+the+SCF+receptor+%28c-kit%29+in+a+human+myeloid+leukemia+cell+line+and+in+acute+myeloid+leukemia+blasts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmolich%26aufirst%3DB.%2BD.%26aulast%3DYuen%26aufirst%3DH.%2BA.%26aulast%3DWest%26aufirst%3DK.%2BA.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520antiangiogenic%2520protein%2520kinase%2520inhibitors%2520SU5416%2520and%2520SU6668%2520inhibit%2520the%2520SCF%2520receptor%2520%2528c-kit%2529%2520in%2520a%2520human%2520myeloid%2520leukemia%2520cell%2520line%2520and%2520in%2520acute%2520myeloid%2520leukemia%2520blasts%26jtitle%3DBlood%26date%3D2001%26volume%3D97%26spage%3D1413%26epage%3D1421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Geissler, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Housman, D. E.</span><span> </span><span class="NLM_article-title">The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">185</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1988&pages=185-92&author=E.+N.+Geisslerauthor=M.+A.+Ryanauthor=D.+E.+Housman&title=The+dominant-white+spotting+%28W%29+locus+of+the+mouse+encodes+the+c-kit+proto-oncogene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeissler%26aufirst%3DE.%2BN.%26aulast%3DRyan%26aufirst%3DM.%2BA.%26aulast%3DHousman%26aufirst%3DD.%2BE.%26atitle%3DThe%2520dominant-white%2520spotting%2520%2528W%2529%2520locus%2520of%2520the%2520mouse%2520encodes%2520the%2520c-kit%2520proto-oncogene%26jtitle%3DCell%26date%3D1988%26volume%3D55%26spage%3D185%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit34b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bijangi-Vishehsaraei, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saadatzadeh, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenzie, K. A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapur, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichijo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haneline, L. S.</span><span> </span><span class="NLM_article-title">Enhanced TNF-alpha-induced apoptosis in Fanconi anemia type C-deficient cells is dependent on apoptosis signal-regulating kinase 1</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">4124</span><span class="NLM_x">–</span> <span class="NLM_lpage">4130</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=4124-4130&author=K.+Bijangi-Vishehsaraeiauthor=M.+R.+Saadatzadehauthor=A.+Werneauthor=K.+A.+W.+McKenzieauthor=R.+Kapurauthor=H.+Ichijoauthor=L.+S.+Haneline&title=Enhanced+TNF-alpha-induced+apoptosis+in+Fanconi+anemia+type+C-deficient+cells+is+dependent+on+apoptosis+signal-regulating+kinase+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBijangi-Vishehsaraei%26aufirst%3DK.%26aulast%3DSaadatzadeh%26aufirst%3DM.%2BR.%26aulast%3DWerne%26aufirst%3DA.%26aulast%3DMcKenzie%26aufirst%3DK.%2BA.%2BW.%26aulast%3DKapur%26aufirst%3DR.%26aulast%3DIchijo%26aufirst%3DH.%26aulast%3DHaneline%26aufirst%3DL.%2BS.%26atitle%3DEnhanced%2520TNF-alpha-induced%2520apoptosis%2520in%2520Fanconi%2520anemia%2520type%2520C-deficient%2520cells%2520is%2520dependent%2520on%2520apoptosis%2520signal-regulating%2520kinase%25201%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D4124%26epage%3D4130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Orlofsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, E. R.</span><span> </span><span class="NLM_article-title">CSF 1-induced gene expression in macrophages: dissociation from the mitogenic response</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2947</span><span class="NLM_x">–</span> <span class="NLM_lpage">2952</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1987&pages=2947-2952&author=A.+Orlofskyauthor=E.+R.+Stanley&title=CSF+1-induced+gene+expression+in+macrophages%3A+dissociation+from+the+mitogenic+response"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrlofsky%26aufirst%3DA.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DCSF%25201-induced%2520gene%2520expression%2520in%2520macrophages%253A%2520dissociation%2520from%2520the%2520mitogenic%2520response%26jtitle%3DEMBO%2520J.%26date%3D1987%26volume%3D6%26spage%3D2947%26epage%3D2952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Chan, J. M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villarreal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stepan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burstein, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, S. M.</span><span> </span><span class="NLM_article-title">Intraarticular gene transfer of TNFR: Fc suppresses experimental arthritis with reduced systemic distribution of the gene product</span> <span class="citation_source-journal">Mol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">736</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1006%2Fmthe.2002.0808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=12498769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD38XpslWksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2002&pages=727-736&author=J.+M.+K.+Chanauthor=G.+Villarrealauthor=W.+W.+Jinauthor=T.+Stepanauthor=H.+Bursteinauthor=S.+M.+Wahl&title=Intraarticular+gene+transfer+of+TNFR%3A+Fc+suppresses+experimental+arthritis+with+reduced+systemic+distribution+of+the+gene+product"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product</span></div><div class="casAuthors">Chan, James M. K.; Villarreal, Gilda; Jin, Wen Wen; Stepan, Tony; Burstein, Haim; Wahl, Sharon M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">727-736</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">Tumor necrosis factor α (TNFα) plays a pivotal role in the pathogenesis of rheumatoid arthritis (RA).  Blockage of TNFα actions by systemic administration of TNF antagonists has recently been shown to ameliorate joint symptoms in RA patients.  In the present study, a streptococcal cell wall (SCW)-induced rat arthritis model was used to evaluate the effect of different gene transfer routes of a TNF antagonist on the development and severity of arthritis.  Successful delivery of a plasmid DNA encoding a rat TNF receptor-Ig Fc (TNFR:Fc) fusion gene prompted the subsequent administration of a recombinant adeno-assocd. virus (rAAV) vector encoding the antagonist, either locally (intraarticular) or systemically (i.m.).  The TNFR:Fc gene, delivered by either route, resulted in profound suppression of the arthritis as reflected in decreased inflammatory cell infiltration, pannus formation, cartilage and bone destruction, and mRNA expression of joint proinflammatory cytokines.  Increased bioactive serum TNFR levels were detected as a result of rAAV-ratTNFR:Fc administration, concomitant with a decrease in circulating TNFα.  Administration of the rAAV-ratTNFR:Fc vector to one joint also suppressed arthritis in the contralateral joint.  Importantly, intraarticular administration resulted in significantly lower systemic distribution of the gene product.  Hence, the use of rAAV as the delivery vector for TNFR:Fc effectively suppressed SCW-induced arthritis and may provide an approach for local delivery of antiarthritic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpROWpmzJMjOrVg90H21EOLACvtfcHk0li9ovpvOugQxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpslWksbs%253D&md5=1ff2e4236623574a892f92c7ba08be06</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1006%2Fmthe.2002.0808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fmthe.2002.0808%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DJ.%2BM.%2BK.%26aulast%3DVillarreal%26aufirst%3DG.%26aulast%3DJin%26aufirst%3DW.%2BW.%26aulast%3DStepan%26aufirst%3DT.%26aulast%3DBurstein%26aufirst%3DH.%26aulast%3DWahl%26aufirst%3DS.%2BM.%26atitle%3DIntraarticular%2520gene%2520transfer%2520of%2520TNFR%253A%2520Fc%2520suppresses%2520experimental%2520arthritis%2520with%2520reduced%2520systemic%2520distribution%2520of%2520the%2520gene%2520product%26jtitle%3DMol.%2520Ther.%26date%3D2002%26volume%3D6%26spage%3D727%26epage%3D736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Cromartie, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craddock, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderlie, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. H.</span><span> </span><span class="NLM_article-title">Arthritis in rats after systemic injection of streptococcal cells or cell walls</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">1585</span><span class="NLM_x">–</span> <span class="NLM_lpage">1602</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=1977&pages=1585-1602&author=W.+J.+Cromartieauthor=J.+G.+Craddockauthor=J.+H.+Schwabauthor=S.+K.+Anderlieauthor=C.+H.+Yang&title=Arthritis+in+rats+after+systemic+injection+of+streptococcal+cells+or+cell+walls"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCromartie%26aufirst%3DW.%2BJ.%26aulast%3DCraddock%26aufirst%3DJ.%2BG.%26aulast%3DSchwab%26aufirst%3DJ.%2BH.%26aulast%3DAnderlie%26aufirst%3DS.%2BK.%26aulast%3DYang%26aufirst%3DC.%2BH.%26atitle%3DArthritis%2520in%2520rats%2520after%2520systemic%2520injection%2520of%2520streptococcal%2520cells%2520or%2520cell%2520walls%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1977%26volume%3D146%26spage%3D1585%26epage%3D1602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Richards, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, A. S.</span><span> </span><span class="NLM_article-title">Suppression of chronic streptococcal cell wall-induced arthritis in lewis rats by liposomal clodronate</span> <span class="citation_source-journal">Rheumatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">978</span><span class="NLM_x">–</span> <span class="NLM_lpage">987</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=978-987&author=P.+J.+Richardsauthor=B.+D.+Williamsauthor=A.+S.+Williams&title=Suppression+of+chronic+streptococcal+cell+wall-induced+arthritis+in+lewis+rats+by+liposomal+clodronate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichards%26aufirst%3DP.%2BJ.%26aulast%3DWilliams%26aufirst%3DB.%2BD.%26aulast%3DWilliams%26aufirst%3DA.%2BS.%26atitle%3DSuppression%2520of%2520chronic%2520streptococcal%2520cell%2520wall-induced%2520arthritis%2520in%2520lewis%2520rats%2520by%2520liposomal%2520clodronate%26jtitle%3DRheumatology%26date%3D2001%26volume%3D40%26spage%3D978%26epage%3D987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tak, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeets, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daha, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluin, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijers, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brand, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinders, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breedveld, F. C.</span><span> </span><span class="NLM_article-title">Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to disease activity</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1002%2Fart.1780400206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=9041933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A280%3ADyaK2s7psVCqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=217-225&author=P.+P.+Takauthor=T.+J.+Smeetsauthor=M.+R.+Dahaauthor=P.+M.+Kluinauthor=K.+A.+Meijersauthor=R.+Brandauthor=A.+E.+Meindersauthor=F.+C.+Breedveld&title=Analysis+of+the+synovial+cell+infiltrate+in+early+rheumatoid+synovial+tissue+in+relation+to+disease+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity</span></div><div class="casAuthors">Tak P P; Smeets T J; Daha M R; Kluin P M; Meijers K A; Brand R; Meinders A E; Breedveld F C</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis and rheumatism</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-25</span>
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    </div><div class="casAbstract">OBJECTIVE:  To define variations in the cellular infiltrate and in the expression of monokines in synovial tissue (ST) from rheumatoid arthritis (RA) patients with different durations of disease and different levels of disease activity.  METHODS:  The immunohistologic features of synovial biopsy specimens from 31 patients with early RA (< 1 year) and 35 patients with longstanding RA (> 5 years) were compared.  The possible associations between these features and local disease activity, as measured by the score for pain in the biopsied knee joint were also evaluated.  RESULTS:  The immunohistologic features were not dependent on disease duration.  We found a positive correlation between the scores for knee pain and the semiquantitative scores for the number of macrophages, as well as the expression of interleukin-6 and tumor necrosis factor alpha, whereas the correlation with the scores for CD4+ T cells was negative.  Multivariate analysis showed that these correlations were highly statistically significant (P < 0.003).  CONCLUSION:  The results do not support the view that inflammatory mechanisms in the synovial tissues of RA patients differ between early and late stages of the disease.  The findings presented here are consistent with the concept that early RA is the result of a synovitis process of longer duration and that macrophage-derived cytokines play an important role in maintaining the clinical signs of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7XPNbuR4ndNbHMBt0mMIXfW6udTcc2eabk1qj59KeUrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7psVCqtw%253D%253D&md5=ce8d3e3ad53739d459b024a049a132cf</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1002%2Fart.1780400206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.1780400206%26sid%3Dliteratum%253Aachs%26aulast%3DTak%26aufirst%3DP.%2BP.%26aulast%3DSmeets%26aufirst%3DT.%2BJ.%26aulast%3DDaha%26aufirst%3DM.%2BR.%26aulast%3DKluin%26aufirst%3DP.%2BM.%26aulast%3DMeijers%26aufirst%3DK.%2BA.%26aulast%3DBrand%26aufirst%3DR.%26aulast%3DMeinders%26aufirst%3DA.%2BE.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26atitle%3DAnalysis%2520of%2520the%2520synovial%2520cell%2520infiltrate%2520in%2520early%2520rheumatoid%2520synovial%2520tissue%2520in%2520relation%2520to%2520disease%2520activity%26jtitle%3DArthritis%2520Rheum.%26date%3D1997%26volume%3D40%26spage%3D217%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit39b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Haringman, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlag, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwinderman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeets, T. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baeten, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInnes, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bresnihan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tak, P. P.</span><span> </span><span class="NLM_article-title">Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">–</span> <span class="NLM_lpage">838</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1136%2Fard.2004.029751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=15576415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXls1als70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2005&pages=834-838&author=J.+J.+Haringmanauthor=D.+M.+Gerlagauthor=A.+H.+Zwindermanauthor=T.+J.+M.+Smeetsauthor=M.+C.+Kraanauthor=D.+Baetenauthor=I.+B.+McInnesauthor=B.+Bresnihanauthor=P.+P.+Tak&title=Synovial+tissue+macrophages%3A+a+sensitive+biomarker+for+response+to+treatment+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39bR"><div class="casContent"><span class="casTitleNuber">39b</span><div class="casTitle"><span class="NLM_cas:atitle">Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis</span></div><div class="casAuthors">Haringman, J. J.; Gerlag, D. M.; Zwinderman, A. H.; Smeets, T. J. M.; Kraan, M. C.; Baeten, D.; McInnes, I. B.; Bresnihan, B.; Tak, P. P.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">834-838</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background: Previous work identified synovial sublining macrophage nos. as a potential biomarker for clin. efficacy in rheumatoid arthritis.  Objective: To investigate the assocn. between changes in infiltration of synovial macrophages and clin. improvement after antirheumatic treatment.  Methods: 88 patients who participated in various clin. trials were studied.  All patients underwent serial arthroscopy before initiation of treatment and after different time intervals.  Immunohistochem. and digital image anal. were performed according to standardized procedures to detect changes in CD68+ synovial sublining macrophages in relationship to changes in the 28 joint count Disease Activity Score (DAS28).  Statistical anal. was performed using one way anal. of variance, the independent samples t test, linear regression, and the standardized response mean (SRM).  Results: For good, moderate, and non-responders, according to the DAS28 response criteria, there was a significant difference in the change in sublining macrophages (mean (SEM) cells/mm2 -643 (124), -270 (64), and -95 (60), resp.; p<0.0003).  There was a significant correlation between the change in the no. of macrophages and the change in DAS28 (Pearson correlation 0.874, p<0.01).  The change in sublining macrophages explained 76% of the variation in the change in DAS28 (p<0.02).  The sensitivity to change of the biomarker was high in patients treated actively (SRM >0.8), whereas the ability to detect changes in placebo treated patients was weak (SRM <0.3).  Conclusion: The results suggest that changes in synovial sublining macrophages can be used to predict possible efficacy of antirheumatic treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoDDuysAUtsbVg90H21EOLACvtfcHk0ljHPGHNmRZrHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXls1als70%253D&md5=3fdb6f7b0d2c170ca58e40af83af054f</span></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=10.1136%2Fard.2004.029751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2004.029751%26sid%3Dliteratum%253Aachs%26aulast%3DHaringman%26aufirst%3DJ.%2BJ.%26aulast%3DGerlag%26aufirst%3DD.%2BM.%26aulast%3DZwinderman%26aufirst%3DA.%2BH.%26aulast%3DSmeets%26aufirst%3DT.%2BJ.%2BM.%26aulast%3DKraan%26aufirst%3DM.%2BC.%26aulast%3DBaeten%26aufirst%3DD.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DBresnihan%26aufirst%3DB.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DSynovial%2520tissue%2520macrophages%253A%2520a%2520sensitive%2520biomarker%2520for%2520response%2520to%2520treatment%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2005%26volume%3D64%26spage%3D834%26epage%3D838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">DAI, x. m.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hapel, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sylvestre, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, E. R.</span><span> </span><span class="NLM_article-title">Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">120</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=111-120&author=x.+m.+DAIauthor=G.+R.+Ryanauthor=A.+J.+Hapelauthor=M.+G.+Dominguezauthor=R.+G.+Russellauthor=S.+Kappauthor=V.+Sylvestreauthor=E.+R.+Stanley&title=Targeted+disruption+of+the+mouse+colony-stimulating+factor+1+receptor+gene+results+in+osteopetrosis%2C+mononuclear+phagocyte+deficiency%2C+increased+primitive+progenitor+cell+frequencies%2C+and+reproductive+defects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDAI%26aufirst%3Dx.%2Bm.%26aulast%3DRyan%26aufirst%3DG.%2BR.%26aulast%3DHapel%26aufirst%3DA.%2BJ.%26aulast%3DDominguez%26aufirst%3DM.%2BG.%26aulast%3DRussell%26aufirst%3DR.%2BG.%26aulast%3DKapp%26aufirst%3DS.%26aulast%3DSylvestre%26aufirst%3DV.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DTargeted%2520disruption%2520of%2520the%2520mouse%2520colony-stimulating%2520factor%25201%2520receptor%2520gene%2520results%2520in%2520osteopetrosis%252C%2520mononuclear%2520phagocyte%2520deficiency%252C%2520increased%2520primitive%2520progenitor%2520cell%2520frequencies%252C%2520and%2520reproductive%2520defects%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26spage%3D111%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Campbell, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischof, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, J. A.</span><span> </span><span class="NLM_article-title">The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by CSF-1 and G-CSF and requirement for endogenous CSF-1</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">144</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=10914502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltVGmtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2000&pages=144-50&author=I.+K.+Campbellauthor=M.+J.+Richauthor=R.+J.+Bischofauthor=J.+A.+Hamilton&title=The+colony-stimulating+factors+and+collagen-induced+arthritis%3A+exacerbation+of+disease+by+CSF-1+and+G-CSF+and+requirement+for+endogenous+CSF-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF</span></div><div class="casAuthors">Campbell, Ian K.; Rich, Melissa J.; Bischof, Robert J.; Hamilton, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">144-150</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">There is increasing evidence that the colony-stimulating factors (CSFs) may play a part in chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA).  The authors examd. the involvement of macrophage CSF (M-CSF or CSF-1) and granulocyte CSF (G-CSF) in collagen-induced arthritis (CIA), a murine model of RA.  Daily injections of M-CSF or G-CSF, 20-24 days postprimary immunization with type II collagen, exacerbated disease symptoms in suboptimally immunized DBA/1 mice.  Support for the involvement of endogenous M-CSF in CIA was obtained by studies in which neutralizing monoclonal antibody reduced the severity of established CIA and also by studies showing the resistance of M-CSF-deficient op/op mice to CIA induction.  These studies show that M-CSF and G-CSF can be proinflammatory in CIA and provide evidence that macrophage- and granulocyte-lineage cells can exacerbate CIA.  The authors' results also show that M-CSF-dependent cells are essential for CIA development, suggesting M-CSF may be a suitable target for therapeutic intervention in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobmj_XMRtR77Vg90H21EOLACvtfcHk0ljHPGHNmRZrHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltVGmtrw%253D&md5=e37a81523dba2270449366102252c4b2</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DI.%2BK.%26aulast%3DRich%26aufirst%3DM.%2BJ.%26aulast%3DBischof%26aufirst%3DR.%2BJ.%26aulast%3DHamilton%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520colony-stimulating%2520factors%2520and%2520collagen-induced%2520arthritis%253A%2520exacerbation%2520of%2520disease%2520by%2520CSF-1%2520and%2520G-CSF%2520and%2520requirement%2520for%2520endogenous%2520CSF-1%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2000%26volume%3D68%26spage%3D144%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Tohda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiraku, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ariga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawashima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, Y.</span><span> </span><span class="NLM_article-title">Nucleophilic reaction upon electron-deficient pyridone derivatives. X. One-pot synthesis of 3-nitropyridines by ring transformation of 1-methyl-3,5-dinitro-2-pyridone with ketones or aldehydes in the presence of ammonia</span> <span class="citation_source-journal">Bull. Chem. Soc. Jpn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">2820</span><span class="NLM_x">–</span> <span class="NLM_lpage">2827</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1990&pages=2820-2827&author=Y.+Tohdaauthor=M.+Eirakuauthor=T.+Nakagawaauthor=Y.+Usamiauthor=M.+Arigaauthor=T.+Kawashimaauthor=K.+Taniauthor=H.+Watanabeauthor=Y.+Mori&title=Nucleophilic+reaction+upon+electron-deficient+pyridone+derivatives.+X.+One-pot+synthesis+of+3-nitropyridines+by+ring+transformation+of+1-methyl-3%2C5-dinitro-2-pyridone+with+ketones+or+aldehydes+in+the+presence+of+ammonia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTohda%26aufirst%3DY.%26aulast%3DEiraku%26aufirst%3DM.%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DUsami%26aufirst%3DY.%26aulast%3DAriga%26aufirst%3DM.%26aulast%3DKawashima%26aufirst%3DT.%26aulast%3DTani%26aufirst%3DK.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DMori%26aufirst%3DY.%26atitle%3DNucleophilic%2520reaction%2520upon%2520electron-deficient%2520pyridone%2520derivatives.%2520X.%2520One-pot%2520synthesis%2520of%25203-nitropyridines%2520by%2520ring%2520transformation%2520of%25201-methyl-3%252C5-dinitro-2-pyridone%2520with%2520ketones%2520or%2520aldehydes%2520in%2520the%2520presence%2520of%2520ammonia%26jtitle%3DBull.%2520Chem.%2520Soc.%2520Jpn.%26date%3D1990%26volume%3D63%26spage%3D2820%26epage%3D2827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10a','cit10b','cit10c'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15a','cit15b','cit15c'],'ref16':['cit16a','cit16b'],'ref17':['cit17','cit17b'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23a','cit23b','cit23c'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33a','cit33b'],'ref34':['cit34a','cit34b'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39a','cit39b'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 36 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhicheng Xie, Bing Wu, Yingqiang Liu, Wenming Ren, Linjiang Tong, Caigui Xiang, Aihuan Wei, Yuanzhuo Gao, Limin Zeng, Hua Xie, Wei Tang, <span class="NLM_string-name hlFld-ContribAuthor">Youhong Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Class of Colony-Stimulating Factor 1 Receptor Kinase Inhibitors Based on an o-Aminopyridyl Alkynyl Scaffold as Potential Treatment for Inflammatory Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (3)
                                     , 1397-1414. <a href="https://doi.org/10.1021/acs.jmedchem.9b01912" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01912</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01912%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BClass%252Bof%252BColony-Stimulating%252BFactor%252B1%252BReceptor%252BKinase%252BInhibitors%252BBased%252Bon%252Ban%252Bo-Aminopyridyl%252BAlkynyl%252BScaffold%252Bas%252BPotential%252BTreatment%252Bfor%252BInflammatory%252BDisorders%26aulast%3DXie%26aufirst%3DZhicheng%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D26112019%26date%3D14012020%26volume%3D63%26issue%3D3%26spage%3D1397%26epage%3D1414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Nicholas A. Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (14)
                                     , 5822-5880. <a href="https://doi.org/10.1021/acs.jmedchem.7b01788" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01788</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFluorine%252Band%252BFluorinated%252BMotifs%252Bin%252Bthe%252BDesign%252Band%252BApplication%252Bof%252BBioisosteres%252Bfor%252BDrug%252BDesign%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D05122017%26date%3D05022018%26volume%3D61%26issue%3D14%26spage%3D5822%26epage%3D5880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shilin  Xu</span>, <span class="hlFld-ContribAuthor ">Tianfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Lianwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Yingxue  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (21)
                                     , 8803-8813. <a href="https://doi.org/10.1021/jm4012388" title="DOI URL">https://doi.org/10.1021/jm4012388</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm4012388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm4012388%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252B2-Oxo-3%25252C4-dihydropyrimido%25255B4%25252C5-d%25255Dpyrimidinyl%252BDerivatives%252Bas%252BNew%252BIrreversible%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitors%252Bwith%252BImproved%252BPharmacokinetic%252BProperties%26aulast%3DXu%26aufirst%3DShilin%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D09082013%26date%3D31102013%26date%3D14112013%26date%3D14102013%26volume%3D56%26issue%3D21%26spage%3D8803%26epage%3D8813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carl R.  Illig</span>, <span class="hlFld-ContribAuthor ">Carl L.  Manthey</span>, <span class="hlFld-ContribAuthor ">Mark J.  Wall</span>, <span class="hlFld-ContribAuthor ">Sanath K.  Meegalla</span>, <span class="hlFld-ContribAuthor ">Jinsheng  Chen</span>, <span class="hlFld-ContribAuthor ">Kenneth J.  Wilson</span>, <span class="hlFld-ContribAuthor ">Shelley K.  Ballentine</span>, <span class="hlFld-ContribAuthor ">Renee L.  DesJarlais</span>, <span class="hlFld-ContribAuthor ">Carsten  Schubert</span>, <span class="hlFld-ContribAuthor ">Carl S.  Crysler</span>, <span class="hlFld-ContribAuthor ">Yanmin  Chen</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Molloy</span>, <span class="hlFld-ContribAuthor ">Margery A.  Chaikin</span>, <span class="hlFld-ContribAuthor ">Robert R.  Donatelli</span>, <span class="hlFld-ContribAuthor ">Edward  Yurkow</span>, <span class="hlFld-ContribAuthor ">Zhao  Zhou</span>, <span class="hlFld-ContribAuthor ">Mark R.  Player</span>, and <span class="hlFld-ContribAuthor ">Bruce E.  Tomczuk</span>  . </span><span class="cited-content_cbyCitation_article-title">Optimization of a Potent Class of Arylamide Colony-Stimulating Factor-1 Receptor Inhibitors Leading to Anti-inflammatory Clinical Candidate 4-Cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2011,</strong> <em>54 </em>
                                    (22)
                                     , 7860-7883. <a href="https://doi.org/10.1021/jm200900q" title="DOI URL">https://doi.org/10.1021/jm200900q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm200900q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm200900q%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOptimization%252Bof%252Ba%252BPotent%252BClass%252Bof%252BArylamide%252BColony-Stimulating%252BFactor-1%252BReceptor%252BInhibitors%252BLeading%252Bto%252BAnti-inflammatory%252BClinical%252BCandidate%252B4-Cyano-N-%25255B2-%2525281-cyclohexen-1-yl%252529-4-%25255B1-%25255B%252528dimethylamino%252529acetyl%25255D-4-piperidinyl%25255Dphenyl%25255D-1H-imidazole-2-carboxamide%252B%252528JNJ-28312141%252529%26aulast%3DIllig%26aufirst%3DCarl%2BR.%26date%3D2011%26date%3D2011%26date%3D2011%26date%3D08072011%26date%3D31102011%26date%3D24112011%26volume%3D54%26issue%3D22%26spage%3D7860%26epage%3D7883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Riccardo  Surmont</span>, <span class="hlFld-ContribAuthor ">Guido  Verniest</span>, <span class="hlFld-ContribAuthor ">Jan Willem  Thuring</span>, <span class="hlFld-ContribAuthor ">Gregor  Macdonald</span>, <span class="hlFld-ContribAuthor ">Frederik  Deroose</span> and <span class="hlFld-ContribAuthor ">Norbert  De Kimpe</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis of 4-Substituted 3,3-Difluoropiperidines. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2010,</strong> <em>75 </em>
                                    (3)
                                     , 929-932. <a href="https://doi.org/10.1021/jo902164z" title="DOI URL">https://doi.org/10.1021/jo902164z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jo902164z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjo902164z%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252B4-Substituted%252B3%25252C3-Difluoropiperidines%26aulast%3DSurmont%26aufirst%3DRiccardo%26date%3D2010%26date%3D2010%26date%3D2009%26date%3D08102009%26date%3D05012010%26date%3D05022010%26volume%3D75%26issue%3D3%26spage%3D929%26epage%3D932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amar Jyoti  Bhuyan</span>, <span class="hlFld-ContribAuthor ">Pubanita  Bhuyan</span>, <span class="hlFld-ContribAuthor ">Bornali  Boruah</span>, <span class="hlFld-ContribAuthor ">Lakhinath  Saikia</span>. </span><span class="cited-content_cbyCitation_article-title">Magnetically recoverable copper ferrite catalyzed cascade synthesis of 1,3‐dimethyl‐6‐nitro‐5‐arylpyrido[2,3‐
              d
              ]pyrimidine‐2,4(1
              H
              ,3
              H
              )‐diones under microwave irradiation and solvent‐less condition. </span><span class="cited-content_cbyCitation_journal-name">Applied Organometallic Chemistry</span><span> <strong>2021,</strong> <em>35 </em>
                                    (2)
                                     <a href="https://doi.org/10.1002/aoc.6091" title="DOI URL">https://doi.org/10.1002/aoc.6091</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/aoc.6091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Faoc.6091%26sid%3Dliteratum%253Aachs%26jtitle%3DApplied%2520Organometallic%2520Chemistry%26atitle%3DMagnetically%252Brecoverable%252Bcopper%252Bferrite%252Bcatalyzed%252Bcascade%252Bsynthesis%252Bof%252B1%25252C3%2525E2%252580%252590dimethyl%2525E2%252580%2525906%2525E2%252580%252590nitro%2525E2%252580%2525905%2525E2%252580%252590arylpyrido%25255B2%25252C3%2525E2%252580%252590%252Bd%252B%25255Dpyrimidine%2525E2%252580%2525902%25252C4%2525281%252BH%252B%25252C3%252BH%252B%252529%2525E2%252580%252590diones%252Bunder%252Bmicrowave%252Birradiation%252Band%252Bsolvent%2525E2%252580%252590less%252Bcondition%26aulast%3DBhuyan%26aufirst%3DAmar%2BJyoti%26date%3D2021%26date%3D2020%26volume%3D35%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E.  Venkatesh</span>, <span class="hlFld-ContribAuthor ">S.  Narsimha</span>, <span class="hlFld-ContribAuthor ">N. S.  Kumar</span>, <span class="hlFld-ContribAuthor ">N. V.  Reddy</span>. </span><span class="cited-content_cbyCitation_article-title">One Pot Synthesis and Antitumor Activity of Isoxazole-Pyrimido[4,5-c]isoquinolines. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of General Chemistry</span><span> <strong>2020,</strong> <em>90 </em>
                                    (12)
                                     , 2444-2450. <a href="https://doi.org/10.1134/S1070363220120361" title="DOI URL">https://doi.org/10.1134/S1070363220120361</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070363220120361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070363220120361%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520General%2520Chemistry%26atitle%3DOne%252BPot%252BSynthesis%252Band%252BAntitumor%252BActivity%252Bof%252BIsoxazole-Pyrimido%25255B4%25252C5-c%25255Disoquinolines%26aulast%3DVenkatesh%26aufirst%3DE.%26date%3D2020%26date%3D2021%26volume%3D90%26issue%3D12%26spage%3D2444%26epage%3D2450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Asha V.  Chate</span>, <span class="hlFld-ContribAuthor ">Ankita S.  Kulkarni</span>, <span class="hlFld-ContribAuthor ">Chetan K.  Jadhav</span>, <span class="hlFld-ContribAuthor ">Amol S.  Nipte</span>, <span class="hlFld-ContribAuthor ">Girabala M.  Bondle</span>. </span><span class="cited-content_cbyCitation_article-title">Multicomponent reactions and supramolecular catalyst: A perfect synergy for eco‐compatible synthesis of pyrido[2,3‐
              d
              ]pyrimidines in water. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2020,</strong> <em>57 </em>
                                    (5)
                                     , 2184-2193. <a href="https://doi.org/10.1002/jhet.3938" title="DOI URL">https://doi.org/10.1002/jhet.3938</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.3938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.3938%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DMulticomponent%252Breactions%252Band%252Bsupramolecular%252Bcatalyst%25253A%252BA%252Bperfect%252Bsynergy%252Bfor%252Beco%2525E2%252580%252590compatible%252Bsynthesis%252Bof%252Bpyrido%25255B2%25252C3%2525E2%252580%252590%252Bd%252B%25255Dpyrimidines%252Bin%252Bwater%26aulast%3DChate%26aufirst%3DAsha%2BV.%26date%3D2020%26volume%3D57%26issue%3D5%26spage%3D2184%26epage%3D2193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ya-ting  Deng</span>, <span class="hlFld-ContribAuthor ">Jun-wei  Wang</span>, <span class="hlFld-ContribAuthor ">Han  Chu</span>, <span class="hlFld-ContribAuthor ">Juan  Wang</span>, <span class="hlFld-ContribAuthor ">Yong  Hu</span>, <span class="hlFld-ContribAuthor ">Yong  lin</span>, <span class="hlFld-ContribAuthor ">Mao  Shu</span>, <span class="hlFld-ContribAuthor ">Zhi-hua  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">3D-QSAR and Docking Studies on Pyrimidine Derivatives as CSF-1R Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Letters in Drug Design & Discovery</span><span> <strong>2020,</strong> <em>17 </em>
                                    (3)
                                     , 341-355. <a href="https://doi.org/10.2174/1570180816666190329224946" title="DOI URL">https://doi.org/10.2174/1570180816666190329224946</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1570180816666190329224946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1570180816666190329224946%26sid%3Dliteratum%253Aachs%26jtitle%3DLetters%2520in%2520Drug%2520Design%2520%2526%2520Discovery%26atitle%3D3D-QSAR%252Band%252BDocking%252BStudies%252Bon%252BPyrimidine%252BDerivatives%252Bas%252BCSF-1R%252BInhibitors%26aulast%3DDeng%26aufirst%3DYa-ting%26date%3D2020%26volume%3D17%26issue%3D3%26spage%3D341%26epage%3D355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheolhee  Kim</span>, <span class="hlFld-ContribAuthor ">Eunae  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>26 </em>
                                    (42)
                                     , 7623-7640. <a href="https://doi.org/10.2174/0929867325666180622143548" title="DOI URL">https://doi.org/10.2174/0929867325666180622143548</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666180622143548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666180622143548%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDrug%252BDesign%252BApproach%252Bof%252BReceptor%252BTyrosine%252BKinase%252BType%252BIII%252BInhibitors%26aulast%3DKim%26aufirst%3DCheolhee%26date%3D2020%26volume%3D26%26issue%3D42%26spage%3D7623%26epage%3D7640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Dai</span>, <span class="hlFld-ContribAuthor ">Kaimin  Mao</span>, <span class="hlFld-ContribAuthor ">Zhengbing  Pan</span>, <span class="hlFld-ContribAuthor ">Liangce  Rong</span>. </span><span class="cited-content_cbyCitation_article-title">Green metal-free synthesis of spiro-fused 3,4′-pyrazolo[4′,3′:5,6]pyrido[2,3-d]pyrimidine derivatives via deamination cyclization reactions in aqueous medium. </span><span class="cited-content_cbyCitation_journal-name">Research on Chemical Intermediates</span><span> <strong>2019,</strong> <em>45 </em>
                                    (2)
                                     , 769-788. <a href="https://doi.org/10.1007/s11164-018-3642-3" title="DOI URL">https://doi.org/10.1007/s11164-018-3642-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11164-018-3642-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11164-018-3642-3%26sid%3Dliteratum%253Aachs%26jtitle%3DResearch%2520on%2520Chemical%2520Intermediates%26atitle%3DGreen%252Bmetal-free%252Bsynthesis%252Bof%252Bspiro-fused%252B3%25252C4%2525E2%252580%2525B2-pyrazolo%25255B4%2525E2%252580%2525B2%25252C3%2525E2%252580%2525B2%25253A5%25252C6%25255Dpyrido%25255B2%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bvia%252Bdeamination%252Bcyclization%252Breactions%252Bin%252Baqueous%252Bmedium%26aulast%3DDai%26aufirst%3DLei%26date%3D2019%26date%3D2018%26volume%3D45%26issue%3D2%26spage%3D769%26epage%3D788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sirassu  Narsimha</span>, <span class="hlFld-ContribAuthor ">Kumara Swamy  Battula</span>, <span class="hlFld-ContribAuthor ">Vasudeva Reddy  Nagavelli</span>. </span><span class="cited-content_cbyCitation_article-title">One-pot synthesis of novel 1,2,3-triazole-pyrimido[4,5-c]isoquinoline hybrids and evaluation of their antioxidant activity. </span><span class="cited-content_cbyCitation_journal-name">Synthetic Communications</span><span> <strong>2018,</strong> <em>48 </em>
                                    (10)
                                     , 1220-1226. <a href="https://doi.org/10.1080/00397911.2018.1440315" title="DOI URL">https://doi.org/10.1080/00397911.2018.1440315</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00397911.2018.1440315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00397911.2018.1440315%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthetic%2520Communications%26atitle%3DOne-pot%252Bsynthesis%252Bof%252Bnovel%252B1%25252C2%25252C3-triazole-pyrimido%25255B4%25252C5-c%25255Disoquinoline%252Bhybrids%252Band%252Bevaluation%252Bof%252Btheir%252Bantioxidant%252Bactivity%26aulast%3DNarsimha%26aufirst%3DSirassu%26date%3D2018%26date%3D2018%26volume%3D48%26issue%3D10%26spage%3D1220%26epage%3D1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed Karam  Farag</span>, <span class="hlFld-ContribAuthor ">Ahmed  Elkamhawy</span>, <span class="hlFld-ContribAuthor ">Ashwini M.  Londhe</span>, <span class="hlFld-ContribAuthor ">Kyung-Tae  Lee</span>, <span class="hlFld-ContribAuthor ">Ae Nim  Pae</span>, <span class="hlFld-ContribAuthor ">Eun Joo  Roh</span>. </span><span class="cited-content_cbyCitation_article-title">Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>141 </em>, 657-675. <a href="https://doi.org/10.1016/j.ejmech.2017.10.003" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.10.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.10.003%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BLCK%25252FFMS%252Binhibitors%252Bbased%252Bon%252Bphenoxypyrimidine%252Bscaffold%252Bas%252Bpotential%252Btreatment%252Bfor%252Binflammatory%252Bdisorders%26aulast%3DFarag%26aufirst%3DAhmed%2BKaram%26date%3D2017%26volume%3D141%26spage%3D657%26epage%3D675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paola  Acosta</span>, <span class="hlFld-ContribAuthor ">Braulio  Insuasty</span>, <span class="hlFld-ContribAuthor ">Rodrigo  Abonia</span>, <span class="hlFld-ContribAuthor ">Margarita  Gutierrez</span>, <span class="hlFld-ContribAuthor ">Jairo  Quiroga</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of novel 7-aryl and 7-spiropyrazolo[4′,3′:5,6]pyrido[2,3-d]pyrimidine derivatives and their study as AChE inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2017,</strong> <em>21 </em>
                                    (4)
                                     , 943-955. <a href="https://doi.org/10.1007/s11030-017-9774-3" title="DOI URL">https://doi.org/10.1007/s11030-017-9774-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-017-9774-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-017-9774-3%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DSynthesis%252Bof%252Bnovel%252B7-aryl%252Band%252B7-spiropyrazolo%25255B4%2525E2%252580%2525B2%25252C3%2525E2%252580%2525B2%25253A5%25252C6%25255Dpyrido%25255B2%25252C3-d%25255Dpyrimidine%252Bderivatives%252Band%252Btheir%252Bstudy%252Bas%252BAChE%252Binhibitors%26aulast%3DAcosta%26aufirst%3DPaola%26date%3D2017%26date%3D2017%26volume%3D21%26issue%3D4%26spage%3D943%26epage%3D955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Toma  Glasnov</span>. </span><span class="cited-content_cbyCitation_article-title">Organic Synthesis in Dedicated Continuous Flow Systems. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 49-67. <a href="https://doi.org/10.1007/978-3-319-32196-7_6" title="DOI URL">https://doi.org/10.1007/978-3-319-32196-7_6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-32196-7_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-32196-7_6%26sid%3Dliteratum%253Aachs%26atitle%3DOrganic%252BSynthesis%252Bin%252BDedicated%252BContinuous%252BFlow%252BSystems%26aulast%3DGlasnov%26aufirst%3DToma%26date%3D2016%26date%3D2016%26spage%3D49%26epage%3D67%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DContinuous-Flow%252BChemistry%252Bin%252Bthe%252BResearch%252BLaboratory%26aulast%3DGlasnov%26aufirst%3DToma%26date%3D2016%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kazuhiro  Kobayashi</span>, <span class="hlFld-ContribAuthor ">Ryoga  Ono</span>, <span class="hlFld-ContribAuthor ">Kouki  Ishitobi</span>, <span class="hlFld-ContribAuthor ">Yuuki  Chikazawa</span>, <span class="hlFld-ContribAuthor ">Hidetaka  Hiyoshi</span>, <span class="hlFld-ContribAuthor ">Kazuto  Umezu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 6,7-Dihydropyrido[2,3-d]pyrimidin-5(8H)-one Derivatives Based on the Reaction of 1-(4-Chloropyrimidin-5-yl)alk-2-en-1-one Derivatives with Primary Amines. </span><span class="cited-content_cbyCitation_journal-name">HETEROCYCLES</span><span> <strong>2016,</strong> <em>92 </em>
                                    (2)
                                     , 260. <a href="https://doi.org/10.3987/COM-15-13373" title="DOI URL">https://doi.org/10.3987/COM-15-13373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3987/COM-15-13373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3987%2FCOM-15-13373%26sid%3Dliteratum%253Aachs%26jtitle%3DHETEROCYCLES%26atitle%3DSynthesis%252Bof%252B6%25252C7-Dihydropyrido%25255B2%25252C3-d%25255Dpyrimidin-5%2525288H%252529-one%252BDerivatives%252BBased%252Bon%252Bthe%252BReaction%252Bof%252B1-%2525284-Chloropyrimidin-5-yl%252529alk-2-en-1-one%252BDerivatives%252Bwith%252BPrimary%252BAmines%26aulast%3DKobayashi%26aufirst%3DKazuhiro%26date%3D2016%26volume%3D92%26issue%3D2%26spage%3D260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria E.  Chizhova</span>, <span class="hlFld-ContribAuthor ">Olga Yu.  Bakulina</span>, <span class="hlFld-ContribAuthor ">Alexander Yu.  Ivanov</span>, <span class="hlFld-ContribAuthor ">Pavel S.  Lobanov</span>, <span class="hlFld-ContribAuthor ">Dmitrii V.  Dar'in</span>. </span><span class="cited-content_cbyCitation_article-title">Facile synthesis of pyrido[2,3-d]pyrimidines via cyclocondensation of 4,6-dichloro-2-methylsulfanylpyrimidine-5-carbaldehyde with β-substituted β-aminoacrylic esters. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2015,</strong> <em>71 </em>
                                    (36)
                                     , 6196-6203. <a href="https://doi.org/10.1016/j.tet.2015.06.085" title="DOI URL">https://doi.org/10.1016/j.tet.2015.06.085</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2015.06.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2015.06.085%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DFacile%252Bsynthesis%252Bof%252Bpyrido%25255B2%25252C3-d%25255Dpyrimidines%252Bvia%252Bcyclocondensation%252Bof%252B4%25252C6-dichloro-2-methylsulfanylpyrimidine-5-carbaldehyde%252Bwith%252B%2525CE%2525B2-substituted%252B%2525CE%2525B2-aminoacrylic%252Besters%26aulast%3DChizhova%26aufirst%3DMaria%2BE.%26date%3D2015%26volume%3D71%26issue%3D36%26spage%3D6196%26epage%3D6203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pallabi  Saikia</span>, <span class="hlFld-ContribAuthor ">Gitarthi  Sharma</span>, <span class="hlFld-ContribAuthor ">Sanjib  Gogoi</span>, <span class="hlFld-ContribAuthor ">Romesh C.  Boruah</span>. </span><span class="cited-content_cbyCitation_article-title">Cascade imination, Buchwald–Hartwig cross coupling and cycloaddition reaction: synthesis of pyrido[2,3-d]pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2015,</strong> <em>5 </em>
                                    (30)
                                     , 23210-23212. <a href="https://doi.org/10.1039/C5RA00725A" title="DOI URL">https://doi.org/10.1039/C5RA00725A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5RA00725A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5RA00725A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DCascade%252Bimination%25252C%252BBuchwald%2525E2%252580%252593Hartwig%252Bcross%252Bcoupling%252Band%252Bcycloaddition%252Breaction%25253A%252Bsynthesis%252Bof%252Bpyrido%25255B2%25252C3-d%25255Dpyrimidines%26aulast%3DSaikia%26aufirst%3DPallabi%26date%3D2015%26date%3D2015%26volume%3D5%26issue%3D30%26spage%3D23210%26epage%3D23212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A. Yu.  Potapov</span>, <span class="hlFld-ContribAuthor ">A. V.  Falaleev</span>, <span class="hlFld-ContribAuthor ">Kh. S.  Shikhaliev</span>, <span class="hlFld-ContribAuthor ">G. V.  Shatalov</span>. </span><span class="cited-content_cbyCitation_article-title">Preparation and synthetic scope of 3-(4-methyl-2-R-pyrimidin-5-yl)-3-oxopropionic esters. </span><span class="cited-content_cbyCitation_journal-name">Russian Chemical Bulletin</span><span> <strong>2014,</strong> <em>63 </em>
                                    (9)
                                     , 2198-2200. <a href="https://doi.org/10.1007/s11172-014-0720-6" title="DOI URL">https://doi.org/10.1007/s11172-014-0720-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11172-014-0720-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11172-014-0720-6%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Chemical%2520Bulletin%26atitle%3DPreparation%252Band%252Bsynthetic%252Bscope%252Bof%252B3-%2525284-methyl-2-R-pyrimidin-5-yl%252529-3-oxopropionic%252Besters%26aulast%3DPotapov%26aufirst%3DA.%2BYu.%26date%3D2014%26date%3D2015%26volume%3D63%26issue%3D9%26spage%3D2198%26epage%3D2200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lakhinath  Saikia</span>, <span class="hlFld-ContribAuthor ">Babulal  Das</span>, <span class="hlFld-ContribAuthor ">Pranjal  Bharali</span>, <span class="hlFld-ContribAuthor ">Ashim Jyoti  Thakur</span>. </span><span class="cited-content_cbyCitation_article-title">A convenient synthesis of novel 5-aryl-pyrido[2,3-d]pyrimidines and screening of their preliminary antibacterial properties. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2014,</strong> <em>55 </em>
                                    (10)
                                     , 1796-1801. <a href="https://doi.org/10.1016/j.tetlet.2014.01.128" title="DOI URL">https://doi.org/10.1016/j.tetlet.2014.01.128</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2014.01.128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2014.01.128%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DA%252Bconvenient%252Bsynthesis%252Bof%252Bnovel%252B5-aryl-pyrido%25255B2%25252C3-d%25255Dpyrimidines%252Band%252Bscreening%252Bof%252Btheir%252Bpreliminary%252Bantibacterial%252Bproperties%26aulast%3DSaikia%26aufirst%3DLakhinath%26date%3D2014%26volume%3D55%26issue%3D10%26spage%3D1796%26epage%3D1801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carl R.  Illig</span>, <span class="hlFld-ContribAuthor ">Carl L.  Manthey</span>, <span class="hlFld-ContribAuthor ">Sanath K.  Meegalla</span>, <span class="hlFld-ContribAuthor ">Mark J.  Wall</span>, <span class="hlFld-ContribAuthor ">Jinsheng  Chen</span>, <span class="hlFld-ContribAuthor ">Kenneth J.  Wilson</span>, <span class="hlFld-ContribAuthor ">Renee L.  DesJarlais</span>, <span class="hlFld-ContribAuthor ">Shelley K.  Ballentine</span>, <span class="hlFld-ContribAuthor ">Carsten  Schubert</span>, <span class="hlFld-ContribAuthor ">Carl S.  Crysler</span>, <span class="hlFld-ContribAuthor ">Yanmin  Chen</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Molloy</span>, <span class="hlFld-ContribAuthor ">Margery A.  Chaikin</span>, <span class="hlFld-ContribAuthor ">Robert R.  Donatelli</span>, <span class="hlFld-ContribAuthor ">Edward  Yurkow</span>, <span class="hlFld-ContribAuthor ">Zhao  Zhou</span>, <span class="hlFld-ContribAuthor ">Mark R.  Player</span>, <span class="hlFld-ContribAuthor ">Bruce E.  Tomczuk</span>. </span><span class="cited-content_cbyCitation_article-title">Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (23)
                                     , 6363-6369. <a href="https://doi.org/10.1016/j.bmcl.2013.09.061" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.09.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.09.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.09.061%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DEnhancement%252Bof%252Bkinase%252Bselectivity%252Bin%252Ba%252Bpotent%252Bclass%252Bof%252Barylamide%252BFMS%252Binhibitors%26aulast%3DIllig%26aufirst%3DCarl%2BR.%26date%3D2013%26volume%3D23%26issue%3D23%26spage%3D6363%26epage%3D6369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Archana  Kumari</span>, <span class="hlFld-ContribAuthor ">Maninder  Kaur</span>, <span class="hlFld-ContribAuthor ">Malkeet Singh  Bahia</span>, <span class="hlFld-ContribAuthor ">Om  Silakari</span>. </span><span class="cited-content_cbyCitation_article-title">3D-QSAR analysis of anilinoquinoline inhibitors of colony stimulating factor-1 kinase (cFMS): implementation of field-based molecular alignment. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2013,</strong> <em>22 </em>
                                    (11)
                                     , 5167-5183. <a href="https://doi.org/10.1007/s00044-013-0513-8" title="DOI URL">https://doi.org/10.1007/s00044-013-0513-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-013-0513-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-013-0513-8%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3D3D-QSAR%252Banalysis%252Bof%252Banilinoquinoline%252Binhibitors%252Bof%252Bcolony%252Bstimulating%252Bfactor-1%252Bkinase%252B%252528cFMS%252529%25253A%252Bimplementation%252Bof%252Bfield-based%252Bmolecular%252Balignment%26aulast%3DKumari%26aufirst%3DArchana%26date%3D2013%26date%3D2013%26volume%3D22%26issue%3D11%26spage%3D5167%26epage%3D5183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikita  Tolstoluzhsky</span>, <span class="hlFld-ContribAuthor ">Pavlo  Nikolaienko</span>, <span class="hlFld-ContribAuthor ">Nikolay  Gorobets</span>, <span class="hlFld-ContribAuthor ">Erik V.  Van der Eycken</span>, <span class="hlFld-ContribAuthor ">Nadezhda  Kolos</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Synthesis of Uracil-Derived Hexa- and Tetrahydropyrido[2,3-
              d
              ]pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2013,</strong> <em>2013 </em>
                                    (24)
                                     , 5364-5369. <a href="https://doi.org/10.1002/ejoc.201300683" title="DOI URL">https://doi.org/10.1002/ejoc.201300683</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201300683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201300683%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DEfficient%252BSynthesis%252Bof%252BUracil-Derived%252BHexa-%252Band%252BTetrahydropyrido%25255B2%25252C3-%252Bd%252B%25255Dpyrimidines%26aulast%3DTolstoluzhsky%26aufirst%3DNikita%26date%3D2013%26date%3D2013%26volume%3D2013%26issue%3D24%26spage%3D5364%26epage%3D5369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammed I.  El-Gamal</span>, <span class="hlFld-ContribAuthor ">Hanan S.  Anbar</span>, <span class="hlFld-ContribAuthor ">Kyung Ho  Yoo</span>, <span class="hlFld-ContribAuthor ">Chang-Hyun  Oh</span>. </span><span class="cited-content_cbyCitation_article-title">FMS Kinase Inhibitors: Current Status and Future Prospects. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2013,</strong> <em>33 </em>
                                    (3)
                                     , 599-636. <a href="https://doi.org/10.1002/med.21258" title="DOI URL">https://doi.org/10.1002/med.21258</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21258%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DFMS%252BKinase%252BInhibitors%25253A%252BCurrent%252BStatus%252Band%252BFuture%252BProspects%26aulast%3DEl-Gamal%26aufirst%3DMohammed%2BI.%26date%3D2013%26date%3D2012%26volume%3D33%26issue%3D3%26spage%3D599%26epage%3D636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daigen  Xu</span>, <span class="hlFld-ContribAuthor ">Yong  Kim</span>, <span class="hlFld-ContribAuthor ">Jennifer  Postelnek</span>, <span class="hlFld-ContribAuthor ">Minh Diem  Vu</span>, <span class="hlFld-ContribAuthor ">Dong-Qing  Hu</span>, <span class="hlFld-ContribAuthor ">Cheng  Liao</span>, <span class="hlFld-ContribAuthor ">Mike  Bradshaw</span>, <span class="hlFld-ContribAuthor ">Jonathan  Hsu</span>, <span class="hlFld-ContribAuthor ">Jun  Zhang</span>, <span class="hlFld-ContribAuthor ">Achal  Pashine</span>, <span class="hlFld-ContribAuthor ">Dinesh  Srinivasan</span>, <span class="hlFld-ContribAuthor ">John  Woods</span>, <span class="hlFld-ContribAuthor ">Anita  Levin</span>, <span class="hlFld-ContribAuthor ">Alison  O'Mahony</span>, <span class="hlFld-ContribAuthor ">Timothy D.  Owens</span>, <span class="hlFld-ContribAuthor ">Yan  Lou</span>, <span class="hlFld-ContribAuthor ">Ronald J.  Hill</span>, <span class="hlFld-ContribAuthor ">Satwant  Narula</span>, <span class="hlFld-ContribAuthor ">Julie  DeMartino</span>, <span class="hlFld-ContribAuthor ">Jay S.  Fine</span>. </span><span class="cited-content_cbyCitation_article-title">RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2012,</strong> <em>341 </em>
                                    (1)
                                     , 90-103. <a href="https://doi.org/10.1124/jpet.111.187740" title="DOI URL">https://doi.org/10.1124/jpet.111.187740</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.111.187740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.111.187740%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DRN486%25252C%252Ba%252BSelective%252BBruton%252527s%252BTyrosine%252BKinase%252BInhibitor%25252C%252BAbrogates%252BImmune%252BHypersensitivity%252BResponses%252Band%252BArthritis%252Bin%252BRodents%26aulast%3DXu%26aufirst%3DDaigen%26date%3D2012%26date%3D2012%26volume%3D341%26issue%3D1%26spage%3D90%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joost C. M.  Uitdehaag</span>, <span class="hlFld-ContribAuthor ">Cecile M.  Sünnen</span>, <span class="hlFld-ContribAuthor ">Antoon M.  van Doornmalen</span>, <span class="hlFld-ContribAuthor ">Nikki  de Rouw</span>, <span class="hlFld-ContribAuthor ">Arthur  Oubrie</span>, <span class="hlFld-ContribAuthor ">Rita  Azevedo</span>, <span class="hlFld-ContribAuthor ">Michael  Ziebell</span>, <span class="hlFld-ContribAuthor ">Elliott  Nickbarg</span>, <span class="hlFld-ContribAuthor ">Willem-Jan  Karstens</span>, <span class="hlFld-ContribAuthor ">Simone  Ruygrok</span>. </span><span class="cited-content_cbyCitation_article-title">Multidimensional Profiling of CSF1R Screening Hits and Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Screening</span><span> <strong>2011,</strong> <em>16 </em>
                                    (9)
                                     , 1007-1017. <a href="https://doi.org/10.1177/1087057111418113" title="DOI URL">https://doi.org/10.1177/1087057111418113</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1087057111418113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1087057111418113%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Screening%26atitle%3DMultidimensional%252BProfiling%252Bof%252BCSF1R%252BScreening%252BHits%252Band%252BInhibitors%26aulast%3DUitdehaag%26aufirst%3DJoost%2BC.%2BM.%26date%3D2011%26date%3D2011%26volume%3D16%26issue%3D9%26spage%3D1007%26epage%3D1017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Toshiaki  Sasada</span>, <span class="hlFld-ContribAuthor ">Youichi  Aoki</span>, <span class="hlFld-ContribAuthor ">Reiko  Ikeda</span>, <span class="hlFld-ContribAuthor ">Norio  Sakai</span>, <span class="hlFld-ContribAuthor ">Takeo  Konakahara</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Tri- or Tetrasubstituted Pyrimidine Derivatives through the [5+1] Annulation of Enamidines with either N,N-Dimethylformamide Dialkyl Acetals or Orthoesters and Their Application in a Ring Transformation of Pyrimidines to Pyrido[2,3-d]pyrimidi. </span><span class="cited-content_cbyCitation_journal-name">Chemistry - A European Journal</span><span> <strong>2011,</strong> <em>17 </em>
                                    (34)
                                     , 9385-9394. <a href="https://doi.org/10.1002/chem.201100040" title="DOI URL">https://doi.org/10.1002/chem.201100040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201100040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201100040%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520-%2520A%2520European%2520Journal%26atitle%3DSynthesis%252Bof%252BTri-%252Bor%252BTetrasubstituted%252BPyrimidine%252BDerivatives%252Bthrough%252Bthe%252B%25255B5%25252B1%25255D%252BAnnulation%252Bof%252BEnamidines%252Bwith%252Beither%252BN%25252CN-Dimethylformamide%252BDialkyl%252BAcetals%252Bor%252BOrthoesters%252Band%252BTheir%252BApplication%252Bin%252Ba%252BRing%252BTransformation%252Bof%252BPyrimidines%252Bto%252BPyrido%25255B2%25252C3-d%25255Dpyrimidi%26aulast%3DSasada%26aufirst%3DToshiaki%26date%3D2011%26date%3D2011%26volume%3D17%26issue%3D34%26spage%3D9385%26epage%3D9394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammad  Irfan</span>, <span class="hlFld-ContribAuthor ">Toma N.  Glasnov</span>, <span class="hlFld-ContribAuthor ">C. Oliver  Kappe</span>. </span><span class="cited-content_cbyCitation_article-title">Heterogeneous Catalytic Hydrogenation Reactions in Continuous-Flow Reactors. </span><span class="cited-content_cbyCitation_journal-name">ChemSusChem</span><span> <strong>2011,</strong> <em>4 </em>
                                    (3)
                                     , 300-316. <a href="https://doi.org/10.1002/cssc.201000354" title="DOI URL">https://doi.org/10.1002/cssc.201000354</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cssc.201000354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcssc.201000354%26sid%3Dliteratum%253Aachs%26jtitle%3DChemSusChem%26atitle%3DHeterogeneous%252BCatalytic%252BHydrogenation%252BReactions%252Bin%252BContinuous-Flow%252BReactors%26aulast%3DIrfan%26aufirst%3DMuhammad%26date%3D2011%26date%3D2011%26volume%3D4%26issue%3D3%26spage%3D300%26epage%3D316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher J  Burns</span>, <span class="hlFld-ContribAuthor ">Andrew F  Wilks</span>. </span><span class="cited-content_cbyCitation_article-title">c-FMS inhibitors: a patent review. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2011,</strong> <em>21 </em>
                                    (2)
                                     , 147-165. <a href="https://doi.org/10.1517/13543776.2011.545348" title="DOI URL">https://doi.org/10.1517/13543776.2011.545348</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2011.545348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2011.545348%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3Dc-FMS%252Binhibitors%25253A%252Ba%252Bpatent%252Breview%26aulast%3DBurns%26aufirst%3DChristopher%2BJ%26date%3D2011%26date%3D2011%26volume%3D21%26issue%3D2%26spage%3D147%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lisa M.  Wodicka</span>, <span class="hlFld-ContribAuthor ">Pietro  Ciceri</span>, <span class="hlFld-ContribAuthor ">Mindy I.  Davis</span>, <span class="hlFld-ContribAuthor ">Jeremy P.  Hunt</span>, <span class="hlFld-ContribAuthor ">Mark  Floyd</span>, <span class="hlFld-ContribAuthor ">Sara  Salerno</span>, <span class="hlFld-ContribAuthor ">Xuequn H.  Hua</span>, <span class="hlFld-ContribAuthor ">Julia M.  Ford</span>, <span class="hlFld-ContribAuthor ">Robert C.  Armstrong</span>, <span class="hlFld-ContribAuthor ">Patrick P.  Zarrinkar</span>, <span class="hlFld-ContribAuthor ">Daniel K.  Treiber</span>. </span><span class="cited-content_cbyCitation_article-title">Activation State-Dependent Binding of Small Molecule Kinase Inhibitors: Structural Insights from Biochemistry. </span><span class="cited-content_cbyCitation_journal-name">Chemistry & Biology</span><span> <strong>2010,</strong> <em>17 </em>
                                    (11)
                                     , 1241-1249. <a href="https://doi.org/10.1016/j.chembiol.2010.09.010" title="DOI URL">https://doi.org/10.1016/j.chembiol.2010.09.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2010.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2010.09.010%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%2526%2520Biology%26atitle%3DActivation%252BState-Dependent%252BBinding%252Bof%252BSmall%252BMolecule%252BKinase%252BInhibitors%25253A%252BStructural%252BInsights%252Bfrom%252BBiochemistry%26aulast%3DWodicka%26aufirst%3DLisa%2BM.%26date%3D2010%26volume%3D17%26issue%3D11%26spage%3D1241%26epage%3D1249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">René  Csuk</span>, <span class="hlFld-ContribAuthor ">Erik  Prell</span>. </span><span class="cited-content_cbyCitation_article-title">Difluorotetrahydropyridothiazinone: A Selective β-Galactosidase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2010,</strong> <em>343 </em>
                                    (10)
                                     , 577-582. <a href="https://doi.org/10.1002/ardp.200900307" title="DOI URL">https://doi.org/10.1002/ardp.200900307</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.200900307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.200900307%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DDifluorotetrahydropyridothiazinone%25253A%252BA%252BSelective%252B%2525CE%2525B2-Galactosidase%252BInhibitor%26aulast%3DCsuk%26aufirst%3DRen%25C3%25A9%26date%3D2010%26date%3D2010%26volume%3D343%26issue%3D10%26spage%3D577%26epage%3D582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haiyan  Liu</span>, <span class="hlFld-ContribAuthor ">Wenpin  Xia</span>, <span class="hlFld-ContribAuthor ">Yu  Luo</span>, <span class="hlFld-ContribAuthor ">Wei  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">A novel synthesis of imatinib and its intermediates. </span><span class="cited-content_cbyCitation_journal-name">Monatshefte für Chemie - Chemical Monthly</span><span> <strong>2010,</strong> <em>141 </em>
                                    (8)
                                     , 907-911. <a href="https://doi.org/10.1007/s00706-010-0334-0" title="DOI URL">https://doi.org/10.1007/s00706-010-0334-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00706-010-0334-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00706-010-0334-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMonatshefte%2520f%25C3%25BCr%2520Chemie%2520-%2520Chemical%2520Monthly%26atitle%3DA%252Bnovel%252Bsynthesis%252Bof%252Bimatinib%252Band%252Bits%252Bintermediates%26aulast%3DLiu%26aufirst%3DHaiyan%26date%3D2010%26date%3D2010%26volume%3D141%26issue%3D8%26spage%3D907%26epage%3D911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kenneth J.  Wilson</span>, <span class="hlFld-ContribAuthor ">Carl R.  Illig</span>, <span class="hlFld-ContribAuthor ">Jinsheng  Chen</span>, <span class="hlFld-ContribAuthor ">Mark J.  Wall</span>, <span class="hlFld-ContribAuthor ">Shelley K.  Ballentine</span>, <span class="hlFld-ContribAuthor ">Renee L.  DesJarlais</span>, <span class="hlFld-ContribAuthor ">Yanmin  Chen</span>, <span class="hlFld-ContribAuthor ">Carsten  Schubert</span>, <span class="hlFld-ContribAuthor ">Robert  Donatelli</span>, <span class="hlFld-ContribAuthor ">Ioanna  Petrounia</span>, <span class="hlFld-ContribAuthor ">Carl S.  Crysler</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Molloy</span>, <span class="hlFld-ContribAuthor ">Margery A.  Chaikin</span>, <span class="hlFld-ContribAuthor ">Carl L.  Manthey</span>, <span class="hlFld-ContribAuthor ">Mark R.  Player</span>, <span class="hlFld-ContribAuthor ">Bruce E.  Tomczuk</span>, <span class="hlFld-ContribAuthor ">Sanath K.  Meegalla</span>. </span><span class="cited-content_cbyCitation_article-title">Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2010,</strong> <em>20 </em>
                                    (13)
                                     , 3925-3929. <a href="https://doi.org/10.1016/j.bmcl.2010.05.013" title="DOI URL">https://doi.org/10.1016/j.bmcl.2010.05.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2010.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2010.05.013%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DReducing%252Bion%252Bchannel%252Bactivity%252Bin%252Ba%252Bseries%252Bof%252B4-heterocyclic%252Barylamide%252BFMS%252Binhibitors%26aulast%3DWilson%26aufirst%3DKenneth%2BJ.%26date%3D2010%26volume%3D20%26issue%3D13%26spage%3D3925%26epage%3D3929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marvin J.  Meyers</span>, <span class="hlFld-ContribAuthor ">Matthew  Pelc</span>, <span class="hlFld-ContribAuthor ">Satwik  Kamtekar</span>, <span class="hlFld-ContribAuthor ">Jacqueline  Day</span>, <span class="hlFld-ContribAuthor ">Gennadiy I.  Poda</span>, <span class="hlFld-ContribAuthor ">Molly K.  Hall</span>, <span class="hlFld-ContribAuthor ">Marshall L.  Michener</span>, <span class="hlFld-ContribAuthor ">Beverly A.  Reitz</span>, <span class="hlFld-ContribAuthor ">Karl J.  Mathis</span>, <span class="hlFld-ContribAuthor ">Betsy S.  Pierce</span>, <span class="hlFld-ContribAuthor ">Mihir D.  Parikh</span>, <span class="hlFld-ContribAuthor ">Deborah A.  Mischke</span>, <span class="hlFld-ContribAuthor ">Scott A.  Long</span>, <span class="hlFld-ContribAuthor ">John J.  Parlow</span>, <span class="hlFld-ContribAuthor ">David R.  Anderson</span>, <span class="hlFld-ContribAuthor ">Atli  Thorarensen</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2010,</strong> <em>20 </em>
                                    (5)
                                     , 1543-1547. <a href="https://doi.org/10.1016/j.bmcl.2010.01.078" title="DOI URL">https://doi.org/10.1016/j.bmcl.2010.01.078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2010.01.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2010.01.078%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure-based%252Bdrug%252Bdesign%252Benables%252Bconversion%252Bof%252Ba%252BDFG-in%252Bbinding%252BCSF-1R%252Bkinase%252Binhibitor%252Bto%252Ba%252BDFG-out%252Bbinding%252Bmode%26aulast%3DMeyers%26aufirst%3DMarvin%2BJ.%26date%3D2010%26volume%3D20%26issue%3D5%26spage%3D1543%26epage%3D1547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carl L.  Manthey</span>, <span class="hlFld-ContribAuthor ">Dana L.  Johnson</span>, <span class="hlFld-ContribAuthor ">Carl R.  Illig</span>, <span class="hlFld-ContribAuthor ">Robert W.  Tuman</span>, <span class="hlFld-ContribAuthor ">Zhao  Zhou</span>, <span class="hlFld-ContribAuthor ">Judith F.  Baker</span>, <span class="hlFld-ContribAuthor ">Margery A.  Chaikin</span>, <span class="hlFld-ContribAuthor ">Robert R.  Donatelli</span>, <span class="hlFld-ContribAuthor ">Carol F.  Franks</span>, <span class="hlFld-ContribAuthor ">Lee  Zeng</span>, <span class="hlFld-ContribAuthor ">Carl  Crysler</span>, <span class="hlFld-ContribAuthor ">Yanmin  Chen</span>, <span class="hlFld-ContribAuthor ">Edward J.  Yurkow</span>, <span class="hlFld-ContribAuthor ">Lisa  Boczon</span>, <span class="hlFld-ContribAuthor ">Sanath K.  Meegalla</span>, <span class="hlFld-ContribAuthor ">Kenneth J.  Wilson</span>, <span class="hlFld-ContribAuthor ">Mark J.  Wall</span>, <span class="hlFld-ContribAuthor ">Jinsheng  Chen</span>, <span class="hlFld-ContribAuthor ">Shelley K.  Ballentine</span>, <span class="hlFld-ContribAuthor ">Heidi  Ott</span>, <span class="hlFld-ContribAuthor ">Christian  Baumann</span>, <span class="hlFld-ContribAuthor ">Danielle  Lawrence</span>, <span class="hlFld-ContribAuthor ">Bruce E.  Tomczuk</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Molloy</span>. </span><span class="cited-content_cbyCitation_article-title">JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2009,</strong> <em>8 </em>
                                    (11)
                                     , 3151-3161. <a href="https://doi.org/10.1158/1535-7163.MCT-09-0255" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-09-0255</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-09-0255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-09-0255%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DJNJ-28312141%25252C%252Ba%252Bnovel%252Borally%252Bactive%252Bcolony-stimulating%252Bfactor-1%252Breceptor%25252FFMS-related%252Breceptor%252Btyrosine%252Bkinase-3%252Breceptor%252Btyrosine%252Bkinase%252Binhibitor%252Bwith%252Bpotential%252Butility%252Bin%252Bsolid%252Btumors%25252C%252Bbone%252Bmetastases%25252C%252Band%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DManthey%26aufirst%3DCarl%2BL.%26date%3D2009%26date%3D2009%26volume%3D8%26issue%3D11%26spage%3D3151%26epage%3D3161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carl L.  Manthey</span>, <span class="hlFld-ContribAuthor ">Mark R.  Player</span>. </span><span class="cited-content_cbyCitation_article-title">Chapter 10 Advances in the Discovery of Anti-Inflammatory FMS Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2009,</strong>,, 211-225. <a href="https://doi.org/10.1016/S0065-7743(09)04410-8" title="DOI URL">https://doi.org/10.1016/S0065-7743(09)04410-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S0065-7743(09)04410-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS0065-7743%2809%2904410-8%26sid%3Dliteratum%253Aachs%26atitle%3DChapter%252B10%252BAdvances%252Bin%252Bthe%252BDiscovery%252Bof%252BAnti-Inflammatory%252BFMS%252BInhibitors%26aulast%3DManthey%26aufirst%3DCarl%2BL.%26date%3D2009%26spage%3D211%26epage%3D225%26pub%3DElsevier%26atitle%3DAnnual%252BReports%252Bin%252BMedicinal%252BChemistry%252BVolume%252B44%26date%3D2009%26volume%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0007.jpeg" id="rightTab-gc1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. FMS Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0017.jpeg" id="rightTab-_i4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Three Novel Classes of FMS Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0008.jpeg" id="rightTab-gs1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ethyl 3-chloropropionate, K<sub>2</sub>CO<sub>3</sub>, Bu<sub>4</sub>NBr (cat.), 100 °C; (b) Et<sub>3</sub>N, <i>n</i>-BuOH, rt; (c) <i>t</i>-BuONa, toluene, 90 °C; (d) Br<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt; (e) Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt; (f) <i>m</i>-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (g) arylamine, <i>i</i>-PrOH, 90 °C; (h) R<sup>1</sup>NH<sub>2</sub>, MeOH, rt or 80−100 °C.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0009.jpeg" id="rightTab-gs2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaOH, methanol, rt; (b) oxalyl chloride, DMF (cat.), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (c) ethyl hydrogen malonate, MeMgBr, 0 °C to rt; (d) triethylorthoformate, Ac<sub>2</sub>O, 130 °C; (e) aminoindan, THF, rt; (f) K<sub>2</sub>CO<sub>3</sub>, THF, rt; (g) 1 N HCl, 1,4-dioxane, 105 °C; (h) oxalyl chloride, DMF (cat.), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (i) methoxyamine hydrochloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (j) <i>m</i>-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (k) R<sup>2</sup>NH<sub>2</sub>, AcOH, 110 °C.</p></p></figure><figure data-id="fig1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0016.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Cocrystal structure of <b>25</b> in FMS (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DPK">3DPK</a>). (A) Ball-and-stick representation of <b>25</b> (yellow) bound in the active site of cFMS (gray). Additionally shown is the 2<i>f</i><sub>o</sub> − <i>f</i><sub>c</sub> electron density map (blue) contoured at 1.4σ and truncated to a radius of 2 Å beyond each atom for clarity. Hydrogen bonds to the backbone of the protein are depicted as green dashed lines. (B) Close-up view of the water-mediated hydrogen-bonding network in the active site. The internal hydrogen bond between the amide nitrogen and the pyridopyrimidinone carbonyl oxygen is drawn in magenta.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0010.jpeg" id="rightTab-gs3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, toluene, ethanol, 110 °C; (b) MeI, acetone, 50 °C; (c) NaBH<sub>4</sub>, 0 °C to rt; (d) 6 N HCl, THF, 60 °C; (e) Deoxo-Fluor, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (f) H<sub>2</sub>, Pd/C, methanol, rt.</p></p></figure><figure data-id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0001.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. In vivo inhibition of FMS 6 h after dosing mice with <b>37</b>. B6C3R1 mice were dosed orally with <b>37</b> 6 h prior to a tail-vein injection of 1 μg recombinant CSF-1. Fifteen minutes following the CSF-1 challenge, mice were sacrificed and the functional status of FMS signaling was assessed by assay of c-fos mRNA in spleens as described in the <a class="ref internalNav" href="#sec3_1" aria-label="Experimental Section">Experimental Section</a>.></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0002.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>37</b> reversed ankle swelling during the chronic phase of SCW-induced arthritis. Arthritis was induced in rats by a single ip injection of SCW on day 0. Twice daily oral dosing with vehicle or <b>37</b> was commenced on day 19 when chronic inflammation was well established. Ankle thickness was measured using calipers as described in the <a class="ref internalNav" href="#sec3_1" aria-label="Experimental Section">Experimental Section</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0003.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>37</b> reduced paw swelling in adjuvant-induced arthritis. Adjuvant arthritis was induced in rats as described in the <a class="ref internalNav" href="#sec3_1" aria-label="Experimental Section">Experimental Section</a>. Twice daily oral dosing with vehicle or <b>37</b> was commenced on day 8. Calipers were used to measure ankle thickness daily (mean ± SEM). **<i>p</i> < 0.001, * <i>p</i> < 0.01 vs arthritis + vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0004.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>37</b> prevented the development of bone lesions in the tibial tarsal joint. Following necropsy on day 21, microradiographic images were prepared of tibial tarsal joints. Representative images are shown obtained from a disease-free rat (A), a rat with adjuvant-arthritis treated with vehicle (B), and a rat with adjuvant-arthritis treated with 1 mg/kg <b>37</b> (C). Note the presence of radiotranslucent pits (arrows) in the tibia, calcanus, talus, and tarsus of the rat with adjuvant-arthritis treated with vehicle, while the tibial tarsal joint of the rat with adjuvant-arthritis treated with <b>37</b> was difficult to discern from the disease-free rat.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/medium/jm-2008-01406h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0005.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>37</b> reduced ankle swelling in adjuvant-induced arthritis in combination with methotrexate. Adjuvant arthritis was induced in rats as described in the <a class="ref internalNav" href="#sec3_1" aria-label="Experimental Section">Experimental Section</a>. Oral dosing was commenced on day 8. Blue squares, dosed twice daily with 20% HPβCD and once daily with 1% carboxymethylcelluose (CMC); black squares, dosed twice daily with 0.33 mg/kg <b>37</b> in 20% HPβCD and once daily with 1% CMC; white squares, dosed twice daily with 20% HPβCD and once daily with 0.1 mg/kg methotrexate in 1% CMC; red squares, dosed twice daily with 0.33 mg/kg <b>37</b> in 20% HPβCD and once daily with 0.1 mg/kg methotrexate in 1% CMC. Calipers were used to measure ankle thickness daily (mean ± SEM). *<i>p</i> < 0.05 vs methotrexate alone.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm801406h/production/images/large/jm-2008-01406h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm801406h&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i82">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71641" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71641" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 42 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sacca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherr, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettenmier, C. W.</span><span> </span><span class="NLM_article-title">Specific binding of the mononuclear phagocyte colony-stimulating factor CSF-1 to the product of the v-fms oncogene</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">3331</span><span class="NLM_x">–</span> <span class="NLM_lpage">3335</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1986&pages=3331-3335&author=R.+Saccaauthor=E.+R.+Stanleyauthor=C.+J.+Sherrauthor=C.+W.+Rettenmier&title=Specific+binding+of+the+mononuclear+phagocyte+colony-stimulating+factor+CSF-1+to+the+product+of+the+v-fms+oncogene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSacca%26aufirst%3DR.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26aulast%3DSherr%26aufirst%3DC.%2BJ.%26aulast%3DRettenmier%26aufirst%3DC.%2BW.%26atitle%3DSpecific%2520binding%2520of%2520the%2520mononuclear%2520phagocyte%2520colony-stimulating%2520factor%2520CSF-1%2520to%2520the%2520product%2520of%2520the%2520v-fms%2520oncogene%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1986%26volume%3D83%26spage%3D3331%26epage%3D3335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pixley, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, E. R.</span><span> </span><span class="NLM_article-title">CSF-1 Regulation of the wandering macrophage: complexity in action</span> <span class="citation_source-journal">Trends Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">628</span><span class="NLM_x">–</span> <span class="NLM_lpage">638</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1016%2Fj.tcb.2004.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=15519852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpt1Wgsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=628-638&author=F.+J.+Pixleyauthor=E.+R.+Stanley&title=CSF-1+Regulation+of+the+wandering+macrophage%3A+complexity+in+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">CSF-1 regulation of the wandering macrophage: complexity in action</span></div><div class="casAuthors">Pixley, Fiona J.; Stanley, E. Richard</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">628-638</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Most tissue macrophages and osteoclasts are regulated by colony-stimulating factor-1 (CSF-1, also known as macrophage CSF).  The effects of CSF-1 are mediated by the CSF-1 receptor tyrosine kinase (CSF-1R), through autophosphorylation of CSF-1R and the subsequent phosphorylation of downstream mols.  Triggering this phosphorylation cascade increases gene transcription and protein translation, and induces cytoskeletal remodeling by several signaling pathways, leading to the survival, proliferation and differentiation of target cells.  CSF-1-regulated tissue macrophages are important for innate immunity and for tissue development and function.  Because CSF-1 regulates the survival, proliferation and chemotaxis of macrophages and supports their activation, this factor is involved in the pathogenesis of several diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouh_AnBDWTs7Vg90H21EOLACvtfcHk0lg1HhXV1mQc8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpt1Wgsrw%253D&md5=0b2639ed4de1366b5fba48fc6c3758ba</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2004.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2004.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DPixley%26aufirst%3DF.%2BJ.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DCSF-1%2520Regulation%2520of%2520the%2520wandering%2520macrophage%253A%2520complexity%2520in%2520action%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2004%26volume%3D14%26spage%3D628%26epage%3D638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Wiktor-Jedrzejczak, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczylik, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelly, R. R.</span><span> </span><span class="NLM_article-title">Hematological characterization of congenital osteopetrosis in op/op mouse</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">1516</span><span class="NLM_x">–</span> <span class="NLM_lpage">1527</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=1982&pages=1516-1527&author=W.+Wiktor-Jedrzejczakauthor=A.+Ahmedauthor=C.+Szczylikauthor=R.+R.+Skelly&title=Hematological+characterization+of+congenital+osteopetrosis+in+op%2Fop+mouse"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWiktor-Jedrzejczak%26aufirst%3DW.%26aulast%3DAhmed%26aufirst%3DA.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DSkelly%26aufirst%3DR.%2BR.%26atitle%3DHematological%2520characterization%2520of%2520congenital%2520osteopetrosis%2520in%2520op%252Fop%2520mouse%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1982%26volume%3D156%26spage%3D1516%26epage%3D1527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Pollard, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, E. R.</span><span> </span><span class="NLM_article-title">Pleotropic roles for CSF-1 in development defined by the mouse mutation osteopetrotic (op)</span> <span class="citation_source-journal">Adv. Dev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1016%2FS1064-2722%2808%2960060-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1995&pages=153-193&author=J.+W.+Pollardauthor=E.+R.+Stanley&title=Pleotropic+roles+for+CSF-1+in+development+defined+by+the+mouse+mutation+osteopetrotic+%28op%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1064-2722%2808%2960060-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1064-2722%252808%252960060-2%26sid%3Dliteratum%253Aachs%26aulast%3DPollard%26aufirst%3DJ.%2BW.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DPleotropic%2520roles%2520for%2520CSF-1%2520in%2520development%2520defined%2520by%2520the%2520mouse%2520mutation%2520osteopetrotic%2520%2528op%2529%26jtitle%3DAdv.%2520Dev.%2520Biochem.%26date%3D1995%26volume%3D4%26spage%3D153%26epage%3D193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">MacDonald, K. P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowe, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bofinger, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasmono, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hume, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. R.</span><span> </span><span class="NLM_article-title">The colony-stimulating factor 1 receptor is expressed on dendritic cells during differentiation and regulates their expansion</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">1399</span><span class="NLM_x">–</span> <span class="NLM_lpage">1405</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2005&pages=1399-1405&author=K.+P.+A.+MacDonaldauthor=V.+Roweauthor=H.+M.+Bofingerauthor=R.+Thomasauthor=T.+Sasmonoauthor=D.+A.+Humeauthor=G.+R.+Hill&title=The+colony-stimulating+factor+1+receptor+is+expressed+on+dendritic+cells+during+differentiation+and+regulates+their+expansion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMacDonald%26aufirst%3DK.%2BP.%2BA.%26aulast%3DRowe%26aufirst%3DV.%26aulast%3DBofinger%26aufirst%3DH.%2BM.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DSasmono%26aufirst%3DT.%26aulast%3DHume%26aufirst%3DD.%2BA.%26aulast%3DHill%26aufirst%3DG.%2BR.%26atitle%3DThe%2520colony-stimulating%2520factor%25201%2520receptor%2520is%2520expressed%2520on%2520dendritic%2520cells%2520during%2520differentiation%2520and%2520regulates%2520their%2520expansion%26jtitle%3DJ.%2520Immunol.%26date%3D2005%26volume%3D175%26spage%3D1399%26epage%3D1405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Pixley, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, E. R.</span><span> </span><span class="NLM_article-title">CSF-1 regulation of the wandering macrophage: complexity in action</span> <span class="citation_source-journal">Trends Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">628</span><span class="NLM_x">–</span> <span class="NLM_lpage">638</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1016%2Fj.tcb.2004.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=15519852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpt1Wgsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=628-638&author=F.+J.+Pixleyauthor=E.+R.+Stanley&title=CSF-1+regulation+of+the+wandering+macrophage%3A+complexity+in+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">CSF-1 regulation of the wandering macrophage: complexity in action</span></div><div class="casAuthors">Pixley, Fiona J.; Stanley, E. Richard</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">628-638</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Most tissue macrophages and osteoclasts are regulated by colony-stimulating factor-1 (CSF-1, also known as macrophage CSF).  The effects of CSF-1 are mediated by the CSF-1 receptor tyrosine kinase (CSF-1R), through autophosphorylation of CSF-1R and the subsequent phosphorylation of downstream mols.  Triggering this phosphorylation cascade increases gene transcription and protein translation, and induces cytoskeletal remodeling by several signaling pathways, leading to the survival, proliferation and differentiation of target cells.  CSF-1-regulated tissue macrophages are important for innate immunity and for tissue development and function.  Because CSF-1 regulates the survival, proliferation and chemotaxis of macrophages and supports their activation, this factor is involved in the pathogenesis of several diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouh_AnBDWTs7Vg90H21EOLACvtfcHk0lhQ30iK6WnpcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpt1Wgsrw%253D&md5=0b2639ed4de1366b5fba48fc6c3758ba</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2004.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2004.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DPixley%26aufirst%3DF.%2BJ.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DCSF-1%2520regulation%2520of%2520the%2520wandering%2520macrophage%253A%2520complexity%2520in%2520action%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2004%26volume%3D14%26spage%3D628%26epage%3D638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Park, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">In, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span> </span><span class="NLM_article-title">Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1714</span><span class="NLM_x">–</span> <span class="NLM_lpage">1719</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1002%2Fart.10359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=12124853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A280%3ADC%252BD38znslyktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=1714-1719&author=Y.+Parkauthor=C.+Ahnauthor=H.+K.+Choiauthor=S.+Leeauthor=B.+Inauthor=H.+Leeauthor=C.+Namauthor=S.+Lee&title=Atherosclerosis+in+rheumatoid+arthritis%3A+morphologic+evidence+obtained+by+carotid+ultrasound"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound</span></div><div class="casAuthors">Park Yong-Beom; Ahn Chul-Woo; Choi Hyon K; Lee Seung-Hoon; In Byung-Hyun; Lee Hyun-Chul; Nam Chung-Mo; Lee Soo-Kon</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis and rheumatism</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1714-9</span>
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    </div><div class="casAbstract">OBJECTIVE:  Recent studies have suggested increased cardiovascular disease among patients with rheumatoid arthritis (RA).  We undertook this study to obtain morphologic evidence of subclinical atherosclerosis in RA patients.  METHODS:  We used high-resolution B-mode ultrasound to compare carotid artery intima-media wall thickness (IMT) between 53 postmenopausal women with RA and 53 controls matched by age, sex, and menopause status.  No subject in either group had a history of atherosclerosis or its complications.  We investigated the association between IMT and relevant clinical and therapeutic variables, including the impact of low-dose corticosteroid therapy (< or = 10 mg/day prednisolone).  RESULTS:  The mean +/- SD IMT of the left and right common carotid arteries in RA patients was significantly greater than that in controls (0.77 +/- 0.09 mm versus 0.68 +/- 0.14 mm; P < 0.001).  Early RA (duration < or = 1 year) was associated with lesser IMT than was RA of longer duration (0.72 +/- 0.03 mm versus 0.78 +/- 0.01 mm; P < 0.04).  Prednisolone use was not associated with increased IMT (0.78 +/- 0.02 mm in nonusers versus 0.76 +/- 0.01 mm in users; P = 0.38).  CONCLUSION:  Our data indicate that RA patients have an ultrasonic marker of early atherosclerosis consistent with an increased risk for atherosclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXPznsnxkDyBFwe7cAcrfPfW6udTcc2eaijYvF4V2uKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38znslyktQ%253D%253D&md5=64eed6937bbd9210928466ae3f6e21a2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fart.10359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.10359%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DY.%26aulast%3DAhn%26aufirst%3DC.%26aulast%3DChoi%26aufirst%3DH.%2BK.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DIn%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DNam%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DS.%26atitle%3DAtherosclerosis%2520in%2520rheumatoid%2520arthritis%253A%2520morphologic%2520evidence%2520obtained%2520by%2520carotid%2520ultrasound%26jtitle%3DArthritis%2520Rheum.%26date%3D2002%26volume%3D46%26spage%3D1714%26epage%3D1719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Joffe, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, S.</span><span> </span><span class="NLM_article-title">Osteoporosis associated with rheumatoid arthritis: pathogenesis and management</span> <span class="citation_source-journal">Semin. Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">256</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1016%2F0049-0172%2891%2990021-Q" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=2042057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A280%3ADyaK3M3lt1ynug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1991&pages=256-272&author=I.+Joffeauthor=S.+Epstein&title=Osteoporosis+associated+with+rheumatoid+arthritis%3A+pathogenesis+and+management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Osteoporosis associated with rheumatoid arthritis: pathogenesis and management</span></div><div class="casAuthors">Joffe I; Epstein S</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in arthritis and rheumatism</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">256-72</span>
        ISSN:<span class="NLM_cas:issn">0049-0172</span>.
    </div><div class="casAbstract">Rheumatoid arthritis is associated with both localized and generalized osteoporosis.  Localized osteoporosis can be considered to be caused by local disease mechanisms, including the generation of factors from activation of the cytokine pathway.  The etiology of generalized osteoporosis has been difficult to elucidate, particularly because of the lack of sensitive techniques to measure bone mineral density.  The introduction of single- and dual-photon absorptiometry and quantitative computed tomography has allowed more accurate assessment of bone mineral density.  In general, bone mineral density loss at appendicular sites does not correlate well with axial bone density loss.  Corticosteroid treatment exaggerates the development of osteoporosis in up to 40% of patients with rheumatoid arthritis.  Sex hormone status, physical activity, disease duration, and functional class are all significant predictors for the development of osteoporosis.  Current therapy for prevention and treatment is based largely on theoretical considerations.  Physical activity should be encouraged once acute joint inflammation has settled.  Postmenopausal women and amenorrheic premenopausal women will benefit from cyclical estrogen replacement.  Patients with low serum 1,25-dihydroxy vitamin D3 levels, and males with low serum testosterone levels, are candidates for replacement therapy with the appropriate hormones.  In patients who are receiving corticosteroids the dose should be limited, and oral calcium supplements are of benefit.  The use of the newer corticosteroid deflazacort, and disease-modifying immunosuppressive drugs, are discussed.  Other therapeutic options which should be considered, although published trials are scarce, are calcitonin and the diphosphonates.  Further studies are awaited concerning the optimum prevention and treatment of osteoporosis associated with rheumatoid arthritis.(ABSTRACT TRUNCATED AT 250 WORDS)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdrBiM3Zv340odMGTatQ7LfW6udTcc2eaijYvF4V2uKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M3lt1ynug%253D%253D&md5=cde992363b22540720e1aa9c61f6fbcf</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2F0049-0172%2891%2990021-Q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0049-0172%252891%252990021-Q%26sid%3Dliteratum%253Aachs%26aulast%3DJoffe%26aufirst%3DI.%26aulast%3DEpstein%26aufirst%3DS.%26atitle%3DOsteoporosis%2520associated%2520with%2520rheumatoid%2520arthritis%253A%2520pathogenesis%2520and%2520management%26jtitle%3DSemin.%2520Arthritis%2520Rheum.%26date%3D1991%26volume%3D20%26spage%3D256%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Lipsky, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Der Heijde, D. M. F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Clair, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furst, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breedveld, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalden, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolen, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maini, R. N.</span><span> </span><span class="NLM_article-title">Infliximab and methotrexate in the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">1594</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1056%2FNEJM200011303432202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=11096166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovVeltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2000&pages=1594-602&author=P.+E.+Lipskyauthor=D.+M.+F.+M.+Van+Der+Heijdeauthor=E.+W.+St.+Clairauthor=D.+E.+Furstauthor=F.+C.+Breedveldauthor=J.+R.+Kaldenauthor=J.+S.+Smolenauthor=M.+Weismanauthor=P.+Emeryauthor=M.+Feldmannauthor=G.+R.+Harrimanauthor=R.+N.+Maini&title=Infliximab+and+methotrexate+in+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Infliximab and methotrexate in the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Lipsky, Peter E.; Van Der Heijde, Desiree M. F. M.; St. Clair, E. William; Furst, Daniel E.; Breedveld, Ferdinand C.; Kalden, Joachim R.; Smolen, Josef S.; Weisman, Michael; Emery, Paul; Feldmann, Marc; Harriman, Gregory R.; Maini, Ravinder N.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1594-1602</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Neutralization of tumor necrosis factor α (TNF-α) for three to six months reduces the symptoms and signs of rheumatoid arthritis.  However, the capacity of this approach to effect a more sustained benefit and its effect on joint damage are not known.  We treated 428 patients who had active rheumatoid arthritis despite methotrexate therapy with placebo or infliximab, a chimeric monoclonal antibody against TNF-α, in i.v. doses of 3 or 10 mg per kg of body wt. every 4 or 8 wk in combination with oral methotrexate for 54 wk.  We assessed clin. responses with use of the criteria of the American College of Rheumatol., the quality of life with a health-status questionnaire, and the effect on joint damage radiog.  The combination of infliximab and methotrexate was well tolerated and resulted in a sustained redn. in the symptoms and signs of rheumatoid arthritis that was significantly greater than the redn. assocd. with methotrexate therapy alone (clin. response, 51.8 % vs. 17.0 %; P<0.001).  The quality of life was also significantly better with infliximab plus methotrexate than with methotrexate alone.  Radiog. evidence of joint damage increased in the group given methotrexate, but not in the groups given infliximab and methotrexate (mean change in radiog. score, 7.0 vs. 0.6; P<0.001).  Radiog. evidence of progression of joint damage was absent in infliximab-treated patients whether or not they had a clin. response.  In patients with persistently active rheumatoid arthritis despite methotrexate therapy, repeated doses of infliximab in combination with methotrexate provided clin. benefit and halted the progression of joint damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqasmJKB3fqgrVg90H21EOLACvtfcHk0lg1h9RFkrWjtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovVeltLk%253D&md5=b67ff09ce24a2c808a265204aac20e53</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJM200011303432202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200011303432202%26sid%3Dliteratum%253Aachs%26aulast%3DLipsky%26aufirst%3DP.%2BE.%26aulast%3DVan%2BDer%2BHeijde%26aufirst%3DD.%2BM.%2BF.%2BM.%26aulast%3DSt.%2BClair%26aufirst%3DE.%2BW.%26aulast%3DFurst%26aufirst%3DD.%2BE.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DKalden%26aufirst%3DJ.%2BR.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DWeisman%26aufirst%3DM.%26aulast%3DEmery%26aufirst%3DP.%26aulast%3DFeldmann%26aufirst%3DM.%26aulast%3DHarriman%26aufirst%3DG.%2BR.%26aulast%3DMaini%26aufirst%3DR.%2BN.%26atitle%3DInfliximab%2520and%2520methotrexate%2520in%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2000%26volume%3D343%26spage%3D1594%26epage%3D602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Borchers, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keen, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheema, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gershwin, M. E.</span><span> </span><span class="NLM_article-title">The use of methotrexate in rheumatoid arthritis</span> <span class="citation_source-journal">Semin. Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">483</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1016%2Fj.semarthrit.2003.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=15305245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslalsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2004&pages=465-483&author=A.+T.+Borchersauthor=C.+L.+Keenauthor=G.+S.+Cheemaauthor=M.+E.+Gershwin&title=The+use+of+methotrexate+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The use of methotrexate in rheumatoid arthritis</span></div><div class="casAuthors">Borchers, Andrea T.; Keen, Carl L.; Cheema, Gurtej S.; Gershwin, M. Eric</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Arthritis and Rheumatism</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">465-483</span>CODEN:
                <span class="NLM_cas:coden">SAHRBF</span>;
        ISSN:<span class="NLM_cas:issn">0049-0172</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objective: To address the long-term efficacy and toxicity issues related to methotrexate (MTX) and compare it with other disease-modifying antirheumatic drugs (DMARDs).  Methods: Review of the international literature on the clin. use of MTX in rheumatoid arthritis (RA) disease.  Results: MTX has emerged as a relatively safe and effective treatment for RA that compares favorably with other therapies, particularly because of its considerably longer median drug survival.  The toxicity profile of MTX is well established and includes serious and sometimes fatal liver disease, pneumonitis, and cytopenias.  Hence, regular and careful monitoring of patients taking MTX is essential, particularly when MTX is combined with other DMARDs.  Folate supplementation can reduce some of the most common side effects of MTX, but it has not yet been established whether this translates into a reduced risk of serious disease.  Another potential approach to reducing the toxicity of MTX is therapeutic drug monitoring and dose individualization.  However, correlations between pharmacokinetics and clin. response have been addressed in only a few studies and with conflicting results.  Conclusions: MTX is an effective DMARD with a relatively safe profile compared with other therapies.  Folate supplementation can significantly reduce the risk of MTX toxicity.  Finally, it is essential that patients be monitored carefully to reduce the potential serious toxicities of MTX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD7IuayGisFLVg90H21EOLACvtfcHk0lg1h9RFkrWjtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslalsbo%253D&md5=1b4d0358af3f1fdd5f2cf94c04dc0ce8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.semarthrit.2003.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semarthrit.2003.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DBorchers%26aufirst%3DA.%2BT.%26aulast%3DKeen%26aufirst%3DC.%2BL.%26aulast%3DCheema%26aufirst%3DG.%2BS.%26aulast%3DGershwin%26aufirst%3DM.%2BE.%26atitle%3DThe%2520use%2520of%2520methotrexate%2520in%2520rheumatoid%2520arthritis%26jtitle%3DSemin.%2520Arthritis%2520Rheum.%26date%3D2004%26volume%3D34%26spage%3D465%26epage%3D483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kawaji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokomuro, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somoto, Y</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirai, Y.</span><span> </span><span class="NLM_article-title">Macrophage colony-stimulating factor in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Nippon Ika Daigaku Zasshi</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1272%2Fjnms1923.62.260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=7615698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADyaK2MXms1WhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1995&pages=260-270&author=H.+Kawajiauthor=K.+Yokomuroauthor=K.+Kikuchiauthor=Y+Somotoauthor=Y.+Shirai&title=Macrophage+colony-stimulating+factor+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage colony-stimulating factor in patients with rheumatoid arthritis</span></div><div class="casAuthors">Kawaji, Hidemi; Yokomuro, Kozo; Kikuchi, Kyoko; Somoto, Youki; Shirai, Yasumasa</div><div class="citationInfo"><span class="NLM_cas:title">Nippon Ika Daigaku Zasshi</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">260-70</span>CODEN:
                <span class="NLM_cas:coden">NIDZAJ</span>;
        ISSN:<span class="NLM_cas:issn">0048-0444</span>.
    </div><div class="casAbstract">We developed a new ELISA technique to measure macrophage colony-stimulating factor (M-CSF) levels in synovial fluid with high sensitivity and reproducibility.  The mean M-CSF level in the synovial fluid of patients with rheumatoid arthritis (RA) was 1.38 ± 0.56 ng/mL, and that of patients with osteoarthritis (OA) was 0.67 ± 0.13 ng/mL.  In contrast, serum levels of M-CSF in patients with RA and in normal controls were 1.32 ± 0.50 ng/mL and 0.90 ± 0.09 ng/mL, resp.  These differences were both statistically significant.  Since serum M-CSF levels correlate with inflammatory signs obtained from examn. of blood, they indicate the general condition of patients with RA.  Synovial fluid M-CSF levels increase even in the early phase of RA and remain high despite drug therapy, which suggests that they reflect the condition of affected joints including joint spaces and inflamed synovia more directly than do the levels of serum M-CSF.  Measurement of the M-CSF level in the synovial fluid may be useful in the diagnosis, clin. evaluation, and assessment of the effects of treatment in patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomBgcRjuSmvLVg90H21EOLACvtfcHk0liBWv1ooDGe8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXms1WhtrY%253D&md5=2d5c872c01ea9a95560af0412a2967e2</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1272%2Fjnms1923.62.260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1272%252Fjnms1923.62.260%26sid%3Dliteratum%253Aachs%26aulast%3DKawaji%26aufirst%3DH.%26aulast%3DYokomuro%26aufirst%3DK.%26aulast%3DKikuchi%26aufirst%3DK.%26aulast%3DSomoto%26aufirst%3DY%26aulast%3DShirai%26aufirst%3DY.%26atitle%3DMacrophage%2520colony-stimulating%2520factor%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DNippon%2520Ika%2520Daigaku%2520Zasshi%26date%3D1995%26volume%3D62%26spage%3D260%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ritchlin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucala, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winchester, R.</span><span> </span><span class="NLM_article-title">Sustained and distinctive patterns of gene activation in synovial fibroblasts and whole synovial tissue obtained from inflammatory synovitis</span> <span class="citation_source-journal">Scand. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1111%2Fj.1365-3083.1994.tb03465.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=8091128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADyaK2cXmt1yls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1994&pages=292-298&author=C.+Ritchlinauthor=E.+Dwyerauthor=R.+Bucalaauthor=R.+Winchester&title=Sustained+and+distinctive+patterns+of+gene+activation+in+synovial+fibroblasts+and+whole+synovial+tissue+obtained+from+inflammatory+synovitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained and distinctive patterns of gene activation in synovial fibroblasts and whole synovial tissue obtained from inflammatory synovitis</span></div><div class="casAuthors">Ritchlin, C.; Dwyer, E.; Bucala, R.; Winchester, R.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">292-8</span>CODEN:
                <span class="NLM_cas:coden">SJIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0300-9475</span>.
    </div><div class="casAbstract">Fibroblastoid synovial lining cells isolated from rheumatoid and other chronic inflammatory synovial tissue exhibit distinctive and sustained alterations in serial culture not commonly found in similarly cultured cells from osteoarthritic synovium.  These are demonstrable using a multi-gene dot blot assay by labeling reverse transcribed fibroblast cDNA which is hybridized to plasmids contg. relevant target gene inserts.  Cultured synovial fibroblastoid cells from patients with chronic inflammatory synovitis expressed significantly higher levels of stromelysin, vimentin and TIMP-1 mRNA and lower levels of c-myc compared to cells isolated from osteoarthritis synovium although with considerable variation.  Early fetal synovial lining cells were similar to cells from osteoarthritis synovium but vimentin expression was higher.  Marked differences in patterns of gene expression between cell lines persisted through 10 serial passages over 6-8 mo.  In whole synovia, the av. level of mRNA for stromelysin, vimentin, IL-4, IL-6, TIMP-1, cathepsin D, gelatinase, TGFα, c-fms and DRβ were preferentially expressed in inflammatory tissue while c-myc expression was higher in osteoarthritis synovium.  Inflammatory synovium also expressed TNFα, IL-1α, IL-1β, IL-2, c-sis, tissue plasminogen activator, CSF-1, and GM-CSF.  This pattern resembles, in part, that found in cultured inflammatory fibroblasts but, in addn., gene products apparently reflecting the presence of activated monocytes and lymphocytes were detected.  These results provide evidence that profiles of certain gene activation in cells from patients with inflammatory synovitis differ from those with non-inflammatory disease and suggest that the fibroblastoid cells are responsible for a considerable proportion of the altered phenotypic expression pattern in whole tissue.  Furthermore, this modulated pattern of gene activation appears to be an intrinsic pro-inflammatory characteristic of the fibroblastoid cells initiated in response to chronic inflammation and persists for a prolonged period in the absence of other inflammatory cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUd6F-8PCMFbVg90H21EOLACvtfcHk0liBWv1ooDGe8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmt1yls7g%253D&md5=0e00011784fe504612c79350cea6a90a</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-3083.1994.tb03465.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-3083.1994.tb03465.x%26sid%3Dliteratum%253Aachs%26aulast%3DRitchlin%26aufirst%3DC.%26aulast%3DDwyer%26aufirst%3DE.%26aulast%3DBucala%26aufirst%3DR.%26aulast%3DWinchester%26aufirst%3DR.%26atitle%3DSustained%2520and%2520distinctive%2520patterns%2520of%2520gene%2520activation%2520in%2520synovial%2520fibroblasts%2520and%2520whole%2520synovial%2520tissue%2520obtained%2520from%2520inflammatory%2520synovitis%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D1994%26volume%3D40%26spage%3D292%26epage%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Takei, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ida, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santavirta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konttinen, Y. T.</span><span> </span><span class="NLM_article-title">High macrophage-colony stimulating factor levels in synovial fluid of loose artificial hip joints</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">894</span><span class="NLM_x">–</span> <span class="NLM_lpage">899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=10782812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXivFOrsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2000&pages=894-899&author=I.+Takeiauthor=M.+Takagiauthor=H.+Idaauthor=T.+Oginoauthor=S.+Santavirtaauthor=Y.+T.+Konttinen&title=High+macrophage-colony+stimulating+factor+levels+in+synovial+fluid+of+loose+artificial+hip+joints"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">High macrophage-colony stimulating factor levels in synovial fluid of loose artificial hip joints</span></div><div class="casAuthors">Takei, Isao; Takagi, Michiaki; Ida, Hideo; Ogino, Toshihiko; Santavirta, Seppo; Konttinen, Yrjo T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">894-899</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective. To clarify a macrophage-colony stimulating factor (M-CSF) related mechanism of aseptic loosening of artificial hip joints.  Methods. Synovium-like interface tissues between bone and prosthesis, regenerated pseudocapsular tissues, and synovial fluid (SF) were collected from 9 patients with loose artificial hip joint at revision surgery.  Tissue distribution, prodn. site, and SF level of M-CSF in loose hip joints were investigated by immunohistochem., reverse transcription-polymerase chain reaction (RT-PCR), and ELISA, resp.  For a comparative assessment of the M-CSF level in loose hip joints, SF of active rheumatoid arthritis (RA) and mild osteoarthritis (OA) also were analyzed by ELISA.  Results. Immunohistochem. anal. showed the presence of M-CSF immunoreactive cells mainly in the interface tissues between bone and prosthesis and inner pseudocapsular tissues, both of which were in contact with joint fluid.  RT-PCR anal. confirmed the local prodn. of M-CSF in these periprosthetic tissues.  Significantly higher M-CSF level in loose hip joint fluid than in active RA and mild OA fluid was revealed by ELISA.  Conclusion. High M-CSF level in loose hip joint fluid suggests transportation of M-CSF from prodn. sites to joint fluid.  This indicates that not only polyethylene wear particles (reported to induce foreign body reaction at the bone-prosthesis interface), but also M-CSF, abundant in joint fluid, are transported to and affect the interface.  Thus, M-CSF is locally produced in periprosthetic tissues of loose hip joints and possibly contributes to periprosthetic weakening and osteolysis via joint fluid, leading to prosthetic loosening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlI9pPe59SQbVg90H21EOLACvtfcHk0liFwzHkX7xoLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXivFOrsb8%253D&md5=08e093f0c23066d5df935638e9fac9d0</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakei%26aufirst%3DI.%26aulast%3DTakagi%26aufirst%3DM.%26aulast%3DIda%26aufirst%3DH.%26aulast%3DOgino%26aufirst%3DT.%26aulast%3DSantavirta%26aufirst%3DS.%26aulast%3DKonttinen%26aufirst%3DY.%2BT.%26atitle%3DHigh%2520macrophage-colony%2520stimulating%2520factor%2520levels%2520in%2520synovial%2520fluid%2520of%2520loose%2520artificial%2520hip%2520joints%26jtitle%3DJ.%2520Rheumatol.%26date%3D2000%26volume%3D27%26spage%3D894%26epage%3D899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Shinohara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirohata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, K.</span><span> </span><span class="NLM_article-title">Phenotypic analysis of peripheral blood monocytes isolated from patients with rheumatoid arthritis</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=1378495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A280%3ADyaK38zjtlCmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1992&pages=211-215&author=S.+Shinoharaauthor=S.+Hirohataauthor=T.+Inoueauthor=K.+Ito&title=Phenotypic+analysis+of+peripheral+blood+monocytes+isolated+from+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic analysis of peripheral blood monocytes isolated from patients with rheumatoid arthritis</span></div><div class="casAuthors">Shinohara S; Hirohata S; Inoue T; Ito K</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of rheumatology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-5</span>
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    </div><div class="casAbstract">The expression of CD14, Fc gamma receptor I (Fc gamma RI), Fc gamma RII, and HLA-DR on peripheral blood monocytes from patients with rheumatoid arthritis (RA) was studied to investigate their nature and their role in the pathogenesis of rheumatoid synovitis.  Peripheral blood mononuclear cells obtained from 9 patients with active RA, 8 patients with RA in complete remission, and 14 healthy individuals, were stained with various monoclonal antibodies and analyzed on a fluorescence activated cell sorter.  The expression of CD14 as well as Fc gamma RI and Fc gamma RII was upregulated on peripheral blood monocytes from patients with active RA, although the expression of HLA-DR was not increased.  In addition, the expression of Fc gamma RI and Fc gamma RII on monocytes was still upregulated in patients with RA in complete remission, whereas the expression of CD14 on monocytes was normalized in these patients.  These results indicate that peripheral blood monocytes in patients with active RA are already activated to express higher densities of CD14.  In addition, our observation that CD14 density was increased on a subset of circulating blood monocytes in active RA, that HLA-DR was not significantly altered and that Fc gamma RI and Fc gamma RII were increased in both active and inactive RA is not compatible with the expected actions of interferon gamma.  Finally, it is suggested that peripheral blood monocytes in patients with RA may have intrinsic abnormalities as evidenced by the enhanced expression of Fc gamma R, which is repeatedly observed regardless of the disease activity of RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqPwmnMlyxYwMthz5_Rx5rfW6udTcc2eb6LlotNZxgi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38zjtlCmtQ%253D%253D&md5=4e6bbbeeee044cd4ac39f73566c9e1e3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShinohara%26aufirst%3DS.%26aulast%3DHirohata%26aufirst%3DS.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DK.%26atitle%3DPhenotypic%2520analysis%2520of%2520peripheral%2520blood%2520monocytes%2520isolated%2520from%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Rheumatol.%26date%3D1992%26volume%3D19%26spage%3D211%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Weiner, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catalano, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dovnarsky, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padavic, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alpaugh, R. K.</span><span> </span><span class="NLM_article-title">Phase 1 trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4084</span><span class="NLM_x">–</span> <span class="NLM_lpage">4090</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1994&pages=4084-4090&author=L.+M.+Weinerauthor=W.+Liauthor=M.+Holmesauthor=R.+B.+Catalanoauthor=M.+Dovnarskyauthor=K.+Padavicauthor=R.+K.+Alpaugh&title=Phase+1+trial+of+recombinant+macrophage+colony-stimulating+factor+and+recombinant+gamma-interferon%3A+toxicity%2C+monocytosis%2C+and+clinical+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DHolmes%26aufirst%3DM.%26aulast%3DCatalano%26aufirst%3DR.%2BB.%26aulast%3DDovnarsky%26aufirst%3DM.%26aulast%3DPadavic%26aufirst%3DK.%26aulast%3DAlpaugh%26aufirst%3DR.%2BK.%26atitle%3DPhase%25201%2520trial%2520of%2520recombinant%2520macrophage%2520colony-stimulating%2520factor%2520and%2520recombinant%2520gamma-interferon%253A%2520toxicity%252C%2520monocytosis%252C%2520and%2520clinical%2520effects%26jtitle%3DCancer%2520Res.%26date%3D1994%26volume%3D54%26spage%3D4084%26epage%3D4090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Hanamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asakura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanabe, T.</span><span> </span><span class="NLM_article-title">Macrophage colony-stimulating factor (CSF-1) augments cytokine induction by lipopolysaccharide (LPS)-stimulation and by bacterial infections in mice</span> <span class="citation_source-journal">Immunopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1016%2FS0162-3109%2896%2900166-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=9285240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADyaK2sXktlGjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1997&pages=15-23&author=T.+Hanamuraauthor=E.+Asakuraauthor=T.+Tanabe&title=Macrophage+colony-stimulating+factor+%28CSF-1%29+augments+cytokine+induction+by+lipopolysaccharide+%28LPS%29-stimulation+and+by+bacterial+infections+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage colony-stimulating factor (M-CSF) augments cytokine induction by lipopolysaccharide (LPS)-stimulation and by bacterial infections in mice</span></div><div class="casAuthors">Hanamura, Takuji; Asakura, Eiji; Tanabe, Toshizumi</div><div class="citationInfo"><span class="NLM_cas:title">Immunopharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-23</span>CODEN:
                <span class="NLM_cas:coden">IMMUDP</span>;
        ISSN:<span class="NLM_cas:issn">0162-3109</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The authors studied the effects of M-CSF on cytokine induction in vivo by LPS or by bacterial infection by comparing between the serum cytokine levels of mice administered with and without M-CSF.  M-CSF at 250 μg/kg/day for 3 days significantly augmented serum IL-6 level induced by a subsequent injection of 25 μg/kg of LPS.  The augmented IL-6-induction was dose-dependent from 50 to 1250 μg/kg/day of M-CSF, and required 2- to 3-doses of M-CSF at 250 μg/kg/day.  Mice primed with M-CSF induced IL-6 in response to a 5-fold lower dose of LPS, and also produced higher levels of IL-1α, IL-10, GM-CSF, TNF-α, and IFN-γ than control mice.  The priming effect of M-CSF was transient and reversible, and elicited independently of T-cells.  An injection with intact bacteria, such as Gram-neg. Escherichia coli and Gram-pos. Staphylococcus aureus also induced IL-6 in normal mice, and M-CSF administration augmented the induction of these cytokines.  These results showed that M-CSF pos. regulates LPS-dependent and -independent cytokine induction, suggesting a defensive effect against infectious agents through enhanced cytokine prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAhwp8qASs0rVg90H21EOLACvtfcHk0ljJI10CnYhK8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlGjt74%253D&md5=108c02bd05528f09a498c36296ff5265</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0162-3109%2896%2900166-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0162-3109%252896%252900166-X%26sid%3Dliteratum%253Aachs%26aulast%3DHanamura%26aufirst%3DT.%26aulast%3DAsakura%26aufirst%3DE.%26aulast%3DTanabe%26aufirst%3DT.%26atitle%3DMacrophage%2520colony-stimulating%2520factor%2520%2528CSF-1%2529%2520augments%2520cytokine%2520induction%2520by%2520lipopolysaccharide%2520%2528LPS%2529-stimulation%2520and%2520by%2520bacterial%2520infections%2520in%2520mice%26jtitle%3DImmunopharmacology%26date%3D1997%26volume%3D37%26spage%3D15%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Hamilton, J. A.</span><span> </span><span class="NLM_article-title">Rheumatoid arthritis: opposing actions of haemopoietic growth factors and slow-acting anti-rheumatic drugs</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">342</span><span class="NLM_x">, </span> <span class="NLM_fpage">536</span><span class="NLM_x">–</span> <span class="NLM_lpage">539</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=1993&pages=536-539&author=J.+A.+Hamilton&title=Rheumatoid+arthritis%3A+opposing+actions+of+haemopoietic+growth+factors+and+slow-acting+anti-rheumatic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamilton%26aufirst%3DJ.%2BA.%26atitle%3DRheumatoid%2520arthritis%253A%2520opposing%2520actions%2520of%2520haemopoietic%2520growth%2520factors%2520and%2520slow-acting%2520anti-rheumatic%2520drugs%26jtitle%3DLancet%26date%3D1993%26volume%3D342%26spage%3D536%26epage%3D539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Castro-Rueda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavanaugh, A.</span><span> </span><span class="NLM_article-title">Biologic therapy for early rheumatoid arthritis: the latest evidence</span> <span class="citation_source-journal">Curr. Opin. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1097%2FBOR.0b013e3282f5fcf6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=18388524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A280%3ADC%252BD1c3ivFaisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2008&pages=314-9&author=H.+Castro-Ruedaauthor=A.+Kavanaugh&title=Biologic+therapy+for+early+rheumatoid+arthritis%3A+the+latest+evidence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Biologic therapy for early rheumatoid arthritis: the latest evidence</span></div><div class="casAuthors">Castro-Rueda Hernan; Kavanaugh Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in rheumatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">314-9</span>
        ISSN:<span class="NLM_cas:issn">1040-8711</span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  To describe current therapeutic trials with biologic agents for early rheumatoid arthritis, analyzing clinical and radiographic outcomes.  RECENT FINDINGS:  The use of tumor necrosis factor-alpha inhibitors in combination with disease-modifying antirheumatic drugs early after the diagnosis of aggressive rheumatoid arthritis seems to provide increased clinical benefit over methotrexate or tumor necrosis factor-alpha inhibitors as monotherapy, with better outcomes in terms of faster and more extensive clinical improvement.  There also seems to be an increased likelihood of low-disease activity in some cases even after tapering therapy.  Control of radiographic progression appears to be most effective among early rheumatoid arthritis patients treated with combination tumor necrosis factor-alpha inhibitors and methotrexate, although radiographic outcomes are better with tumor necrosis factor-alpha inhibitor monotherapy than with methotrexate alone.  SUMMARY:  The addition of antitumor necrosis factor-alpha agents to traditional disease-modifying antirheumatic drugs in early rheumatoid arthritis is a novel strategy which follows the principle of early and aggressive therapeutic intervention.  Results from recent trials show greater levels of disease control.  The impact on long-term safety and cost-efficacy are factors which will need to be better characterized over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWKzyGlFkUClf1XRtfYM0dfW6udTcc2ea5qF7buSSjPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3ivFaisw%253D%253D&md5=10d5b46198ef31506e94697c056aa84b</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1097%2FBOR.0b013e3282f5fcf6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FBOR.0b013e3282f5fcf6%26sid%3Dliteratum%253Aachs%26aulast%3DCastro-Rueda%26aufirst%3DH.%26aulast%3DKavanaugh%26aufirst%3DA.%26atitle%3DBiologic%2520therapy%2520for%2520early%2520rheumatoid%2520arthritis%253A%2520the%2520latest%2520evidence%26jtitle%3DCurr.%2520Opin.%2520Rheumatol.%26date%3D2008%26volume%3D20%26spage%3D314%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ilowite, N. T.</span><span> </span><span class="NLM_article-title">Update on biologics in juvenile idiopathic arthritis</span> <span class="citation_source-journal">Curr. Opin. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">613</span><span class="NLM_x">–</span> <span class="NLM_lpage">618</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1097%2FBOR.0b013e3283060778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=18698187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A280%3ADC%252BD1crhsV2htg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2008&pages=613-618&author=N.+T.+Ilowite&title=Update+on+biologics+in+juvenile+idiopathic+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Update on biologics in juvenile idiopathic arthritis</span></div><div class="casAuthors">Ilowite Norman T</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in rheumatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">613-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  The purpose of this review is to summarize the recent data on biologic therapies in juvenile rheumatoid arthritis.  The armamentarium for treatment of juvenile idiopathic arthritis is expanding at a rapid rate, and improved physical and functional outcomes are anticipated.  New data from large prospective randomized trials have demonstrated efficacy of anti-tumor necrosis factor agents and a costimulator signal inhibitor.  RECENT FINDINGS:  The results of a pivotal trial of infliximab in polyarticular juvenile idiopathic arthritis suggested efficacy, but the primary outcome was not significantly different from placebo.  Important information regarding dosing in children was obtained, however.  A pivotal trial of adalimumab did prove efficacy, and resulted in U.S.  Food and Drug Administration (FDA) approval.  The monoclonal antibodies to tumor necrosis factor appear to be more effective in treating chronic uveitis associated with juvenile idiopathic arthritis than etanercept.  Anti-IL-1 and anti-IL-6 therapy, particularly for systemic disease patients, looks very promising, as well.  The costimulation modifier abatacept was shown to be effective and relatively well tolerated in the short term, also resulting in FDA approval this year.  Continued experience with these agents and appropriate systems-based methods such as formal registries, to complement existing FDA procedures for monitoring safety, will improve our ability to identify short-term and long-term toxicities of these new agents.  SUMMARY:  As experience is gained, and longer-term safety is demonstrated, it is likely that biologics will be introduced as therapy earlier in the course of patients who inadequately respond to conventional disease-modifying antirheumatic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuDvMZ7pFzijToTC3aBaesfW6udTcc2ea5qF7buSSjPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1crhsV2htg%253D%253D&md5=8c331db6f34c9a8ad7663905aed917df</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1097%2FBOR.0b013e3283060778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FBOR.0b013e3283060778%26sid%3Dliteratum%253Aachs%26aulast%3DIlowite%26aufirst%3DN.%2BT.%26atitle%3DUpdate%2520on%2520biologics%2520in%2520juvenile%2520idiopathic%2520arthritis%26jtitle%3DCurr.%2520Opin.%2520Rheumatol.%26date%3D2008%26volume%3D20%26spage%3D613%26epage%3D618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kitaura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novack, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teitelbaum, S. L.</span><span> </span><span class="NLM_article-title">M-CSF mediates TNF-induced inflammatory osteolysis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">3418</span><span class="NLM_x">–</span> <span class="NLM_lpage">3427</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=3418-3427&author=H.+Kitauraauthor=P.+Zhouauthor=H.+Kimauthor=D.+V.+Novackauthor=F.+P.+Rossauthor=S.+L.+Teitelbaum&title=M-CSF+mediates+TNF-induced+inflammatory+osteolysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKitaura%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DNovack%26aufirst%3DD.%2BV.%26aulast%3DRoss%26aufirst%3DF.%2BP.%26aulast%3DTeitelbaum%26aufirst%3DS.%2BL.%26atitle%3DM-CSF%2520mediates%2520TNF-induced%2520inflammatory%2520osteolysis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D3418%26epage%3D3427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Uemura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohzeki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murooka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serizawa, I.</span><span> </span><span class="NLM_article-title">The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis</span> <span class="citation_source-journal">J. Neuroimmunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">195</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">80</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1016%2Fj.jneuroim.2008.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=18378004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvVOrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2008&pages=73-80&author=Y.+Uemuraauthor=H.+Ohnoauthor=Y.+Ohzekiauthor=H.+Takanashiauthor=H.+Murookaauthor=K.+Kuboauthor=I.+Serizawa&title=The+selective+M-CSF+receptor+tyrosine+kinase+inhibitor+Ki20227+suppresses+experimental+autoimmune+encephalomyelitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis</span></div><div class="casAuthors">Uemura, Yasunori; Ohno, Hiroaki; Ohzeki, Yumiko; Takanashi, Hiromi; Murooka, Hideko; Kubo, Kazuo; Serizawa, Isao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroimmunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">73-80</span>CODEN:
                <span class="NLM_cas:coden">JNRIDW</span>;
        ISSN:<span class="NLM_cas:issn">0165-5728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Exptl. autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), can be induced by the immunization of mice with myelin antigens in the form of myelin oligodendrocyte glycoprotein (MOG).  Macrophage colony-stimulating factor (M-CSF) is required for the development of individual mononuclear phagocyte populations and is involved in the immune response.  We previously reported that Ki20227 (N-{4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-methoxyphenyl}-N'-[1-(1,3-thiazole-2-yl)ethyl]urea) is a highly selective M-CSF receptor (c-fms) tyrosine kinase inhibitor.  In our current study, we investigated whether Ki20227 has suppressive effects upon EAE and indeed found that this drug significantly reduced the severity of this disease both preventively and therapeutically.  Notably also, Ki20227 treatments inhibited the turn-over/expansion of myeloid cells provoked by the immunization and subsequent MOG-specific T cell responses in our EAE animal model.  These findings suggest that M-CSF plays a pivotal role in the development of EAE and that Ki20227 and its derivs. may be candidate drugs for the treatment of human MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobS3ECXzImwbVg90H21EOLACvtfcHk0ljptSz3ik_jRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvVOrsbc%253D&md5=92b102002c788d12d3ad7d7194b9607f</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1016%2Fj.jneuroim.2008.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jneuroim.2008.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DUemura%26aufirst%3DY.%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DOhzeki%26aufirst%3DY.%26aulast%3DTakanashi%26aufirst%3DH.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DSerizawa%26aufirst%3DI.%26atitle%3DThe%2520selective%2520M-CSF%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520Ki20227%2520suppresses%2520experimental%2520autoimmune%2520encephalomyelitis%26jtitle%3DJ.%2520Neuroimmunol.%26date%3D2008%26volume%3D195%26spage%3D73%26epage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ohno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uemura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murooka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokieda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohzeki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serizawa, I.</span><span> </span><span class="NLM_article-title">The orally-active and selective c-FMS tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model</span> <span class="citation_source-journal">Eur. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">291</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=283-291&author=H.+Ohnoauthor=Y.+Uemuraauthor=H.+Murookaauthor=H.+Takanashiauthor=T.+Tokiedaauthor=Y.+Ohzekiauthor=K.+Kuboauthor=I.+Serizawa&title=The+orally-active+and+selective+c-FMS+tyrosine+kinase+inhibitor+Ki20227+inhibits+disease+progression+in+a+collagen-induced+arthritis+mouse+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DUemura%26aufirst%3DY.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DTakanashi%26aufirst%3DH.%26aulast%3DTokieda%26aufirst%3DT.%26aulast%3DOhzeki%26aufirst%3DY.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DSerizawa%26aufirst%3DI.%26atitle%3DThe%2520orally-active%2520and%2520selective%2520c-FMS%2520tyrosine%2520kinase%2520inhibitor%2520Ki20227%2520inhibits%2520disease%2520progression%2520in%2520a%2520collagen-induced%2520arthritis%2520mouse%2520model%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2008%26volume%3D38%26spage%3D283%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Conway, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parham, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frick, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadepalli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Votta, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kull, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chamberlain, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchins, J. T.</span><span> </span><span class="NLM_article-title">Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580</span> <span class="citation_source-journal">Proc. Nat. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">16078</span><span class="NLM_x">–</span> <span class="NLM_lpage">16083</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1073%2Fpnas.0502000102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=16249345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WqsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=16078-16083&author=J.+G.+Conwayauthor=B.+McDonaldauthor=J.+Parhamauthor=B.+Keithauthor=D.+W.+Rusnakauthor=E.+Shawauthor=M.+Jansenauthor=P.+Linauthor=A.+Payneauthor=R.+M.+Crosbyauthor=J.+H.+Johnsonauthor=L.+Frickauthor=M.+J.+Linauthor=S.+Depeeauthor=S.+Tadepalliauthor=B.+Vottaauthor=I.+Jamesauthor=K.+Fullerauthor=T.+J.+Chambersauthor=F.+C.+Kullauthor=S.+D.+Chamberlainauthor=J.+T.+Hutchins&title=Inhibition+of+colony-stimulating-factor-1+signaling+in+vivo+with+the+orally+bioavailable+cFMS+kinase+inhibitor+GW2580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580</span></div><div class="casAuthors">Conway, James G.; McDonald, Brad; Parham, Janet; Keith, Barry; Rusnak, David W.; Shaw, Eva; Jansen, Marilyn; Lin, Peiyuan; Payne, Alan; Crosby, Renae M.; Johnson, Jennifer H.; Frick, Lloyd; Lin, Min-Hwa Jasmine; Depee, Scott; Tadepalli, Sarva; Votta, Bart; James, Ian; Fuller, Karen; Chambers, Timothy J.; Kull, Frederick C.; Chamberlain, Stanley D.; Hutchins, Jeff T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">16078-16083</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Colony-stimulating-factor-1 (CSF-1) signaling through cFMS receptor kinase is increased in several diseases.  To help investigate the role of cFMS kinase in disease, the authors identified GW2580, an orally bioavailable inhibitor of cFMS kinase.  GW2580 completely inhibited human cFMS kinase in vitro at 0.06 μM and was inactive against 26 other kinases.  GW2580 at 1 μM completely inhibited CSF-1-induced growth of mouse M-NFS-60 myeloid cells and human monocytes and completely inhibited bone degrdn. in cultures of human osteoclasts, rat calvaria, and rat fetal long bone.  In contrast, GW2580 did not affect the growth of mouse NS0 lymphoblastoid cells, human endothelial cells, human fibroblasts, or five human tumor cell lines.  GW2580 also did not affect lipopolysaccharide (LPS)-induced TNF, IL-6, and prostaglandin E2 prodn. in freshly isolated human monocytes and mouse macrophages.  After oral administration, GW2580 blocked the ability of exogenous CSF-1 to increase LPS-induced IL-6 prodn. in mice, inhibited the growth of CSF-1-dependent M-NFS-60 tumor cells in the peritoneal cavity, and diminished the accumulation of macrophages in the peritoneal cavity after thioglycolate injection.  Unexpectedly, GW2580 inhibited LPS-induced TNF prodn. in mice, in contrast to effects on monocytes and macrophages in vitro.  In conclusion, GW2580's selective inhibition of monocyte growth and bone degrdn. is consistent with cFMS kinase inhibition.  The ability of GW2580 to chronically inhibit CSF-1 signaling through cFMS kinase in normal and tumor cells in vivo makes GW2580 a useful tool in assessing the role of cFMS kinase in normal and disease processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR5EGN2P59OrVg90H21EOLACvtfcHk0ljptSz3ik_jRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WqsrzM&md5=6a5afc80faa9acec528fdbf766ad05bd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0502000102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0502000102%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DJ.%2BG.%26aulast%3DMcDonald%26aufirst%3DB.%26aulast%3DParham%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DB.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DShaw%26aufirst%3DE.%26aulast%3DJansen%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DPayne%26aufirst%3DA.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DFrick%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DM.%2BJ.%26aulast%3DDepee%26aufirst%3DS.%26aulast%3DTadepalli%26aufirst%3DS.%26aulast%3DVotta%26aufirst%3DB.%26aulast%3DJames%26aufirst%3DI.%26aulast%3DFuller%26aufirst%3DK.%26aulast%3DChambers%26aufirst%3DT.%2BJ.%26aulast%3DKull%26aufirst%3DF.%2BC.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DHutchins%26aufirst%3DJ.%2BT.%26atitle%3DInhibition%2520of%2520colony-stimulating-factor-1%2520signaling%2520in%2520vivo%2520with%2520the%2520orally%2520bioavailable%2520cFMS%2520kinase%2520inhibitor%2520GW2580%26jtitle%3DProc.%2520Nat.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D16078%26epage%3D16083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Conway, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pink, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergquist, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadepalli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumrine, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selph, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stimpson, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchins, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chamberlain, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodie, T. A.</span><span> </span><span class="NLM_article-title">Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in mormal and arthritic rats</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">326</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1124%2Fjpet.107.129429" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=18434589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlylsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=2008&pages=41-50&author=J.+G.+Conwayauthor=H.+Pinkauthor=M.+L.+Bergquistauthor=B.+Hanauthor=S.+Depeeauthor=S.+Tadepalliauthor=P.+Linauthor=R.+C.+Crumrineauthor=J.+Binzauthor=R.+L.+Clarkauthor=J.+L.+Selphauthor=S.+A.+Stimpsonauthor=T.+J.+Hutchinsauthor=S.+D.+Chamberlainauthor=T.+A.+Brodie&title=Effects+of+the+cFMS+kinase+inhibitor+5-%283-methoxy-4-%28%284-methoxybenzyl%29oxy%29benzyl%29pyrimidine-2%2C4-diamine+%28GW2580%29+in+mormal+and+arthritic+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats</span></div><div class="casAuthors">Conway, James G.; Pink, Heather; Bergquist, Mandy L.; Han, Bajin; Depee, Scott; Tadepalli, Sarva; Lin, Peiyuan; Crumrine, R. Christian; Binz, Jane; Clark, Richard L.; Selph, Jeffrey L.; Stimpson, Stephen A.; Hutchins, Jeff T.; Chamberlain, Stanley D.; Brodie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">326</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The cFMS (cellular homolog of the V-FMS oncogene product of the Susan McDonough strain of feline sarcoma virus) kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) inhibits colony-stimulating factor (CSF)-1-induced monocyte growth and bone degrdn. in vitro and inhibits CSF-1 signaling through cFMS kinase in 4-day models in mice.  In the present study, the kinase selectivity of GW2580 was further characterized, and the effects of chronic treatment were evaluated in normal and arthritic rats.  GW2580 selectively inhibited cFMS kinase compared with 186 other kinases in vitro and completely inhibited CSF-1-induced growth of rat monocytes, with an IC50 value of 0.2 μM.  GW2580 dosed orally at 25 and 75 mg/kg 1 and 5 h before the injection of lipopolysaccharide inhibited tumor necrosis factor-α prodn. by 60 to 85%, indicating a duration of action of at least 5 h.  In a 21-day adjuvant arthritis model, GW2580 dosed twice a day (b.i.d.) from days 0 to 21, 7 to 21, or 14 to 21 inhibited joint connective tissue and bone destruction as assessed by radiol., histol. and bone mineral content measurements.  In contrast, GW2580 did not affect ankle swelling in the adjuvant model nor did it affect ankle swelling in a model where local arthritis is reactivated by peptidoglycan polysaccharide polymers.  GW2580 administered to normal rats for 21 days showed no effects on tissue histol. and only modest changes in serum clin. chem. and blood hematol.  In conclusion, GW2580 was effective in preserving joint integrity in the adjuvant arthritis model while showing minimal effects in normal rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtnXf8t6eWrLVg90H21EOLACvtfcHk0lgFg5_9IH--9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlylsL0%253D&md5=51bf18b72ebba4c5ea862b088d0c1ad1</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.129429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.129429%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DJ.%2BG.%26aulast%3DPink%26aufirst%3DH.%26aulast%3DBergquist%26aufirst%3DM.%2BL.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DDepee%26aufirst%3DS.%26aulast%3DTadepalli%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DCrumrine%26aufirst%3DR.%2BC.%26aulast%3DBinz%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DR.%2BL.%26aulast%3DSelph%26aufirst%3DJ.%2BL.%26aulast%3DStimpson%26aufirst%3DS.%2BA.%26aulast%3DHutchins%26aufirst%3DT.%2BJ.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DBrodie%26aufirst%3DT.%2BA.%26atitle%3DEffects%2520of%2520the%2520cFMS%2520kinase%2520inhibitor%25205-%25283-methoxy-4-%2528%25284-methoxybenzyl%2529oxy%2529benzyl%2529pyrimidine-2%252C4-diamine%2520%2528GW2580%2529%2520in%2520mormal%2520and%2520arthritic%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D326%26spage%3D41%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Ibrahim, P. N.; Artis, D. R.; Bremer, R.; Habets, G.; Mamo, S.; Nespi, M.; Zhang, C.; Zhang, J.; Zhu, Y.; Zuckerman, R.; West, B.; Suzuki, Y.; Tsai, J.; Hirth, K.-P.; Bollag, G.; Spevak, W.; Cho, H.; Gillette, S. J.; Wu, G.; Zhu, H.; Shi, S.</span><span> </span><span class="NLM_article-title">Pyrrolo[2,3-<i>b</i>]pyridine derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases</span>. PCT Int. Appl. WO 2007002433,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=P.+N.+Ibrahim&author=D.+R.+Artis&author=R.+Bremer&author=G.+Habets&author=S.+Mamo&author=M.+Nespi&author=C.+Zhang&author=J.+Zhang&author=Y.+Zhu&author=R.+Zuckerman&author=B.+West&author=Y.+Suzuki&author=J.+Tsai&author=K.-P.+Hirth&author=G.+Bollag&author=W.+Spevak&author=H.+Cho&author=S.+J.+Gillette&author=G.+Wu&author=H.+Zhu&author=S.+Shi&title=Pyrrolo%5B2%2C3-b%5Dpyridine+derivatives+as+protein+kinase+inhibitors+and+their+preparation%2C+pharmaceutical+compositions+and+use+in+the+treatment+of+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26atitle%3DPyrrolo%255B2%252C3-b%255Dpyridine%2520derivatives%2520as%2520protein%2520kinase%2520inhibitors%2520and%2520their%2520preparation%252C%2520pharmaceutical%2520compositions%2520and%2520use%2520in%2520the%2520treatment%2520of%2520diseases%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Ajami, A. M.; Boss, M. A.; Paterson, J.</span><span> </span><span class="NLM_article-title">Treatment of autoimmune and demyelinating diseases with Symadex and related imidazoacridine derivatives</span>. PCT Int. Appl. WO 2006081431,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=A.+M.+Ajami&author=M.+A.+Boss&author=J.+Paterson&title=Treatment+of+autoimmune+and+demyelinating+diseases+with+Symadex+and+related+imidazoacridine+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAjami%26aufirst%3DA.%2BM.%26atitle%3DTreatment%2520of%2520autoimmune%2520and%2520demyelinating%2520diseases%2520with%2520Symadex%2520and%2520related%2520imidazoacridine%2520derivatives%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Patyna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Farrell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vojkovsky, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasile, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grazzini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haznedar, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sukbuntherng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu-Lowe, D.</span><span> </span><span class="NLM_article-title">SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1774</span><span class="NLM_x">–</span> <span class="NLM_lpage">1782</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1158%2F1535-7163.MCT-05-0333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=16891463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslWksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1774-1782&author=S.+Patynaauthor=A.+D.+Lairdauthor=D.+B.+Mendelauthor=A.+O%E2%80%99Farrellauthor=C.+Liangauthor=H.+Guanauthor=T.+Vojkovskyauthor=S.+Vasileauthor=X.+Wangauthor=J.+Chenauthor=M.+Grazziniauthor=C.+Y.+Yangauthor=J.+O.+Haznedarauthor=J.+Sukbuntherngauthor=W.+Zhongauthor=J.+M.+Cherringtonauthor=D.+Hu-Lowe&title=SU14813%3A+a+novel+multiple+receptor+tyrosine+kinase+inhibitor+with+potent+antiangiogenic+and+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity</span></div><div class="casAuthors">Patyna, Shem; Laird, A. Douglas; Mendel, Dirk B.; O'Farrell, Anne-Marie; Liang, Chris; Guan, Huiping; Vojkovsky, Tomas; Vasile, Stefan; Wang, Xueyan; Chen, Jeffrey; Grazzini, Maren; Yang, Cheng Y.; Haznedar, Joshua Oe.; Sukbuntherng, Juthamas; Zhong, Wei-Zhu; Cherrington, Julie M.; Hu-Lowe, Dana</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1774-1782</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases (RTK), such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (KIT), and fms-like tyrosine kinase 3 (FLT3), are expressed in malignant tissues and act in concert, playing diverse and major roles in angiogenesis, tumor growth, and metastasis.  With the exception of a few malignancies, seemingly driven by a single genetic mutation in a signaling protein, most tumors are the product of multiple mutations in multiple aberrant signaling pathways.  Consequently, simultaneous targeted inhibition of multiple signaling pathways could be more effective than inhibiting a single pathway in cancer therapies.  Such a multitargeted strategy has recently been validated in a no. of preclin. and clin. studies using RTK inhibitors with broad target selectivity.  SU14813, a small mol. identified from the same chem. library used to isolate sunitinib, has broad-spectrum RTK inhibitory activity through binding to and inhibition of VEGFR, PDGFR, KIT, and FLT3.  In cellular assays, SU14813 inhibited ligand-dependent and ligand-independent proliferation, migration, and survival of endothelial cells and/or tumor cells expressing these targets.  SU14813 inhibited VEGFR-2, PDGFR-{szligbeta}, and FLT3 phosphorylation in xenograft tumors in a dose- and time-dependent fashion.  The plasma concn. required for in vivo target inhibition was estd. to be 100 to 200 ng/mL.  Used as monotherapy, SU14813 exhibited broad and potent antitumor activity resulting in regression, growth arrest, or substantially reduced growth of various established xenografts derived from human or rat tumor cell lines.  Treatment in combination with docetaxel significantly enhanced both the inhibition of primary tumor growth and the survival of the tumor-bearing mice compared with administration of either agent alone.  In summary, SU14813 inhibited target RTK activity in vivo in assocn. with redn. in angiogenesis, target RTK-mediated proliferation, and survival of tumor cells, leading to broad and potent antitumor efficacy.  These data support the ongoing phase I clin. evaluation of SU14813 in advanced malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpEfsqMfo2jbVg90H21EOLACvtfcHk0lgFg5_9IH--9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslWksb4%253D&md5=e35e1d0f5695b03d7341689e12b2aef2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0333%26sid%3Dliteratum%253Aachs%26aulast%3DPatyna%26aufirst%3DS.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DMendel%26aufirst%3DD.%2BB.%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DGuan%26aufirst%3DH.%26aulast%3DVojkovsky%26aufirst%3DT.%26aulast%3DVasile%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DGrazzini%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DHaznedar%26aufirst%3DJ.%2BO.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DW.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DHu-Lowe%26aufirst%3DD.%26atitle%3DSU14813%253A%2520a%2520novel%2520multiple%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520with%2520potent%2520antiangiogenic%2520and%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1774%26epage%3D1782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Tamaskar, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mekhail, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreicer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rini, B. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukowski, R. M.</span><span> </span><span class="NLM_article-title">Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy</span> <span class="citation_source-journal">J. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">179</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1016%2Fj.juro.2007.08.127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=17997441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2008&pages=81-86&author=I.+Tamaskarauthor=J.+A.+Garciaauthor=P.+Elsonauthor=L.+Woodauthor=T.+Mekhailauthor=R.+Dreicerauthor=B.+I.+Riniauthor=R.+M.+Bukowski&title=Antitumor+effects+of+sunitinib+or+sorafenib+in+patients+with+metastatic+renal+cell+carcinoma+who+received+prior+antiangiogenic+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy</span></div><div class="casAuthors">Tamaskar, Ila; Garcia, Jorge A.; Elson, Paul; Wood, Laura; Mekhail, Tarek; Dreicer, Robert; Rini, Brian I.; Bukowski, Ronald M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-86</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Purpose: Antiangiogenic therapy with sunitinib and sorafenib has become the std. of care for patients with advanced renal cell carcinoma.  However, the clin. benefit of these agents after prior antiangiogenic therapy has not been defined.  Currently, several agents with a putative antiangiogenic mechanism exist and they are often being used in sequence with little to no data regarding activity in a second line or later setting.  Materials and Methods: Patients with advanced renal cell carcinoma currently being treated with either sunitinib or sorafenib after receiving 1 or more prior antiangiogenic agent(s) were investigated in a retrospective anal.  Time to progression and the overall response rate by Response Evaluation Criteria in Solid Tumors were evaluated.  Results: Thirty patients receiving current sunitinib (16 patients) or sorafenib (14 patients) were identified.  Patients received 1 or more prior antiangiogenic therapies: thalidomide, lenalidomide, bevacizumab, volociximab, AG13736, sorafenib or sunitinib.  Of 16 patients treated with sunitinib 13 had some degree of tumor shrinkage, including 9 with a partial response by Response Evaluation Criteria in Solid Tumors.  Of 14 patients treated with sorafenib 10 had some degree of tumor shrinkage, including 1 with a partial response.  The median time to progression for the entire cohort was 10.4 mo.  Conclusions: Significant antitumor activity is obsd. when sorafenib or sunitinib are used in patients who have failed prior therapy with an antiangiogenic agent.  Prior response to an antiangiogenic agent does not appear to predict subsequent clin. benefit to either sunitinib or sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX2_pRDPqsY7Vg90H21EOLACvtfcHk0li4hyERpjADZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1Wnsw%253D%253D&md5=25b13dc69fc85da49d4575fc60bf1978</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2007.08.127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2007.08.127%26sid%3Dliteratum%253Aachs%26aulast%3DTamaskar%26aufirst%3DI.%26aulast%3DGarcia%26aufirst%3DJ.%2BA.%26aulast%3DElson%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DL.%26aulast%3DMekhail%26aufirst%3DT.%26aulast%3DDreicer%26aufirst%3DR.%26aulast%3DRini%26aufirst%3DB.%2BI.%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26atitle%3DAntitumor%2520effects%2520of%2520sunitinib%2520or%2520sorafenib%2520in%2520patients%2520with%2520metastatic%2520renal%2520cell%2520carcinoma%2520who%2520received%2520prior%2520antiangiogenic%2520therapy%26jtitle%3DJ.%2520Urol.%26date%3D2008%26volume%3D179%26spage%3D81%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCall, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span> </span><span class="NLM_article-title">Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-FMS) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1007</span><span class="NLM_x">–</span> <span class="NLM_lpage">1013</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1158%2F1535-7163.MCT-05-0359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=16648572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFCksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1007-1013&author=J.+Guoauthor=P.+A.+Marcotteauthor=J.+O.+McCallauthor=Y.+Daiauthor=L.+J.+Peaseauthor=M.+R.+Michaelidesauthor=S.+K.+Davidsenauthor=K.+B.+Glaser&title=Inhibition+of+phosphorylation+of+the+colony-stimulating+factor-1+receptor+%28c-FMS%29+tyrosine+kinase+in+transfected+cells+by+ABT-869+and+other+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors</span></div><div class="casAuthors">Guo, Jun; Marcotte, Patrick A.; McCall, J. Owen; Dai, Yujia; Pease, Lori J.; Michaelides, Michael R.; Davidsen, Steven K.; Glaser, Keith B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1007-1013</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The properties of several multitargeted receptor tyrosine kinase inhibitors were studied for their inhibition of colony-stimulating factor-1 receptor (CSF-1R) signaling.  A structurally novel, multitargeted tyrosine kinase inhibitor (ABT-869), imatinib (STI571), and 4 compds. currently in clin. development (AG013736, BAY 43-9006, CHIR258, and SU11248) were tested for inhibition of CSF-1R signaling in both the enzymic and cellular assays.  ABT-869 showed potent CSF-1R inhibition in both the enzyme and cell-based assays (IC50s < 20 nmol/L).  In contrast to a previous report, we have found that imatinib has activity against human CSF-1R in both assays at submicromolar concns.  In enzyme assays, we have found that the inhibition of CSF-1R by both ABT-869 and imatinib are competitive with ATP, with Ki values of 3 and 120 nmol/L, resp.  SU11248 is a potent inhibitor of CSF-1R in the enzyme assay (IC50 = 7 nmol/L) and inhibits receptor phosphorylation in the cellular assay (IC50 = 61 nmol/L).  AG013736 was also a potent inhibitor of CSF-1R in both assays (enzyme, IC50 = 16 nmol/L; cellular, IC50 = 21 nmol/L), whereas BAY 43-9006 is less potent in the enzyme assay (IC50 = 107 nmol/L) than in the cellular system (IC50 = 20 nmol/L).  In contrast, we found that CHIR258 had less activity in the cellular assay (IC50 = 535 nmol/L) relative to its enzymic potency (IC50 = 26 nmol/L).  These results show the use of a cell-based assay to confirm the inhibitory activity of lead compds. and drug candidates, such as ABT-869, against the CSF-1R protein in situ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ5C32GMFCGbVg90H21EOLACvtfcHk0li4hyERpjADZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFCksL4%253D&md5=b8ce108aba7cd655ef627a8248b8cb7f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0359%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DMcCall%26aufirst%3DJ.%2BO.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26atitle%3DInhibition%2520of%2520phosphorylation%2520of%2520the%2520colony-stimulating%2520factor-1%2520receptor%2520%2528c-FMS%2529%2520tyrosine%2520kinase%2520in%2520transfected%2520cells%2520by%2520ABT-869%2520and%2520other%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1007%26epage%3D1013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Patch, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asgari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baindur, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chadha, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georgiadis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span> </span><span class="NLM_article-title">Potent 2′-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6070</span><span class="NLM_x">–</span> <span class="NLM_lpage">6074</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6070-6074&author=R.+J.+Patchauthor=B.+M.+Brandtauthor=D.+Asgariauthor=N.+Baindurauthor=N.+K.+Chadhaauthor=T.+Georgiadisauthor=W.+S.+Cheungauthor=I.+P.+Petrouniaauthor=R.+R.+Donatelliauthor=M.+A.+Chaikinauthor=M.+R.+Player&title=Potent+2%E2%80%B2-aminoanilide+inhibitors+of+cFMS+as+potential+anti-inflammatory+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPatch%26aufirst%3DR.%2BJ.%26aulast%3DBrandt%26aufirst%3DB.%2BM.%26aulast%3DAsgari%26aufirst%3DD.%26aulast%3DBaindur%26aufirst%3DN.%26aulast%3DChadha%26aufirst%3DN.%2BK.%26aulast%3DGeorgiadis%26aufirst%3DT.%26aulast%3DCheung%26aufirst%3DW.%2BS.%26aulast%3DPetrounia%26aufirst%3DI.%2BP.%26aulast%3DDonatelli%26aufirst%3DR.%2BR.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26atitle%3DPotent%25202%25E2%2580%25B2-aminoanilide%2520inhibitors%2520of%2520cFMS%2520as%2520potential%2520anti-inflammatory%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6070%26epage%3D6074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Illig, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballentine, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczuk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegalla, S. K.</span><span> </span><span class="NLM_article-title">Discovery of novel FMS kinase inhibitors as anti-inflammatory agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1642</span><span class="NLM_x">–</span> <span class="NLM_lpage">1648</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1642-1648&author=C.+R.+Illigauthor=J.+Chenauthor=M.+J.+Wallauthor=K.+J.+Wilsonauthor=S.+K.+Ballentineauthor=M.+J.+Rudolphauthor=R.+L.+DesJarlaisauthor=Y.+Chenauthor=C.+Schubertauthor=I.+Petrouniaauthor=C.+S.+Cryslerauthor=C.+J.+Molloyauthor=M.+A.+Chaikinauthor=C.+L.+Mantheyauthor=M.+R.+Playerauthor=B.+E.+Tomczukauthor=S.+K.+Meegalla&title=Discovery+of+novel+FMS+kinase+inhibitors+as+anti-inflammatory+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIllig%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DRudolph%26aufirst%3DM.%2BJ.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DPetrounia%26aufirst%3DI.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DMolloy%26aufirst%3DC.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26aulast%3DMeegalla%26aufirst%3DS.%2BK.%26atitle%3DDiscovery%2520of%2520novel%2520FMS%2520kinase%2520inhibitors%2520as%2520anti-inflammatory%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1642%26epage%3D1648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Meegalla, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballentine, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczuk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illig, C. R.</span><span> </span><span class="NLM_article-title">Structure-based optimization of a potent class of arylamide FMS inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3632</span><span class="NLM_x">–</span> <span class="NLM_lpage">3637</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3632-3637&author=S.+K.+Meegallaauthor=M.+J.+Wallauthor=J.+Chenauthor=K.+J.+Wilsonauthor=S.+K.+Ballentineauthor=R.+L.+DesJarlaisauthor=C.+Schubertauthor=C.+S.+Cryslerauthor=Y.+Chenauthor=C.+J.+Molloyauthor=M.+A.+Chaikinauthor=C.+L.+Mantheyauthor=M.+R.+Playerauthor=B.+E.+Tomczukauthor=C.+R.+Illig&title=Structure-based+optimization+of+a+potent+class+of+arylamide+FMS+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeegalla%26aufirst%3DS.%2BK.%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMolloy%26aufirst%3DC.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26aulast%3DIllig%26aufirst%3DC.%2BR.%26atitle%3DStructure-based%2520optimization%2520of%2520a%2520potent%2520class%2520of%2520arylamide%2520FMS%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3632%26epage%3D3637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegalla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballentine, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurkow, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boczon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzulla, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patch, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczuk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illig, C. R.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2097</span><span class="NLM_x">–</span> <span class="NLM_lpage">2102</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2097-2102&author=M.+J.+Wallauthor=J.+Chenauthor=S.+Meegallaauthor=S.+K.+Ballentineauthor=K.+J.+Wilsonauthor=R.+L.+DesJarlaisauthor=C.+Schubertauthor=M.+A.+Chaikinauthor=C.+Cryslerauthor=I.+P.+Petrouniaauthor=R.+R.+Donatelliauthor=E.+J.+Yurkowauthor=L.+Boczonauthor=M.+Mazzullaauthor=M.+R.+Playerauthor=R.+J.+Patchauthor=C.+L.+Mantheyauthor=C.+Molloyauthor=B.+E.+Tomczukauthor=C.+R.+Illig&title=Synthesis+and+evaluation+of+novel+3%2C4%2C6-substituted+2-quinolones+as+FMS+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMeegalla%26aufirst%3DS.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DCrysler%26aufirst%3DC.%26aulast%3DPetrounia%26aufirst%3DI.%2BP.%26aulast%3DDonatelli%26aufirst%3DR.%2BR.%26aulast%3DYurkow%26aufirst%3DE.%2BJ.%26aulast%3DBoczon%26aufirst%3DL.%26aulast%3DMazzulla%26aufirst%3DM.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DPatch%26aufirst%3DR.%2BJ.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DMolloy%26aufirst%3DC.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26aulast%3DIllig%26aufirst%3DC.%2BR.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%25203%252C4%252C6-substituted%25202-quinolones%2520as%2520FMS%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2097%26epage%3D2102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutta, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span> </span><span class="NLM_article-title">Design and Synthesis of a Pyrido[2,3-<i>d</i>]pyrimidin-5-one Class of Anti-inflammatory FMS Inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2355</span><span class="NLM_x">–</span> <span class="NLM_lpage">2361</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2355-2361&author=H.+Huangauthor=D.+A.+Huttaauthor=H.+Huauthor=R.+L.+DesJarlaisauthor=C.+Schubertauthor=I.+P.+Petrouniaauthor=M.+A.+Chaikinauthor=C.+L.+Mantheyauthor=M.+R.+Player&title=Design+and+Synthesis+of+a+Pyrido%5B2%2C3-d%5Dpyrimidin-5-one+Class+of+Anti-inflammatory+FMS+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHutta%26aufirst%3DD.%2BA.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DPetrounia%26aufirst%3DI.%2BP.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520a%2520Pyrido%255B2%252C3-d%255Dpyrimidin-5-one%2520Class%2520of%2520Anti-inflammatory%2520FMS%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2355%26epage%3D2361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Pesson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoine, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabassier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geiger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Lajudie, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leriche, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patte, S.</span><span> </span><span class="NLM_article-title">Antibacterial derivatives of 8-alkyl-5-<i>oxo</i>-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic acids. I. New procedure of preparation</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1974</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">585</span><span class="NLM_x">–</span> <span class="NLM_lpage">590</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1974&pages=585-590&author=M.+Pessonauthor=M.+Antoineauthor=S.+Chabassierauthor=S.+Geigerauthor=P.+Girardauthor=D.+Richerauthor=P.+De+Lajudieauthor=E.+Horvathauthor=B.+Lericheauthor=S.+Patte&title=Antibacterial+derivatives+of+8-alkyl-5-oxo-5%2C8-dihydropyrido%5B2%2C3-d%5Dpyrimidine-6-carboxylic+acids.+I.+New+procedure+of+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPesson%26aufirst%3DM.%26aulast%3DAntoine%26aufirst%3DM.%26aulast%3DChabassier%26aufirst%3DS.%26aulast%3DGeiger%26aufirst%3DS.%26aulast%3DGirard%26aufirst%3DP.%26aulast%3DRicher%26aufirst%3DD.%26aulast%3DDe%2BLajudie%26aufirst%3DP.%26aulast%3DHorvath%26aufirst%3DE.%26aulast%3DLeriche%26aufirst%3DB.%26aulast%3DPatte%26aufirst%3DS.%26atitle%3DAntibacterial%2520derivatives%2520of%25208-alkyl-5-oxo-5%252C8-dihydropyrido%255B2%252C3-d%255Dpyrimidine-6-carboxylic%2520acids.%2520I.%2520New%2520procedure%2520of%2520preparation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D1974%26volume%3D9%26spage%3D585%26epage%3D590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Tomita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuzuki, Y.i</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibamori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tashima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kajikawa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashimoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hino, K.</span><span> </span><span class="NLM_article-title">Synthesis and structure−activity relationships of novel 7-substituted 1,4-dihydro-4-<i>oxo</i>-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor Agents. Part 1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">5564</span><span class="NLM_x">–</span> <span class="NLM_lpage">5575</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm010057b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=5564-5575&author=K.+Tomitaauthor=Y.i+Tsuzukiauthor=K.+Shibamoriauthor=M.+Tashimaauthor=F.+Kajikawaauthor=Y.+Satoauthor=S.+Kashimotoauthor=K.+Chibaauthor=K.+Hino&title=Synthesis+and+structure%E2%88%92activity+relationships+of+novel+7-substituted+1%2C4-dihydro-4-oxo-1-%282-thiazolyl%29-1%2C8-naphthyridine-3-carboxylic+acids+as+antitumor+Agents.+Part+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm010057b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010057b%26sid%3Dliteratum%253Aachs%26aulast%3DTomita%26aufirst%3DK.%26aulast%3DTsuzuki%26aufirst%3DY.i%26aulast%3DShibamori%26aufirst%3DK.%26aulast%3DTashima%26aufirst%3DM.%26aulast%3DKajikawa%26aufirst%3DF.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DKashimoto%26aufirst%3DS.%26aulast%3DChiba%26aufirst%3DK.%26aulast%3DHino%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520structure%25E2%2588%2592activity%2520relationships%2520of%2520novel%25207-substituted%25201%252C4-dihydro-4-oxo-1-%25282-thiazolyl%2529-1%252C8-naphthyridine-3-carboxylic%2520acids%2520as%2520antitumor%2520Agents.%2520Part%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D5564%26epage%3D5575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Ruesdale, L. K.; Sherbine, J. P.; Vanasse, B. J.</span><span> </span><span class="NLM_article-title">Preparation of 2,4-dihydroxypyridine and 2,4-dihydroxy-3-nitropyridine and nucleoside derivatives useful for treating cardiovascular diseases</span>. PCT Int. Appl. WO9724327A1,<span class="NLM_x"> </span><span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=L.+K.+Ruesdale&author=J.+P.+Sherbine&author=B.+J.+Vanasse&title=Preparation+of+2%2C4-dihydroxypyridine+and+2%2C4-dihydroxy-3-nitropyridine+and+nucleoside+derivatives+useful+for+treating+cardiovascular+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRuesdale%26aufirst%3DL.%2BK.%26atitle%3DPreparation%2520of%25202%252C4-dihydroxypyridine%2520and%25202%252C4-dihydroxy-3-nitropyridine%2520and%2520nucleoside%2520derivatives%2520useful%2520for%2520treating%2520cardiovascular%2520diseases%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Schalk-Hihi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struble, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayoumy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mezzasalma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasberger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deckman, I. C.</span><span> </span><span class="NLM_article-title">Protein engineering of the colony-stimulating factor-1 receptor kinase domain for structural studies</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">4085</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=4085&author=C.+Schalk-Hihiauthor=H.+C.+Maauthor=G.+T.+Strubleauthor=S.+Bayoumyauthor=R.+Williamsauthor=E.+Devineauthor=I.+P.+Petrouniaauthor=T.+Mezzasalmaauthor=L.+Zengauthor=C.+Schubertauthor=B.+Grasbergerauthor=B.+A.+Springerauthor=I.+C.+Deckman&title=Protein+engineering+of+the+colony-stimulating+factor-1+receptor+kinase+domain+for+structural+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchalk-Hihi%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DH.%2BC.%26aulast%3DStruble%26aufirst%3DG.%2BT.%26aulast%3DBayoumy%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DDevine%26aufirst%3DE.%26aulast%3DPetrounia%26aufirst%3DI.%2BP.%26aulast%3DMezzasalma%26aufirst%3DT.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DGrasberger%26aufirst%3DB.%26aulast%3DSpringer%26aufirst%3DB.%2BA.%26aulast%3DDeckman%26aufirst%3DI.%2BC.%26atitle%3DProtein%2520engineering%2520of%2520the%2520colony-stimulating%2520factor-1%2520receptor%2520kinase%2520domain%2520for%2520structural%2520studies%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D4085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Schubert, C.; Schalk-Hihi, C.; Struble, G. T.; Ma, H. C.; Petrounia, I. P.; Brandt, B.; Deckman, I. C.; Patch, R. J.; Player, M. R.; Spurlino, J. C.; Springer, B. A.</span><span> </span><span class="NLM_article-title">Crystal Structure of the Tyrosine Kinase Domain of Colony-stimulating Factor-1 Receptor (cFMS) in Complex with Two Inhibitors</span>.  <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">4094</span><div class="note"><p class="first last">(PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2I0Y">2I0Y</a>)</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=4094&author=C.+Schubert&author=C.+Schalk-Hihi&author=G.+T.+Struble&author=H.+C.+Ma&author=I.+P.+Petrounia&author=B.+Brandt&author=I.+C.+Deckman&author=R.+J.+Patch&author=M.+R.+Player&author=J.+C.+Spurlino&author=B.+A.+Springer&title=Crystal+Structure+of+the+Tyrosine+Kinase+Domain+of+Colony-stimulating+Factor-1+Receptor+%28cFMS%29+in+Complex+with+Two+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchubert%26aufirst%3DC.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Tyrosine%2520Kinase%2520Domain%2520of%2520Colony-stimulating%2520Factor-1%2520Receptor%2520%2528cFMS%2529%2520in%2520Complex%2520with%2520Two%2520Inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D4094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><div class="note"><p class="first last">The Cerep high-throughput profile consists of a broad collection of 50 transmembrane and soluble receptors, ion channels, and monoamine transporters. It has been specifically designed to provide information not only on potential limitations or liabilities of drug candidates, but also for off-target activity identification. For the test compounds, the results are expressed as a percent inhibition of control specific binding (mean values, <i>n</i> = 2).</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+Cerep+high-throughput+profile+consists+of+a+broad+collection+of+50+transmembrane+and+soluble+receptors%2C+ion+channels%2C+and+monoamine+transporters.+It+has+been+specifically+designed+to+provide+information+not+only+on+potential+limitations+or+liabilities+of+drug+candidates%2C+but+also+for+off-target+activity+identification.+For+the+test+compounds%2C+the+results+are+expressed+as+a+percent+inhibition+of+control+specific+binding+%28mean+values%2C+n+%3D+2%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Swindell, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, R. H.</span><span> </span><span class="NLM_article-title">A Useful Construction of 4-Substituted 1-Alkylpiperid-3-ones</span> <span class="citation_source-journal">Heterocycles</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">3373</span><span class="NLM_x">–</span> <span class="NLM_lpage">3377</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1986&pages=3373-3377&author=C.+S.+Swindellauthor=R.+H.+Duffy&title=A+Useful+Construction+of+4-Substituted+1-Alkylpiperid-3-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSwindell%26aufirst%3DC.%2BS.%26aulast%3DDuffy%26aufirst%3DR.%2BH.%26atitle%3DA%2520Useful%2520Construction%2520of%25204-Substituted%25201-Alkylpiperid-3-ones%26jtitle%3DHeterocycles%26date%3D1986%26volume%3D24%26spage%3D3373%26epage%3D3377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ratajczak, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luger, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerwirtz, A. M.</span><span> </span><span class="NLM_article-title">The c-kit proto-oncogene in normal and malignant human hematopoiesis</span> <span class="citation_source-journal">Int. J. Cell Cloning</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">214</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=1379619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADyaK38XlvV2itrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1992&pages=205-214&author=M.+Z.+Ratajczakauthor=S.+M.+Lugerauthor=A.+M.+Gerwirtz&title=The+c-kit+proto-oncogene+in+normal+and+malignant+human+hematopoiesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">The c-kit proto-oncogene in normal and malignant human hematopoiesis</span></div><div class="casAuthors">Ratajczak, Mariusz Z.; Luger, Selina M.; Gewirtz, Alan M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cell Cloning</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">205-14</span>CODEN:
                <span class="NLM_cas:coden">IJCCE3</span>;
        ISSN:<span class="NLM_cas:issn">0737-1454</span>.
    </div><div class="casAbstract">A review with 94 refs.  The c-kit proto-oncogene encodes a tyrosine kinase receptor (KIT) which is expressed on many types of human cells, including ∼4% of bone marrow mononuclear cells.  Numerous studies attest to the importance of the c-kit receptor and its ligand, known variously as stem cell factor (SCF), mast cell growth factor (MGF), Steel factor (SF), or kit ligand (KL) (the nomenclature the authors prefer), in the development of human hematopoietic cells.  KL, which is produced in membrane-bound and sol. froms by bone marrow stromal cells, acts on pre-colony forming units (pre-CFU) and CFU cells.  In synergistic combination with other cytokines, KL enhances the growth of myeloid progenitor cells.  However, using an antisense oligodeoxynucleotide strategy to disrupt c-kit function, the author demonstrated that the KL-KIT complex is of greatest importance for generation and/or proliferation of normal human erythropoietic progenitor cells.  In malignant hematopoietic cells, the complex also appears to be important for growth of granulocyte/macrophage (GM) CFU as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9TGmflMqWsrVg90H21EOLACvtfcHk0lj5GNRsaSa6hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvV2itrk%253D&md5=1ebd90ce8ec954eff24eed7a225b3832</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRatajczak%26aufirst%3DM.%2BZ.%26aulast%3DLuger%26aufirst%3DS.%2BM.%26aulast%3DGerwirtz%26aufirst%3DA.%2BM.%26atitle%3DThe%2520c-kit%2520proto-oncogene%2520in%2520normal%2520and%2520malignant%2520human%2520hematopoiesis%26jtitle%3DInt.%2520J.%2520Cell%2520Cloning%26date%3D1992%26volume%3D10%26spage%3D205%26epage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Smolich, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span> </span><span class="NLM_article-title">The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">1413</span><span class="NLM_x">–</span> <span class="NLM_lpage">1421</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2001&pages=1413-1421&author=B.+D.+Smolichauthor=H.+A.+Yuenauthor=K.+A.+Westauthor=F.+J.+Gilesauthor=M.+Albitarauthor=J.+M.+Cherrington&title=The+antiangiogenic+protein+kinase+inhibitors+SU5416+and+SU6668+inhibit+the+SCF+receptor+%28c-kit%29+in+a+human+myeloid+leukemia+cell+line+and+in+acute+myeloid+leukemia+blasts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmolich%26aufirst%3DB.%2BD.%26aulast%3DYuen%26aufirst%3DH.%2BA.%26aulast%3DWest%26aufirst%3DK.%2BA.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520antiangiogenic%2520protein%2520kinase%2520inhibitors%2520SU5416%2520and%2520SU6668%2520inhibit%2520the%2520SCF%2520receptor%2520%2528c-kit%2529%2520in%2520a%2520human%2520myeloid%2520leukemia%2520cell%2520line%2520and%2520in%2520acute%2520myeloid%2520leukemia%2520blasts%26jtitle%3DBlood%26date%3D2001%26volume%3D97%26spage%3D1413%26epage%3D1421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Geissler, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Housman, D. E.</span><span> </span><span class="NLM_article-title">The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">185</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1988&pages=185-92&author=E.+N.+Geisslerauthor=M.+A.+Ryanauthor=D.+E.+Housman&title=The+dominant-white+spotting+%28W%29+locus+of+the+mouse+encodes+the+c-kit+proto-oncogene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeissler%26aufirst%3DE.%2BN.%26aulast%3DRyan%26aufirst%3DM.%2BA.%26aulast%3DHousman%26aufirst%3DD.%2BE.%26atitle%3DThe%2520dominant-white%2520spotting%2520%2528W%2529%2520locus%2520of%2520the%2520mouse%2520encodes%2520the%2520c-kit%2520proto-oncogene%26jtitle%3DCell%26date%3D1988%26volume%3D55%26spage%3D185%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit34b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bijangi-Vishehsaraei, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saadatzadeh, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenzie, K. A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapur, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichijo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haneline, L. S.</span><span> </span><span class="NLM_article-title">Enhanced TNF-alpha-induced apoptosis in Fanconi anemia type C-deficient cells is dependent on apoptosis signal-regulating kinase 1</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">4124</span><span class="NLM_x">–</span> <span class="NLM_lpage">4130</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=4124-4130&author=K.+Bijangi-Vishehsaraeiauthor=M.+R.+Saadatzadehauthor=A.+Werneauthor=K.+A.+W.+McKenzieauthor=R.+Kapurauthor=H.+Ichijoauthor=L.+S.+Haneline&title=Enhanced+TNF-alpha-induced+apoptosis+in+Fanconi+anemia+type+C-deficient+cells+is+dependent+on+apoptosis+signal-regulating+kinase+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBijangi-Vishehsaraei%26aufirst%3DK.%26aulast%3DSaadatzadeh%26aufirst%3DM.%2BR.%26aulast%3DWerne%26aufirst%3DA.%26aulast%3DMcKenzie%26aufirst%3DK.%2BA.%2BW.%26aulast%3DKapur%26aufirst%3DR.%26aulast%3DIchijo%26aufirst%3DH.%26aulast%3DHaneline%26aufirst%3DL.%2BS.%26atitle%3DEnhanced%2520TNF-alpha-induced%2520apoptosis%2520in%2520Fanconi%2520anemia%2520type%2520C-deficient%2520cells%2520is%2520dependent%2520on%2520apoptosis%2520signal-regulating%2520kinase%25201%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D4124%26epage%3D4130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Orlofsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, E. R.</span><span> </span><span class="NLM_article-title">CSF 1-induced gene expression in macrophages: dissociation from the mitogenic response</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2947</span><span class="NLM_x">–</span> <span class="NLM_lpage">2952</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1987&pages=2947-2952&author=A.+Orlofskyauthor=E.+R.+Stanley&title=CSF+1-induced+gene+expression+in+macrophages%3A+dissociation+from+the+mitogenic+response"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrlofsky%26aufirst%3DA.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DCSF%25201-induced%2520gene%2520expression%2520in%2520macrophages%253A%2520dissociation%2520from%2520the%2520mitogenic%2520response%26jtitle%3DEMBO%2520J.%26date%3D1987%26volume%3D6%26spage%3D2947%26epage%3D2952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Chan, J. M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villarreal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stepan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burstein, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, S. M.</span><span> </span><span class="NLM_article-title">Intraarticular gene transfer of TNFR: Fc suppresses experimental arthritis with reduced systemic distribution of the gene product</span> <span class="citation_source-journal">Mol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">736</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1006%2Fmthe.2002.0808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=12498769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD38XpslWksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2002&pages=727-736&author=J.+M.+K.+Chanauthor=G.+Villarrealauthor=W.+W.+Jinauthor=T.+Stepanauthor=H.+Bursteinauthor=S.+M.+Wahl&title=Intraarticular+gene+transfer+of+TNFR%3A+Fc+suppresses+experimental+arthritis+with+reduced+systemic+distribution+of+the+gene+product"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product</span></div><div class="casAuthors">Chan, James M. K.; Villarreal, Gilda; Jin, Wen Wen; Stepan, Tony; Burstein, Haim; Wahl, Sharon M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">727-736</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">Tumor necrosis factor α (TNFα) plays a pivotal role in the pathogenesis of rheumatoid arthritis (RA).  Blockage of TNFα actions by systemic administration of TNF antagonists has recently been shown to ameliorate joint symptoms in RA patients.  In the present study, a streptococcal cell wall (SCW)-induced rat arthritis model was used to evaluate the effect of different gene transfer routes of a TNF antagonist on the development and severity of arthritis.  Successful delivery of a plasmid DNA encoding a rat TNF receptor-Ig Fc (TNFR:Fc) fusion gene prompted the subsequent administration of a recombinant adeno-assocd. virus (rAAV) vector encoding the antagonist, either locally (intraarticular) or systemically (i.m.).  The TNFR:Fc gene, delivered by either route, resulted in profound suppression of the arthritis as reflected in decreased inflammatory cell infiltration, pannus formation, cartilage and bone destruction, and mRNA expression of joint proinflammatory cytokines.  Increased bioactive serum TNFR levels were detected as a result of rAAV-ratTNFR:Fc administration, concomitant with a decrease in circulating TNFα.  Administration of the rAAV-ratTNFR:Fc vector to one joint also suppressed arthritis in the contralateral joint.  Importantly, intraarticular administration resulted in significantly lower systemic distribution of the gene product.  Hence, the use of rAAV as the delivery vector for TNFR:Fc effectively suppressed SCW-induced arthritis and may provide an approach for local delivery of antiarthritic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpROWpmzJMjOrVg90H21EOLACvtfcHk0lj5GNRsaSa6hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpslWksbs%253D&md5=1ff2e4236623574a892f92c7ba08be06</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1006%2Fmthe.2002.0808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fmthe.2002.0808%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DJ.%2BM.%2BK.%26aulast%3DVillarreal%26aufirst%3DG.%26aulast%3DJin%26aufirst%3DW.%2BW.%26aulast%3DStepan%26aufirst%3DT.%26aulast%3DBurstein%26aufirst%3DH.%26aulast%3DWahl%26aufirst%3DS.%2BM.%26atitle%3DIntraarticular%2520gene%2520transfer%2520of%2520TNFR%253A%2520Fc%2520suppresses%2520experimental%2520arthritis%2520with%2520reduced%2520systemic%2520distribution%2520of%2520the%2520gene%2520product%26jtitle%3DMol.%2520Ther.%26date%3D2002%26volume%3D6%26spage%3D727%26epage%3D736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Cromartie, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craddock, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderlie, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. H.</span><span> </span><span class="NLM_article-title">Arthritis in rats after systemic injection of streptococcal cells or cell walls</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">1585</span><span class="NLM_x">–</span> <span class="NLM_lpage">1602</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=1977&pages=1585-1602&author=W.+J.+Cromartieauthor=J.+G.+Craddockauthor=J.+H.+Schwabauthor=S.+K.+Anderlieauthor=C.+H.+Yang&title=Arthritis+in+rats+after+systemic+injection+of+streptococcal+cells+or+cell+walls"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCromartie%26aufirst%3DW.%2BJ.%26aulast%3DCraddock%26aufirst%3DJ.%2BG.%26aulast%3DSchwab%26aufirst%3DJ.%2BH.%26aulast%3DAnderlie%26aufirst%3DS.%2BK.%26aulast%3DYang%26aufirst%3DC.%2BH.%26atitle%3DArthritis%2520in%2520rats%2520after%2520systemic%2520injection%2520of%2520streptococcal%2520cells%2520or%2520cell%2520walls%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1977%26volume%3D146%26spage%3D1585%26epage%3D1602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Richards, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, A. S.</span><span> </span><span class="NLM_article-title">Suppression of chronic streptococcal cell wall-induced arthritis in lewis rats by liposomal clodronate</span> <span class="citation_source-journal">Rheumatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">978</span><span class="NLM_x">–</span> <span class="NLM_lpage">987</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=978-987&author=P.+J.+Richardsauthor=B.+D.+Williamsauthor=A.+S.+Williams&title=Suppression+of+chronic+streptococcal+cell+wall-induced+arthritis+in+lewis+rats+by+liposomal+clodronate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichards%26aufirst%3DP.%2BJ.%26aulast%3DWilliams%26aufirst%3DB.%2BD.%26aulast%3DWilliams%26aufirst%3DA.%2BS.%26atitle%3DSuppression%2520of%2520chronic%2520streptococcal%2520cell%2520wall-induced%2520arthritis%2520in%2520lewis%2520rats%2520by%2520liposomal%2520clodronate%26jtitle%3DRheumatology%26date%3D2001%26volume%3D40%26spage%3D978%26epage%3D987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tak, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeets, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daha, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluin, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijers, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brand, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinders, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breedveld, F. C.</span><span> </span><span class="NLM_article-title">Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to disease activity</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1002%2Fart.1780400206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=9041933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A280%3ADyaK2s7psVCqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=217-225&author=P.+P.+Takauthor=T.+J.+Smeetsauthor=M.+R.+Dahaauthor=P.+M.+Kluinauthor=K.+A.+Meijersauthor=R.+Brandauthor=A.+E.+Meindersauthor=F.+C.+Breedveld&title=Analysis+of+the+synovial+cell+infiltrate+in+early+rheumatoid+synovial+tissue+in+relation+to+disease+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity</span></div><div class="casAuthors">Tak P P; Smeets T J; Daha M R; Kluin P M; Meijers K A; Brand R; Meinders A E; Breedveld F C</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis and rheumatism</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-25</span>
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    </div><div class="casAbstract">OBJECTIVE:  To define variations in the cellular infiltrate and in the expression of monokines in synovial tissue (ST) from rheumatoid arthritis (RA) patients with different durations of disease and different levels of disease activity.  METHODS:  The immunohistologic features of synovial biopsy specimens from 31 patients with early RA (< 1 year) and 35 patients with longstanding RA (> 5 years) were compared.  The possible associations between these features and local disease activity, as measured by the score for pain in the biopsied knee joint were also evaluated.  RESULTS:  The immunohistologic features were not dependent on disease duration.  We found a positive correlation between the scores for knee pain and the semiquantitative scores for the number of macrophages, as well as the expression of interleukin-6 and tumor necrosis factor alpha, whereas the correlation with the scores for CD4+ T cells was negative.  Multivariate analysis showed that these correlations were highly statistically significant (P < 0.003).  CONCLUSION:  The results do not support the view that inflammatory mechanisms in the synovial tissues of RA patients differ between early and late stages of the disease.  The findings presented here are consistent with the concept that early RA is the result of a synovitis process of longer duration and that macrophage-derived cytokines play an important role in maintaining the clinical signs of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7XPNbuR4ndNbHMBt0mMIXfW6udTcc2eZjxkM6-lKKcLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7psVCqtw%253D%253D&md5=ce8d3e3ad53739d459b024a049a132cf</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1002%2Fart.1780400206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.1780400206%26sid%3Dliteratum%253Aachs%26aulast%3DTak%26aufirst%3DP.%2BP.%26aulast%3DSmeets%26aufirst%3DT.%2BJ.%26aulast%3DDaha%26aufirst%3DM.%2BR.%26aulast%3DKluin%26aufirst%3DP.%2BM.%26aulast%3DMeijers%26aufirst%3DK.%2BA.%26aulast%3DBrand%26aufirst%3DR.%26aulast%3DMeinders%26aufirst%3DA.%2BE.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26atitle%3DAnalysis%2520of%2520the%2520synovial%2520cell%2520infiltrate%2520in%2520early%2520rheumatoid%2520synovial%2520tissue%2520in%2520relation%2520to%2520disease%2520activity%26jtitle%3DArthritis%2520Rheum.%26date%3D1997%26volume%3D40%26spage%3D217%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit39b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Haringman, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlag, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwinderman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeets, T. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baeten, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInnes, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bresnihan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tak, P. P.</span><span> </span><span class="NLM_article-title">Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">–</span> <span class="NLM_lpage">838</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=16&amp;doi=10.1021%2Fjm801406h&amp;key=10.1136%2Fard.2004.029751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=15576415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXls1als70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2005&pages=834-838&author=J.+J.+Haringmanauthor=D.+M.+Gerlagauthor=A.+H.+Zwindermanauthor=T.+J.+M.+Smeetsauthor=M.+C.+Kraanauthor=D.+Baetenauthor=I.+B.+McInnesauthor=B.+Bresnihanauthor=P.+P.+Tak&title=Synovial+tissue+macrophages%3A+a+sensitive+biomarker+for+response+to+treatment+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39bR"><div class="casContent"><span class="casTitleNuber">39b</span><div class="casTitle"><span class="NLM_cas:atitle">Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis</span></div><div class="casAuthors">Haringman, J. J.; Gerlag, D. M.; Zwinderman, A. H.; Smeets, T. J. M.; Kraan, M. C.; Baeten, D.; McInnes, I. B.; Bresnihan, B.; Tak, P. P.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">834-838</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background: Previous work identified synovial sublining macrophage nos. as a potential biomarker for clin. efficacy in rheumatoid arthritis.  Objective: To investigate the assocn. between changes in infiltration of synovial macrophages and clin. improvement after antirheumatic treatment.  Methods: 88 patients who participated in various clin. trials were studied.  All patients underwent serial arthroscopy before initiation of treatment and after different time intervals.  Immunohistochem. and digital image anal. were performed according to standardized procedures to detect changes in CD68+ synovial sublining macrophages in relationship to changes in the 28 joint count Disease Activity Score (DAS28).  Statistical anal. was performed using one way anal. of variance, the independent samples t test, linear regression, and the standardized response mean (SRM).  Results: For good, moderate, and non-responders, according to the DAS28 response criteria, there was a significant difference in the change in sublining macrophages (mean (SEM) cells/mm2 -643 (124), -270 (64), and -95 (60), resp.; p<0.0003).  There was a significant correlation between the change in the no. of macrophages and the change in DAS28 (Pearson correlation 0.874, p<0.01).  The change in sublining macrophages explained 76% of the variation in the change in DAS28 (p<0.02).  The sensitivity to change of the biomarker was high in patients treated actively (SRM >0.8), whereas the ability to detect changes in placebo treated patients was weak (SRM <0.3).  Conclusion: The results suggest that changes in synovial sublining macrophages can be used to predict possible efficacy of antirheumatic treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoDDuysAUtsbVg90H21EOLACvtfcHk0ljmaqIqHN_qCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXls1als70%253D&md5=3fdb6f7b0d2c170ca58e40af83af054f</span></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=10.1136%2Fard.2004.029751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2004.029751%26sid%3Dliteratum%253Aachs%26aulast%3DHaringman%26aufirst%3DJ.%2BJ.%26aulast%3DGerlag%26aufirst%3DD.%2BM.%26aulast%3DZwinderman%26aufirst%3DA.%2BH.%26aulast%3DSmeets%26aufirst%3DT.%2BJ.%2BM.%26aulast%3DKraan%26aufirst%3DM.%2BC.%26aulast%3DBaeten%26aufirst%3DD.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DBresnihan%26aufirst%3DB.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DSynovial%2520tissue%2520macrophages%253A%2520a%2520sensitive%2520biomarker%2520for%2520response%2520to%2520treatment%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2005%26volume%3D64%26spage%3D834%26epage%3D838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">DAI, x. m.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hapel, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sylvestre, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, E. R.</span><span> </span><span class="NLM_article-title">Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">120</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=111-120&author=x.+m.+DAIauthor=G.+R.+Ryanauthor=A.+J.+Hapelauthor=M.+G.+Dominguezauthor=R.+G.+Russellauthor=S.+Kappauthor=V.+Sylvestreauthor=E.+R.+Stanley&title=Targeted+disruption+of+the+mouse+colony-stimulating+factor+1+receptor+gene+results+in+osteopetrosis%2C+mononuclear+phagocyte+deficiency%2C+increased+primitive+progenitor+cell+frequencies%2C+and+reproductive+defects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDAI%26aufirst%3Dx.%2Bm.%26aulast%3DRyan%26aufirst%3DG.%2BR.%26aulast%3DHapel%26aufirst%3DA.%2BJ.%26aulast%3DDominguez%26aufirst%3DM.%2BG.%26aulast%3DRussell%26aufirst%3DR.%2BG.%26aulast%3DKapp%26aufirst%3DS.%26aulast%3DSylvestre%26aufirst%3DV.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DTargeted%2520disruption%2520of%2520the%2520mouse%2520colony-stimulating%2520factor%25201%2520receptor%2520gene%2520results%2520in%2520osteopetrosis%252C%2520mononuclear%2520phagocyte%2520deficiency%252C%2520increased%2520primitive%2520progenitor%2520cell%2520frequencies%252C%2520and%2520reproductive%2520defects%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26spage%3D111%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Campbell, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischof, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, J. A.</span><span> </span><span class="NLM_article-title">The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by CSF-1 and G-CSF and requirement for endogenous CSF-1</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">144</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm801406h&amp;key=10914502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm801406h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltVGmtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2000&pages=144-50&author=I.+K.+Campbellauthor=M.+J.+Richauthor=R.+J.+Bischofauthor=J.+A.+Hamilton&title=The+colony-stimulating+factors+and+collagen-induced+arthritis%3A+exacerbation+of+disease+by+CSF-1+and+G-CSF+and+requirement+for+endogenous+CSF-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF</span></div><div class="casAuthors">Campbell, Ian K.; Rich, Melissa J.; Bischof, Robert J.; Hamilton, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">144-150</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">There is increasing evidence that the colony-stimulating factors (CSFs) may play a part in chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA).  The authors examd. the involvement of macrophage CSF (M-CSF or CSF-1) and granulocyte CSF (G-CSF) in collagen-induced arthritis (CIA), a murine model of RA.  Daily injections of M-CSF or G-CSF, 20-24 days postprimary immunization with type II collagen, exacerbated disease symptoms in suboptimally immunized DBA/1 mice.  Support for the involvement of endogenous M-CSF in CIA was obtained by studies in which neutralizing monoclonal antibody reduced the severity of established CIA and also by studies showing the resistance of M-CSF-deficient op/op mice to CIA induction.  These studies show that M-CSF and G-CSF can be proinflammatory in CIA and provide evidence that macrophage- and granulocyte-lineage cells can exacerbate CIA.  The authors' results also show that M-CSF-dependent cells are essential for CIA development, suggesting M-CSF may be a suitable target for therapeutic intervention in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobmj_XMRtR77Vg90H21EOLACvtfcHk0ljwCSJiQ3jHBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltVGmtrw%253D&md5=e37a81523dba2270449366102252c4b2</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DI.%2BK.%26aulast%3DRich%26aufirst%3DM.%2BJ.%26aulast%3DBischof%26aufirst%3DR.%2BJ.%26aulast%3DHamilton%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520colony-stimulating%2520factors%2520and%2520collagen-induced%2520arthritis%253A%2520exacerbation%2520of%2520disease%2520by%2520CSF-1%2520and%2520G-CSF%2520and%2520requirement%2520for%2520endogenous%2520CSF-1%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2000%26volume%3D68%26spage%3D144%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Tohda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiraku, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ariga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawashima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, Y.</span><span> </span><span class="NLM_article-title">Nucleophilic reaction upon electron-deficient pyridone derivatives. X. One-pot synthesis of 3-nitropyridines by ring transformation of 1-methyl-3,5-dinitro-2-pyridone with ketones or aldehydes in the presence of ammonia</span> <span class="citation_source-journal">Bull. Chem. Soc. Jpn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">2820</span><span class="NLM_x">–</span> <span class="NLM_lpage">2827</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1990&pages=2820-2827&author=Y.+Tohdaauthor=M.+Eirakuauthor=T.+Nakagawaauthor=Y.+Usamiauthor=M.+Arigaauthor=T.+Kawashimaauthor=K.+Taniauthor=H.+Watanabeauthor=Y.+Mori&title=Nucleophilic+reaction+upon+electron-deficient+pyridone+derivatives.+X.+One-pot+synthesis+of+3-nitropyridines+by+ring+transformation+of+1-methyl-3%2C5-dinitro-2-pyridone+with+ketones+or+aldehydes+in+the+presence+of+ammonia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTohda%26aufirst%3DY.%26aulast%3DEiraku%26aufirst%3DM.%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DUsami%26aufirst%3DY.%26aulast%3DAriga%26aufirst%3DM.%26aulast%3DKawashima%26aufirst%3DT.%26aulast%3DTani%26aufirst%3DK.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DMori%26aufirst%3DY.%26atitle%3DNucleophilic%2520reaction%2520upon%2520electron-deficient%2520pyridone%2520derivatives.%2520X.%2520One-pot%2520synthesis%2520of%25203-nitropyridines%2520by%2520ring%2520transformation%2520of%25201-methyl-3%252C5-dinitro-2-pyridone%2520with%2520ketones%2520or%2520aldehydes%2520in%2520the%2520presence%2520of%2520ammonia%26jtitle%3DBull.%2520Chem.%2520Soc.%2520Jpn.%26date%3D1990%26volume%3D63%26spage%3D2820%26epage%3D2827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DPK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DPK','PDB','3DPK'); return false;">PDB: 3DPK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2I0Y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2I0Y','PDB','2I0Y'); return false;">PDB: 2I0Y</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-si1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i81"><a href="/doi/suppl/10.1021/jm801406h">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_32725"></div></div></div></div></div><hr /></hr><p class="last">LC-MS data for target compounds. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm801406h/suppl_file/jm801406h_si_001.pdf">jm801406h_si_001.pdf (653.56 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm801406h&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2009.52.issue-4%3Barticle%3Aarticle%3A10.1021%2Fjm801406h%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm801406h" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b7a32d723d1e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
